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Abstract: The special issue “Ion Channels of Nociception” contains 13 articles published by 73 authors
from different countries united by the main focusing on the peripheral mechanisms of pain. The content
covers the mechanisms of neuropathic, inflammatory, and dental pain as well as pain in migraine and
diabetes, nociceptive roles of P2X3, ASIC, Piezo and TRP channels, pain control through GPCRs and
pharmacological agents and non-pharmacological treatment with electroacupuncture.
Keywords: pain; nociception; sensory neurons; ion channels; P2X3; TRPV1; TRPA1; ASIC; Piezo channels;
migraine; tooth pain
Sensation of pain is one of the fundamental attributes of most species, including humans.
Physiological (acute) pain protects our physical and mental health from harmful stimuli, whereas chronic
and pathological pain are debilitating and contribute to the disease state.
Despite active studies for decades, molecular mechanisms of pain—especially of pathological
pain—remain largely unaddressed, as evidenced by the growing number of patients with chronic forms
of pain. There are, however, some very promising advances emerging. A new field of pain treatment
via neuromodulation is quickly growing, as well as novel mechanistic explanations unleashing the
efficiency of traditional techniques of Chinese medicine. New molecular actors with important roles in
pain mechanisms are being characterized, such as the mechanosensitive Piezo ion channels [1].
Pain signals are detected by specialized sensory neurons, emitting nerve impulses encoding pain
in response to noxious stimuli. Many of these nociceptive neurons are equipped with a rich repertoire of
specific ion channels which serve as pain transducers. These ion channels are located at the peripheral
terminals of dorsal root or trigeminal ganglia neurons as well as in sensory neurons of the viscera
(Figure 1). Pain transducers react to a variety of chemical or physical stimuli (algogens) by opening
the ion channels and inducing neuronal depolarization known as the generator potential. These pain
transducers include ATP-gated P2X3, classical heat/capsaicin-sensitive TRPV1 and cold/redox-sensitive
TRPA1 channels, acid sensitive ion channels (ASICs), and mechanosensitive Piezo, to name just a few
(Figure 1, for further details see the classical review [2]). Sufficiently high generator potential, assisted by
voltage-gated sodium channels, initiates the propagating action potentials (spikes). Some voltage-gated
channels are expressed exclusively in nociceptive neurons, for instance, sodium Nav1.8 and Nav1.9
channels [3]. The peripheral pain signals travel via the multi-synaptic network of the nociceptive
system to the higher pain centers to be perceived as a feeling of pain.
A remarkable property of nociceptive neurons is sensitisation (enhanced responsiveness to triggers
of pain). This phenomenon, a type of neuronal plasticity, can be mediated by a plethora of metabotropic
receptors for different classes of pain modulators: classical mediators, neurotrophins, cytokines,
and other active molecules (Figure 1). Normally, many pain transducers are in “sleeping” or low
activity mode, but they can become very active during the action of these endogenous modulators
triggering neuronal sensitization.
The fundamental approach: “treat pain at the source” provides a strategic rationale to diminish
pain by counteracting its peripheral mechanisms. The knowledge of the function and structure of
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pain transducers and associated ion channels is essential to develop new medicines. The fact that
the molecular structures of most ion channels implicated in nociception are known facilitates the
development of new anti-nociceptive (analgesic) medicines. Direct targeting of pain transducers by
specific blockers provides an opportunity to block pain mediated by these ion channels. However, this is
a challenging task since the lifetime of channels on the membrane is limited because of the continuous
traffic and renewal as it was shown for the nociceptive P2X3 receptors [4].
Figure 1. Chemical and physical stimuli (algogens) activating ion channel of nociception and pain
modulators acting at the nerve terminal of the nociceptive neuron. The nerve terminal expresses
specific ion channels of nociception such as ATP-gated P2X3, heat/capsaicin-sensitive TRPV1 and
cold/redox-sensitive TRPA1 channels, acid-sensitive ion channels (ASICs) and mechanosensitive Piezo
channels. The activity of these pain transducers can be enhanced leading to the neuronal sensitization,
via metabotropic receptors, by different classes of pain modulators including neuropeptides, hormones,
classical mediators, neurotrophins, cytokines, and other endogenous pro-nociceptive molecules.
This special issue “Ion Channels of Nociception” contains 13 articles published by 73 authors from
different countries united by the main focusing on the peripheral mechanisms of pain. The content
covers the mechanisms of neuropathic, inflammatory, and dental pain as well as pain in migraine and
diabetes, nociceptive roles of P2X3, ASIC, Piezo and TRP channels, pain control through GPCRs and
pharmacological agents and non-pharmacological treatment with electroacupuncture.
Not surprisingly, the majority of papers in this collection are devoted to the functioning of
TRP channels, which are the best-studied transducers of noxious stimuli but still a puzzling issue
for the researchers. In the large family of TRP channels, TRPV1 and TRPA1 are best known for
their leading role in key pain mechanisms. TRPV1 receptors are often co-expressed with TRPA1 in
nociceptive neurons and probably can interact by means of the protein TMEM100. The details of such
interactions are discussed in the well-illustrated review by Takayama and co-workers [5] summarizing
the role TRP channels play in the pain states including acute pain, inflammatory pain, migraine pain,
and other disorders. Much attention in this review is paid to the ANO1 protein, a calcium-activated
chloride channel expressed in nociceptive neurons. The authors propose that TRP channels and ANO1
can collaborate to generate a strong pain signal in primary sensory neurons. This is an interesting
“marriage” between cation and anion permeable ion channels to control the neuronal excitability.
By focusing on TRPA1 channels, Feng and colleagues [6], using electrophysiological recordings from
brainstem slices, detected activation of presynaptic polymodal TRPA1 ion channels in glutamatergic
terminals synapsing on the caudal nucleus of the solitary tract neurons. The enhanced glutamatergic
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synaptic neurotransmission onto the second-order sensory neurons was activated by TRPA1 agonists.
These findings were supported by data from the TRPA1 knockout mice where TRPA1 agonists failed to
alter synaptic efficacy. The study suggests that in the caudal brainstem the input from visceral noxious
stimuli can be targeted by multiple endogenous TRPA1 ligands including reactive oxygen species and
probably by the classic analgesic paracetamol via its derivatives [6].
The original view on the role of ion channels, including TRP and other unrelated channels in
nociception, was presented by Ciotu with co-workers [7]. As stated by the authors, they describe
“more novel and less known features” of ion channels. In particular, they summarize not commonly
considered ion channel properties such as a memory of the previous voltage and chemical stimulation,
alternative ion conduction pathways, cluster formation, and role of the silent accessory subunits.
This fresh view on the channels function in a realistic membrane environment should stimulate the
interest to these little appreciated phenomena and can suggest new ideas for many researchers studying
the pain mechanisms.
One study in this special issue, reports the expression of TRPA1 channels not only in neurons but
also in non-neuronal cells. Thus, Kameda with colleagues [8], studied the expression and activity of the
pro-nociceptive TRPA1 and TRPV1 in the intervertebral disc (IVD) as its degeneration is associated with
inflammatory pain. As the object of the study, they analyzed human fetal, healthy, and degenerated
IVD tissues. They found that the TRPA1 agonist AITC activated inflamed IVD cells, induced expression
of IL-8, but reduced disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5).
By comparing knockout TRPA1 versus TRPV1 mice, they further confirmed the leading role of TRPA1
in control of inflammation in IVD cells.
The experimental study by Demartini with collaborators [9], has a significant translational impact
as they describe a new treatment approach for neuropathic pain. Notably, neuropathic pain is a severe
disabling and often intractable condition and new therapeutic targets are of high interest. They used
a drug candidate compound ADM-12 blocking the nociceptive TRPA1 receptors in the trigeminal
nerve fibers. The authors used the well-established model of the neuropathic pain based on the
chronic constriction injury of the infraorbital nerve. Apart from the antagonism of TRPA1 receptors,
they found also other benefits of this treatment including reduced expression of TRPA1/V1 receptors
and pro-nociceptive neuropeptides and cytokines, collectively contributing to diminished mechanical
allodynia, a leading symptom of neuropathic pain.
Whereas the trigeminal neuralgia is a relatively rare type of head pain, migraine headaches are very
common. Migraine headache is characterized by a severe pulsatile (throbbing) type of pain also transmitted
by trigeminal nerve fibers. Review by Della Pietra et al. [10] provides a new explanation for the throbbing
pain in migraine by proposing a rhythmic activation, by pulsatile blood flow, of mechanosensitive Piezo
channels in trigeminal fibers in meninges. Piezo ion channels (presented by Piezo1 and Piezo2 isoforms)
with the highest sensitivity to mechanical stimuli were recently discovered [1]. The Piezo 1 subtype
sensitive to mechanical and chemical agonists such as Yoda1, is found in trigeminal neurons along
with Piezo2 subtype [11]. Della Pietra and co-authors describe the function and modulation of Piezo
mechanotransducers in the trigeminovascular system as sensors generating the rhythmic migraine pain
signals. The emerging field of Piezo currently attracts much attention as a new way for efficient control of
Piezo-related diseases, including migraine and chronic pain.
The review by Tardiolo et al. [12] expands our knowledge of current and novel therapeutic
approaches to migraine. The particular focus in this review is on the pharmacological targets for novel
drugs based on 5-HT receptor agonists (ditans), CGRP receptor antagonists (new generation of gepants),
and CGRP receptor or ligand antagonists such as monoclinal antibodies (mAbs). Of note, this review
contains a detailed description of these and other new emerging treatments in migraine. Further in
this review, the authors present the animal models of migraine including the dural application of the
inflammatory soup or high potassium to induce CSD, nitroglycerin, and transgenic migraine models.
Apart from the clear role in migraine of the neuropeptide CGRP, another neuropeptide, substance
P, often co-expressed with CGRP in nociceptive neurons, contributes to other types of pain. For decades,
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substance P was considered a putative promoter of pain. A review included in this collection by Chang
with colleagues [13] highlights a new paradoxical role of substance P in anti-nociception, in particular,
in muscle pain. The authors suggest that the anti-nociception by the substance P in muscle pain is
mediated via the enhancement of the M-channel outward currents in local sensory neurons. The review
contains a detailed description of ion channels modulated by substance P. Elucidating the dual role of
substance P in pain control would further improve our understanding of the biological functions of
this neuropeptide for better development of anti-nociceptive treatments.
The nociceptive neurons express also a high level of P2X3 receptors activated by extracellular
ATP, which is a powerful algogenic substance (Figure 1). Xiang and co-workers [14] uncovered the
role of ATP-gated P2X3 receptors in analgesia by electroacupuncture in CFA-induced inflammatory
pain. P2X3 receptors, opening a cationic ion channel after ATP binding, are primarily implicated in
the inflammatory type of pain. The authors found that the short-term or long-term application of
100 Hz electroacupuncture increased the paw withdrawal threshold and reversed the elevation of P2X3
receptors in sensory DRG neurons.
Mustăciosu with collaborators [15] analyzed the expression of the neuron-specific Elav-like
Hu RNA-binding proteins in sensory DRG neurons in mice with the streptozotocin (STZ)-induced
diabetes. These proteins presented with three isoforms HuB, HuC, and HuD, typically play a role in
neurogenesis and neuronal plasticity. As the original approach, the authors compared STZ-sensitive to
STZ-resistant mice with high or low glycemia, respectively. With thermal pain testing, they found
that the hypoalgesia was observed only in the diabetic mice. This effect was associated with HuD
downregulation and HuB upregulation, which might be related to the altered post-transcriptional
control of RNAs involved in the regulation of thermal hypoalgesia.
In their comprehensive review, Salzer and co-workers [16] discuss how the members of the big
family of G-protein coupled receptors (GPCRs) control the function of different types of ion channels
implicated in nociception (see also Figure 1). Notably, these CGRPs not only detect the endogenous
active molecules such as opioids or cannabinoids operating as modulators of pain transducing ion
channels but also represent the most important targets for various analgesic therapeutics. The authors
provide in-depth analysis of GPCRs-mediated modulation of the main subtypes of ligand- (TRPs, ASIC,
CaCCs), mechano- (K2P and Piezo) as well as voltage-gated (sodium, calcium, and potassium) channels
implicated in nociception.
Lee and collaborators [17] present an interesting review on the mechanisms of the dental pain,
which is often extremely severe and based on the unique anatomical structure of the tooth. Along with
other chemical stimuli, they paid much attention to the heat-/cold-induced nociceptive signaling
via TRP type ion channels. Although thermal stimuli are the primary signals to trigger tooth pain,
this cannot explain the sudden and intense tooth pain elicited by innocuous mechanical stimuli.
Moreover, similar to migraine headaches, dental pain often has a pulsating character. The latter can be
activated by mechanical stimulation from the rhythmic movement of dentinal fluid or deformation
of tooth microstructure. Logically, as in the migraine paper by Della Pietra et al, Lee and colleagues
have considered the role of the professional Piezo ion channels as detectors of these mechanical forces.
As Piezo2 channels are expressed mainly in low threshold mechanoreceptive neurons, the authors
proposed that, in the tooth, these neurons serve as nociceptors. Interestingly, Piezo2 were also detected
in odontoblastic processes in dentinal tubules, suggesting the complex role of these mechanosensitive
channels in dental pain.
Shteinikov and co-workers [18] report the results of the experimental study on the action of the
hydrophobic amines and their guanidine analogs on activation and desensitization of acid-sensing
ion channels (ASIC). The ASIC3 subtype, studied here, with the highest acid sensitivity is primarily
expressed in nociceptive neurons and likely implicated in various types of chronic and inflammatory
pain associated with tissue acidosis. By testing a series of hydrophobic monoamines on CHO cells
expressing rat ASIC3 channels, they found an interesting combination of two opposite effects of these
potentially analgesic agents. This finding can explain previous contradictory results obtained with
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these ASIC modulators. They showed the inhibition of ASIC3 activation due to the acidic shift of
proton sensitivity but they also detected the reduced desensitization of ion channels, which is normally
very fast and limits the activity of these membrane proteins.
In summary, this collection of articles provides an overview of different aspects of peripheral
pain mechanisms. These papers are extending our understanding of the role of ion channels in situ,
ion channel interactions, functional role of sensitization-desensitization and ion channel inactivation,
endogenous modulators, and other important aspects of the functioning of excitable nociceptive
neurons partnering with non-excitable cells. We believe that this issue will provide new insights into
the remarkable field of pain research.
Author Contributions: Writing, review, and editing, R.G.
Funding: The author is supported by the Finnish Academy (grant number 325392).
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Abstract: Receptor-type ion channels are critical for detection of noxious stimuli in primary sensory
neurons. Transient receptor potential (TRP) channels mediate pain sensations and promote a variety of
neuronal signals that elicit secondary neural functions (such as calcitonin gene-related peptide [CGRP]
secretion), which are important for physiological functions throughout the body. In this review,
we focus on the involvement of TRP channels in sensing acute pain, inflammatory pain, headache,
migraine, pain due to fungal infections, and osteo-inflammation. Furthermore, action potentials
mediated via interactions between TRP channels and the chloride channel, anoctamin 1 (ANO1), can
also generate strong pain sensations in primary sensory neurons. Thus, we also discuss mechanisms
that enhance neuronal excitation and are dependent on ANO1, and consider modulation of pain
sensation from the perspective of both cation and anion dynamics.
Keywords: TRPA1; TRPV1; TRPM3; ANO1; acute pain; inflammatory pain; migraine; Candidiasis
1. Introduction
The ability to sense elements of the natural environment (including temperature, pH, pressure,
light, and noxious compounds) is critical for survival. Detection and response to environmental agents
and stimuli are frequently mediated by receptor-type plasma membrane proteins, particularly ion
channels that show versatile function in a range of organisms from prokaryotes to eukaryotes. Relative
to G-protein coupled receptors (GPCRs), ion channels can directly impact neural excitation by both
sensing natural stimuli and converting these signals into electrical changes to affect the polarization
state of the plasma membrane.
In this review, we focus on several transient receptor potential (TRP) channels that are specifically
activated by natural compounds and largely localize to primary sensory neurons. There are three types
of nerves in primary sensory neurons, including Aβ-, Aδ-, and C-fibers. Aβ-fibers are myelinated
afferent nerves that respond to innocuous mechanical stimuli. Aδ-fibers are also myelinated nerves,
but alternatively this nervous pathway responds to rapid noxious stimuli. C-fibers are nonmyelinated
nerves involved in slow pain [1]. The TRP channel superfamily comprises six subfamilies: TRP
vanilloid (TRPV), canonical (TRPC), mucolipin (TRPML), polycystin (TRPP), ankyrin (TRPA), and
melastatin (TRPM). Several TRP channels are expressed in small-size dorsal root ganglion (DRG) and
trigeminal ganglion (TG) neurons (C fibers and Aδ fibers) [2]. While TRPV1 and TRPA1 are considered
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to be the major receptors of this superfamily involved in nociception [3]. In particular, TRPV1 and
sensitized TRPA1 are activated by heat and cold, respectively, and as such are important for detection
of noxious temperature changes. Recently, TRPM3 involvement in heat sensation was also reported
in mice [4].
The calcium-activated chloride channel, anoctamin 1 (ANO1, also known as TMEM16A) [5–7],
was recently reported to be directly activated in DRG neurons by extremely rapid temperature
changes that reach noxious ranges [8,9]. ANO1 can also be activated immediately downstream
of Gq protein-coupled receptors (GqPCRs), including the bradykinin receptor, as evidenced by
direct interaction of ANO1 with inositol trisphosphate (IP3) receptors on endoplasmic reticulum
membranes [10]. Chloride channels typically function in neuronal suppression in the central nervous
system, in part because intracellular chloride concentrations are maintained at low levels by the
potassium–chloride co-transporter type 2 (KCC2). However, in DRG neurons, KCC2 expression is
either absent or very low, whereas expression of the sodium–potassium–chloride co-transporter type 1
(which is an important molecule in the chloride intake pathway) is high [11]. Thus, chloride efflux
through ANO1 activation is a key pathway for generation of neuronal excitation in many primary
sensory neurons.
Here, we summarize the physiological significance of TRP and ANO1 channels. First, we describe
current understanding of representative ion channels, namely TRPA1, TRPV1, and ANO1 (Part 1).
Second, we discuss the multiple functions of TRP channels and ANO1 (Part 2). Finally, we propose
the significance of those functions in clinical situations, including headache, migraine, and fungus
infection (Parts 3 and 4).
2. Basic Understanding of Ion Channels in Primary Sensory Neurons
2.1. TRPA1
2.1.1. TRPA1 Activation by Natural Ligands
TRPA1 is activated by many natural ligands such as allyl isothiocyanate (AITC),
tetrahydrocannabinol, cinnamaldehyde, allicin, diallyl sulfide, carvacrol, eugenol, gingerol, methyl
salicylate, capsiate, thymol, propofol, 1,4-cineole, oleocanthal, and carbon dioxide, and by membrane
extension and intracellular alkalization [12–26]. Moreover, TRPA1 is activated by calcium [27].
The magnitude of TRPA1 currents gradually increases during application of a given agonist, as
observed for the lagging peak current induced after application of -eudesmol from hops to HEK293
cells expressing human TRPA1 [28]. Although the precise mechanism of TRPA1 activation remains
unclear, covalent protein modification is involved. Carbons of AITC and N-methyl maleimide
covalently bind to cysteine in the N-terminus of TRPA1 to enhance channel activation, whereas
C-terminal lysine and arginine are important for AITC-mediated activation [29–31]. Menthol also has
agonistic effects on human and mouse TRPA1, although the effects are bimodal [32,33]. The agonistic
and antagonistic effects on mouse TRPA1 involves serine 876 and threonine 877 in the transmembrane
(TM)-5 region [33]. Interestingly, G878 is also important for TRPA1-mediated cold sensitivity in
rodents [34]. Rodent TRPA1 can be activated by cold stimulation and is involved in cold hyperalgesia
after application of complete Freund’s adjuvant (CFA) [35,36]. Although human TRPA1 does not
show a cold response, it nonetheless responds to cold at approximately 18 ◦C if oxidization with
dehydroxylation at proline 394 occurs [37].
2.1.2. TRPA1 in Pathological Conditions
TRPA1 activation induces hyperalgesia during inflammation because inflammatory factors (such
as bradykinin released by tissue injury) activate and sensitize TRPA1 in DRG neurons. In this pathway,
protein kinase A (PKA) and phospholipase C (PLC) are important for TRPA1 sensitization [38].
Adenosine triphosphate (ATP) is another important inducer in inflammatory pain. Pain sensations
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are enhanced via a similar pathway through activation of purinergic P2Y receptors expressed in DRG
neurons. Moreover, P2X receptors are involved in neuropathic pain via phospholipase A2 (PLA2)
signaling [39], which activates protein kinase C (PKC), and in turn sensitizes TRPA1 [40].
TRPA1 expression increases after application of nerve growth factor (NGF) and is inhibited by the
p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580. In DRG neurons, NGF released
from inflamed tissue phosphorylates p38, which subsequently enhances TRPA1 expression [36]. Thus,
the NGF–p38 MAPK–TRPA1 axis is one of the pathways that exacerbates TRPA1-mediated pain
sensation in DRG neurons. For example, gastric distension-induced visceral pain relies on activation
of both TRPA1 and p38 [41]. TRPA1 localization can be modified by pathological stimulation. TRPA1
localization to the plasma membrane is enhanced in forskolin-treated DRG neurons [42]. Further, in
mice, full-length TRPA1 positively translocates to the plasma membrane by co-expression of a TRPA1
splicing variant [43]. There are two TRPA1 splicing variants: TRPA1a is the full-length protein whereas
TRPA1b lacks exon 20, which encodes part of TM2 and the intracellular domain between TM2 and
TM3. TRPA1b has no ion channel activity but instead enhances TRPA1a translocation to the plasma
membrane. One-day of CFA treatment or partial sciatic nerve ligation (PSL) causes inflammatory
and neuropathic pain, respectively. In both cases, TRPA1a expression levels increase transiently.
Interestingly, TRPA1b expression levels significantly increase while TRPA1a expression reduces to
basal levels at five days after CFA treatment or PSL. As such, up-regulation of TRPA1a translocation
via TRPA1b overexpression causes a continuous pathological condition.
As with CFA, lipopolysaccharide (LPS) is also often used to induce the inflammatory condition.
LPS can activate Toll-like receptor (TLR)-4, and cause subsequent release of multiple cytokines from
immune cells [44]. The cytokine, tumor necrosis factor-alpha (TNF-α), enhances AITC-induced calcium
increases in nodose and jugular ganglion neurons from rats [45]. However, a recent report suggested
that LPS-induced calcium increases in nodose ganglion neurons from mice do not depend on TLR4,
even although the responses are reduced in TRPA1 knockout mice [46]. Altogether, these results suggest
that LPS directly activates TRPA1. Further, LPS increases single channel activity in TRPA1-expressing
CHO cells. Ultimately, this novel relationship between bacteria and primary sensory nerves suggests
that TRPA1 antagonists could be valuable for reducing pain induced by bacterial infections.
2.1.3. TRPA1 Activation by Reactive Oxygen Species and Hypoxia
In addition to thermal stimuli and environmental agents, TRPA1 is activated by reactive oxygen
species (ROS) such as hydrogen peroxide (H2O2) [47–49]. Responses to certain pathological conditions
involving increased ROS synthesis (such as dysesthesia in ischemia and reperfusion of blood flow)
are dependent on TRPA1 activity in mice [50]. Pain-related behavior due to dysesthesia is reduced
by activation of prolyl hydroxylase (PHD)-2 involving hydroxylation at proline. Under normoxic
conditions, TRPA1 steady status activity is maintained by PHD-mediated hydroxylation of proline
394, but under hypoxic conditions hydroxylation is inhibited and H2O2-induced TRPA1 activity is
enhanced [50]. In contrast, high concentrations of oxygen also activate TRPA1 by directly modifying
TRPA1 cysteines [51]. Collectively, these two functions allow TRPA1 to act as an oxygen sensor under
both hypoxic and hyperoxic conditions.
Side effects of the anti-cancer agent oxaliplatin include induction of various dysesthesias,
including peripheral nerve disorder and cold hyperalgesia. These dysesthesias are associated with
enhanced TRPA1 expression in DRG and PHD-induced modification of TRPA1 [52–54]. Moreover,
the oxaliplatin degradation product, oxalate, inhibits PHD and subsequently TRPA1 dehydroxylation,
and also promotes cold hypersensitivity upon activation of TRPA1 in response to ROS production
by mitochondria [37,55]. Mechanical allodynia associated with oxaliplatin treatment can be inhibited
by the TRPA1 antagonist, ADM_09 [56]. Together, these results clearly indicate the importance of the
relationship between TRPA1 and the PHD cascade, and also that TRPA1 could be targeted as part
of treatment for dysesthesia induced by ischemia and hypoxia, as well as drug-induced cold and
mechanical hyperalgesia.
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2.1.4. pH Sensing by TRPA1
The relationship between oxygen and pH is physiologically important because hypoxic conditions
caused by ischemia induce intracellular acidification. Neuronal death may occur upon low levels of
oxygen and glucose, as well as excessive release of glutamic acid from astrocytes, which induces a fatal
calcium influx in neurons. Intracellular pH of astrocytes is drastically reduced by lactic acid production
due to anaerobic respiration in response to hypoxia. Subsequent acidification induces glutamic acid
exocytosis led to brain damage [57]. Importantly, TRPA1 expressed in astrocytes may be activated
by acidification [58–60]. In addition, activation of TRPA1 expressed in oligodendrocytes can damage
myelin [61]. In contrast, intracellular alkalization also affects TRPA1 activity [26]. TRPA1 is activated
at approximately pH 8.0, and the alkalization-induced pain-related behavior is significantly reduced in
TRPA1 deficient mice. Consequently, the pH dependency of TRPA1 may be beneficial target for the
treatment of central nervous system diseases, not only pain.
2.1.5. Neural Networks Involving TRPA1-Mediated Pain Sensation
A-fiber and C-fiber primary sensory nerves govern fast and slow responses to pain, respectively.
Aδ-fibers (mid-sized DRG neurons) innervate lamina I and V, whereas C-fibers (small-sized DRG
neurons) innervate lamina I and II of the dorsal horn of the spinal cord [1]. C-fibers also contain
peptidergic and nonpeptidergic neurons. Peptidergic neurons contain substance P and CGRP, with
both peptides released upon neural excitation. TRPA1-positive neurons are immunoreactive for CGRP
in DRG neurons [15]. In healthy mice, these CGRP-positive neurons enhance heat sensation and
suppress cold sensation [62]. These findings suggest that TRPA1 in CGRP-positive DRG neurons
contributes less significantly to noxious cold sensation.
Neural transmission in the spinal cord can modify pain perception. Substantia gelatinosa (SG)
neurons in lamina II are important targets for investigation of how pain sensations are transmitted from
the periphery to the central nervous system. Initial understanding on in vivo SG neuronal responses
to peripheral stimulation is that SG neuronal activity mediated through non-N-methyl-D-aspartate
(non-NMDA) receptors is enhanced by mechanical stimuli, such as pinch and air flow, but not thermal
changes [63]. However, excitatory postsynaptic currents enhanced by capsaicin treatment are detected
in approximately 80% of SG neurons in slice patch-clamp recordings [64]. Interestingly, there is no
neuronal response to AITC alone (Figure 1).
Since AITC responses depend on both NMDA and non-NMDA receptors [65], TRPA1-mediated
pain signals are likely integrated with TRPV1-mediated pain signals in lamina II of the spinal cord.
Importantly, there are three types of DRG neurons: those that express both TRPA1 and TRPV1,
TRPA1 alone, or TRPV1 alone. Meanwhile, one study demonstrated that spinal TRPA1 activation by
intrathecal administration of the acetaminophen metabolite, N-acetyl-p-benzoquinone imine, enhanced
anti-nociception in the spinal cord of mice [66]. Therefore, components of TRPA1-mediated neural
systems may participate in pain reduction, while nociception by TRPA1 activation can function in
central termini of DRG neurons. For instance, TRPA1 activation by hepoxilin causes mechanical
allodynia in rats, whereas pinch-evoked SG neuronal excitation is reduced by increases in inhibitory
postsynaptic currents mediated by TRPA1 activation in vivo [67,68]. Thus, consideration of TRPA1
activation in the central nervous system may also be important for investigating pain mechanisms.
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Figure 1. Nociceptor populations in substantia gelatinosa (SG) neurons of lamina II, which
receive nociceptive inputs from dorsal root ganglion (DRG) neurons, no neurons respond only
to TRPA1-associated stimuli. Approximately 30% of SG neurons are double-positive to capsaicin (CAP)
and cinnamaldehyde (CA), 45% of SG neurons response to only CAP, and 25% of neurons show no effect
to either CAP or CA. There are calcitonin gene-related peptide (CGRP)-positive and -negative neurons
in peripheral sensory nerves. Most TRPV1–TMEM100–TRPA1 complexes and TRPV1–TRPA1–TRPM3
trios are expressed in CGRP-positive neurons. Anoctamin 1 (ANO1) is also expressed in CGRP-positive
neurons, however approximately 70% of ANO1-expressing neurons are CGRP-negative.
2.1.6. TRPA1 Activation by microRNA in the Central Nervous System
Although TRPA1 is expressed in both brain and spinal cord cells, whether it is activated via direct
or indirect pathways is unclear. In the central nervous system, only one obvious possibility exists
for direct activation of TRPA1 by an endogenous ligand, namely microRNA (miRNA). Among the
miRNAs present in cerebrospinal fluid, increased levels of let-7b are particularly associated with the
incidence of Alzheimer’s disease. Meanwhile, astrocytes can exacerbate symptoms associated with
amyloid-induced TRPA1 activation [69,70]. Let-7b activates TLR7, which is followed by cytotoxicity
and direct activation of TRPA1 [71]. Importantly, let-7b release is enhanced by formalin application
to DRG, while let-7b injection induces both nociceptive behavior and mechanical allodynia, which
are reduced in TRPA1- and TLR7-deficient mice. These results demonstrate a relationship between
let-7b and TRPA1 as a possible molecular mechanism of inflammatory symptoms in central nervous
system diseases.
2.2. TRPV1
Among TRP channels expressed in primary sensory neurons, TRPV1 is well-known for its
role in pain [3]. TRPV1 is mainly expressed in small DRG and TG neurons and is activated by
capsaicin, capsiate, camphor, allicin, 2-aminoethoxydiphenyl borate, anandamide, N-arachidonoyl
dopamine, resiniferatoxin, nitrogen oxide, low pH, noxious heat, hypertonicity, and the double-knot
toxin in tarantula venom [14,72–81]. Expression levels of TRPV1 are enhanced by NGF receptor
activation in DRG neurons, while TRPV1 is transported to peripheral termini [82]. TRPV1 activation
is enhanced upon phosphorylation by PKA and PKC via A-kinase anchor protein in DRG neurons
activated by GPCRs [83–86]. Due to the lowered thermal threshold of phosphorylated TRPV1
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at body temperature, allodynia can be caused by inflammatory pathways depending on GqPCR
activation. Many inflammatory factors, including prostaglandin E2, adenosine, ATP, bradykinin,
protease, and NGF, are released following tissue injury, with protein kinases activated downstream of
each GPCR [1]. In addition, the ionotropic ATP receptor, P2X, may also be involved in modulating
activity of protein kinases that target TRP channels, as evidenced by activation of cytosolic PLA2 by
P2X3 and P2X2/3 receptors during neuropathic pain [39]. Activated PLA2 can in turn activate PKC
to promote phosphorylation of TRP [40]. Taken together, these findings suggest that TRP channel
phosphorylation may be caused by both P2X and metabotropic P2Y receptor activation in primary
sensory neurons.
2.3. Anoctamin 1
ANO1 is a calcium-activated chloride channel [5–7]. Although the ANO family includes ten
subtypes, only ANO1 and ANO2 exhibit marked activity as calcium-activated chloride channels, and
conductance of ANO1 is larger than ANO2. The crystal structure of fungal ANO has recently been
determined at high resolution [87]. Furthermore, the dimer structure of mouse ANO1 (which contains
ten TM regions in one subunit) has been clarified by cryo-electron microscopy [88,89]. Accordingly,
the calcium binding site was shown to be encompassed by TM6 to TM8. Interestingly, each ANO1
subunit has one pore region surrounded by TM3 to TM8. Structural analysis showed that the dynamic
movement of TM6 may be critical for calcium-mediated channel opening.
Although ANO1 can be activated by global increases in intracellular calcium via activation of
voltage-gated calcium channels, ANO1 activation through GqPCR is also likely to be important due to
direct interactions between ANO1 and IP3R in endoplasmic reticulum calcium stores [10,90]. Therefore,
ANO1 is possibly involved in nociception induced by inflammatory factors such as bradykinin [91].
ANO1 is also activated by noxious heat in DRG neurons and induces a burning pain sensation [8]. These
characteristics may explain why chloride channel activity evokes neural excitation in primary sensory
neurons, in that higher intracellular chloride concentrations can be maintained as the equilibrium
potential in these cells is more positive than the resting potential in DRG neurons [11].
3. Collaboration of Ion Channels
Although each ion channel, including TRP channels, independently work as detectors of nociceptive
stimuli, some ion channels make physical or functional complexes that are critically involved in pain
sensation. In this part, we summarize ion channel interactions and nociceptor populations according
to recent reports (Figure 1).
3.1. TRPV1–TMEM100–TRPA1 Interaction
TRPV1 is co-expressed with TRPA1 in DRG neurons. Since TRPA1 activity is enhanced by
intracellular calcium, it had been thought that calcium influx through TRPV1 activation could affect
TRPA1 function. However, the TRPV1 entity reduces the probability of TRPA1 ion channel opening
accelerated by mustard oil [92]. It appears that TRPA1-associated pain is normally reduced by TRPV1
expression, which may be prevented by TMEM100 [92]. TMEM100 is a small membrane protein, and
its expression pattern highly overlaps with CGRP. Interestingly, TRPA1 almost co-localizes with TRPV1,
TMEM100, and CGRP in DRG neurons (Figure 1). Together, TRPV1, TRPA1, and TMEM100 form a
complex, and the interaction between TRPV1 and TRPA1 is suppressed by interposition of TMEM100.
Furthermore, a mutant peptide of TMEM100 (T100-Mut) can permeate the plasma membrane and
disturb correct binding of TMEM100, thereby inhibiting TRPA1-associated pain-related behavior.
This may provide a novel strategy for reducing pain sensation.
3.2. TRPV1–ANO1 Interaction
Approximately 80% of TRPV1-positive DRG neurons also express ANO1 by immunostaining [8,93].
To examine the function of this co-expression, we investigated whether these ion channels interact in
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a setting of acute pain induced by capsaicin. We found that capsaicin-induced currents in isolated
DRG neurons were suppressed by the ANO1 inhibitor, T16Ainh-A01 [94]. Although capsaicin-induced
action potentials were also inhibited by T16Ainh-A01, inhibition was observed in response to second
application of capsaicin (10 min after first capsaicin application). Some DRG neurons may not have
exhibited second action potentials, yet there were DRG neurons that did show action potentials in the
second application [93]. Another study showed that TRPV1 is desensitized by calmodulin binding.
Moreover, TRPV1 function spontaneously and fully recovered after one hour, while desensitization
was inhibited by TRPV1 phosphorylation [85]. Accordingly, the second response in some neurons
is thought to depend on random phosphorylation levels in each neuron. Nonetheless, T16Ainh-A01
almost completely inhibits these second action potentials. These results suggest that chloride efflux
elicited by ANO1 activation may accelerate depolarization to induce secondary action potentials,
and that ANO1 inhibition may be effective at reducing pain sensation. In fact, capsaicin-induced
pain-related behavior in mice is inhibited by T16Ainh-A01 [93]. Taken together, these findings indicate
that the TRPV1–ANO1 interaction is critical for sensation of noxious stimuli.
ANO1 is also co-expressed with TRPV1 in TG neurons and is functionally involved in heat
sensation [95,96]. In addition, TRPV1 and ANO1 expression levels are enhanced by estrogen in
female rats [97]. Based on these observations, the TRPV1–ANO1 interaction may be a crucial
target for pain therapies. According to a previous report, approximately 70% of ANO1-positive
neurons do not colocalize with CGRP [8]. Although contribution of the TRPV1–ANO1 interaction in
CGRP release is unknown, the TRPV1–ANO1 interaction may encompass the alternative side of the
TRPV1–TMEM100–TRPA1 interaction system (Figure 1).
3.3. Triple Conjugation of TRPV1, TRPA1, and TRPM3
TRPM3 is a heat sensitive TRP channel that functionally couples with TRPV1 and TRPA1 [98].
Although TRPM3-deficient mice show a delayed tail flick at 57 ◦C, the effect of TRPM3 alone on heat
sensation is unclear because tail flick behavior induced at 57 ◦C in TRPM3/TRPA1 double-deficient
mice is no different to wild-type mice [4]. However, triple conjugation of TRPV1, TRPA1, and TRPM3
is important for detecting the noxious heat environment [4]. Withdrawal latency of TRPM3-deficient
mice in the hot-plate test (50 ◦C) is the same as in wild-type mice [98]. Interestingly, this behavior
disappears in TRPV1/TRPA1/TRPM3 triple-deficient mice, while the other responses to nociceptive
stimuli are normal. Furthermore, wild-type and triple-deficient mice show a similar distribution on a
gradient temperature plate (from 5 to 50 ◦C). In addition, CGRP-expressing DRG neurons are involved
in heat sensation [62], and CGRP release from skin preparations is enhanced by the TRPM3 agonist,
CIM0216, which is the same as for capsaicin treatment [99]. These findings indicate that the likely
multiple function of TRPV1, TRPA1, and TRPM3 in peptidergic DRG neurons is to escape from a
noxious heat environment.
4. Headache and Migraine
Primary headaches (i.e., those that are not associated with another disorder) are one of the most
common causes of disability worldwide. The various types of headache include migraine, tension, and
trigeminal autonomic cephalalgia [100]. Migraine is a multifactorial and incapacitating neurovascular
disorder characterized by recurrent attacks of severe, unilateral, and throbbing headache, which can be
aggravated by routine physical activity and can last from several hours to several days [100]. Migraine
attacks often involve not only head pain, but also several premonitory and postdromal symptoms
that occur before the headache initiates and persist after the headache ends, respectively. These
symptoms are diverse and may include hypersensitivity to light, sound, smell, fatigue, neck stiffness,
yawning, mood change, nausea, vomiting, cutaneous allodynia, and transient visual disturbances
termed aura [101–104]. Migraine attacks can be triggered by many internal and external stimuli such
as stress, hormonal fluctuations, sleep disturbances, skipping meals, weather changes, and ingestion of
alcoholic beverage or certain types of food [105,106]. This multifactorial origin, as well as the variety
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of symptoms, have complicated identification of the underlying mechanisms of migraines. Although
the events that trigger migraines remain unknown, the pain phase of migraine headaches is thought
to involve activation and sensitization of primary afferent nociceptors that innervate the dural and
meningeal vasculature. Indeed, the trigeminovascular system (TGVS) is a key component in pain
initiation and transmission in migraine. Specifically, perivascular TG nerve endings are known to
release CGRP, which induces vasodilation of cranial blood vessels and degranulation of meningeal
mast cells, leading to neurogenic inflammation [107,108]. Interestingly, recent evidence indicated
that a variety of ion channels, including TRP channels, make important contributions to migraine
physiopathology (Figure 2 and Table 1). Several recent reviews discussed involvement of TRP channels
in migraine, confirming significant interest in these channels as molecular targets for treatment of
migraine [109–111]. In the following sections, we will discuss recent findings regarding TRP channels
in migraine.
Figure 2. Transient receptor potential (TRP) channels in the trigeminovascular system and migraine
development. Migraine triggering events remain unknown and may be a central or peripheral process.
The precise order of events contributing to migraine pain is also debated. It is generally admitted that
activation and sensitization of primary afferent nociceptors that innervate the dural and meningeal
vasculature trigger both calcitonin gene-related peptide (CGRP)-induced vasodilatation and neurogenic
inflammation. Pain signals pass through the trigeminal nucleus caudalis, which relays signals to higher
order neurons in the thalamus and cortex (green arrows). A trigemino–parasympathetic or trigeminal
autonomic reflex arc passes through the sphenopalatine ganglion and is responsible for migraine pain
by mediating neurogenic inflammation (blue arrow). Central and peripheral sensitization (pink arrows)
may contribute to maintenance of pain signals and predispose to future migraine attacks. Transient
receptor potential (TRP) vanilloid 1 (TRPV1) and anoctamin 1 (ANO1) might be involved in initiation,
nociception, and sensitization processes of migraine. TRP ankyrin 1 (TRPA1) might be more relevant in
the initiation phase. There are few studies available on TRPV4 and TRP melastatin 8 (TRPM8), yet these
receptors might be important in pain signal transmission or neurogenic inflammation.
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Table 1. Roles of transient receptor potential (TRP) channels in migraine and their potential as
therapeutic targets. RNS: reactive nitrogen species, ROS: reactive oxygen species, TRPA1: transient
receptor potential ankyrin 1, TRPM8: transient receptor potential melastatin 8, TRPV1: transient
receptor potential vanilloid 1, TRPV4: transient receptor potential vanilloid 4.
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4.1. TRPV1 as a Crucial Migraine Initiator
The first hint that TRPV1 is involved in migraine was demonstration of its co-expression with
CGRP in rat TG neurons [134,135] and mouse dural afferent neurons [136], suggesting a crucial role
for TRPV1 in migraine. Moreover, in rat dura mater, application of capsaicin is accompanied by
vasodilatation mediated by CGRP release from sensory afferent nerves [112]. Another substantial link
between migraine and TRPV1 was the demonstration that a frequent migraine trigger, ethanol, induced
neurogenic vasodilation via TRPV1 activation and subsequent CGRP release in the TGVS of guinea
pigs [118]. Although the triggering event that actually initiates a migraine attack remains elusive,
Meents et al., proposed that the premonitory aura exhibited by some migraineurs promotes endogenous
activation of TRPV1 [137]. Aura arises from a phenomenon called cortical spreading depression (CSD),
a short-lasting depolarization of cortical neurons that is known to increase extracellular concentrations
of H+, which can ultimately activate TRPV1 and induce CGRP release [119]. However, not all
migraineurs experience aura, indicating that other endogenous mechanisms likely contribute to TRPV1
activation within the dura. Hence, although TRPV1 is currently recognized as a key player in migraine
initiation, it is also likely involved in other phases and characteristics of migraine.
Sensitization of peripheral and central trigeminovascular neurons is usually observed following
migraine attack onset. Peripheral sensitization mediates the throbbing perception of a headache,
whereas sensitization of second-order neurons from the spinal trigeminal nucleus mediates cephalic
allodynia and muscle tenderness [138]. Sensitization of TG neurons may contribute to direct
sensitization of TRPV1, either by its increased activity or translocation to the cell membrane, or by
increased protein production. Interestingly, the cerebrospinal fluid of chronic migraineurs (i.e., patients
who have more than 15 migraine attacks per month) exhibit elevated levels of inflammatory mediators,
including NGF [139]. Bradykinin and prostaglandin E2 are inflammatory mediators also released
during neurogenic inflammation, and are commonly used in an animal model of headache to induce
a chronic state of trigeminal hypersensitivity [113–115]. As already noted, NGF can trigger TRPV1
translocation to the plasma membrane, while bradykinin and prostaglandin E2 can orchestrate TRPV1
phosphorylation, which lowers its activation threshold. Moreover, TRPV1 expression is up-regulated in
nerve fibers that innervate arteries in the scalp of chronic migraine patients [116]. Therefore, neurogenic
inflammation that occurs during migraine attacks likely contributes to sensitization by modulating
TRPV1 channel activity and expression.
Schwedt and colleagues proposed an interesting idea, namely that a state of persistent sensitization
is maintained in migraineurs that enable more ready firing of TGVS [117]. They hypothesized that a
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cyclical process of migraine headaches causes interictal sensitization that contributes to predisposition
to future migraine attacks. In their study, episodic and chronic migraineurs displayed enhanced
sensitivity to thermal stimulation (decreased heat and cold pain threshold and tolerance) during the
interictal period, compared with non-migraine controls. Such sensitization can partly be attributed to
TRPV1 and may also explain why migraine patients do not tolerate ambient temperature changes [140].
In the same manner, a recent study showed that migraine patients exhibit enhanced extracephalic
capsaicin-induced pain sensation during interictal periods, supporting the contribution of TRPV1 to
interictal sensitization [141].
Another characteristic of migraines is their difference in prevalence and perception between
men and women. Women are three-times more likely to suffer from migraine than men, and women
experience more frequent, longer-lasting, and more intense migraine attacks than men [142]. Higher
estrogen levels may in part be responsible for these differences. Interestingly, estrogen was recently
shown to increase pain sensation by up-regulating expression of TRPV1 and ANO1 in TG neurons
from female rats [97]. This could explain why women exhibit a higher susceptibility to migraine,
and suggests that potential interaction of TRPV1 and ANO1 in TG neurons may be involved in
migraine initiation.
Obesity has also been linked to migraine prevalence since it increases the risk of developing a
migraine. Further persons with obesity suffer from more frequent and severe headache attacks [143].
A study involving mice fed a high-fat diet showed that facial intradermal injection of lower capsaicin
doses are needed to induce photophobic behavior in obese mice compared to non-obese control
mice [120]. Also, cell size distribution among TRPV1-positive cultured TG neurons from obese mice
shifted towards larger cell diameters compared with control mice, and a higher capsaicin-induced
calcium influx was observed in these neurons. In another mouse model that induced obesity through
feeding of a high-fat and high-sucrose diet, dural application of capsaicin induced enhanced vasodilatory
and vasoconstrictor responses compared with control animals. Basal and capsaicin-induced CGRP
release from meningeal afferents was also increased [144]. These findings may explain why diet-induced
obesity is associated with TGVS sensitization, which might occur via TRPV1 modulation, although the
precise molecular mechanism is unclear.
4.2. TRPA1 as an Intriguing Migraine Contributor
TRPA1 is also co-expressed in CGRP-positive nociceptors [136,145] and has attracted significant
attention in the context of migraine pathophysiology due to its sensitivity to numerous exogenous and
endogenous compounds. Indeed, environmental irritants such as cigarette smoke or formaldehyde,
as well as ROS and reactive nitrogen species (RNS), can activate TRPA1 (for review see [123]). A link
with migraine can subsequently be readily deduced from the ability of these compounds to generate
headache. Appropriately, TRPA1 activation in trigeminal nerve endings located in the nasal mucosa are
suspected to trigger headache when irritants are inhaled. Indeed, intranasal administration of irritant
compounds in rats can induce CGRP release via TRPA1 activation and increase cerebral blood flow [122].
Similarly, intranasal administration of umbellulone, the volatile active compound from Umbellaria
californica, known as the “headache tree”, evokes TRPA1-mediated and CGRP-dependent neurogenic
meningeal vasodilation in mice [146,147]. In contrast, compounds known for their anti-headache
properties were shown to desensitize TRPA1. For example, stimulation of rat TG neurons with
parthenolide, a compound extracted from the feverfew herb (Tanacetum parthenium L.), which has
been used for centuries to reduce pain, fever, and headaches [148]), induced potent and prolonged
desensitization of TRPA1 channels, which rendered peptidergic neurons unresponsive to any stimulus
and unable to release CGRP [149]. Similar properties were observed for isopetasin, a major constituent
of extracts from butterbur, a plant known to have anti-migraine effects. Isopetasin visibly desensitized
TRPA1 in patch-clamp experiments with rat TG neurons, while it also inhibited nociception and
neurogenic dural vasodilatation mediated by TRPA1 in vivo [150].
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Another important migraine trigger is ROS. Several studies reported increased oxidative stress
in migraine patients both during headache attacks and in the interictal period (the period between
migraine attacks) [151–153]. As already noted, ROS are potent TRPA1 activators, and in a recent
study were shown to mediate the CSD responsible for aura [154]. In that study, exogenous H2O2
activated TRPA1 expressed in cortical neurons in mice brain slices, raising their susceptibility to CSD.
Conversely, endogenous ROS produced upon CSD development [155] activated TRPA1 expression in
TG neurons and mediated CGRP production, leading to a positive feedback loop that regulates cortical
susceptibility to CSD. Based on these findings, it was proposed that reducing ROS production together
with blockade of neuronal TRPA1 could help prevent stress-triggered migraine.
RNS can also act as TRPA1 agonists [79], and have been linked to headaches and migraine
development. Indeed, an increase in endogenous nitric oxide (NO) production is observed during
migraine attacks [156]. Eberhardt and colleagues reported that nitroxyl, generated by a redox reaction
between NO and hydrogen sulfide can trigger TRPA1 activation in the TGVS, leading to CGRP release
in the cranial dura mater of rats [145]. This pathway ultimately resulted in vasodilation and increased
meningeal blood flow, and could also account for the headache phase of a migraine attack. Similarly, the
well-known headache inducer, glyceryl trinitrate, targets TRPA1 in TG neurons to generate periorbital
oxidative stress and mechanical allodynia [157].
4.3. TRPM8 as a Familial Migraine Instigator
TRPM8 is found on both Aδ and C fiber afferents, and is important for the activation of peripheral
sensory neurons by cold temperature. It is activated at non-noxious cold temperatures (< 26 ◦C) and
by compounds that produce a cooling sensation such as menthol or eucalyptol [158,159]. While its role
as a cold sensor has been firmly established, it is not the case regarding its role in pain sensation. It is
still under debate whether TRPM8 reduces or exacerbates pain sensation, and the most recent view
on the matter is that TRPM8-expressing afferent fibers have the ability to both produce and alleviate
pain, and the outcome will be determined by context (see for review [133,160]). As such, TRPM8 has
begun to gather attention in the migraine field. A genetic predisposition to migraine is well-recognized:
migraineurs presenting a hereditary component account for 42% of patients with migraine, as shown in
studies on families and twins [161,162]. Migraine is genetically complex because many genetic variants
with small effects and environmental factors can confer migraine susceptibility [163]. However, several
genome-wide association studies from different cohorts identified single nucleotide polymorphisms
(SNPs) in the gene encoding TRPM8, suggesting an important role for this TRP channel in migraine
pathophysiology [128–132]. Several of these variants are located in regions involved in transcriptional
regulation and may therefore impact upon TRPM8 expression levels. Moreover, in calcium imaging
experiments, some TRPM8 SNP variants heterologously expressed in HEK293 cells showed alterations
of channel functionality [164]. Based on these results, TRPM8 variants identified in migraine patients
likely contribute to migraine pathology. In adult mice, TRPM8 is also expressed in dural trigeminal
nerve endings, albeit rather sparsely [136,165]. Age-dependent decreases in TRPM8 expression in TG
neurons appears to play a role in pathways that are differentially regulated with age, in that both the
density and number of branches of TRPM8-expressing fibers are comparable to CGRP-expressing fibers
in postnatal mouse dura. Specifically, both are reduced by half in adult mouse dura [165]. However,
the functional consequence of this reduction remains unclear.
Although TRPM8 is a well-established cold transducer, limited temperature fluctuations in the
skull suggest that this activity is less important in dural tissue. Thus, endogenous TRPM8 activators
within the dura are unknown. Similarly, whether TRPM8 activation within the dura has a pro-
or anti-nociception effect is unclear. The most recent studies yielded opposite results. Ren and
colleagues observed that dural application of menthol resulted in inhibition of nocifensive behavior in
a mouse migraine model induced by inflammatory mediators, suggesting an anti-nociceptive effect
of TRPM8 [165]. In contrast, dural application of icilin produced migraine-like behavior in mice,
such as cutaneous facial and hind paw allodynia. Pretreatment with the TRPM8 antagonist, AMG1161,
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attenuated these behaviors [133]. The contrary results obtained in these two studies may be due to the
model used: when activated alone, dural TRPM8 appears to have a pro-nociceptive effect, but when
activated together with inflammatory mediators, TRPM8 has an anti-nociceptive effect. Ultimately,
TRPM8 activation may act as a migraine initiator in the first instance, but have another role during
the neurogenic inflammation phase. Moreover, as suggested by Dussor and Cao, these different
outcomes might also reflect how TRPM8-expressing fibers project to central neurons as well as the
context dependence of TRPM8 activation [166]. More studies are needed to fully understand the role
of TRPM8 in dural afferents and migraine pathophysiology.
4.4. TRPV4 as an Indirect Migraine Modulator
TRP Vanilloid 4 (TRPV4) is a widely distributed cationic channel that participates in the
transduction of both physical (osmotic, mechanical, and heat) and chemical (endogenous, plant-derived,
and synthetic ligands) stimuli (see for review [126]). As a mechanosensitive channel, TRPV4 has
attracted increasing interest in the context of migraine. Indeed, headaches can be influenced by
changes in intracranial pressure. Recently, TRPV4 was shown to be expressed in dural afferents,
and its activation in the dura of freely-moving rats could produce migraine-like behavior such as
cutaneous allodynia [125]. Although dural afferents are known to be mechanically sensitive, whether
TRPV4 activation that contributes to migraine is due to mechanical stimulation or another endogenous
mechanism remains to be elucidated. Another study showed that both TRPV4 and TRPA1 can be
activated by the irritant formalin in the TGVS, and result in downstream MEK–ERK pathway activation
and pain behavior in mice [127]. However, whether formalin directly or indirectly activates TRPV4 is
unknown. Nevertheless, taken together, these findings suggest that TRPV4 could also be a promising
target for agents that provide relief from pain that originates in the trigeminal system.
4.5. TRP Channel Modulators for Acute Treatment of Migraine Attacks
As an initial line of investigation, TRPV1 agonists were considered as potential analgesics to treat
headaches. Intranasal applications of civamide and capsaicin were reported to alleviate headache pain
during migraine attack [167,168]. However, in most patients these agents caused severe side effects,
such as nasal burning and lacrimation, and thus impeded their clinical use for the treatment of acute
migraine. Instead, TRP channels antagonists show more promise as a novel approach to prevent or
treat acute migraine attacks. However, an initial clinical randomized trial conducted in 2009 showed
that TRPV1 channel blockers failed to treat migraine attacks. In this study, the compound SB-705498
did not relieve headache pain for up to 24 h post-dose [169]. Although this outcome does not exclude a
contribution of TRPV1 to migraine pathology, it indicates that selectively targeting TRPV1 alone is not
sufficient for acute treatment of migraine attacks. Another explanation for the lack of success with
TRPV1 channel blockers is that SB-705498 is largely ineffective in humans. Several other clinical trials
using this compound showed no or poor efficacy for treating different conditions. Notably, SB-705498
did not relieve itching arising from histamine-induced pruritus, prevent coughing in refractory chronic
cough, or alleviate symptoms elicited by cold, dry air in non-allergic rhinitis [170–172], despite
documented involvement of TRPV1 in these disorders. To date, no other clinical trials using TRP
channel antagonists have been performed for migraine, but numerous in vivo studies show their
potential for the development of new therapeutic strategies. Indeed, in a recent study, two TRPV1
antagonists, JNJ-38893777 and JNJ-17203212, reduced or even completely abolished capsaicin-induced
CGRP release from TG neurons in two different animal models of migraine [121]. These compounds,
used alone or together with other blockers of important molecular players, could be promising pain
relief medicines.
Interestingly, a new molecule, Compound 16-8, which specifically co-targets TRPV4 and TRPA1,
was developed based on the TRPV4 antagonist, GSK205 [124]. Compound 16-8 was reported to inhibit
both channels at sub-micromolar potency and also abolish formalin-induced trigeminal pain in an
in vivo model. This suggests that dual inhibitors may be more effective in treating pain elicited by
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several molecular players, such as pain that occurs in headaches and migraine induced by irritant
compounds. To date, no clinical study has focused on TRPV4. This may be due to limited research
concerning TRPV4, and the fact that dual inhibition strategies have not yet been considered for
the treatment of migraine. Moreover, although the contribution of ANO1 to pain mechanisms in
TG neurons is not fully elucidated [96] and interactions between TRP channels and ANO1 await
investigation in the TGVS, we contend that ANO1 in TG neurons likely behaves similarly to that seen
in DRG neurons. Thus, simultaneous blockage of TRP and ANO1 channels has potential to provide
strong pain relief from headache.
Although TRPM8 variants are associated with migraine susceptibility, whether therapeutic
strategies that target this channel should be agonists or antagonists, is unclear. As such, additional
information about the role of TRPM8 in migraine development is needed before new therapeutics that
focus on this channel can be pursued.
5. Infection and Immunity
Pain sensation is a negative stress for animals, and CGRP release from nociceptors exacerbates
symptoms. Conversely, we recently clarified that CGRP release dependent on TRPV1 and TRPA1
activity in DRG neurons is involved in bone protection during fungus infection. This phenomenon is
supported by several physiological mechanisms, including ATP release from keratinocytes, neural
excitation of sodium channel 1.8 (Nav1.8)-positive DRG neurons, and CGRP-dependent suppression
of osteoclasts activated via TNF-. Thus, in this part, we comprehensively describe the physiological
and pathological systems involved in cutaneous infection to bone inflammation (Figure 3).
Figure 3. Bone protection system from Candida infection. Bone disruption followed by inflammation is
worsened by overactive osteoclasts. Nociceptors suppress osteoclast development through calcitonin
gene-related peptide (CGRP) release. The process involves: (1) Candida albicans is activated in an
optimal environment (e.g., body temperature); (2) β-glucan released from pseudohyphae bind to
its receptor, dectin-1, on the plasma membrane of keratinocytes; (3) ATP release from keratinocytes
is enhanced through the phospholipase C (PLC) pathway; (4) neuronal excitation in voltage-gated
sodium channel 1.8 (Nav1.8)-positive dorsal root ganglion (DRG) neurons; and (5) CGRP release
from DRG neurons. Jun dimerization protein 2 (Jdp2) is activated by CGRP through a cAMP cascade
in myeloid cells. In turn, tumor necrosis factor-alpha (TNF-α release (which accelerates osteoclast
development) is suppressed. TNF-α-dependent inflammation is induced by the direct effect of β-glucan
on myeloid cells. Furthermore, the CGRP–cAMP axis in osteoclasts also inhibits over-development.
Thus, these pathways from skin to bone induce bone protection and inhibit bone inflammation during
fungus infection.
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5.1. Nociception by C. albicans
Candida albicans infections can cause skin or vulvar pain. Breast candidiasis is characterized
by severe pain around the nipple [173]. C. albicans in the vagina causes itching and mechanical
allodynia [174]. C. albicans can also enter skeletal tissue and induce painful bone infection [175].
Although C. albicans has algesic activity, the mechanisms by which this fungus triggers pain remains
completely unknown.
TLR4 expressed on myeloid cells are involved in recognition of fungal mannan and cytokine
production upon MyD88 and TIR-domain-containing adapter-inducing interferon-beta (TRIF)
activation. The fungal cell wall contains β-glucan and mannan on the intracellular and extracellular
face, respectively [176]. Surface exposure of β-glucan is sensed by dectin-1 [177]. Activated dectin-1
assembles as a multimeric complex and induces signaling via an ITAM-like motif, promoting formation
of CARD-9–Bcl-10–Malt-1 trimers (CBM trimer) and activation of the NLRP3–ASC–ICE complex
(NLRP3 inflammasome). CBM trimers and NLRP3 inflammasome activation are both required to
induce cytokine production [178].
Candidalysin was recently discovered and is the first fungal cytolytic peptide [179]. This peptide
may also contribute to the pathogenesis of fungal invasion. Pain induced by fungal infections is thought
to be caused by inflammation, but a recent study suggested that both Staphylococcus aureus-derived
N-formulated peptides andα-hemolysin can directly stimulate nociceptors [180]. Therefore, nociceptors
may be able to sense pathogens, but the underlying molecular mechanisms behind fungal nociception
remain unclear.
In the colonization phase, C. albicans forms yeast-like structures that are harmless because colony
growth is suppressed by host immunity and the natural antagonistic effects of microbial flora. When
the yeast form of C. albicans attaches to the skin of an immunocompromised host, budding growth is
immediately induced and the soluble β-glucan form is secreted. Notably, β-glucan-induced allodynia
is relatively severe compared with that induced by mannan and other pathological components
such as Candidalysin. Furthermore, dectin-1-deficient mice are completely unresponsive to C.
albicans or β-glucan-induced pain in a MyD88/TRIF/inflammasome-independent manner. Moreover,
we discovered that C. albicans induces acute pain by stimulating Nav1.8-positive nociceptors in
primary sensory neurons via the dectin-1-mediated PLCγ2–TRPV1/TRPA1 axis. β-Glucan also induces
allodynia, which is dependent on dectin-1-mediated ATP secretion from keratinocytes. Notably,
keratinocyte-derived extracellular ATP stimulates sensory neurons via P2X receptors. We also found
that mice deficient in the ATP transporter, vesicular nucleotide transporter (VNUT), are unresponsive
to β-glucan-induced allodynia, while the VNUT inhibitor clodronate has potent prophylactic potential
to target fungal nociceptive symptoms. Together, these findings suggest that ATP- or VNUT-targeted
therapies such as clodronate treatment may be a promising therapeutic option for treating pain or
allodynia associated with fungal infections [181].
5.2. Secondary Symptoms Following Nociception
Nociceptor innervation is seen in skin and bone. Although the function of nociceptors in the
osteo–immune system is unclear, ion channels in the DRG may be responsible for sensing noxious
stimuli [182]. During inflammation, pro-algesic cytokines derived from immune cells gradually
evoke allodynia, leading to production of neuropeptides such as CGRP [183], which in turn causes
vasodilatation, impaired insulin release, and enhanced Th17 cell function [184–186]. Meanwhile,
depletion of TRPV1-positive neurons or CGRP deficiency can lead to osteoporosis [187,188]. Thus,
nociceptors may modulate osteo–immune system activity, but how they influence pathogen-induced
inflammation and bone destruction in a physiological context remains unknown.
To investigate these questions, we injected LPS or β-glucan into the hind paw of
Nav1.8CreRosa26DTA mice, a nociceptor-deficient line. Notably, LPS-induced osteo-inflammation was
unaffected, suggesting that nociceptors do not affect TLR-induced osteo-inflammation. In contrast,
Nav1.8CreRosa26DTA mice injected with β-glucan exhibit severe skin inflammation and bone
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destruction, indicating that nociceptors are negative regulators of fungal osteo-inflammation. Similar
to Nav1.8CreRosa26DTA mice, TRPV1/TRPA1 double-deficient mice exhibit severe osteo-inflammation
in response to β-glucan, and this phenotype was rescued by CGRP administration. Notably, β-glucan
injection into the hind paws of both Nav1.8CreRosa26DTA and TRPV1/TRPA1 double-deficient mice
abolished serum CGRP, indicating that TRP channels acting as nociceptors are required for CGRP
induction. To address how CGRP inhibits osteo-inflammation, we assessed the effects of CGRP
on osteoclast formation and cytokine production. Intriguingly, we discovered that nerve-derived
CGRP inhibits osteoclast actin polymerization via cAMP induction, leading to impaired osteoclast
multinucleation. We also found that the CGRP-induced transcriptional repressor, Jun dimerization
protein 2, selectively blocks dectin-1-mediated pro-inflammatory cytokine production in myeloid cells
via direct inhibition of p65. These unexpected roles for β-glucan-stimulated nociceptors suggests the
existence of novel sensocrine pathways that may play a role in fungal osteo-inflammation [181].
6. Conclusions
Studies from the last two decades show the importance of TRP channels in pain sensations
caused by noxious temperatures and many chemicals. In particular, TRPA1 is activated in many
conditions and its activity evokes an extremely uncomfortable sensation. Therefore, TRPA1 may be a
crucial target for pain treatment, although TRPV1 contribution to more specific nociception cannot
be disregarded. While some pharmaceutical companies are already focused on the development of
TRPA1 and TRPV1 antagonists [189], ANO1 inhibition may also be effective in treating pain because
the role of ANO1 is akin to an amplifier, and its suppression does not generate a painless condition.
Namely, a level of nociception that is sufficient enough to sense damage for survival can be maintained
in an ANO1-blocked state, but not with shutdown of the detectors, i.e., TRP channels.
Sensory systems do not only detect noxious stimuli but also participate in the establishment
of inflammation or chronic pain. Neural excitation induces CGRP release from nociceptor termini,
inducing inflammation that can ultimately lead to sensitization of nociceptors. Therefore, inhibition of
CGRP release by suppression of TRP channel activity is expected to provide relief for intractable pain,
headache, and migraine. However, this strategy may result in dangerous secondary effects in some
diseases, including fungus infection. Bone is often disrupted in Candida infection, a situation induced
by osteoclast activity. It remains unclear why osteoclast activity is up-regulated during infection, but in
this case, CGRP release from nociceptors becomes beneficial by suppressing two pathways: TNF-α
release from myeloid cells and overactivation of osteoclasts. Thus, inflammation induced by CGRP is
not detrimental in some pathological conditions, yet targeting it for pain relief might not always be the
best strategy.
In fact, pain sensation negatively controls our physiological conditions, including our emotions.
Recent reports indicate that complete abolishment of pain induces a severe pathological condition to
our body. Therefore, we believe that the important point of pain management is to decrease pain to a
tolerable level, but one that is sufficient enough to maintain natural protection against tissue damage.
To develop this strategy, there is a need for the discovery of new TRP channels and ANO1 inhibitors
that could be used concomitantly and adjusted depending on each patient’s condition.
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Abstract: The nucleus of the solitary tract (NTS) receives visceral information via the solitary tract (ST)
that comprises the sensory components of the cranial nerves VII, IX and X. The Transient Receptor
Potential Ankyrin 1 (TRPA1) ion channels are non-selective cation channels that are expressed
primarily in pain-related sensory neurons and nerve fibers. Thus, TRPA1 expressed in the primary
sensory afferents may modulate the function of second order NTS neurons. This hypothesis was
tested and confirmed in the present study using acute brainstem slices and caudal NTS neurons by
RT-PCR, immunostaining and patch-clamp electrophysiology. The expression of TRPA1 was detected
in presynaptic locations, but not the somata of caudal NTS neurons that did not express TRPA1 mRNA
or proteins. Moreover, caudal NTS neurons did not show somatodendritic responsiveness to TRPA1
agonists, while TRPA1 immunostaining was detected only in the afferent fibers. Electrophysiological
recordings detected activation of presynaptic TRPA1 in glutamatergic terminals synapsing on caudal
NTS neurons evidenced by the enhanced glutamatergic synaptic neurotransmission in the presence
of TRPA1 agonists. The requirement of TRPA1 for modulation of spontaneous synaptic activity
was confirmed using TRPA1 knockout mice where TRPA1 agonists failed to alter synaptic efficacy.
Thus, this study provides the first evidence of the TRPA1-dependent modulation of the primary
afferent inputs to the caudal NTS. These results suggest that the second order caudal NTS neurons
act as a TRPA1-dependent interface for visceral noxious-innocuous integration at the level of the
caudal brainstem.
Keywords: ion channel; transient receptor potential ankyrin 1 (TRPA1); synaptic transmission;
nucleus tractus solitarius (NTS)
1. Introduction
The brainstem nucleus of the solitary tract (NTS) is the key integrating relay in the central processing
of sensory information from the thoracic and most subdiaphragmatic viscera [1–3]. The solitary tract
(ST) is a bundle of sensory nerve fibers that extends longitudinally and bilaterally through the
brainstem medulla. It comprises the sensory components of the cranial nerves VII, IX and X and
relays information from both nociceptors and innocuous sensory receptors of the visceral organs and
other tissues to the NTS. The ST relays information to the NTS from sensory receptors of the visceral
organs and other tissues [4–9]. The NTS is a highly heterogeneous population of neurons, where
seemingly indistinguishable neighboring neurons could participate in very different autonomic (e.g.,
gastrointestinal and cardiorespiratory reflexes) and nociceptive functions [8,10–14].
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While glutamate is the major excitatory neurotransmitter in the brainstem, synaptic transmission
at the level of the NTS can be modulated via the activation of multiple types of presynaptic ligand-gated
ion channels such as transient receptor potential (TRP) channels [15–20]. The TRP ankyrin 1 (TRPA1)
ion channels are nonselective cation channels highly permeable to Ca2+ ions. Results from animal
models of visceral pain suggest that activation of TRPA1 is critical for transmission of visceral pain and
may be implicated in visceral pain sensation in patients with colitis, gastric distention and inflammatory
bowel disease [21–27].
TRPA1 may modulate neuronal and synaptic activity via diverse pathways because thermal,
chemical and mechanical stimuli have been shown to activate TRPA1 in various animal models [28–34].
However, while TRPA1 are expressed predominantly in sensory neurons (trigeminal, superior cervical,
nodose and dorsal root ganglia neurons), but not in second order neurons [30,35–37] and thus, not
expected to be expressed in the NTS. Activation of TRPA1 in nerve terminals that synapse onto NTS
neurons may have prominent effects on neuronal function and synaptic transmission within the NTS.
This hypothesis is tested in the present study using acute brainstem slices of caudal NTS neurons.
Our findings suggest that the second order caudal NTS neurons act as a TRPA1-dependent interface
for visceral noxious-innocuous integration at the level of the caudal brainstem.
2. Results
2.1. Presynaptic Expression of TRPA1 in the Caudal NTS
The existing literature indicates that sensory TRP channels are predominantly expressed in
peripheral neurons and their expression in central neurons is limited [38,39]. To determine whether this
rule applies to TRPA1 in the NTS, we used RT-PCR and immunohistochemistry. The TRPA1 mRNA
was not detected in caudal NTS neurons while its presence was clearly detected in DRG neurons
that served as a positive control (Figure 1A). Immunofluorescent staining then revealed that TRPA1
in the caudal NTS are selectively expressed only in nerve fibers i.e., pre-synaptically (Figure 1B,C),
which is consistent with the expression of TRPA1 in the solitary tract fibers, but not the somatic
expression in the second order caudal NTS neurons. However, these results alone do not rule out the
expression of TRPA1 in non-solitary tract terminals and will be further confirmed in conjunction with
our electrophysiological data (see Figures 2–4).
Figure 1. The lack of expression of TRPA1 in the nucleus of the solitary tract (NTS). (A) Expression of
TRPA1 mRNA in sensory neurons but not in the NTS. (B,C) Immunostaining of TRPA1 (green), DAPI
(blue) in the NTS. The TRPA1 staining was detected abundantly on the solitary tract, but not within the
NTS. DRG: dorsal root ganglion.
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2.2. Modulation of Synaptic Transmission by AITC in the Caudal NTS
To determine the functional characteristics of TRPA1 expressed in pre-synaptic terminals that
synapse onto caudal NTS neurons, we used acute horizontal brainstem slices and patch-clamp
electrophysiology. In voltage-clamp experiments, visualized caudal NTS neurons were held at −60 mV
and synaptic currents were recorded at various experimental conditions. The expression of functional
TRPA1 was confirmed using TRPA1 agonist, allyl isothiocyanate (i.e., AITC). Focal pressure puffs
of AITC applied to recording caudal NTS neurons robustly increased the frequency of spontaneous
excitatory synaptic currents (sEPSCs) (data not shown). To determine the effects of AITC on miniature
excitatory synaptic activity (mEPSCs), patch-clamp recordings were conducted in the presence of 1 μM
tetrodotoxin (TTX) to inhibit voltage-gated Na+ channels and prevent action potential-dependent
synaptic events. In these experiments, application of AITC (200 μM) significantly increased the
frequency of mEPSCs in a pulse duration-/concentration-dependent manner (Figure 2).
Figure 2. Modulation of synaptic transmission in the NTS by allyl isothiocyanate (AITC). (A) Application
of AITC (200 μM) increases the frequency of miniature excitatory synaptic activity (mEPSCs) in a
reversible manner. The synaptic events are shown in higher time resolution below. (B) Cumulative
probability plot showing decreased inter-event intervals representing increased frequency of mEPSCs
(p < 0.0001, KS test). (C) The increase in frequency is not accompanied by a change in the amplitude.
(D) Summary graph showing AITC-mediated increases in the frequency of mEPSCs in a dose-dependent
manner (* p < 0.05). Furthermore, the increase in AITC -induced synaptic events are blocked by 300 μM
HC030031 (n = 5, * p < 0.05). The asterisk (*) represents p < 0.05 as compared to control.
The increase in mEPSC frequency is expressed as a percentage of control (i.e., no drugs applied):
500 ms, 230.25 ± 20.41% (n = 8, p < 0.05): 2 s, 450.63 ± 22.74% (n = 13, p < 0.05); 30 s, 610.79 ± 30.81%
(n = 9, p < 0.05) (Figure 2A,B,D). The means mEPSC amplitude did not significantly change (control,
19.53 ± 2.53 pA, n = 5; after AITC, 21.2 ± 3.09 pA, n = 12) (Figure 2C). The increase in the mEPSC
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frequency, but not the amplitude suggests that AITC acts only pre-synaptically, which is consistent
with the pre-synaptic expression of TRPA1 (Figure 1). These potentiating effects of AITC were observed
in ~40% (n = 143/358) of tested caudal NTS neurons. These results suggest that only neurons that
received primary sensory afferent input responded by increasing the frequency of mEPSCs following
AITC application.
mEPSCs were completely blocked by 6,7-Dinitroquinoxaline-2,3-dione (i.e., DNQX; 16 μM),
a selective antagonist of AMPA receptors (Figure 2D). The involvement of TRPA1 was confirmed using
HC030031 (i.e., HC), a TRPA1 selective antagonist. HC (300 μM) abolished the effects of AITC on
mEPSC frequency without affecting the background synaptic activity (Figure 2D).
Similar results were obtained in experiments where two other TRPA1 agonists (i.e.,
N-methylmaleimide (i.e., NMM), an oxidizing agent that forms a covalent bond with TRPA1 and
methylglyoxal (i.e., MG), a reactive molecule and an endogenous TRPA1 agonist, produced during
hyperglycemia) were used. Pressure puffs of NMM or MG increased the frequency, but not amplitude
of mEPSCs in caudal NTS neurons (Figures 3 and 4): 100 μM NMM (421.61 ± 24.09%, n = 8, p < 0.05;
Figure 3B,D) and 50 μM MG (334.76 ± 30.62% n = 7, p < 0.05; Figure 4B,D).
By contrast, the somatodendritic responsiveness between NTS neurons to AITC, NMM and MG
has not been detected in this study. Together with the molecular biological results (Figure 1), these data
(Figures 2–4) support a strictly pre-synaptic expression of TRPA1 either in the primary afferent (solitary)
terminals and/or pre-synaptic glutamatergic terminals of second- or higher-order NTS neurons.
Figure 3. Modulation of synaptic transmission in the NTS by N-methylmaleimide (NMM).
(A) Application of NMM (100 μM) increases the frequency of mEPSCs in a reversible manner.
The synaptic events are shown in higher time resolution below. (B) Cumulative probability plot
showing decreased inter-event intervals representing increased frequency of mEPSCs (p < 0.0001,
KS test). (C) The increase in frequency is not accompanied by a change in the amplitude. (D) Summary
graphs showing that the NMM-mediated increase in mEPSCs (n = 8, * p < 0.05). The asterisk (*)
represents p < 0.05 as compared to control.
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Figure 4. Modulation of synaptic transmission in the NTS by methylglyoxal (MG). (A) Application of
MG (50 μM) increases the frequency of mEPSCs in a reversible manner. The synaptic events are shown
in higher time resolution below. (B) Cumulative probability plot showing decreased interevent intervals
representing increased frequency of mEPSCs (p < 0.0001, KS test). (C) The increase in frequency is not
accompanied by a change in the amplitude. (D) Summary graphs showing that MG-mediated increase
in mEPSCs (n = 7, * p < 0.05). The asterisk (*) represents p < 0.05 as compared to control.
2.3. Changes in mEPSCs in Response to Continuous and Repeated Application of AITC
TRPA1 agonists AITC, NMM and MG have been shown to activate the channel by covalent
modification of cysteine and lysine residues [34,40]. Although covalent modification is expected to be
an irreversible process, within the time course of electrophysiological experiments, NMM and AITC
activate TRPA1 in a reversible manner [34,41]. We found that brief (2–10 s) puffs of AITC (200 μM),
NMM (100 μM) or MG (50 μM) induced responses that were readily reversible (Figures 2–4) and a
continuous application of AITC decreased the frequency of mEPSCs over time (Figure 2A).
In a separate experiment, changes in mEPSC frequency were analyzed with continuous application
of AITC (Figure 5A,B). The AITC-mediated facilitation of mEPSCs showed a gradual decrease with
time (Figure 5B). A persistent depolarization of presynaptic terminal and/or Ca2+-dependent decrease
in TRPA1 activity and/or desensitization of TRPA1 may be responsible for the observed run-down of
synaptic activity.
To determine whether AITC causes tachyphylaxis, AITC (2 s duration) was repeatedly applied to
the recorded caudal NTS neurons every 10 s separated by a washout. Successive applications of AITC
(200 μM) gradually decreased the mEPSC frequency (first application, 657.53 ± 135.2%, n = 5; second
application, 487.64± 122.57%, n = 5; third application, 374.85± 73.50% of control, n = 6) (Figure 5A,C,D).
These data support that TRPA1-mediated transmitter release is decreased with repeated application of
AITC. Thus, in all experiments with multiple applications of agonists, at least 3 min of washout was
given after each agonist application to avoid desensitization.
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Figure 5. The tachyphylaxis of TRPA1. (A) AITC (200μM) causes enhancement of mEPSCs progressively
decreases with repeated AITC application. Synaptic currents are shown in a higher time resolution
below. (B) Summary graph representing a progressive decrease in the number of mEPSC events
immediately following AITC application. (C) Cumulative probability plots showing decreased mEPSC
frequency as indicated by a progressive increase in the inter-event intervals with each subsequent
AITC application. (D) Summary graph representing a progressive decline in mEPSC frequency with
repeated AITC application. A significant decrease in frequency is observed only between the first and
third AITC application (first application, n = 5; third application, n = 5, p < 0.05) (first application,
357.53 ± 135.2%, n = 5; second application, 271.64 ± 122.57%, n = 5; third application, 203.85 ± 73.50%
of control, n = 6). The asterisk (*) represents p < 0.05 as compared to control.
2.4. The Lack of Sensitization of Presynaptic TRPA1 by PDBu in the Caudal NTS
Application of phorbol-12,13-dibutyrate (PDBu, 1–5 μM, a PKC activator) alone induced a
dose-dependent increase in the frequency, but not amplitude of mEPSCs in caudal NTS neurons
(Figure 6A,B,D). The effects of PDBu on mEPSC frequency were significant: 1 μM, 117.84 ± 19.66%,
n = 6; 3 μM, 195.76 ± 22.15%, n = 5, p < 0.01; 5 μM, 295.13 ± 28.57%, n = 6, p < 0.01 (Figure 6D), whereas
the mEPSC amplitudes remained unaltered (Figure 6C), supporting a presynaptic mechanism of action
of PDBu [42–45].
Following application of PDBu (3 μM) to the ACSF, AITC increased the mEPSC frequency, but
not amplitude (AITC alone, 298.51 ± 21.86%; AITC + PDBu, 358.69 ± 42.58% (n = 9, p > 0.05))
(Figure 7A,B,D). The effects of PDBu and AITC on mEPSC frequency appear to be additive, not
synergistic suggesting that PDBu and AITC employ two different and independent mechanisms of
action in presyanptic terminals of caudal NTS neurons.
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Figure 6. Modulation of synaptic transmission in the NTS by phorbol-12,13-dibutyrate (PDBu).
(A) PDBu increases the frequency of mEPSCs in a reversible manner. Synaptic currents are shown in
higher time resolution below. (B,C) Cumulative probability graphs showing enhanced frequency of
mEPSCs (p < 0.001,KS test) in response to PDBu without change in their amplitudes. (D) Summary
graphs showing that PDBu-mediated increase in mEPSCs (1 μM, 117.84 ± 19.66%, n = 6; 3 μM,
195.76 ± 30.15%, n = 5, * p < 0.01; 5 μM, 295.13 ± 38.57%, n = 6, * p < 0.01). The asterisk (*) represents
p < 0.05 as compared to control.
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Figure 7. Interaction between AITC and PDBu in the NTS. (A) Application of AITC (200 μM) increases
the frequency of mEPSCs and this action is enhanced by incubation in 3 μM PDBu. Synaptic events are
shown at a higher time resolution below. (B) The cumulative probability plots show an AITC-mediated
increase in the frequency of synaptic events. These effects are further significantly enhanced by PDBu.
(C) The increase in frequency of events is not accompanied by a change in the amplitude. (D) Summary
graphs showing AITC-induced an increase in mEPSC frequency (n = 9) and potentiation by PDBu
(n = 8). The asterisk (*) represents p < 0.05 as compared to control.
2.5. The Lack of Modulatory Effects of AITC on Inhibitory Synapses in the Caudal NTS
In experiments where AMPA and NMDA receptors were blocked with DNQX (16 μM) and
2-amino-5-phosphonovaleric acid (APV, 20 μM), respectively, added to ACSF, pressure application of
AITC (500 μM) failed to alter either the frequency or the amplitude of mIPSCs (AITC, 97.86 ± 8.64%,
n = 10, Figure 8). Therefore, AITC does not affect the release of inhibitory synaptic neurotransmitters.
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Figure 8. AITC does not alter inhibitory synaptic transmission in the NTS. (A) Administration of AITC
(500 μM) or capsaicin (i.e., CAP; 200 nM) did not have any effect on the frequency of mIPSCs (top trace).
Bottom four traces: the same synaptic events are shown at a higher time resolution. (B,C) The cumulative
probability plots show no significant changes (p < 0.0001, KS test) in the distributions of inter-event
intervals (B) and amplitudes (C) of mIPSCs. (D) A summary graph illustrating a lack of effects of AITC
on the mIPSC frequency (n = 10).
2.6. Modulation of Evoked EPSCs by AITC in the Caudal NTS
AITC significantly modulated evoked EPSCs generated by electrical stimulation of the solitary
tract (50–400 μs, pulse duration; 100–500 μA, pulse intensity; 60 s inter-pulse interval). The average
amplitude of EPSCs was 131.86 pA ± 41.29 (n = 14) (ranged between 40.00 pA to 396.19 pA) and AITC
(100 μM) failed to alter the EPSC amplitude or kinetics (p > 0.05; n = 14, Figure 9A,C). In experiments
where a paired-pulse protocol was employed, AITC significantly depressed the paired-pulse ratio (PPR)
in a concentration-dependent manner (control, 0.6877 ± 0.163, n = 12; 100 μM, 0.770 ± 0.060, n = 10;
200 μM, 0.7 ± 0.086, n = 4; 500 μM, 0.517 ± 0.051, n = 7, p < 0.05; 1 mM, 0.117 ± 0.179, n = 8, p < 0.05;
Figure 9B,D). It is interesting to note that stimulation of TRPV1 significantly inhibited the evoked
responses as reported by Peters et al., 2010 [46]. The differential modulation of synaptic transmission
by TRPA1 and TRPV1 is intriguing. These results are consistent with the expression of TRPA1 in the
primary afferent solitary tract terminals in the caudal NTS.
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Figure 9. AITC-induced effects on solitary tract-evoked synaptic responses in horizontal brainstem
slices. (A,B) Representative traces of solitary tract-stimulated EPSCs (ST-EPSCs) showing seven
overlapping sweeps. (A,C) AITC does not have any significant effect on the amplitude of the ST-EPSCs
(n = 14). (B,E) AITC depressed the paired pulse ratio (PPR, EPSC2/EPSC1) in a concentration dependent
manner. (D) AITC does not show any significant effect on the failure rate (% failures = (number of
failures/total stimulations) × 100%) in NTS neurons (n = 11). The asterisk (*) represents p < 0.05 as
compared to control.
2.7. Data from TRPA1 Knockout Mice Support the Modulatory Role of TRPA1 in the Caudal NTS
TRPA1 knockout mice were used to further elucidate the modulatory role of presynaptic
TRPA1 in the caudal NTS. In experiments using brainstem slices from TRPA1 knockout mice, AITC
(200 μM) was ineffective in increasing mEPSC frequency (as a percent of control): 105.21 ± 12.23%
(n = 15, Figure 10A,B,D; vs. effects of AITC in caudal NTS neurons obtained from wild-type mice:
450.63 ± 22.74% (n = 13, p < 0.05) Figure 2A,B,D). In the same experiments, TRPV1 agonist, capsaicin
(100 nM) significantly increased the frequency of mEPSCs (309.88 ± 42.06%, n = 7, Figure 10A,B,D).
These experiments further confirmed that the observed effects of AITC were mediated by TRPA1.
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Figure 10. AITC does not induce enhancement of synaptic transmission in the TRPA1 knockout
mice. (A) Application of AITC (200 μM) does not increases the frequency of mEPSC in the TRPA1
knockout mice (105.21 ± 12.23%, n = 15, p > 0.05); whereas, capsaicin increase the frequency of mEPSC
significantly (309 ± 42%, n = 7, p < 0.05); The synaptic events are shown in higher time resolution
below. (B) Cumulative probability plot showing decreased interevent intervals representing increased
frequency of mEPSCs mediated by capsaicin (i.e., CAP; p < 0.0001, KS test), but no change of interevent
intervals mediated by AITC. (C) There was no change in the amplitude in all three groups. (D) Summary
graph showing only capsaicin-mediated increases but no AITC mediated changes in the frequency of
mEPSCs (* p < 0.05). The asterisk (*) represents p < 0.05 as compared to control.
3. Discussion
In this study, the molecular biological and electrophysiological techniques were used to
demonstrate TRPA1-mediated modulation of synaptic transmission at the NTS and the expression
of TRPA1 in caudal NTS is strictly presynaptic. Together with the existing literature, these results
support the exclusive expression of TRPA1 in the first order sensory neurons and indicate that
the expression of TRPA1 in the caudal NTS is restricted to the primary afferent solitary tract
terminals [30,35,36,47]. Activation of presynaptic TRPA1 by selective agonists was detected by
its facilitating and modulatory effects on spontaneous and evoked glutamatergic synaptic transmission,
respectively, recorded electrophysiologically in acute horizontal brainstem slices; while the specificity
of TRPA1 in triggering synaptic glutamate release was confirmed in TRPA1 knockout mice. The effects
of TRPA1 activation on glutamatergic synaptic transmission in the caudal NTS are consistent with those
observed previously in other central sensory nuclei: the substantia gelatinosa and the caudal spinal
trigeminal nucleus [30,48–53]. Agonists of TRPA1 (AITC) and TRPV1 (capsaicin; i.e., CAP) caused
paired pulse depression. However, AITC did not depress evoked EPSC amplitude, while capsaicin did
depress the evoked EPSC amplitude as described previously [45]. This observation is curious because
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TRPA1 and TRPV1 channels are often co-expressed in the same subset of neurons [30] and their effects
on synaptic neurotransmitter release are expected to be comparable. Differences in the sensitivity
of presynaptic terminals to AITC and capsaicin, as well as the exact channel distribution within
presynaptic terminals may be responsible for the apparent dichotomy of TRPA1- and TRPV1-mediated
evoked presynaptic responses, respectively.
The functional role of TRPA1 in sensory signaling is suggested by the expression of these channels
in subsets of primary sensory neurons in the trigeminal, jugular, geniculate, nodose and dorsal root
ganglia [43,54–56]. The TRPA1 channels act as primary sensors for thermal (cold), mechanical and
inflammatory noxious stimuli generated by environmental and endogenous agents [30–32,43,57–62].
Because TRPA1 channels are critical for transmission of visceral and inflammatory pain [21–27], the
expression of functional presynaptic TRPA1 in primary afferents within the caudal NTS suggests a
potential for TRPA1-dependent central component of nociception and its sensitization by TRPA1 agents
at the level of the caudal brainstem.
Visceral pain is a common symptom of functional gastrointestinal disorder such as irritable bowel
syndrome, ulcerative colitis and dyspepsia. As visceral structures are highly sensitive to distention,
ischemia and inflammation, the features of chronic visceral pain are inflammatory and mechanical
hyperalgesia and allodynia. Adopting strategies to reduce inflammatory and mechanosensory
transduction may be particularly useful in relieving visceral pain [63–66]. The role of TRPA1 in
gastrointestinal inflammatory disorders is becoming increasingly important as TRPA1 up-regulation
has been confirmed in several disease model systems. Thus, TRPA1 may represent a useful target in
treatments of chronic visceral pain. In fact, several TRPA1 antagonists have already entered clinical
trials including one in phase II clinical trial [66].
A potential role of protein kinase C (PKC) in modulating TRPA1-mediated synaptic transmission
was examined using PDBu, a PKC activator. The PKC-mediated phosphorylation plays an important
role in modulation of synaptic neurotransmission [40,43–45,67,68]. For example, PDBu substantially
increased the amplitude of TRPV1-mediated currents but had no effect on TRPA1-mediated currents
in dorsal root ganglia neurons [41,69]. The direct PDBu-mediated facilitation of the frequency of
synaptic events was observed in all neurons tested in this study, even in those cases where AITC
failed to facilitate synaptic release. However, the effects of AITC and PDBu were simply additive (i.e.,
not synergistic) suggesting that AITC and PDBu likely employ independent pathways and thus, the
TRPA1-dependent machinery is unlikely to involve PKC-mediated phosphorylation. This finding
may reflect the nature of agonists used. AITC and NMM activate TRPA1 by covalent modification
of cysteine residues. As a result, the affinity of these ligands for TRPA1 binding site(s) may not be
altered by phosphorylation. In that event, the TRPA1 activity may still be susceptible to modulation by
non-covalent modifying agonists and physical inputs, such as thermal (cold) and mechanical stimuli.
Taken together, the results of this study provide the first evidence of the TRPA1-dependent
modulation of the primary afferent inputs to the caudal NTS and suggest that second order caudal
NTS neurons serve as a TRPA1-dependent interface for visceral noxious-innocuous integration at the
level of the caudal brainstem. Thus, TRPA1 may represent a useful target in treatments of chronic
visceral and inflammatory pain.
4. Materials and Methods
4.1. Animals
Young adult male Sprague-Dawley rats (P30-50) and TRPA1 knockout mice (Jackson Laboratories,
Bar Harbor, ME, USA) were used in accordance with the Guide for the Care and Use of Laboratory
Animals (NIH 865-23, Bethesda, MD, USA), and was approved by the Animal Care and Use Committee
of Southern Illinois University (A3209-01; Approval date: 7/25/2013).
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4.2. Preparation of Brainstem Slices
Brains were removed and placed in an ice-cold oxygenated solution of the following composition
(in mM): sucrose 250, KCl 1.5, NaH2PO4 2.23, MgCl2 5, CaCl2 0.5, NaHCO3 26, glucose 10 (pH 7.4)
and bubbled with carbogen (95% O2 and 5% CO2). The brainstem was isolated and transferred
to the cutting chamber of Vibratome-1000+ slicer (Leica Microsystems, Wetzlar, Germany) where
horizontal brainstem slices (250–300 μm thickness) containing the NTS were prepared. The slices were
then transferred to a storage chamber and incubated at 30 ◦C for ~60 min in an oxygenated artificial
cerebrospinal fluid (ACSF) of the following composition (in mM): NaCl 125, KCl 1.5, NaH2PO4 2.23,
MgCl2 1, CaCl2 2, NaHCO3 26, glucose 10 (pH 7.4). Slices were then stored in the identical oxygenated
ACSF at 24 ◦C for up to 8 h.
4.3. Electrophysiological Patch-Clamp Recordings
For patch-clamp recordings, brainstem slices were placed in the recording chamber and perfused
with oxygenated ACSF at a rate of 1 mL/min using a 2232 Microperpex S peristaltic pump (LK.B, Upsalla,
Sweden). Slices were secured using a nylon mesh attached to platinum ring insert. Whole-cell recordings
were conducted at room temperature. The patch electrode solution contained (in mM): K-gluconate
140, NaCl 1, MgCl2 2, Mg-ATP 2, Na-GTP 0.3, HEPES 10, KOH 0.42 (pH 7.4). Membrane voltages
were not corrected for the liquid junction potential which was calculated using software available
through pCamp: VLJ = 16.2 mV. The electrophysiological data were recorded using MultiClamp-700B
patch-clamp amplifier (Molecular Devices, Sunyvale, CA, USA). The seal resistance was >2 GΩ.
The access resistance was <30 MΩ and was not compensated. Patches with access resistances >30 MΩ
were corrected by applying additional negative suction or discarded. Input resistance and series
resistance were measured every five minutes and cells showing greater that 20% change in series
resistance were not included in analysis. Data were sampled at 10–20 kHz and filtered at 5 kHz.
The final drug concentration in the bath was calculated based on the known concentration of the
stock solution and adjustable rates of pumps [70]. A picospritzer (Parker Hannifin Instrumentation,
Cleveland, OH, USA) was used for agonist applications via pipettes (4–7 MΩ) identical to those
used for patch clamp recordings. Agonist application was standardized by positioning the tip of the
application pipette 15 μm from the recorded neuron. This distance was calibrated and marked on the
TV monitor and used for visualization of neurons while patching. Off-line data analysis was done with
the program Clampfit 9 (Molecular Devices, Sunnyvale, CA, USA). To obtain evoked EPSCs, a Grass
Stimulator (S88) with stimulus isolation unit with constant current output (Grass Instrument, Quincy,
MA, USA) was used to stimulate a concentric bipolar electrode (Rhodes Medical Instruments, Tujunga,
CA, USA) placed on the solitary tract. The following parameters of electrical stimulation were used:
stimulus duration, 50–400 μs; stimulus intensity,100–500 μA; inter-stimulus interval, 60 s.
4.4. Immunohistochemistry and Peptide Absorption Studies
Rats were anesthetized by intraperitoneal (i.p.) injections of ketamine (85 mg/kg) and xylazine
(10 mg/kg). The anesthetized animals were perfused transcardially with 4% paraformaldehyde.
The brainstem was harvested and stored in the phosphate buffer saline (PBS, pH7.4) containing 30%
sucrose for at least 24 h. Then the tissue was frozen in powdered dry ice and stored at −80 ◦C.
Serial horizontal sections were cut at 20 μm using a Leica CM1850 cryostat at −18 ◦C. Selected sections
were thawed and mounted onto Superfrost/Plus slides. The sections were rinsed in PBS and then
blocked in 10% normal donkey serum in PBS for 60 min. The sections were incubated with rabbit
anti-TRPA1 antibody (1:100, Santa Cruz, Dallas, TX, USA) overnight at 4 ◦C and FITC donkey anti-rabbit
IgG (1:100, Jackson Immunoresearch Laboratories Inc., West Grove, PA, USA). Images were captured
by a fluorescence microscope.
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4.5. Total RNA Extraction and RT-PCR
Total RNA was extracted by Trizol reagent (Invitrogen Co., Carlsbad, CA, USA) from nucleus of
the solitary tract (NTS) and dorsal root ganglion (DRG). cDNAs were prepared by reverse transcription.
PCR was performed using a standard approach and PCR green master mix (Promega Corporation,
Madison, WI, USA). The PCR products were electrophoresed in 1.5% agarose gel with ethidium
bromide in Tris/Borate/EDTA buffer. The gel was scanned using Versa Doc imaging system (Bio-Rad,
Hercules, CA, USA) and the blot band density was quantified by Quantity One (Bio-Rad, Hercules,
CA, USA).
4.6. Data Analysis
All data are shown as means ± SEM. Significance is tested using unpaired Student’s t-test, and the
data were considered significant at p < 0.05. For analysis of synaptic currents, Kolmogorov-Smirnov
(KS) test was used to compare the cumulative probability plots for inter-event intervals and amplitude
between various treatment groups. Data are represented as means ± SE and expressed as percentage
of control, which is scaled to 100%.
The spontaneous/miniature postsynaptic currents (s/mPSCs) were analyzed off-line using
MiniAnalysis 6.0.3 (Synaptosoft Inc., Fort Lee, NJ, USA) and the threshold for event detection
(usually 10 pA) was at least three times baseline noise levels.
All the chemicals used in this study were obtained from Sigma (St. Louis, MO, USA).
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Abstract: Ion channels contribute fundamental properties to cell membranes. Although highly
diverse in conductivity, structure, location, and function, many of them can be regulated by common
mechanisms, such as voltage or (de-)phosphorylation. Primarily considering ion channels involved
in the nociceptive system, this review covers more novel and less known features. Accordingly,
we outline noncanonical operation of voltage-gated sodium, potassium, transient receptor potential
(TRP), and hyperpolarization-activated cyclic nucleotide (HCN)-gated channels. Noncanonical
features discussed include properties as a memory for prior voltage and chemical exposure, alternative
ion conduction pathways, cluster formation, and silent subunits. Complementary to this main focus,
the intention is also to transfer knowledge between fields, which become inevitably more separate
due to their size.
Keywords: pharmacology; drug development; sodium channel; potassium channel; TRP channel;
HCN channel
1. Overview
The main aim of this review is to illustrate unexpected behaviour of ion channels, which might
cross-pollinate advances between fields. To at least partly fulfil this aim, we restricted coverage to
the pain field and the subsections are written by authors with a focus on the respective ion channel
families. We consider as canonical any feature of an ion channel pore-forming protein, which can allow
the flow of ions across membranes [1]. Although not universal, common features include regulation of
the permeation (gating) by ligands and voltage; preference or selectivity for some ions over others;
interaction with other cytoplasmic or membrane proteins; trafficking between the plasma membrane
and reserve pools; heteromerisation of the channels; modulation by intracellular cascades e.g., by a
change of phosphorylation state; and a change of expression levels, e.g., in inflammatory conditions.
Less common and more on the line between canonical and noncanonical are features such as interaction
with phospholipids or accessory subunits.
2. Sodium Channels
Voltage-gated sodium channels (Navs) are responsible for the generation of action potentials in
most excitable cells, such as neurons and muscle cells. Ten different isoforms have been described
in mammals (Nav1.1-1.9 and Nax), which vary in tissue expression and electrophysiological
properties [2,3]. Generally, Navs are highly voltage sensitive and open in response to small membrane
depolarisations. They are selective for the conduction of sodium ions, thus amplifying membrane
Int. J. Mol. Sci. 2019, 20, 4572; doi:10.3390/ijms20184572 www.mdpi.com/journal/ijms51
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depolarisation and initiating action potentials. For the study and treatment of pain, the subtypes
Nav1.7, Nav1.8, and Nav1.9, mostly expressed in peripheral sensory neurons, have received large
interest over recent years considering that mutations in these channel isoforms can lead to a variety of
pain syndromes in patients [4,5]. Well-described canonical features of Nav channel activity comprise
voltage-dependent gating and fast inactivation during membrane depolarisation as well as channel
deactivation upon cell membrane repolarisation [2,6,7]. Of note in this respect are the recently published
3-D crystal structures of different Nav isoforms that have shed a new light on these well-known
functions [8–11]. There are, however, a number of rather unexpected and less well-understood channel
functions that will be discussed in the following. Some of these have already been reviewed in a similar
context by Barbosa and Cummins [12].
In addition to fast inactivation, which occurs within milliseconds after channel opening, Navs can
also undergo slow inactivation, a process that takes place on a time scale of seconds to minutes.
Under experimental conditions, this process can be observed during prolonged depolarisations (e.g.,
30–60 s). Physiologically, slow inactivation is believed to take place during high-frequency firing,
also serving to modulate it. Slow inactivation in Navs has been known for several decades [13,14].
Slow inactivation is different depending on Nav channel isoform, and the exact molecular determinants
for slow inactivation are difficult to pinpoint as many positions and residues have been described that
seem to affect slow inactivation. Generally, the process of slow inactivation in Navs bears similarities
to the C-type inactivation of potassium channels and involves the channel pore [15]. Especially a
ring of four negatively charged amino acids directly above the selectivity filter (E409, E764, D1248,
and D1539 in hNav1.4 [9]) seems to be involved in this process [16]. However, many other residues
both inside and outside the channel pore have been implicated in slow inactivation (reviewed in
References [13,14]). With regards to nociception, slow inactivation has been found to be modulated by
different mutations in Nav1.7 that cause the chronic pain syndrome erythromelalgia [17–29] (reviewed
in References [12,30]). Slow inactivation in peripheral Navs seems to be enhanced by cold temperatures,
with the exception of Nav1.8, which inactivates cold-independently and thus mediates cold nociception
in mice [31].
Slow inactivation can be regarded as a sort of negative hysteresis, i.e., Nav channels “remember”
a previous prolonged or high-frequency stimulation and, as a result, remain inactive. In other ion
channels, such as transient receptor potential and potassium channels, different forms of hysteresis
have been described, including an increase in conduction or sensitivity upon prolonged or repeated
stimulation (see below and in Reference [32]. However, our group has failed to show changes in
voltage dependence of activation of Nav1.7 after a series of depolarizing pre-pulses, thus questioning
the role of positive hysteresis in Nav1.7 [33].
According to the canonical view, Nav channels inactivate milliseconds after opening and remain
impassive to sodium flux until the cell membrane has repolarised and the channel has returned to
its resting state. However, an unusual Nav current, termed resurgent current, has been described
to occur during membrane repolarisation. Since their first description in the late ‘90s in cerebellar
Purkinje neurons [34], resurgent currents have become highly investigated and are believed to
modulate high-frequency action-potential firing in different types of neurons, including nociceptors [35].
The molecular process of resurgent currents consists of an open channel block by a positively charged
intracellular blocking particle, which occludes the channel pore before fast inactivation occurs. During
membrane repolarisation, this particle is released from the channel pore due to its positive charge,
thus leading to a very brief inward sodium current before the channel inactivates [35,36]. The most likely
candidate for the open channel blocking particle is the C-terminal end of the Navβ4 subunit [35,37].
Peripheral sensory neurons express fast and slow resurgent currents, mainly mediated by Nav1.6,
Nav1.2, and potentially Nav1.8 [38–40]. Nav1.7 has also been shown to produce resurgent currents of
small amplitudes. However, mutations in Nav1.7 that cause the chronic pain phenotype paroxysmal
extreme pain disorder (PEPD) enhance resurgent currents in this Nav subtype, whereas mutations
leading to erythromelalgia do not [29,41]. Interestingly, there seems to be a direct correlation between
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resurgent current generation and slow inactivation in Nav1.6 and Nav1.7: enhanced slow inactivation
impairs resurgent currents and vice-versa [29].
Local anaesthetics can be a useful tool for quick and localized pain treatment. These drugs
have been shown to bind inside the central cavity of the channel pore [42–44]. Recent findings in
prokaryotic and mammalian Nav channels have substantiated earlier reports, which suggested that
entry of local anaesthetics into the central cavity can be mediated via the lipid phase of the cell
membrane [45]. The recently published 3-D crystal structures as well as earlier models show side
fenestrations of the channel pore, which are large enough to be permeated by small molecules, such as
local anaesthetics [9,10,46–49]. This may have important implications for the future development of
Nav channel blocking compounds.
Several naturally occurring mutations in Nav1.2, Nav1.4, and Nav1.5 have been reported to
conduct so-called gating pore (or omega) currents. These currents originate from mutations of gating
charge residues in the S4 voltage sensor, leading to an alternative ion permeation pathway across
the membrane [50–54] (reviewed in Reference [55]). Whereas such gating pore currents have not yet,
to our knowledge, been investigated in nociceptive Nav channel isoforms, it might still be worthwhile
to check for such currents, especially in Nav1.6–Nav1.9, as leak currents through these channels would
almost certainly affect nociceptor excitability and pain perception.
3. Potassium Channels
Potassium channels are the most populous, diverse, and widely distributed ion channel superfamily.
Once regarded as “innocent bystanders” that could nevertheless be pharmacologically exploited to
counteract neuronal hyperexcitability rising from maladaptive activity of other ion channels, potassium
channels are increasingly viewed as key players that can directly promote pain pathogenesis [56].
Indeed, an ever-growing number of studies report causative links between reduced function of
specific potassium channel subunits and development of neuronal hyperexcitability and pain
sensation [57]. Furthermore, in not electrically excitable cells, potassium channels participate in
several neurophysiological processes that are independent of ion conduction, such as proliferation,
migration, and exocytosis, and the mechanisms governing these noncanonical functions may also be of
relevance to pain syndromes [58–60].
The best studied group, voltage-gated potassium channels (Kv), comprises 40 members which
assemble as homo- or hetero-tetramers and mediate a hyperpolarising K+ efflux that limits neuronal
excitability by opposing action-potential generation. Membrane depolarisation triggers Kv opening
via movement of the voltage sensor, which is coupled through a 15aa helical S4-S5 linker to the channel
pore [61]. Recent work, however, in Drosophila’s Shaker potassium channels (closely related to human
Kv1 channels) identified an additional electromechanical coupling between residues of transmembrane
domains S4 and S5 which facilitate movement of the helices in a “rack-and-pinion” fashion [62].
This noncanonical mechanism is a good candidate to explain pore opening in channels like hERG
(Kv11.1), which contain a short S4–S5 linker, expendable for voltage-gating [63,64].
The traditional view of Kv opening exclusively gated by voltage was challenged by Hao et al.,
who demonstrated that Kv1.1 is a bona fide mechanoreceptor in sensory neurons [65]. In thorough
experiments, it was shown that a variety of mechanical manipulations such as piezo-electrically
driven force, membrane stretching, and hypoosmotic shock directly activate Kv1.1 channels to mediate
a mechanosusceptive current, dubbed IKmech. Mechanistically, generation of IKmech results from a
change in the voltage dependence of the open probability, favouring the open conformation of the
channel. Traditional mechanotransducers use a mechanical sensor linked to cytoskeletal elements to
convert membrane tension energy into conformation changes. In contrast, Kv1.1 mechanoactivation
may depend on inherent properties of the voltage sensor because mechanosensitivity is retained in
excised patches of DRG neurons [65]. The authors postulated that the local membrane distortion
induced by applied forces alters the energetic stability of the voltage-sensing machinery by physical
movement of charges within the channel. Whatever the precise mechanism, Kv1.1 activation by
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mechanical stimulation can—because it reduces neuronal excitability—tune sensory neuron excitability
by opposing excitatory influences of mechanosensitive cation channels. The net outcome of this process
depends on the exact ionic channel complement of the neuron; in C-high threshold mechanoreceptors
which mediate slowly adapting mechanosensitive cation currents [66], IKmech opposes depolarisation
and increases mechanical thresholds. In contrast, in Aβ mechanoreceptors which encode rapidly
adapting mechanosensitive currents, IKmech is not engaged sufficiently to influence firing thresholds but
can nevertheless regulate firing rates. This elaborate control of mechanosensitivity by a Kv channel is a
novel mechanism of mechanosensation, and inhibition of this pathway due to injury or inflammation
could promote mechanically induced pain. Consistent with this, blocking Kv1.1 activity in mice either
genetically or pharmacologically triggers mechanical hypersensitivity, without affecting heat pain
responses [65].
The closely related member Kv1.2 also stands out because its function is subject to epigenetic
silencing by G9a (histone-lysine N-methyltransferase 2) [67]. Neuropathic injury induces the Myeloid
Zinc Finger 1 transcription factor, which in turn upregulates a long noncoding antisense RNA
which attenuates Kv1.2 expression and activity, leading to hyperexcitability and pain sensitivity
in rodents. Blocking induction of the antisense RNA spares Kv1.2 expression and is protective
against pain [68]. This and other emerging pathways regulating Kv-dependent excitability via
epigenetic modifications [69] might constitute a dynamic mechanism which shapes neuronal activity
in development and disease [70,71]; the applicability of this theme in pain pathology remains to be
further established but could critically inform gene therapy approaches in the near future.
Kv2.1 is another interesting channel as it features unique subcellular localisation, regulation by
silent subunits, and nonconducting functions. Being a high-threshold channel with characteristically
slow kinetics, Kv2.1 becomes particularly important during prolonged stimulation, like that encountered
in central neurons during seizures [72,73], or in peripheral nociceptors during spontaneous firing.
Accordingly, inhibiting Kv2.1 currents in DRG neurons allows higher firing rates during sustained
input [74], while Kv2.1 knockout in the CNS results in neuronal hyperexcitability reminiscent of
epilepsy [72]. It therefore appears that Kv2.1 acts as a resistor that filters elevated neuronal firing and
is compromised in syndromes linked to neuronal hyperexcitability, including chronic pain. Kv2.1
is downregulated in damaged sensory neurons thus promoting hyperexcitability [74], but as Kv2.1
levels are not completely abolished, this may be exploitable for pharmacological enhancement with
Kv openers. Constituent reduction of Kv2.1 activity can also occur via mutations in the KNCB1 gene;
missense variants located within the pore domain result in loss of K+ selectivity and generation of
a depolarizing inward sodium current at negative voltages [75] or even loss of voltage dependence,
causing Kv2.1 to remain tonically open [73]. It will be interesting to investigate whether similar Kv2.1
mutations are linked to human pain channelopathies.
Kv2.1 is robustly regulated by members of the Kv5, Kv6, Kv8, and Kv9 families, which comprise
the so-called “silent subunits” (KvS). These enigmatic proteins are incapable of conducting currents on
their own but can form functional tetramers with Kv2.1, substantially altering the biophysical properties
of the channel [76]. For instance, association of Kv2.1 with any of Kv5.1, Kv6.1, Kv9.1, or Kv9.3
hyperpolarises the voltage dependence of inactivation in pyramidal neurons, while Kv2.1/Kv5.1
exhibits accelerated rates of (open-state) inactivation and slower closing rates upon repolarization
(deactivation) [77]. Mechanistically, these modulatory effects can be mediated by direct changes in the
gating mechanism or indirectly by promoting Ca2+/calmodulin-dependent dephosphorylation [77,78].
It is becoming increasingly evident that heteromerization of Kv2.1 with different KvS endows neurons
with functional diversity that is often essential for normal physiology. For example, mammalian
photoreceptors depend on Kv2.1/Kv8.2 channels to mediate transient hyperpolarizing overshoots of
the membrane potential [79,80] and Kv8.2 mutations cause a cone dystrophy disorder [81]. Kv6.1,
Kv8.1, and Kv8.2 have also been implicated in hyperexcitability of hippocampal neurons relevant to
epilepsy [82–84].
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KvS have also been implicated in chronic pain. Kv9.1 co-localises with Kv2.1 in myelinated sensory
neurons that become hyperexcitable following nerve damage. Injury-induced Kv9.1 downregulation
decreases Kv2.1 activity and enhances excitability, including spontaneous and evoked firing, and triggers
pain hypersensitivity in rodents [85]. Consistent with this, deletion of the KCNS1 gene encoding Kv9.1
in mice results in basal and neuropathic pain sensitivity [86]. Kv2.1, but not Kv9.1, is also expressed in
small nociceptors [74], but the composition of the native tetramers is not known. Since Kv2.1 conduction
is sculpted by the modulatory influence of silent subunits, it is plausible that different Kv2.1/KvS
combinations and stoichiometry can fine-tune excitability in distinct classes of sensory neurons.
For example, Kv9.3 hyperpolarises the voltage dependence of Kv2 inactivation more substantially
than Kv9.1 [78,87,88] and, even for a given KvS, the physiological impact is predicted to depend
on whether firing is limited by the inactivation of inward currents [88]. The importance of Kv2.1
modulation by Kv9.1 in nociception is further underscored by the identification of two SNPs in the
human Kv9.1 gene, which predisposes to the development of chronic pain [89]. Similarly, mutations in
Kv6.4 may promote excitability of trigeminal neurons during migraine attacks [90] as well as pain
during labor [91]. The role of KvS in pain is still poorly understood, and it may even include regulation
of noncanonical Kv2.1 functions such as channel clustering and protein trafficking, as discussed below.
Untangling this pathway could provide unique opportunities for pain treatments, which may prove
advantageous compared to targeting the ubiquitously expressed Kv2.1 subunit.
A prime example of noncanonical Kv function is the formation of large clusters by Kv2.1 channels
which localise to the neuronal membrane of the soma, proximal dendrites, and axon initial segment
of CNS neurons [92]. In contrast to the active, diffused form of the channel, these micrometer-sized
clusters are found to be primarily nonconductive [93,94] and are dispersed in response to neuronal
activity, glutamate-induced excitotoxicity, hypoxia, or second messengers [95,96]. Regulation of cluster
formation was originally thought to fine-tune neuronal excitability by dynamic control of the active vs.
inactive forms but recent evidence hints towards a nonconducting role for Kv2 clusters. Thus, Kv2.1
and Kv2.2 clusters play a structural role in the formation of plasma membrane–endoplasmic reticulum
junctions which serve as trafficking hubs for recruitment of several proteins (e.g., voltage-activated Ca2+
channels, VAMPs, AKAPs, kinases, and syntaxin), important for many neurophysiological processes
like trafficking, neurotransmitter release, Ca2+ homeostasis, and burst firing [97–101]. Such a role is
consistent with the identification of three Kv2.1 mutations which cause neurodevelopmental disorders
despite the fact that they do not alter Kv2.1 conductance per se [102]. While Kv2 cluster formation has
not been confirmed in peripheral sensory neurons, it is plausible that similar mechanisms operate in
the pain-signaling pathways and that disruption of normal Kv2 clustering due to inflammation or
injury affects nociceptive excitability.
Two P(ore) domain potassium channels (K2Ps) are known for facilitating a passive and rapid K+
flow at a range of membrane potentials. This leak (also called background) outward conductance
stabilises resting membrane potential, assists repolarisation, and even enables AP generation in the
absence of classical Kv channels [103]. Surprisingly, however, additional voltage-dependent activation
has been documented in some K2P channels despite the absence of a canonical voltage-sensing domain
with a positively charged S4-helix for gating by depolarisation [104,105]. Instead, voltage sensitivity
appears to derive from movement of three or four ions into the high electric field of the selectivity
filter [106], which then acts to “gate” the movement of K+ ions. Thus, in contrast to classical Kv
channels where the properties of voltage sensing, activation, and inactivation can be mapped to distinct
regions of the channel, K2Ps carry out these functions by employing different structural states of the
selectivity filter. Moreover, many stimuli relevant to physiological functions such as PIP2, acidosis,
and membrane stretch can switch off this voltage activation [107], limiting K2Ps to leak conductance by
locking them open. Altogether, K2P channels are increasingly recognised as important modulators of
polymodal pain perception. The best studied members TRAAK, TREK1, and TREK2 are mechano- and
thermosensitive, albeit at different temperature ranges (TRAAK and TREK1, noxious temperatures;
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TREK2, moderate temperatures) [108–112]. Accordingly, deletion of these channels affects mechanical,
heat, and oxaliplatin-induced cold sensitivity [108,109,112,113].
When covering atypical potassium channel function, a special mention should be made on
inwardly rectifying potassium channels (Kir) which are mainly found in supporting cells such as glia.
Kir channels are unique in that, at depolarised potentials, they preferentially mediate movement of K+
ions towards the inside of the cell in contrast to other potassium channels. The resulting inward currents
help maintain resting membrane potentials and are therefore important in a number of physiological
processes such as microglial activation during inflammation [114]. In addition, the buffering activity of
Kir in nonneuronal cells prevents extracellular K+ accumulation, which would cause action potential
“short-circuiting” and could detrimentally impact neuronal excitability [115,116]. Several members of
the seven Kir subfamilies (Kir1–Kir7) have been specifically implicated in pain modulation. Kir4.1
channels expressed in satellite glia cells of the trigeminal ganglion appear to be important for facial
pain. Silencing Kir4.1 expression in rats to mimic the effect of nerve injury or inflammation induces
hyperexcitability and facial pain behaviours [117,118], while Kir4.1 knockout mice exhibit depolarised
membrane potentials and inhibition of K+ uptake [119,120]. Members of the Kir3 family (also known
as G protein-regulated inward rectifiers K+ channels, GIRK) are crucial mediators of spinal analgesia
because their coupling to G proteins underlies analgesia conferred by endogenous and exogenous
opioids [121,122]. Consistent with this, variations in the gene encoding GIRK2 are associated with
pain phenotypes, as well as analgesic responses in humans [121–123]. Besides their established role
in the CNS, GIRK2 expressed in sensory neurons may also contribute to peripheral antinociception
induced by opioids [124].
Together, there is considerable interest in developing novel forms of analgesia by modulating K+
channel function, either correcting a primary pathology underpinning a pain state or nonspecifically
reducing neuronal excitability. Much of the early interest focused on Kv channel openers, but more
recent data suggests that drugs activating K2Ps may prove useful for a variety of pain symptoms [125].
Recently, a somewhat counterintuitive observation was that opening of ATP-sensitive potassium
channels induces migraine attacks in migraineurs using a randomized, double-blind, placebo-controlled,
crossover design [126]. The mechanism is not clear but might involve neuronal or nonneuronal processes,
given the widespread distribution of these channels. It is worth noting that other K+ channels have a
much more restricted distribution to nociceptive neurons.
4. TRP Channels
Transient receptor potential (TRP) channels form a group of 28 ion channels (27 in humans)
organized into 7 families TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin),
TRPML (mucolipin), TRPP (polycystic), and TRPN (no mechanoreceptor potential C) [127,128].
Members of this family continue to be among the most studied in the ion channel field, in particular
for pain as their relevance for certain pathophysiological conditions and peripheral sensory perception
prompts them as targets for therapeutic modulation [129–131]. Canonical features of this family
would be weak voltage-dependence [132], conductance for cations including divalent cations [133],
and frequently, channel-specific rectification [134]. Below, some unexpected channel behavior
is discussed.
TRPM3 has been found to generate an unexpected conductance when a combination of agonists
was applied, namely pregnenolone sulfate and clotrimazole (or sole application of the agonist
CIM0216) [135,136]. This ion permeation pathway, that allows inward rectification driven by Na+,
has been likened to the omega pore in classical voltage-gated cation channels; however, the latter
has been uncovered in disease-inducing mutations, whereas in the case of TRMP3, it exists in the
wild-type channel. Moreover, in the case of clinically relevant clotrimazole plasma levels, it is
feasible that, at 37 ◦C, circulating levels of pregnenolone sulfate can open this alternative pore [135].
Further analysis of the voltage-sensing domain of TRPM3 by means of site-directed mutagenesis
revealed a critical role of several amino acids in the voltage-sensing domain for the formation of
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this alternative ion-permeation pathway [136]. In other channel families, including potassium,
sodium, and proton channels, channel mutations have also been shown to cause noncanonical pores,
as discussed above [51,137,138]. Ultimately, such unexpected behaviour can contribute to a larger goal,
understanding the gating and overall ion channel molecular mechanics.
The majority of TRP channels is outwardly rectifying, despite some exceptions such as
TRPML1/2/3 [139] and TRPV5/6 [140]. In case the rectification is not dependent on divalent cations,
causing asymmetry by an open channel block [141,142], this is an intrinsic property of the channel.
This property can be changed by a single helix-breaking amino acid, as shown for the TRPML3-A419P
mutation [143].
Increasing response to continuous agonist exposure: TRPA1 stands out by being most sensitive to
modification by electrophilic molecules, a feature which critically involves cysteine residues on the N
terminus of the channel [144–147]. Irrespective of the mode of activation, a dilation of the pore has
been described for TRPA1, a feature attributed only to a few ion channels, including TRPV1 [148].
This pore dilation has a time constant below 10 s [149,150]. It should be mentioned that an alternative
explanation to dilations of the pore has been proposed [151] (summarized in Reference [152]).
However, a slow but several-fold increase in conductance upon continuous agonist exposure
with a much longer time course has been demonstrated [153]. These current increases can be better
studied in the absence of calcium, as calcium influx causes a calcium-dependent desensitisation,
and both mechanisms seem to balance each other. This allows continuous activation through TRPA1,
where other channels show extensive tachyphylaxis or desensitisation. The mechanism is not PKA- or
PKC-dependent. The topic has been further investigated using the noncovalent agonist carvacrol [154].
In contrast to the slow covalent action of TRPA1 by allyl isothiocyanate, the time constant for activation
by carvacrol was 3.1 s, which allowed for tracking the current faster. A similar agonist-induced
current increase was detected, and the current observed after a previous exposure is picked up almost
invariable to the period between stimuli. The time constant of agonist-induced sensitisation was
130 s, which is well above all other described processes. Agonist exposure is required for this effect,
as it could not be reproduced by opening the channel using voltage stimulation. Agonist-induced
sensitisation occurred between covalent and non-covalent agonists, indicating a modification which is
common to all agonists but upstream or independent of voltage-induced gating. However, a current
through the channel was not required, as the exposure time-dependent current increase progresses
when flux is inhibited by the additional presence of an antagonist. Similar to allyl isothiocyanate,
a desensitisation was observed for saturating concentrations of carvacrol; the reason for this remaining
unclear. The agonist-induced sensitisation was assumed to bring TRPA1 into a hypothesized state,
which has a far left-shifted voltage dependence [154]. Inhibition of ATP-dependent mechanisms
and membrane trafficking also did not affect the observation. TRPA1 has been investigated using
long exposures mainly due to the slow onset required for the covalent agonists. This is not required
for other channels; therefore, such protocols might simply not have been tested so far. It should be
mentioned that a shift in concentration-dependent binding with prolonged agonist exposure has been
reported in other receptors [155]; an “imprinting” by a lasting conformational change was hypothesized.
For TRPA1, the change in receptor binding after prolonged exposure has not been investigated.
5. HCN Channels
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels comprise a small family with
four members, HCN1–HCN4 [156–160]. The channels are related to CNG and Kv channels [161–163]
but are distinguished by several unique features. HCN channels are controlled by the membrane
potential; however, in contrast to most other voltage-gated ion channels, hyperpolarization but
not depolarization opens them. Second, the channels contain the GYG motif in the pore region,
which constitutes the potassium selectivity filter in potassium channels. Nevertheless, HCN channels
are nonselective cation channels conducting both sodium and potassium ions (selectivity for K+/Na+
~4:1). Under physiological conditions, activation of the channels leads to influx of sodium ions, resulting
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in depolarization. Third, cyclic nucleotides, particularly cAMP, stimulate the channels by accelerating
their activation kinetics and by shifting the activation curve in the positive direction. However, cAMP is
not required for channel opening. HCN channels contain a cyclic nucleotide-binding domain (CNBD)
in the carboxyterminus. Truncation experiments have shown that the cyclic nucleotide-binding domain
inhibits gating in the cAMP-unbound state, whereas cAMP binding relieves this inhibition [164].
The recent cryo-EM structure of HCN1 [165] together with the crystal structure of a cyclic
nucleotide-binding domain [166] yielded important insights into the peculiar characteristic outlined
above. As compared to potassium channels, the outer half of the selectivity filter in HCNs is enlarged
and two of the potential four potassium binding sites are lacking. This results in a loss of the kinetic
selectivity for potassium present in potassium channels, where four binding sites in the permeation
pathway are present. Second, the closed pore is stabilized by the voltage sensor (S4 segment) and
other domains in the depolarized state. It is proposed that the hyperpolarization-induced downward
movement of S4 disrupts these interactions, leading to spontaneous pore opening. Third, binding of
cAMP induces small conformational changes, leading to a rotation towards opening of the inner gate.
However, HCN1 is barely modulated by cyclic nucleotides, so it remains to be seen if this structural
mechanism also operates in HCN2 and HCN4, which are strongly modulated by cAMP.
The individual isoforms possess characteristic properties, which have been investigated in
heterologous expression systems and were confirmed by using knockout mice of each isoform [167–171].
Beneath the different sensitivities toward cyclic nucleotides, the isoforms strongly differ in the rate of
channel opening. HCN1 is the fastest activating isoform, HCN2 and HCN3 possess an intermediate
activation kinetic, and HCN4 is the slowest HCN channel with an activation time constant up to
several seconds.
In principle, activation of HCN channels leads to depolarisation and promotes AP generation.
Since neuronal hyperexcitability and spontaneous AP generation of nociceptors contribute to the
generation of pathological pain, HCN channels and, in particular, HCN2 may be involved in the
sensitization of nociceptors in chronic pain conditions. In line with this assumption, an enhancement
of the current flowing through these channels (Ih) has been directly shown in different models of
neuropathic [172–174] and inflammatory [175] pain. The increase in Ih has been attributed to an
upregulation of HCN transcript and/or protein [113,175–179], upregulation of the potential auxiliary
subunit MiRP1 [174], increased intracellular cAMP levels [180], and PKA-dependent phosphorylation
of HCN2 [181]. Nociceptor-specific deletion of HCN2 by using a Nav1.8-Cre transgene to delete the
floxed HCN2 exons directly demonstrated the important role of this channel in pathological pain
conditions [179,182]. In two different models of neuropathic pain, HCN2 emerged as a key regulator
since its deletion strongly reduced [183] and even abolished [182] the increase in nociceptive sensitivity.
Moreover, in diabetic mice, deletion or block of HCN2 prevented the mechanical allodynia following
diabetic neuropathy [180]. In inflammatory pain, the importance of HCN2 was also shown, but the
extent differed between the inflammatory compound (carrageenan, PGE2, 8-bromo-cAMP, zymosan A,
and CFA) and behavioural test (mechanical and heat hypersensitivity) used [179,182]. It is proposed
that HCN2 channels determine nociceptor hypersensitivity if the inflammatory signal transduction
pathways result in an increase of cAMP, which may directly modulate channel activity via binding
to the CNBD [184] or indirectly via activation of PKA and phosphorylation of HCN2 or associated
proteins [183].
However, in spite of these promising findings in murine models, a recent human phase 2 study did
not find any effect of ivabradine on capsaicin-induced hyperalgesia and pain in healthy volunteers [185].
Ivabradine caused a significant heart-rate reduction, indicating that the dose was sufficient to block
HCN4 and HCN1 channels in the sinoatrial node. These results suggest that it might be necessary
to develop HCN2-selective substances (which do not cross the blood–brain barrier [167]) to serve as
analgesics. Beyond that, it is still possible that ivabradine is effective in other human pain models
distinct from the neurogenic inflammation induced by TRPV1 activation.
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6. Conclusion
Unexpected properties of several ion channels with importance for the pain field were discussed
(Table 1). We hope that the selective and non-comprehensive choices help to transfer knowledge within
the field. Considering the possibility that such findings in other channels might explain otherwise not
understood issues and facilitate scientific progress.
Table 1. Overview for the mentioned noncanonical ion channel features: canonical features not
discussed in the review are considered ligand- and voltage-gating, selective permeability, interaction
with other proteins, fractional presence at the plasma membrane, heteromerisation, modulation by
intracellular cascades, and a change of expression.
Noncanonical Property Ion Channel and References
slow inactivation Nav [9,12–33]
resurgent current during membrane repolarisation Nav (1.2, 1.5, 1.6, 1.7, 1.8) [29,34–41]
side fenestrations of the channel pore Nav [9,10,46–49]
alternative ion permeation pathway across the membrane Nav (1.2, 1.4, 1.5) [50–55]
TRPM3 [135–138]
electromechanical coupling of transmembrane domain S4
and S5 residues, facilitating “rack-and-pinion” movements Kv [62–64]
mechanically induced current Kv (1.1) [65,66]
susceptibility to epigenetic silencing Kv (1.2) [67–71]
action potential frequency filtering by silent subunits Kv (2.1)–KvS (members of the Kv5, 6,
8, 9 families) [72–88]
formation of channel clusters Kv (2.1, 2.2) [92–101]
voltage-dependent activation in the absence of a canonical
voltage-sensing domain K2P [104–107]




pore dilation TRPA1 [149,150,152]
TRPV1 [148]
sensitization due to continuous agonist exposure TRPA1 [32,147,149–154]
open probability increases upon hyperpolarization HCN 1–4 [156–163]
nonselective cation channel despite a typical potassium
selectivity filter motif HCN 1–4 [156–163]
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Abbreviations
AKAP A-kinase anchor protein
HCN Hyperpolarization-activated cyclic nucleotide-gated channel
Kv voltage-gated potassium channel
KvS Silent potassium channel subunit
K2P Two Pore domain potassium channel
Kir Kir inwardly rectifying potassium channel
Nav Voltage-gated sodium channel
TRP Transient receptor potential channels
VAMP Vesicle-associated membrane protein
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Abstract: Transient receptor potential (TRP) channels have emerged as potential sensors
and transducers of inflammatory pain. The aims of this study were to investigate (1) the expression
of TRP channels in intervertebral disc (IVD) cells in normal and inflammatory conditions
and (2) the function of Transient receptor potential ankyrin 1 (TRPA1) and Transient receptor potential
vanilloid 1 (TRPV1) in IVD inflammation and matrix homeostasis. RT-qPCR was used to analyze
human fetal, healthy, and degenerated IVD tissues for the gene expression of TRPA1 and TRPV1.
The primary IVD cell cultures were stimulated with either interleukin-1 beta (IL-1β) or tumor necrosis
factor alpha (TNF-α) alone or in combination with TRPA1/V1 agonist allyl isothiocyanate (AITC,
3 and 10 μM), followed by analysis of calcium flux and the expression of inflammation mediators
(RT-qPCR/ELISA) and matrix constituents (RT-qPCR). The matrix structure and composition in
caudal motion segments from TRPA1 and TRPV1 wild-type (WT) and knock-out (KO) mice was
visualized by FAST staining. Gene expression of other TRP channels (A1, C1, C3, C6, V1, V2, V4, V6,
M2, M7, M8) was also tested in cytokine-treated cells. TRPA1 was expressed in fetal IVD cells, 20% of
degenerated IVDs, but not in healthy mature IVDs. TRPA1 expression was not detectable in untreated
cells and it increased upon cytokine treatment, while TRPV1 was expressed and concomitantly
reduced. In inflamed IVD cells, 10 μM AITC activated calcium flux, induced gene expression of
IL-8, and reduced disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5)
and collagen 1A1, possibly via upregulated TRPA1. TRPA1 KO in mice was associated with signs of
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Int. J. Mol. Sci. 2019, 20, 1767
degeneration in the nucleus pulposus and the vertebral growth plate, whereas TRPV1 KO did
not show profound changes. Cytokine treatment also affected the gene expression of TRPV2
(increase), TRPV4 (increase), and TRPC6 (decrease). TRPA1 might be expressed in developing
IVD, downregulated during its maturation, and upregulated again in degenerative disc disease,
participating in matrix homeostasis. However, follow-up studies with larger sample sizes are needed
to fully elucidate the role of TRPA1 and other TRP channels in degenerative disc disease.
Keywords: low back pain; TRP channels; pro-inflammatory cytokines; aggrecanases; collagen;
TRPA1; TRPV1; TRPV2; TRPV4; TRPC6
1. Introduction
Low back pain (LBP) is the leading cause of disability, activity limitation and lost productivity
throughout the world today, with approximately 80% of all people suffering from back pain at least
once in their life [1]. Degenerative disc disease (DDD), which is a progressive multifactorial disorder
of the intervertebral disc (IVD), is an important factor that is involved in the development of LBP [1].
DDD is characterized by the release of inflammatory and catabolic mediators, including interleukin-1
beta (IL-1β), tumor necrosis factor alpha (TNF-α), prostaglandins, and proteases, which further
promote the degradation of extracellular matrix (ECM) [2,3]. Pro-inflammatory cytokines IL-1β
and TNF-α directly act as nociceptive triggers, but also activate the expression of other potentially
nociceptive molecules including neuropeptides, interleukin-6 (IL-6), and interleukin-8 (IL-8) [4,5].
Molecular mechanisms involved in transduction and modulation of IL-1β and TNF-α signaling in
DDD are not yet well-understood [6–8].
Signals that are provided by pro-inflammatory cytokines can be mediated via membrane
channels [9,10]. Recently, transient receptor potential (TRP) channels have emerged as putative
receptors for inflammation-associated molecules, positive/negative regulators of inflammation,
and transducers of inflammatory pain [11–13]. TRP channels are cation selective transmembrane
receptors with diverse physiological functions. Six families of mammalian TRP channels have been
identified, classifying TRP channels according to their sequence homology and topological differences:
TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPV (vanillin), TRPP (polycystin), and TRPML
(mucolipin). Apart from TRPA, every subfamily has several members [14,15]. The dysregulation of TRP
channels is implicated in many pathologies, including cardiovascular diseases, muscular dystrophies,
and hyperalgesia [14,16]. Interestingly, the expression and activity of certain TRP channels is
altered in painful joints and IVDs [11,12]. For example, the expression of TRPV4 in human IVDs
was found to be elevated in regions of aggrecan depletion [17], while the gene expression of
TRPC6 was associated with the severity of disc degeneration, increased expression of IL-6, and cell
senescence [18,19]. TRPA1 and TRPV1 are involved in inflammation/nociception in sensory neurons
and non-neuronal tissues [20–22]. TRPV1 is a non-selective calcium channel, the expression and activity
of which increases after inflammatory stimulation in dorsal root ganglions (DRGs), possibly causing
chronic hyperalgesia. TRPV1 also expressed in chondrocytes [23]. TRPA1 is a calcium permeable
non-selective cation channel that is also widely expressed in sensory neurons and in non-neuronal
cells, including chondrocytes [11]. TRPA1 is involved in various sensory and homeostatic functions,
depending on the cell type [12,24]. TRPA1 and TRPV1 were shown to complement each other’s
activities [21,25]. As numerous publications have linked TRPA1 and TRPV1 with inflammatory
pain [21], therapeutic inhibition or the activation of TRPA1 and/or TRPV1 channels may be beneficial
in the treatment of DDD. Therefore, the aims of this study were to investigate the (1) expression of TRP
channels in IVD cells in normal and inflammatory conditions and (2) the function of TRPA1 and TRPV1
in disc inflammation and matrix homeostasis.
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2. Results
2.1. Gene Expression of TRPA1 in Human IVD Tissue
Gene expression of TRPA1 was tested in human non-degenerated (n = 4) and degenerated
(n = 20) IVD tissue in relation to disc region, disease type, pain score (for degenerated discs only),
grade, and age. In the degenerated tissue, TRPA1 was found expressed in 20% of tested donors
(four out of 20). Although only expressed in a subset of degenerated donors, TRPA1 was found
in both annulus fibrosus (AF) and nucleus pulposus (NP), in an age range of 39–76 years, at pain
scores 2 (= intense) and 3 (= disabling) and at Pfirrmann grades 2 and 3 (Table 1). TRPA1 was only
expressed in one non-degenerated NP sample (in one out of four donors: male, 17 years old, grade 1,
2−dCt = 4.57 × 10−5). Interestingly, TRPA1 was found expressed in cells isolated from human fetal
IVD tissue (n = 4; 2−dCt = 0.0463 ± 0.04742). It is known that TRPA1 can associate with TRPV1,
thereby regulating its intrinsic properties independently of intracellular calcium. Table 1 summarizes
the expression of TRPV1. A manuscript that provides details on the expression of TRPV1 in IVD tissue
is currently in revision [26].
Table 1. Gene expression of TRPA1 and TRPV1 in human intervertebral disc (IVD) tissue. Some donor
tissues were divided into nucleus pulposus (NP) and annulus fibrosus (AF), resulting in more AF
and NP samples (n = 21 in region, pain score, grade) than a total number of donors (n = 20).
Degenerated
Lumbar IVDs
n 2−dCt (Mean ± SD) Region Pain score Grade Age (Mean ± SD)
TRPA1 in 4 out of 20 0.0006 ± 0.001 2 in AF2 in NP
2 pain score 2;










6 in pain score 1;
11 in pain score 2;








2.2. Gene Expression of TRPA1 and TRPV1 in Human IVD Cells Treated with Pro-Inflammatory Cytokines
TRPA1 and TRPV1 can be involved in modulating inflammation in both neuronal and non-neuronal
cells [25]. Therefore, changes in the gene expression of TRPA1 and TRPV1 were tested in IVD
cells stimulated with pro-inflammatory cytokines IL-1β and TNF-α (both 5 and 10 ng/mL) (n = 5)
(Table 2). TRPA1 was under the detection limit in most untreated IVD cells, while its gene
expression tended to increase with IL-1β treatment (p = 0.07 for IL-1 5 ng/mL) and it significantly
increased with TNF-α (Figure 1A). TNF-α, but not IL-1β, significantly reduced gene expression of
TRPV1 (Figure 1B). The induction of an inflammatory-catabolic shift upon cytokine treatment was
demonstrated by an increase of IL-6, IL-8, cyclooxygenase-2 (COX-2), nerve growth factor (NGF), matrix
metalloproteinase 1 (MMP1), matrix metalloproteinase 3 (MMP3), a disintegrin and metalloproteinase
with thrombospondin motifs 4 (ADAMTS4), a disintegrin and metalloproteinase with thrombospondin
motifs 5 (ADAMTS5), and a reduction in COL2A1. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1),
tissue inhibitor of matrix metalloproteinase 2 (TIMP2), Aggrecan and COL1A1 were unchanged
(Supplementary Figure S1). In IVD cells seeded in three-dimensional (3D) alginate beads and treated
with IL-1β (5 ng/mL, 15 days, n = 4–10), gene expression of TRPA1 significantly increased on day
1, 8, and 15 (Figure 1C), while the gene expression of TRPV1 remained unchanged (Figure 1D).
Immunostaining confirmed TRPA1 protein induction upon IL-1β treatment (5 ng/mL) (n = 3) (Figure 1E).
Cell viability in alginate beads was monitored by Calcein/Ethidium homodimer staining and an average
of 87% of living cells per treatment and time point was found (Supplementary Figure S2).
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Figure 1. Gene expression of TRPA1 and TRPV1 in IVD cells treated with 5 and 10 ng/mL interleukin-1
beta (IL-1β) or tumor necrosis factor alpha (TNF-α). Gene expression of (A) TRPA1 and (B) TRPV1 in
two-dimensional (2D) culture (Graph shows 2−ddCt (mean ± SD, n = 5). Gene expression of (C) TRPA1
and (D) TRPV1 in IVD cells cultured in three-dimensional (3D) alginate beads and treated with IL-1β
for 15 days. Graph shows 2−ddCt (mean ± SD, n = 4–10). Asterisks indicate statistical significance
(* p < 0.05, ** p < 0.01, Kruskal–Wallis test and Dunn’s multiple comparison test). (E) Protein expression
of TRPA1 in IVD cells treated with IL-1β and untreated (DAPI = blue, TRPA1 = green). Negative control
images show cells without secondary antibody. Scale bar is 50 μm.
Table 2. Gene expression of TRPA1 and TRPV1 in untreated and treated human IVD cells (2D).
n = 5 donors. Values show fold change relative to the untreated cells. In case of expression under
the detection limit, dCt was set at 40 cycles.
Treatment Untreated IL-1β 5 ng/mL IL-1β 10 ng/mL TNF-α 5 ng/mL TNF-α 10 ng/mL
TRPA1
No
expression 385.18 ± 233.06 333.42 ± 199.80 842.06 ± 659.98 780.23 ± 600.17
TRPV1 Expression 0.64 ± 0.18 0.69 ± 0.23 0.53 ± 0.11 0.45 ± 0.22
2.3. Gene Expression of Other TRP Channels in Human IVD Cells Treated with Pro-Inflammatory Cytokines
Changes in the gene expression of other TRP channels, namely TRPC1, TRPC3, TRPC6, TRPV2,
TRPV4, TRPV6, TRPM2, TRPM7, and TRPM8, were also tested in IVD cells upon cytokine stimulation
(IL-1β and TNF-α, both 5 and 10 ng/mL) (n = 5). IL-1β significantly induced gene expression of TRPV4
and reduced TRPC6. TNF-α significantly activated the gene expression of TRPV2. The expression
of other TRP channels showed no clear association with a pro-inflammatory treatment in the tested
experimental settings (Figure 2A–G). Gene expression of TRPM2 and TRPM8 was under the detection
limit in all of the treatment groups.
72
Int. J. Mol. Sci. 2019, 20, 1767
Figure 2. Gene expression of TRP channels in IVD cells treated with 5 and 10 ng/mL IL-1β or TNF-α.
Gene expression of (A) TRPC1, (B) TRPC3, (C) TRPC6, (D) TRPV2, (E) TRPV4, (F) TRPV6, and (G)
TRPM7. Graphs show 2−ddCt (mean ± SD, n = 5). Asterisks indicate statistical significance (* p < 0.05,
** p < 0.01, Kruskal–Wallis test and Dunn’s multiple comparison test).
2.4. Functional Analysis of TRPA1 and TRPV1 in IVD Cells
Allyl isothiocyanate (AITC, 3 and 10 μM), which is an agonist for TRPA1 and TRPV1, was used to
test the involvement of these channels in (1) inflammation responses and (2) matrix homeostasis within
the IVD compartment. The activity of AITC was tested by Calcium flux assay (n = 3). AITC was applied
in untreated IVD cells (expressing TRPV1) as well as in cells that were treated with pro-inflammatory
cytokines (expressing TRPA1 and TRPV1). AITC did not induce calcium flux in the untreated IVD
cells. AITC significantly induced calcium flux in both IL-1β and TNF-α-treated cells, suggesting
the involvement of TRPA1 (Figure 3). Calcium flux in the TNF-α treated cells was significantly higher
than in IL-1β-treated cells, likely due to the overall higher induction of TRPA1 expression by TNF-α.
Therefore, it is possible that TRPA1 (not TRPV1) can be functionally involved in the calcium-induced
responses of inflamed IVD cells. To verify the function of TRPA1/TRPV1, AITC was used to study gene
and protein expression of inflammation and catabolic mediators in untreated as well as cytokine-treated
IVD cells.
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Figure 3. Calcium flux in IVD cells untreated (control) and treated with 100 μM Allyl isothiocyanate
(AITC) with and without 10 ng/mL IL-1β or 10 ng/mL TNF-α. Graph shows calcium flux as 340/380
signal ratio (mean ± SD, n = 3). Asterisks indicate statistical significance (* p < 0.05, Kruskal–Wallis test
and Dunn’s multiple comparison test). The arrow indicates AITC application.
Cytokine untreated IVD cells (expressing TRPV1) were used to test the downstream effects of
TRPV1 activation (n = 3–4). In unstimulated IVD cells, the gene expression of inflammation/pain
mediators (IL-6, IL-8, NGF, COX-2) (Figure 4A–D) and most of the ECM remodeling enzymes
(ADAMTS4, ADAMTS5, MMP3, TIMP1, TIMP2) was unchanged by AITC (Figure 4E–J). IL-6 and IL-8
concentration in culture media was close to the lower detection limit (~zero) (not shown). MMP1 was
significantly induced by 10μM AITC (Figure 4H). The gene expression of COL1A1, COL2A1,
and aggrecan in AITC-treated cells was not significantly different from the control (Figure 4K–M).
Due to the fact that cytokine-untreated cells did not express TRPA1, the observed changes in MMP1
expression were not TRPA1-dependent. MMP1 upregulation by AITC may be an unrelated non-specific
effect (as AITC did not induce calcium flux in untreated IVD cells).
IVD cells treated with pro-inflammatory cytokines (expressing TRPA1 and TRPV1) were used to
test the downstream effects of TRPA1 activation (n = 3–4). In IL-1β-treated cells, AITC did not influence
gene expression of inflammation mediators IL-6 and IL-8 (Figure 5A,D) and pain mediators NGF
and COX-2 (Figure 5C,F). Interestingly, the protein release of IL-8 was significantly reduced by 3 μM
AITC (Figure 5E). 10 μM AITC significantly reduced the gene expression of ADAMTS5 (Figure 5H),
while MMP1 was induced (Figure 5J). Gene expression of other ECM remodeling enzymes (ADAMTS4,
MMP3, TIMP1, TIMP2) and ECM genes (Figure 5M–O) in AITC + IL-1β-treated cells was not different
from the IL-1β-only controls.
10 μM AITC significantly induced the gene and protein expression of IL-8 (Figure 6D,E)
in TNF-α-treated cells (expressing TRPA1, reduced TRPV1). AITC did not influence the expression of
IL-6 (Figure 6A,B), NGF, and COX-2 (Figure 6C,F). The gene expression of ADAMTS5 was significantly
reduced (Figure 6H), while MMP1 was induced by 10 μM AITC in TNF-α-treated cells (Figure 6J).
Gene expression of other ECM remodeling enzymes (MMP3, ADAMTS4, TIMP1, and TIMP2) was not
different from TNF-α-treated control. Gene expression of COL1A1 was significantly reduced (Figure 6M),
while the other tested ECM proteins (COL2A1 and aggrecan) were not influenced by AITC in
TNF-α-treated cells. AITC did not affect the gene expression of TRPA1 itself (Supplementary Figure S3).
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Figure 4. The effects of TRPA1 agonist allyl isothiocyanate (AITC) on the gene expression of
inflammation markers and extracellular matrix (ECM) molecules in IVD cells without cytokine
pre-treatment. Gene expression of (A) interleukin-6 (IL-6), (B) nerve growth factor (NGF),
(C) interleukin 8 (IL-8), (D) cyclooxygenase-2 (COX-2), (E) ADAMTS4, (F) ADAMTS5, (G) tissue
inhibitor of matrix metalloproteinase 1 (TIMP1), (H) matrix metalloproteinase 1 (MMP1), (I) matrix
metalloproteinase 3 (MMP3), (J) tissue inhibitor of matrix metalloproteinase 2 (TIMP2), (K) COL1A1,
(L) COL2A1, and (M) Aggrecan in IVD cells treated with 3 and 10 μM AITC. Graphs show gene
expression and protein release calculated relative control (2−ddCt, mean ± SD, n = 3). Asterisks indicate
statistical significance (* p < 0.05, Kruskal–Wallis test and Dunn’s multiple comparison test).
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Figure 5. The effects of TRPA1 agonist allyl isothiocyanate (AITC) on the expression of inflammation
markers and ECM molecules in IL-1β-treated cells. Gene expression of (A) IL-6 and (D) IL-8 in IVD cells
treated with 10 ng/mL IL-1β ± 3 and 10 μM AITC. Protein release of (B) IL-6 and (E) IL-8 in IVD cells
that were treated with 10 ng/mL IL-1β ± 3 and 10 μM AITC. Gene expression of (C) NGF, (F) COX-2,
(G) ADAMTS4, (H) ADAMTS5, (J) MMP1, (K) MMP3, (I) TIMP1 and (L) TIMP2, (M) COL1A1,
(N) COL2A1, and (O) Aggrecan in IVD cells that were treated with 10 ng/mL IL-1β± 3 or 10 μM AITC.
Graphs show gene expression and protein release calculated relative to IL-1β treatment (mean ± SD,
n = 3–4). Asterisks indicate statistical significance (* p < 0.05, Kruskal–Wallis test and Dunn’s multiple
comparison test).
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Figure 6. The effects of TRPA1 agonist allyl isothiocyanate (AITC) on gene expression of inflammation
markers and ECM molecules in TNF-α-treated cells. Gene expression of (A) IL-6 and (D) IL-8 in IVD
cells treated with 10 ng/mL TNF-α ± 3 or 10 μM AITC. Protein release of (B) IL-6 and (E) IL-8 in
IVD cells treated with 10 ng/mL TNF-α ± 3 or 10 μM AITC. Gene expression of (C) NGF, (F) COX-2,
(G) ADAMTS4, (H) ADAMTS5, (I) TIMP1, (J) MMP1, (K) MMP3, and (L) TIMP2, (M) COL1A1,
(N) COL2A1, and (O) Aggrecan in IVD cells treated with 10 ng/mL TNF-α ± 3 and 10 μM AITC.
Graphs show gene expression and protein release calculated relative to TNF-α treatment (mean ± SD,
n = 3-4). Asterisks indicate statistical significance (* p < 0.05, Kruskal–Wallis test and Dunn’s multiple
comparison test).
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2.5. Motion Segments of TRPA1 and TRPV1-Deficient Mice
As our in vitro study showed a possible involvement of TRPA1/TRPV1 in IVD metabolism,
we also focused at their effects in vivo. The possible involvement of TRPA1 and TRPV1 in ECM
homeostasis was studied by comparing the tail motion segments of young (two months old) and mature
(seven months old) TRPA1 wild type (WT) and knock-out (KO) mice (n = 5 in each group) as well
as young (four months old) and mature (seven months old) TRPV1 KO mice (n = 5 in each group).
Anatomically, IVD structures from TRPA1 KO and TRPV1 KO mouse were intact with a distinctive
central NP tissue, surrounded by lamella fibers of annulus fibrosus (AF) and sandwiched with
cartilaginous endplates. However, FAST staining revealed a depletion of sulfated glycoproteins
(Alcian blue) in the NP and a reduction of glycosaminoglycan (GAGs) (Safranin O) in the outer AF
and vertebral growth plates of matured TRPA1 KO mice, when compared with TRPA1 WT matured
controls. No discernible changes of GAG contents were detected in the young TRPA1 KO mouse IVD
(Figure 7). On the contrary, no significant changes in the GAG contents were evidenced in the NP
and vertebral growth plates of TRPV1 KO mice (Figure 8). The data suggested a functional importance
of TRPA1 in GAG production during IVD maturation.
 
Figure 7. FAST staining of IVDs of TRPA1 wild-type (WT) and knock-out (KO) mice. The tail motion
segments of TRPA1 young WT (A,E,I,M), TRPA1 young KO (B,F,J,N), TRPA1 old WT (C,G,K,O),
and TRPA1 old KO (D,H,L,P) mice. The nucleus pulposus: NP (E–H); inner annulus fibrosus:
IAF and outer annulus fibrosus: OAF (I–L); vertebral growth plate: GP (M–P) are also shown in higher
magnification. Asterisks (*) indicate depletion of glycosaminoglycan deposition in IVD. Scale bars
indicate 500 μm in upper panel (A–D), but 50 μm in lower panels (E–P).
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Figure 8. FAST staining of IVDs of TRPA1 WT and TRPV1 KO mice. The tail motion segments of C57 BL/6
young WT (A,D,G,J), TRPV1 young KO (B,E,H,K), and TRPV1 old KO (C,F,I,L) mice. The nucleus pulposus:
NP (D–F); inner annulus fibrosus: IAF and outer annulus fibrosus: OAF (G–I); and, vertebral growth plate:
GP (J–L) are also shown in higher magnification. Scale bars indicate 500 μm in upper panel (A–C), but 50 μm
in lower panels (D–L).
3. Discussion
Several TRP channels are expressed in joints and IVDs, but their potential biological function
and therapeutic relevance are not fully understood. The first aim of this study was to investigate
the expression of TRP channels in IVD cells in normal and inflammatory conditions, as inflammation
is one of the major hallmarks of DDD. We showed that IL-1β significantly induced gene expression of
TRPA1 and TRPV4 and reduced TRPC6. TNF-α significantly increased the gene expression of TRPA1
and TRPV2, while reducing TRPV1. It was previously reported that TRPA1 and TRPV1 are commonly
expressed in sensory neurons that can innervate joints and IVDs as well as in chondrocytes, where they
are associated with degenerative changes [24,27,28].
We found that gene expression of TRPA1 is undetectable in mature healthy human IVDs
and untreated cultured IVD cells. Interestingly, TRPA1 was expressed in 20% of degenerated IVDs,
possibly due to the presence of pro-inflammatory cytokines. TRPA1 was also expressed in cells isolated
from fetal disc tissue and in healthy juvenile samples, which pointed towards its involvement in disc
development and/or maturation. FAST staining of tail motion segments of TRPA1 KO and TRPV1
KO mice suggested that TRPA1 might be involved in the homeostasis of GAG maintenance during
the development of the IVD. Although these results corresponded to our findings in human IVD
tissues/cells, they should be interpreted with caution, as differences between mice and human IVDs
exist (e.g., the presence of notochordal cells in mice, degenerative status of mature mouse disc vs.
human disc).
To evaluate the possible effects of TRPA1/TRPV1 activation in IVD cells, we used
the TRPA1/TRPV1 agonist allyl isothiocyanate (AITC) [29]. AITC (or mustard oil) is commonly
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regarded as pro-inflammatory and nociceptive [30]. For example, TRPA1-deficient mice do not display
acute pain-related behavior after the application of AITC to paws [31]. Our data indicated that
the activation of TRPA1 may be the main mechanism for AITC-evoked increase in [Ca2+]i in IVD
cells. In the non-inflamed IVD cells (expressing TRPV1), 10 μM AITC stimulation was not associated
with significant pro-inflammatory/catabolic effects, except for an increase in MMP1. In contrast,
AITC-mediated regulation of gene expression of ADAMTS5, IL-8, and COL1A1 in cytokine-stimulated
cells was likely to be TRPA1 dependent. The TRPA1 downstream effects may depend on agonist
concentration, as previously shown by others [32,33] and in our study (reduced IL-8 in cells treated with
3 μM AITC vs. upregulated IL-8 in in cells treated with 10 μM AITC). The expression level of TRPA1
itself can be another reason for the observed differences in IL-8 release between IL-1β and TNF-α
treated cells (lower relative TRPA1 expression in IL-1β-stimulated cells vs. TNF-α-stimulated cells).
The downregulation of COL1A1 and upregulation of IL-8 in TNF-α, but not IL-1β-treated cells, may be
related to lower expression of TRPV1. Altogether, our data suggested that TRPA1 might be involved
in the regulation of ECM homeostasis. However, major limitation of this study is low sample number,
which prevents definite conclusions.
DDD is considered to be similar to chronic arthritis, due to the fact that common mechanisms
are involved in the progression of both diseases [12]. Similar to our findings, the expression of
TRPA1 in primary human osteoarthritic (OA) chondrocytes increased upon stimulation with IL-1β,
IL-17, LPS, and resistin [24]. Horvath et al. (2016) showed that the markers of chronic arthritis
(chronic mechanical hypersensitivity, joint swelling, histopathological alterations, vascular leakage)
were significantly reduced in TRPA1 KO mice (vs. wt), which indicated the involvement of
TRPA1 in this disease [34]. A similar association of TRPV1 with chronic arthritis was previously
demonstrated [35,36]. Interestingly, acute joint pain behaviors were not modified in TRPA1 KO
mice [34]. The distinct roles of TRPA1 in chronic vs. acute arthritis could be attributed to a different
distribution of TRPA1 (and possibly TRPV1) on sensory nerves and non-neuronal cells in these
pathological conditions [34], e.g., due to the presence of pro-inflammatory cytokines. In this context,
the modulation of inflammation itself can possibly regulate TRP channel activities (e.g., TRPV1 can be
sensitized/desensitized by endogenous products of inflammation [37]). Importantly, pro-inflammatory
cytokines (IL-1β and TNF-α) can cause [Ca2+]i increase in OA chondrocytes [34], but likely not in IVD
cells [34], which might be related to differences in the TRP channel expression/activation/function in
OA and DDD.
Chronic inflammation in both OA and DDD is associated with neuronal plasticity, which is
an important mechanism in the development and maintenance of chronic pain [38]. Our current study
did not employ an IVD degeneration/pain model, and thus it did not test the involvement of sensory
neurons. Future studies will focus on the interplay between TRPA1/TRPV1 in inflamed IVD cells
and DRG neurons, as well as on more specific activation/inhibition experiments by gene editing,
both in vitro and in experimental animals.
Although TRPA1/TRPV1 antagonists/agonists have reached clinical trials for the treatment of
inflammatory and neuropathic pain [39–41], discrepancies as to whether and how these channels
contribute to the underlying mechanisms of inflammatory and neuropathic hypersensitivity can still
be found in the literature [42]. Some endogenous ligands of TRPA1 might not yet be discovered and it
is still unclear how physiological loading, which is an important parameter in IVD health, regulates
the activity of TRPA1. It is likely that TRPA1 activation may be protective under certain circumstances
and/or in particular cell types, possibly including the IVD. The protective anti-inflammatory
effects of TRPA1 were recently demonstrated in mouse model of colitis [43], with TRPA1 KO mice
having a significantly higher ‘Disease Activity Index’ and levels of pro-inflammatory neuropeptides
and cytokines in the distal colon [43]. Another study showed that both the colonic and systemic
administration of AITC and capsazepine (another TRPA1 agonist) induced a profound, body-wide
TRPA1-mediated desensitization of nociception in mice [44]. The authors suggested that systemic
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desensitization through TRPA1 might provide a novel strategy for the medicinal treatment of various
chronic inflammatory and pain states [44], which possibly included DDD.
Concerning other TRP channels that were regulated by an inflammatory environment in this study,
increased TRPV4 expression/signaling in the IVD has been associated with decreased tissue osmolarity
and the production of pro-inflammatory cytokines [17]. Our study provided evidence that IL-1β itself
can regulate gene expression of TRPV4 in IVD cells., the Gene expression of TRPC6 was shown to
be reduced in IVD cells under microgravity [18], but elevated in IVDs with increasing degeneration
grade [19]. In our study, TRPC6 was downregulated by IL-1β treatment. To explain these inconsistencies
and their pathophysiological relevance, the activity, stability, and subcellular localization of TRPC6
will be investigated in the future. Possibly, the activity of TRPC6 may be regulated by exocytosis [45],
while cytoplasmic calcium may influence its expression and degradation [46,47], the levels of which are
dysregulated in degenerated IVD cells [48]. To our knowledge, this is the first study that reported
the downregulation of TRPV1 and upregulation of TRPV2 by TNF-α in IVD cells. The expression of
TRPV2 was shown upregulated in inflamed DRGs [49], where it possibly participated in calcitonin
gene-related peptide (CGRP) release [50].
4. Materials and Methods
4.1. Subjects
4.1.1. Non-Degenerated Human IVD Tissue
cDNA was synthesized from the non-degenerated human IVD cells, (gift provided by
Prof. Lisbet Haglund from the Department of Surgery at McGill University, Canada), and prepared
as previously described [51]. Informed consent for tissue collection was obtained from family members
and the study was approved through the local ethics committee (A04-M53-08B).
4.1.2. Human IVD Tissue
25 human degenerated lumbar IVD samples were used for direct tissue analysis. These biopsies
were obtained from 20 donors [mean age = 46.2 years (16–76 years); nine male and eleven
female] undergoing elective spinal surgery. IVD samples were intraoperatively separated into
annulus fibrosus (AF, n = 11) and nucleus pulposus (NP, n = 14), followed by macroscopic tissue
evaluation. The assessment of the disease state was performed using Pfirrmann and Modic grading.
Demographic details are shown in Table 3—Tissue and [19]. An additional 30 lumbar degenerated IVDs,
removed during surgeries for disc herniation (DH) or degenerative disc disease (DDD), were used for
preparation of primary cell cultures. All of the biopsies were obtained with patient’s informed consents.
The Ethics Committee of Cantons Zurich and Lucerne approved the study (#1007). Demographic details
are shown in Table 3—Cells.
Table 3. Donors used for tissue and cell culture analyses. DH = herniation, DDD = degenerative disc
disease, AF = annulus fibrosus, NP = nucleus pulposus, uk = unknown.
Tissue
Donor Age Gender Pathology Tissue Level Grade Experiments
T1 30 m DDD AF, NP L4/5 II qPCR
T2 46 f DH AF, NP L5/S1 III qPCR
T3 34 m DH AF, NP L5/S1 III qPCR
T4 46 f DH AF, NP L4-S1 V qPCR
T5 59 f DDD AF, NP L5/S1 V qPCR
T6 62 f DDD AF L5/S1 V qPCR
T7 66 f DH AF L4/5 II qPCR
T8 53 m DH NP L5/S1 II qPCR
T9 59 m DH NP L4/L5 II qPCR
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Table 3. Cont.
Tissue
Donor Age Gender Pathology Tissue Level Grade Experiments
T10 52 m DDD NP L4/L5 III qPCR
T11 64 f DDD NP L4/L5 IV qPCR
T12 76 f DH NP L4/L5 III qPCR
T13 16 f DH NP L4/L5 III qPCR
T14 31 m DDD AF L4/5L5/S1 IV qPCR
T15 54 f DH NP L5/S1 II qPCR
T16 33 m DH AF L5/S1 II qPCR
T17 70 f DDD NP L4/5 IV qPCR
T18 39 m DH AF L5/S1 III qPCR
T19 28 m DH NP L5/S1 II qPCR
T20 21 f DDD AF L4/5 III qPCR
Cells
Donor Age Gender Pathology Tissue Level Grade Experiments
C1 44 F uk uk L3/L4 uk qPCR
C2 82 M uk uk L5/S1 uk qPCR
C3 28 M uk uk L5/S1 uk qPCR
C4 uk uk uk uk uk uk qPCR, ELISA
C5 uk uk uk uk uk uk qPCR, ELISA
C6 39 M DDD, DH Mix L4/L5 IV ELISA
C7 58 M DDD, DH Mix L5/S1 IV qPCR, ELISA
C8 46 F DH - L5/S1 IV qPCR, ELISA
C9 52 M DDD, DH Mix L5/S1 V qPCR, ELISA
C10 46 F DDD, DH Mix L4/L5 IV qPCR, Ca imaging
C11 58 M uk Mix L4/L5 IV Ca imaging
C12 31 M DDD, DH Mix L5/S1 IV qPCR
C13 46 M DH Mix C5/C6 III qPCR
C14 40 F DH Mix L4/L5 III qPCR
C15 40 M DH NP L4/L5 III qPCR
C16 66 F DH NP L4/L5 III Ca imaging
C17 uk uk uk uk uk uk qPCR, ELISA
C18 50 F DH Mix L5/S1 IV qPCR
C19 42 M DH Mix L5/S1 V qPCR
C20 68 F listhesis Mix L4/L5 III qPCR
C21 38 M DH Mix L5/S1 III qPCR, ELISA
C22 41 F DH Mix L4/5 III qPCR, ELISA
C23 42 M DH NP L5/S1 IV qPCR, ELISA
C24 41 F DH Mix L5/S1 III qPCR, ELISA
C25 45 M DH NP L4/L5 IV qPCR, ELISA
C26 71 uk DDD Mix L4/5 III qPCR, ELISA
C27 55 F DH NP L5/6 I qPCR, ELISA
C28 55 F DH NP L5/6 II Immuno
C29 55 M DH Mix L5/S1 II Immuno
C30 58 M DH Mix L4/5 IV Immuno
C31 34 M - NP, AF L1/2-L2/3-L3/4I qPCR
C32 55 F - NP, AF L1/2 III qPCR
C33 52 M - NP L1-L5 I qPCR
C34 17 M - NP T12-S1 I qPCR
LC1 16 M - mix uk II qPCR
LFC2 Fetal IVD cells, Male, 16 weeks: p5 qPCR
LFC3 Fetal IVD cells, Male, 14 weeks: p4 qPCR
LFC4 Fetal IVD cells, Male, 14 weeks: p4 qPCR
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4.1.3. Human Fetal IVD Cells
The cell cultures were derived from biopsies that were obtained in accordance with the Ethics
Committee of the University Hospital of Lausanne (Ethics Protocol 51/01) and following the Federal
Transplantation Program guidelines. The cell banks are managed in the Department Biobank following
the regulations of the Biobank for clinical research for both the fetal and adult tissue. Specific biopsies
consisting of a spinal unit of three vertebra and two discs representing tissue of 6.5 mm × 5 mm in
size were obtained from fetal tissue following the voluntary interruption of pregnancy at 14–16 weeks
of gestation. Biopsies were first rinsed in 1% penicillin/strepotomycin in phosphate buffer saline (PBS)
and adjacent soft tissue that was delicately dissected from the main disc tissue. We thereafter prepared
one IVD and two adjacent vertebrae from a fetal spine unit; primary cultures used Dulbecco’s
Modified Eagle’s medium (DMEM) (41966-029, Gibco, Waltham, MA, USA) that was supplemented
with 10% fetal bovine serum and 100 mM L-Glutamine (25030-024, Gibco). Culture conditions were
at 37 ◦C under 5% CO2. One juvenile patient was also used. Cell cultures from the juvenile patient
following discectomy were established as above, except type II collagenase digestion, was implemented.
Cells were expanded and stored frozen in liquid nitrogen at passage 1 or 2 and the cells were thawed,
expanded in monolayer at passage 3, and used for analysis following passage 4. Table 3 shows
donor details.
4.1.4. Knock-Out Mice
Tails from C57BL/6 TRPA1 wild-type (WT) and knock out (KO) mice and 15 TRPV1 WT and KO
mice were used (Table 4). The mice were divided into two groups: young (two, four months old)
and mature (seven months old) and euthanized in the context of other research activities. C57BL/6
mice were use as control for TRPV1 KO as this strain was backcrossed 10× to the C57BL/6 background.
Immediately after euthanasia with pentobarbital (100 mg/kg i.p.), the tails were dissected, skinned,
rinsed in PBS, and fixed in 4% paraformaldehyde solution (Szkarabeusz Kft., Pecs, Hungary) in 0.1 M
phosphate buffer. After two days, the fixed tails were washed with PBS and then placed into 10%
EDTA (E6758, Sigma, St. Louis, MO, USA) exchanged every two days. After 10 days, the decalcified
samples were washed in PBS and placed into 70% ethanol (51976, Sigma) at 4 ◦C until paraffin
embedding. Paraffin blocks were then used to prepare 5 μm sections.
Table 4. Mouse spines used for FAST staining.
Mice 2 Months Old 4 Months Old 7 Months Old
TRPA1 WT n = 5 - n = 5
TRPA1 KO n = 5 - n = 5
TRPV1 KO - n = 5 n = 5
C57BL/6 - n = 5 -
4.2. Cell Culture
4.2.1. 2D Cell Culture
IVD tissue was diced to around 1 mm3 pieces and treated with a mixture of 0.3%
dispase (04942078001, Roche Diagnostics, Mannheim, Germany) and 0.2% collagenase
(17454, SERVA Electrophoresis, Heidelberg, Germany) in PBS at 37 ◦C for 4–8 h to isolate the cells.
After the incubation, the suspension was filtered through a 70 μm cell strainer (542070, Greiner
Bio-One, Kremsmünster, Austria), centrifuged at 700× g for 5 min, and resuspended in DMEM/F12
(31330-038, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum
(FCS, F7524, Merck, Darmstadt, Germany), 100 units/mL penicillin, 100 μg/mL streptomycin,
and 250 ng/mL amphotericin B (15240-062, Gibco, Carlsbad, CA, USA). The primary IVD cells were
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expanded in monolayer in a standard cell culture incubator (5% CO2, 37 ◦C) up to passage 3 before
being used in the experiments.
4.2.2. 3D Cell Culture
The IVD cells were detached using 1.5% trypsin (15090-046, Thermo Fisher Scientific) and seeded
in 1.2% alginate (71238-50G, Sigma, St. Louis, MO, USA) at a density of 4 × 106 IVD cells per
1 mL alginate, as described previously [52]. Briefly, the cells-alginate mixture was dropped into
102 mM calcium chloride solution (1.02382, Merck) while using a sterile syringe and needle and left for
8 min to polymerize under gentle stirring until beads were formed. After washing with 0.9% NaCl
(1.06404, Merck) and PBS (3 × 1 min), the beads were transferred into six well plates and pre-cultured
for seven days.
4.2.3. Cell Viability of 3D Cell Culture
Cell viability in the alginate beads was tested using calcein/ethidium homodimer staining.
Staining solution was prepared by mixing culture media with 2 μM ethidium homodimer
(46043, Sigma) and 2 μM calcein-AM (17783, Sigma). 200 μL/well of the staining solution was added
into a 96-well plate containing beads (one bead per culture condition per well) and then incubated
for 30 min. Subsequently, the beads were gently squeezed between cover slips and three photos were
randomly captured with a fluorescence microscope (Olympus IX51, Tokyo, Japan) at the wavelength
of 515 nm (calcein: living cells) and 620 nm (ethidium: dead cells). The cell numbers in each image
were counted by ImageJ ver.1.51j8 and averaged. Cell viability is shown as the number of living cells
per total cells.
4.3. Treatments
4.3.1. 2D Cell Cultures
Table 5 shows all treatments. Experiments were conducted in culture media without antibiotics
and FCS (= experimental media). For gene expression analysis and ELISA, the IVD cells were seeded into
T25 flasks (3.5 × 105 cells/flask) or six-well plates (3 × 105 cells/well). For immunofluorescence,
1 × 105 cells were seeded into the wells of chambered slides (155380, Thermo Fisher Scientific).
For Calcium imaging, the 4 × 104 cells were seeded into 96-well plates in triplicates and incubated for 18 h.
The next day, complete media was changed to the experimental media. After 2 h in experimental media,
the cells were exposed to 5 or 10 ng/mL recombinant TNF-α (315-01A, PeproTech, Umkirch, Germany)
or IL-1β (200-01B, PeproTech) for 18 h. Non-stimulated cells were used as the controls. To investigate
the effects of TRPA1 and TRPV1 activation, 3 and 10 μM allyl isothiocyanate (AITC, TRPA1 agonist,
377430, Sigma) was used either in untreated cells or in IL1-β and TNF-α treated cells (focus on TRPA1,
whose expression is increased in an inflammatory environment). The EC50 value for AITC that is
reported in the literature is approximately 3 μM, while AITC concentrations higher than 10 μM may
cause channel desensitization [32,33].
4.3.2. 3D Cell Cultures
The experiments were conducted in culture media without antibiotics and with FCS. On day 7,
cells in alginate beads were stimulated with 5 ng/mL IL-1β and collected after 24 h (day 1), eight days
(day 8), and 15 days (day 15) (Table 5). Culture media for the latter group was exchanged on day 8,
with new 5 ng/mL IL-1β. At the end of the experiment, the cells were liberated from the beads
in 1.9 mL of 55 mM sodium citrate solution (71406, Sigma) and centrifuged at 700× g for 5 min.
Cell pellets were used for subsequent analyses.
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Table 5. Details of cell culture treatments.
Compound Catalog Number Function Concentration Exposure Time Experiment
TNF-α 315-01A PeproTech Inflammatory cytokine 5, 10 ng/mL 18 h qPCR Ca imaging
IL-1β 200-01B PeproTech Inflammatory cytokine
5, 10 ng/mL 18 h qPCR Ca imaging
5 ng/mL 1, 8, 15 days qPCR (from 3D)
5 ng/mL 18 h Immuno
AITC 377430 Sigma TRPA1 agonist
3 μM, 10 μM 18 h qPCR, ELISA
100 μM during the measurement Ca imaging
4.4. Analyses
4.4.1. Gene Expression Analysis of IVD Tissue
RNA extraction from IVD tissue and the following steps were performed according to [19].
For cDNA synthesis, two micrograms of RNA were used in a total volume of 60 μL, while using
the reverse transcription kit (4374966, Applied Biosystems, Foster City, CA, USA). For samples with
lower yields, the reverse transcription was conducted at reduced concentrations. cDNA (10 ng/well)
was mixed with TaqMan Fast Universal PCR Master Mix and TaqMan primers (Table 6) to quantify
gene expression. The obtained Ct values were analyzed by a comparative method and displayed
as 2−dCt values, with GAPDH as housekeeping gene.
4.4.2. FAST Staining
To study the glycosaminoglycan (GAG) contents in IVD, a multi-dye histological staining
using Fast green, Alcian blue, Saffranin-O, and tartrazine was performed on IVD tissue sections
accordingly [53]. In brief, parafilm embedded tissue sections were first dewaxed in xylene and then
rehydrated in a stepwise gradient of ethanol. The IVD sections were first stained with 1% Alcian blue
8GX (A3157, Sigma) pH 1.0 for 1 min, followed by 0.1% Saffranin-O (S8884, Sigma) for 3 min.
Saffranin-O reddish colour differentiation was performed in 25% ethanol for 15 s. The tissue sections
were then stained in 0.08% Tartrazine (T0388, Sigma) with 0.25% acetic acid for 45 s and finally
counterstained by 0.01% Fast green (F7258, Sigma) solution for 5 min. Sections were finally air-dried,
mounted in DePeX (BDH Laboratory; Poole, UK), and examined under a Nikon Eclipse 80i microscope
(Tokyo, Japan).
4.4.3. Gene Expression Analysis of IVD Cells
RT-qPCR was performed to analyze the expression of target genes (Table 6). The cells were
lysed with 1 mL Trizol (Genezol, GZR200, Geneaid biotech, New Taipei City, Taiwan) and RNA was
isolated according to the manufacturer’s recommendations. Briefly, after adding chloroform
(132950, Sigma), the samples were mixed well for 15 s, left for 5 min at RT, and centrifuged (12,000× g
for 15 min). Supernatants were carefully transferred to new RNase free tubes, 500 μL of isopropanol
(20842, VWR chemicals, Fontenay-sous-Bois, France) was added and mixed well. After 5 min,
the samples were centrifuged again (12,000× g for 15 min). The pellets were washed with 75% ethanol
(1.00983, Merck) at 7500× g for 5 min and then dissolved in RNase free water (10977, Invitrogen,
Carlsbad, CA, USA). The purity and concentration of the resulting RNA were measured using
the NanoDrop (ND-1000, Thermo Fisher Scientific). 1 μg of total RNA was reverse-transcribed to
cDNA using a reverse transcription kit (4374966, Applied Biosystems, Foster City, CA, USA). qPCR of
the mixture of primers/probes (Table 6) and master mix (4367846, Applied Biosystems) was performed
on the CFX96 Real-Time System (Bio-Rad Laboratories, Hercules, CA, USA). The amplification program
was as follows: heating at 95 ◦C for 10 min; 40 cycles of 95 ◦C for 1 s and 60 ◦C for 20 s. The relative
expression level was calculated by the ddCt method. For normalization purposes, the samples with
undetectable expression were assigned Ct value 40. The results are shown as fold change, relative to
control or relative to cytokine treatment.
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Table 6. Target genes and assay identification (ID) numbers of corresponding TaqMan primers
(TaqMan Gene Expression Assays; Thermo Fisher Scientific). TRP = transient receptor
potential; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase;
ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; COX-2 = cyclooxygenase-2;
NGF = nerve growth factor. IL-6 = interleukin 6; IL-8 = interleukin 8; HKG = housekeeping gene.
Target Gene Assay ID Putative Association with Inflammation
TBP Hs00427620_m1 HKG in the cell culture study and fetal cells
GAPDH Hs02758991_g1 HKG in the tissue study
TRPA1 Hs00175798_m1 inflammatory pain [12]
TRPC1 Hs00608195_m1 bladder inflammation (neuronal) [54]
TRPC3 Hs00162985_m1 inflammatory pain [55]
TRPC6 Hs00988479_m1 IVD inflammation (putative) [18,19]
TRPV1 Hs00218912_m1 neuroinflammation [20]
TRPV2 Hs00901648_m1 inflammation in DRG [49]
TRPV4 Hs01099348_m1 lung inflammation [56]
TRPV6 Hs00367960_m1 association with TNF-α [57]
TRPM2 Hs01066091_m1 inflammatory and neuropathic pain [58]
TRPM7 Hs00559080_m1 inflammation in colitis [59]
IL-6 Hs00174131_m1 inflammation mediator [60]
IL-8 Hs00174103_m1 inflammation mediator [60]
MMP1 Hs00233958_m1 cleaves mainly collagens (I, II, III) [61]
MMP3 Hs00968305_m1 cleaves proteoglycans and collagens (II, III) [61]
ADAMTS4 Hs00192708_m1 cleaves mainly aggrecan [61]
ADAMTS5 Hs01095518_m1 cleaves mainly aggrecan [61]
TIMP1 Hs00234278_m1 inhibits MMPs (1, 3) and ADAMTS (4) [61]
TIMP2 Hs01092512_g1 inhibits all MMPs [61]
COX-2 Hs00153133_m1 pain mediator [62]
NGF Hs00171458_m1 nerve ingrowth [38]
COL2A1 Hs00264051_m1 ECM constituent
COL1A1 Hs00164004_m1 ECM constituent
Aggrecan Hs00153936_m1 ECM constituent
4.4.4. Immunofluorescence
The cells were seeded into the wells of chambered slides, washed with PBS, fixed with ice
cold methanol (10 min), and blocked with 5% normal goat serum in PBS (1 h at RT). A primary
antibody recognizing the N-terminus of the human TRPA1 protein (NB110-40763, Novus Biologicals)
was diluted in 1% normal goat serum in PBS (1:200) (G9023, Sigma) and applied 1h under agitation
at RT. Cells without primary antibody were used as immunospecificity control. After washing with PBS
(3 × 5 min), a secondary antibody that was diluted in 1% normal goat serum (1:200) (Cy2 anti-rabbit
IgG, 111-225-144, Jackson Immuno Research) was applied for 1 h at RT under agitation. Next, cells
were washed with PBS (3 × 5 min), coverslipped with 1–2 drops of antifade mounting medium with
DAPI (VECTASHIELD; H-1200), and imaged with a fluorescence microscope (Olympus IX51).
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4.4.5. Enzyme-Linked Immunosorbent Assay (ELISA)
To quantify the release of inflammatory markers from IVD cells, the cell culture medium was
collected and analyzed with IL-6 and IL-8 ELISA kit, according to the manufacturer’s protocol
(IL-6 555220, IL-8 555244, BD Biosciences, San Jose, CA, USA). 96-well plates were coated with
capture antibody overnight. After washing, the wells were blocked in assay diluent, washed, loaded
with samples or human recombinant IL-6 or IL-8 protein standards, and incubated for 2 h at RT.
After washing, detection antibody and streptavidin-horseradish peroxidase (HRP) were applied for 1 h.
Next, the plates were washed and substrate solution was added. After 30 min, the reaction was
stopped by kit stop solution and the absorbance was measured at 450 nm, with 570 nm correction.
The IL-6 and IL-8 concentrations were calculated based on the standard curve. IL-6 and IL-8 in culture
media are shown relative to the cytokine treatment.
4.4.6. [Ca2+]i Imaging
Fura-2 QBT™ Calcium Kit was used to measure the increase in intracellular calcium
(R8197, Molecular Devises, San Jose, CA, USA). Briefly, culture media was replaced with Fura-2-AM kit
solution and the cells were incubated for 1 h. Basal Fura-2 fluorescence was recorded for 5 min using
a plate reader (infinite M200 pro, Tecan, Männedorf, Switzerland) at an excitation wavelength of 340
and 380 nm and an emission wavelength of 510 nm. After five cycles, the cells were exposed in 100 μM
of AITC (to activate disc cells within a short timeline) and the measurement was continued. Ionomycin
(13909, Sigma) was used as a positive control for channel stimulation. Data is shown as the ratio of
340/380 wavelengths.
4.4.7. Statistical Analysis
Statistical analysis was performed in GraphPad Prism 8.0.0. Groups were compared using
the Kruskal–Wallis nonparametric test followed by Dunn’s multiple comparison test. Data is shown
as mean ± SD. p < 0.05 was considered to be statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.001).
5. Conclusions
To our knowledge, this is the first study that demonstrated a cytokine-dependent increase
in the gene expression of TRPA1, TRPV2, and TRPV4 and a decrease in the gene expression of
TRPC6 and TRPV1 in human IVD cells. Although TRPA1 and TRPV1 are commonly associated with
inflammatory pain, their activation in inflamed IVD cells did not have profound pro-inflammatory
and catabolic effects. Instead, TRPA1 expression and activation was associated with ECM metabolism.
Future studies will use targeted gene editing techniques to elucidate the exact role of TRPA1/TRPV1
in DDD.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/7/
1767/s1.
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Abstract: Transient receptor potential ankyrin type-1 (TRPA1) channels are known to actively
participate in different pain conditions, including trigeminal neuropathic pain, whose clinical
treatment is still unsatisfactory. The aim of this study was to evaluate the involvement of TRPA1
channels by means of the antagonist ADM_12 in trigeminal neuropathic pain, in order to identify
possible therapeutic targets. A single treatment of ADM_12 in rats 4 weeks after the chronic
constriction injury of the infraorbital nerve (IoN-CCI) significantly reduced the mechanical allodynia
induced in the IoN-CCI rats. Additionally, ADM_12 was able to abolish the increased levels of
TRPA1, calcitonin gene-related peptide (CGRP), substance P (SP), and cytokines gene expression
in trigeminal ganglia, cervical spinal cord, and medulla induced in the IoN-CCI rats. By contrast,
no significant differences between groups were seen as regards CGRP and SP protein expression in
the pars caudalis of the spinal nucleus of the trigeminal nerve. ADM_12 also reduced TRP vanilloid
type-1 (TRPV1) gene expression in the same areas after IoN-CCI. Our findings show the involvement
of both TRPA1 and TRPV1 channels in trigeminal neuropathic pain, and in particular, in trigeminal
mechanical allodynia. Furthermore, they provide grounds for the use of ADM_12 in the treatment of
trigeminal neuropathic pain.
Keywords: neuropathic pain; trigeminal system; allodynia; TRPA1; TRPV1
1. Introduction
Trigeminal neuralgia (TN) is a rare condition characterized by paroxysmal attacks of sharp pain,
frequently described as an “electric shock”. Up to 50% of patients with trigeminal neuralgia also
have continuous pain in the same territory, which results in greater diagnostic difficulties, higher
disability, and lower response to medical and surgical treatments [1]. Three diagnostic categories
of TN are identified by the recent classification of headache disorders: Classical (without apparent
cause other than neurovascular compression), secondary (caused by an underlying neurological
disorder), and idiopathic (no cause is found) [2]. TN has a negative impact on activities of daily living,
Int. J. Mol. Sci. 2018, 19, 3320; doi:10.3390/ijms19113320 www.mdpi.com/journal/ijms93
Int. J. Mol. Sci. 2018, 19, 3320
with up to 45% of patients being absent from usual daily activities for 15 days or more, and one third
suffering from mild-to-severe depression [3]. Medications for TN exist, but they are poorly tolerated
or ineffective. For this reason, multiple surgical approaches have been developed, but a portion of
patients are refractory to both medical and surgical approaches [4,5]. Hence, there is need for further
investigation into the mechanisms underlying pain in TN in order to identify new, possibly more
effective, therapeutic targets.
In recent years, transient receptor potential (TRP) channels have attracted much attention in
the pain field. These channels are non-selective cation channel proteins, widely distributed in many
tissues and cell types, localized in the plasma membrane and membranes of intracellular organelles [6].
The TRP ankyrin type-1 (TRPA1) channels, mainly expressed with the vanilloid type-1 (TRPV1),
are localized in a subpopulation of C- and Aδ-fibers of neurons located in the dorsal root ganglia
(DRG) and trigeminal ganglia (TG) that produce and release neuropeptides, such as substance P
(SP), neurokinin A, and calcitonin gene-related peptide (CGRP) [7–9]. Many experimental studies,
from genetic knockouts to pharmacological manipulation models, reported a critical involvement of
TRPA1 channels in different aspects of pain [10] and a role in several models of nerve injury, such as the
lumbar spinal nerve ligation [11], and sciatic nerve injury by chronic constriction or transection [12–14].
In these models, it was demonstrated that an up-regulation of TRPA1 is associated with mechanical
and thermal hyperalgesia, a condition reversed by TRPA1 antagonists [15,16]. In a recent study,
Trevisan and colleagues [17] reported that pain-like behaviors are mediated by the TRPA1 channel
in an animal model of TN based on the constriction of the infraorbital nerve (IoN) via the increased
oxidative stress by-products released from monocytes and macrophages that gather at the site of
nerve injury.
The aim of this study was to further investigate the role of TRP channels in trigeminal neuropathic
pain induced by the model of a chronic constriction injury of the IoN (IoN-CCI) [18]. More specifically
we evaluated: (i) The modulatory effect of TRPA1 antagonism, by means of ADM_12 treatment,
on IoN-CCI-induced allodynia; (ii) the levels of TRPA1 and TRPV1 mRNA in specific cerebral and
peripheral areas involved in trigeminal sensitization, with particular attention to changes in expression
levels of genes coding for CGRP, SP, and cytokines after TRPA1 antagonism; and (iii) the expression of
CGRP and SP proteins in the Spinal Nucleus of trigeminal nerve pars caudalis (Sp5C).
2. Results
2.1. ADM_12 Effect on Behavioral Response
In agreement with Deseure and Hans [18], 5 days after surgery, the two groups of rats that
underwent IoN-CCI displayed a lack of responsiveness to ipsilateral mechanical stimulation testing
(MST) of the IoN territory (Figure 1A). At day 12, the hyporesponsiveness was recovering to be
replaced at day +26 by a significant increase in the MST response score as compared to the two Sham
groups (Figure 1A). On day +27, the administration of the TRPA1 antagonist treatment in operated rats
(IoN-CCI2 group) reduced the response score of the mechanical stimulation compared to the IoN-CCI1
group (injected with saline) (Figure 1B); whereas, ADM_12 treatment in sham-operated rats (Sham2
group) did not change the mechanical response. It is of note that the response to MST in the IoN-CCI2
group was significantly different between day +26 (before ADM_12 injection) and +27 (after drug
treatment) (Figure 1C).
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Figure 1. Mechanical stimulation testing (MST): (A) Mean response score to Von Frey hair stimulation
of the ligated/sham infraorbital nerve (IoN) territory, on pre-operative day (PO) and on +5, +12, +18,
and +26 days post operation. Data is expressed as mean ± SEM. Two-way ANOVA followed by
Bonferroni post-hoc test, * p < 0.05 and *** p < 0.001 for chronic constriction injury of the infraorbital
nerve (IoN-CCI) groups vs. Sham groups. Drug treatment effect on MST: (B) Mean response score to
Von Frey hair stimulation on day +27, 1 h after ADM_12 (or saline) treatment. Data is expressed as mean
± SEM. One-way ANOVA followed by Tukey’s Multiple Comparison Test, * p < 0.05 vs. Sham1 and
Sham2, *** p < 0.001 vs. IoN-CCI1. (C) Comparison of the IoN-CCI2 group without treatment (day +26)
and after ADM_12 treatment (on day +27). Data is expressed as mean ± SEM. Paired Student’s t test,
§§§ p < 0.001 vs. day +26.
2.2. ADM_12 Effect on Gene Expression
The expression of Trpa1, calcitonin-related polypeptide alpha (Calca), and preprotachykinin-A,
(PPT-A) was evaluated in the TG and cervical spinal cord (CSC) ipsilateral (ipsi) and contralateral
(contra) to the IoN ligation, and in the medulla in toto. Because of the strong relationship between
TRPA1 and TRPV1 channels [19–21], we also investigated the Trpv1 mRNA expression levels in the
same areas.
2.2.1. Trpa1 mRNA Expression
In the ipsilateral TG and CSC, and in medulla region, Trpa1 mRNA expression levels were
significantly increased in the IoN-CCI1 group compared with Sham1 and Sham2 groups (Figure 2).
The increased mRNA levels were significantly reduced after treatment with ADM_12 in IoN-CCI
rats (IoN-CCI2 group) in the same regions (Figure 2). ADM_12 administration did not provoke any
changes in sham-operated rats.
A significant difference in mRNA levels, both in TG and CSC, was detected between sides in the
IoN-CCI1 group; whereas, there was no difference between groups when comparing Trpa1 mRNA
levels on the contralateral side of TG and CSC (Figure 2A,B).
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Figure 2. Trpa1 mRNA expression in trigeminal ganglia (TGs) (A), cervical spinal cord (CSC)
(B), and medulla (C). Data is expressed as mean + SEM. One way analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison Test or Two-way ANOVA followed by Bonferroni post-hoc
test, *** p < 0.001 vs. Sham1 and Sham2 (ipsi), ◦◦◦ p < 0.001 vs. IoN-CCI1 (ipsi), ˆˆˆ p < 0.001 vs.
IoN-CCI1 (contra).
2.2.2. Trpv1 mRNA Expression
In the ipsilateral TG and CSC, and in the medulla region, Trpv1 mRNA expression levels were
significantly increased in the IoN-CCI1 group compared with Sham1 and Sham2 groups (Figure 3). The
mRNA levels of Trpv1 were also significantly higher in the IoN-CCI1 group in the contralateral CSC
when compared to Sham groups (Figure 3B), though this increase was less marked than the increase
observed on the ipsilateral side. The increased mRNA levels in these areas were significantly reduced
by ADM_12 treatment in CCI rats (IoN-CCI2 group) in ipsilateral TG and CSC, and in medulla in toto
(Figure 3). ADM_12 administration did not provoke any changes in sham-operated rats.
Figure 3. Trpv1 mRNA expression in TGs (A), CSC (B), and medulla (C). Data is expressed as mean
+ SEM. One way analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test or
Two-way ANOVA followed by Bonferroni post-hoc test, *** p < 0.001 vs. Sham1 and Sham 2 (ipsi),
◦◦◦ p < 0.001 vs. IoN-CCI1 (ipsi), ˆˆˆ p < 0.001 vs. IoN-CCI1 (contra), # p < 0.05 vs. Sham1 and
Sham2 (contra).
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A significant difference was seen between the ipsi- and contralateral side (both in TG and CSC) in
the IoN-CCI1 (Figure 3A,B).
2.2.3. Calca mRNA Expression
In the ipsilateral TG and CSC, and in the medulla region, Calca mRNA expression levels were
significantly increased in the IoN-CCI1 group compared with Sham1 and Sham2 groups (Figure 4).
Moreover, Calca mRNA levels in IoN-CCI1 and IoN-CCI2 groups were also significantly increased
in the contralateral TG as compared to Sham groups (Figure 4A). The increased mRNA levels were
significantly reduced after treatment with ADM_12 in IoN-CCI2 rats in ipsilateral TG and CSC, and in
medulla in toto (Figure 4). ADM_12 administration did not provoke any changes in sham-operated
rats (Figure 4).
Figure 4. Calca mRNA expression in TGs (A), CSC (B), and medulla (C). Data is expressed as mean
+ SEM. One way analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test or
Two-way ANOVA followed by Bonferroni post-hoc test, *** p < 0.001 vs. Sham1 and Sham2 (ipsi),
◦◦ p < 0.01 and ◦◦◦ p < 0.001 vs. IoN-CCI1 (ipsi), ˆ p < 0.05 and ˆˆˆ p < 0.001 vs. IoN-CCI1 (contra),
# p < 0.05 and ## p < 0.01 vs. Sham1 and Sham2 (contra).
A significant difference was seen between the ipsi- and contralateral side (both in TG and CSC) in
the IoN-CCI1 group (Figure 4A,B).
2.2.4. PPT-A mRNA Expression
In the ipsilateral TG and CSC, and in the medulla region, PPT-A mRNA expression levels were
significantly increased in the IoN-CCI1 group compared with Sham1 and Sham2 groups (Figure 5).
The increased mRNA levels were significantly reduced after treatment with ADM_12 in IoN-CCI rats
(IoN-CCI2 group) in the same regions (Figure 5). ADM_12 administration did not cause any changes
in sham-operated rats.
A significant difference was seen between the ipsi- and contralateral side (both in TG and CSC) in
the IoN-CCI1 group, as well as in the IoN-CCI2 group at the TG level; whereas, there was no difference
between groups on the contralateral side of TG and CSC (Figure 5A,B).
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Figure 5. PPT-A mRNA expression in TGs (A), CSC (B), and medulla (C). Data is expressed as mean
+ SEM. One way analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test or
Two-way ANOVA followed by Bonferroni post-hoc test, * p < 0.05 and *** p < 0.001 vs. Sham1 and
Sham2 groups (ipsi), ◦◦◦ p < 0.001 vs. IoN-CCI1 group (ipsi), ˆˆˆ p < 0.001 vs. IoN-CCI1 group (contra),
§§§ p < 0.001 vs. IoN-CCI2 (contra).
2.2.5. IL-1beta, IL-6, and TNF-alpha mRNA Expression
Since the effects of the surgery, and consequently of the TRPA1 antagonist, on the transcript
levels were seen mainly at the ipsilateral side, the cytokines mRNA expression was not
evaluated contralaterally.
Interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha mRNA expression levels were
significantly increased in all the areas under evaluation in the IoN-CCI1 group compared with Sham1
and Sham2 groups (Figure 6). Such increases were significantly reduced after treatment with ADM_12
in IoN-CCI rats (IoN-CCI2 group) in the same regions (Figure 6).
 
Figure 6. mRNA expression of IL-1beta (A), IL-6 (B), and TNF-alpha (C) in ipsilateral TG and CSC,
and in medulla in toto. Data are expressed as mean + SEM. One way analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison Test, *** p < 0.001 vs. Sham1 and Sham2, ◦◦◦ p < 0.001 vs.
IoN-CCI1, # p < 0.05 vs. Sham1.
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2.3. ADM_12 Effect on Neuropeptide Protein Expression
CGRP and SP protein expression was evaluated in Sp5C on both sides. A slight, but not significant
difference in the density of immunoreactive fibers for CGRP and SP protein was observed between the
ipsilateral and contralateral side in both the IoN-CCI1 and IoN-CCI2 groups (Figure 7). No significant
change was seen between sham and operated rats (Figure 7). ADM_12 administration did not induce
any change in CGRP and SP expression either in sham or in CCI operated rats (Figure 7).
 
Figure 7. (A) Optical density (OD) values of calcitonin gene-related peptide (CGRP) with representative
photomicrographs of CGRP immunoreactive fibers in the spinal nucleus of trigeminal nerve
pars caudalis (Sp5C) ipsilateral (ipsi) and contralateral (contra) of Sham1 and IoN-CCI1 groups.
(B) OD values of substance P (SP) with representative photomicrographs of SP immunoreactive
fibers in the Sp5C ipsilateral (ipsi) and contralateral (contra) of Sham1 and IoN-CCI1 groups. Data is
expressed as mean + SEM. Two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc
test. Scale bar: 100 μm.
3. Discussion
The pathways of trigeminal neuropathic pain are poorly understood. Experimental evidences
suggest a strong involvement of TRPA1 in different patterns of neuropathic pain, and recently its role
was also demonstrated in a trigeminal neuropathic pain model [17].
Here we evaluated the role of TRPA1 channels in an animal model of trigeminal neuropathic pain
(IoN-CCI model), investigating the effects of the TRPA1 antagonist ADM_12 on mechanical allodynia,
and neurochemical and transcriptional changes.
ADM_12 was previously shown to revert in vivo the Oxaliplatin-induced neuropathy [22]. At the
trigeminal level, ADM_12 was able to reduce orofacial pain in a model of temporomandibular joint
inflammation [23], and to counteract trigeminal hyperalgesia in a model of migraine pain, together with
decreased Trpa1 and neuropeptide mRNA expression levels in specific areas implicated in trigeminal
pain [24].
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3.1. Behavioral Response
Infraorbital nerve injury in rats leads to the development, in the ipsilateral side, of a
hyporesponsiveness to mechanical stimulation within the first week post operation, followed by
a hyperresponsiveness, that according to several studies [18,25], reflects a condition of mechanical
allodynia. This biphasic response is probably related to the demyelination process, occurring in
the early post-operative period, and remyelination process, that occurs in the late post-operative
period [26]. Compared to the above cited papers [18,25,26], the time needed in this study to develop
allodynia was somewhat longer. This may have been the result of small differences in the degree of
nerve constriction; indeed, different degrees of IoN constriction have been shown to produce different
time courses in isolated face grooming behavior [27], and this can also be true for mechanical allodynia.
The allodynic response of operated rats was abolished after treatment with the TRPA1 antagonist
ADM_12, suggesting that the blockade of TRPA1 channels located on the trigeminal afferents
prevented the release of neuropeptides (CGRP and SP) [28,29], thus resulting in a reduced neurogenic
inflammation, and ultimately nociceptor sensitization [30]. Accordingly, Wu and colleagues reported
an increase in TRPA1 protein, as well as TRPV1 channels, in the Sp5C region of rats that underwent
IoN-CCI surgery [31], confirming their involvement in this process. An additional mechanism
is represented by the reduction in the release of pro-inflammatory factors via the inhibition of
TRPA1 located on glial cells in the nervous system, as suggested by our results, in which we
observed a reduction of the IL-1beta, IL-6, and TNF-alpha transcripts that possibly parallel protein
expression [32–34], which could account for reduced glial cells activation [32]; or via the inhibition
of TRPA1 located on non-neuronal cells, such as keratinocytes and macrophages, in the tissues
surrounding the damaged nerve [35]. Pro-inflammatory mediators released in the tissues that
surround the damaged nerve, and glial cell activation, are indeed known to play a crucial role
in the pathophysiology of neuropathic pain [36,37]. Glial activation and pro-inflammatory cytokines
are associated with the onset of neuropathic pain symptoms such as allodynia or hyperalgesia [38–42].
The involvement of TRPA1 in mechanosensation has been extensively studied; both genetic
deletion of TRPA1 and its pharmacological blockade abrogate mechanical pain-like behaviors [17,43,44].
Recently, Trevisan and colleagues [17] confirmed the critical role played by TRPA1 channels in
mechanical allodynia induced by trigeminal neuropathic pain; conversely, in a model of sciatic
nerve injury, Lehto and co-workers [45] reported a non-significant involvement of these channels
in the mechanical sensitivity. On the other hand, other authors showed that TRPA1 blockade
attenuated mechanical hypersensitivity following spinal injury [46,47] or neuropathic pain induced
by chemotherapeutic agents [48,49]. Altogether these observations suggest that mechanical allodynia
might be differently mediated by TRPA1 channels depending on the type of pain, site of damage,
or distribution profile in TG and DRGs [50]. Moreover, the different responses observed in the
experimental models could also be related to the different TRPA1 antagonists used, that may inhibit
the channel through binding at different sites, with specific regulatory mechanisms [51].
3.2. Trpa1 and Trpv1 mRNA Expression
Chronic constriction injury of the IoN produced a marked increase in the Trpa1 and Trpv1 mRNA
expression in central and peripheral areas ipsilaterally, and a slight increase even at the contralateral
side, compared to the sham group. This contralateral increase is probably due to activation of
inflammatory processes occurring after nerve injury, which can also affect the contralateral side [52].
The elevated TRP transcripts are accompanied by increased IL-1beta, IL-6, and TNF-alpha mRNA levels
in the medulla region, and ipsilateral TG and CSC. It is known that TRPA1 and TRPV1 channels can
be sensitized by inflammatory agents, causing up-regulation of these channels [53–55]. For example,
Trpa1 expression has been shown to be up-regulated by TNF-alpha and IL-1 alpha via transcriptional
factor hypoxia-inducible factor-1α [56]. Similarly, TNF-alpha can up-regulate TRPV1 protein and
mRNA in DRG and TG neurons [57,58]; one of the suggested pathways for Trpv1 regulation is the
p38 mitogen-activated protein kinase pathway [59], which may also be partly involved in Trpa1
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expression [60]. As regards TRPA1, its activation seems to depend on the activation of the nuclear
factor-κB signaling pathway [61].
Furthermore, an important role in neuropathic pain seems to be played by oxidative stress [62–64],
whose components can directly activate TRPA1 channels [65], thereby contributing to inflammation in
a TRPA1-dependent manner. Indeed, it was recently found that trigeminal neuropathic pain behaviors
were mediated by TRPA1 targeted by oxidative stress by-products released from monocytes and
macrophages surrounding the site of the nerve injury [17].
In agreement with our study, an up-regulation of Trpa1 and Trpv1 mRNA levels, as well as
protein levels in TG, DRGs, and dorsal horns, has been seen in different models of neuropathic
pain [11,47,60,66–71]. Increased mRNA levels may reflect an increase in functional TRPA1 and TRPV1
channels [72,73].
The increased mRNA levels detected in our experiments in CSC and medulla may have different
origins: Trpv1 mRNA undergoes bidirectional axon transport along primary afferents [74], and the
same could be true for Trpa1, since both TRPV1 and TRPA1 are (co-)expressed, not only on peripheral,
but also on central terminals of primary afferent neurons where their activation can lead to the release
of transmitters that promote the sensitization of postsynaptic pain transmission pathways [75–78].
In addition, Trpv1 mRNA could originate from GABAergic interneurons and glial cells in the rat dorsal
horn, which are known to express TRPV1 [69,79].
Systemic administration of ADM_12 markedly reduced the mRNA expression levels of both
TRPs induced by IoN ligation. The effect of drug treatment on mRNA transcripts is likely to be due
to an indirect effect rather than a direct one. It can be reasonably hypothesized that the effect of
ADM_12 on TRPA1 mRNA expression is indirectly due to the blockade of the channel, located either
on neuronal and non-neuronal cells, which is followed by two events. On one side, the reduction of
calcium (Ca2+) entry provokes a reduced activation of second messenger (Ca2+ dependent) molecules
(e.g., via the phospholipase C/Ca2+ signaling pathway and Ca(2+)/calmodulin-dependent protein
kinase II [CaMKII]) and interfering with the Ca2+-interacting proteins [80,81], with the consequent
reduction in transcriptional rate; for example, through the CaMK—cAMP response element-binding
protein (CaMK—CREB) cascade. The other event that follows TRPA1 antagonism is the reduction in
neuropeptide (CGRP and SP) release [28,29], and pro-inflammatory agents from neuronal fibers and
non-neuronal cells. In this frame, we hypothesize that ADM_12 may break off a self-feeding loop in
which TRPA1 channels are directly activated or sensitized by Ca2+ [51,81], endogenous substances
produced by intracellular Ca2+ elevation [82], and pro-inflammatory molecules [83–85], and indirectly
by the activation of nociceptive fibers caused by neuropeptide-induced neuroinflammation.
Moreover, we can also speculate that since TRPA1 and TRPV1 functions may be influenced by
each other [20,86,87], a re-organization in the expression and nature of these channels after nerve
injury [88–90] enabled ADM_12 to modulate TRPV1 channels as well. Although a physical interaction
between these two channels may be questionable, even if some studies described it in vitro [19,21],
many studies reported a functional interaction between them [20,86,91–93]. For instance, Masuoka
et al. [87] showed in DRG neurons that TRPA1 channels suppress TRPV1 channel activity, possibly
through the regulation of basal intracellular calcium concentration, and that the TRPA1 sensitization,
induced by inflammatory agents, enhance TRPV1-mediated currents [87].
These observations, including our data, show a relationship between these two TRP channels,
although more information and studies are needed to understand the precise mechanisms of this
putative interaction.
3.3. Neuropeptide Expression
After nerve injury, an inflammatory process leads to the release of many pro-inflammatory
mediators, which participate in peripheral sensitization, promoting an excessive release of
neurotransmitters [94]. Together with the inflammatory process, neuropeptides and degenerative
changes affecting the nervous fibers are also crucial peripheral mechanisms [95].
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In our experimental setting, the mRNA expression levels of genes coding for CGRP (Calca) and
SP (PTT-A) markedly increased in the central areas containing the Sp5C, as well as in the TG ipsilateral
to the IoN ligation. Interestingly, Calca mRNA expression in IoN ligated rats was also elevated on the
contralateral TG. It has been shown that projections from the TG reach the medullary and cervical
dorsal horns on both sides [96,97], and that unilateral TG stimulation activates neurons in both ipsi-
and contralateral Sp5C [98,99].
One of the mechanisms that could contribute to neuropeptide expression is the CaMK—CREB
cascade, which is probably triggered following TRP channel activation [100], and that may represent
the target mechanism for the observed inhibitory effect of ADM_12 on the mRNA expression of
CGRP and SP. The blockade of TRP channels, which co-localize with CGRP and SP in the trigeminal
neurons [7,101], can inhibit Calca and PPT-A mRNA expression, thus reducing the neuropeptide
release and the trigeminal sensitization process. The data supports the pivotal involvement of CGRP
and SP in the delivery and transmission of pain sensation to the central nervous system, and their
role in trigeminal pain syndrome. In fact, an increased concentration of neuropeptides was found in
the cerebrospinal fluid and venous blood of patients with trigeminal neuralgia compared to healthy
controls [102,103].
In this frame, it was quite surprising that we did not detect any significant difference in
neuropeptide protein expression at the Sp5C level, neither among groups, nor between sides. Lynds
and co-workers [104] reported no differences in neuropeptide (CGRP and SP) levels between ipsi- and
contralateral TG two weeks after IoN transection injury, while Xu and colleagues [105] described a
reduction of CGRP and SP protein levels in the ipsilateral caudal medulla eight days after partial IoN
ligation. Taken together, these findings suggest that in our model the neuropeptide release at central
sites might have taken place at early time points after surgery, and therefore went undetected since we
only measured it on day +27, or alternatively, that CGRP and SP are mostly involved at the peripheral
terminals [26]. These apparently contrasting findings prompt the need for specifically targeted studies
in order to investigate in more depth the role of neuropeptide release in central and peripheral sites in
this model of trigeminal neuropathic pain.
3.4. Limitations of the Study and Future Perspectives
We evaluated changes of behavioral responses and mRNA expression after a short period (1 h) of
drug exposure. This approach may be questionable, however there are many studies that support our
observations. For instance, the mRNA expression of metabotropic glutamate receptors was found to
be upregulated 1 h after treatment in mice DRG neurons [106]. Ambalavanar et al. [107] were able to
detect changes in CGRP mRNA levels in rat’s TG even 30 minutes after complete Freund’s adjuvant
injection. Furthermore, Nesic and co-workers [108] reported change in the mRNA signal of cytokines
1 h after treatment with MK-801, a NMDA receptor antagonist, in the spinal cord of rats subjected to
spinal cord injury.
Nevertheless, to elucidate and confirm the present findings, additional experiments with different
techniques are necessary. It will be interesting to evaluate in this model the effects of ADM_12 at later
time points, as well as after chronic treatment. Another limitation of the present study is the absence of
a time course of the expression of CRGP and SP. This was motivated by the ethical and organizational
need to keep the number of rats as low as possible. However, based on the present findings, it seems
important to address in future studies the parallel evaluation of mRNA and protein expression of
CGRP and SP in order to elucidate more clearly the role of these neuropeptides in peripheral and
central sites.
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4. Materials and Methods
4.1. Animals
Male Sprague-Dawley rats (Charles River, weighing 225–250 g at arrival) were used following the
International Association for the Study of Pain (IASP)’s guidelines for pain research in animals [109].
Animals were housed in groups of 2 with water and food available ad libitum, and kept in a
colony room (humidity: 45 ± 5%; room temperature: 21 ± 1 ◦C). Rats were kept under a reversed
12:12 h dark/light cycle (lights on at 20 h). All procedures were in accordance with the European
Convention for Care and Use of Laboratory Animals, and were approved by the Ethical Committee for
Animal Testing (Ethische Commissie Dierproeven, ECD) of the University of Antwerp (number 2017-16,
approval 20/02/2017).
Rats were allowed to acclimate for 8 days to the housing conditions before the surgery;
they were habituated to the behavioral test procedure daily for three days before pre-operative
testing. Habituation and testing were conducted in a darkened room (light provided by a 60 W red
light bulb suspended 1 m above the observation area) with a 45 dB background noise.
4.2. Surgery
The IoN-CCI was performed as previously described [18,25,27]. Rats were anaesthetized
with pentobarbital (60 mg/kg, intraperitoneally (i.p.)) and treated with atropine (0.1 mg/kg, i.p.).
The surgery was performed under direct visual control using a Zeiss operation microscope (×10–25).
The rat’s head was fixed in a stereotaxic frame and a mid-line scalp incision was made, exposing the
skull and nasal bone. The edge of the orbit was dissected free, and the orbital contents were deflected
with a cotton-tipped wooden rod to give access to the left IoN, which was loosely ligated with two
chromic catgut ligatures (5-0) (2 mm apart). The scalp incision was closed using polyester sutures (4-0;
Ethicon, Johnson & Johnson, Belgium). In sham operated rats, the IoN was exposed using the same
procedure, but the nerve was not ligated.
4.3. Mechanical Stimulation Testing (MST)
Baseline data were obtained 1 day before surgery. Following surgery, rats were tested on
post-operative days +5, +12, +18, +26, and +27 (Figure 1). A graded series of five Von Frey hairs
(0.015 g, 0.127 g, 0.217 g, 0.745 g, and 2.150 g) (Pressure Aesthesiometer®, Stoelting Co, Chicago, IL,
USA) were applied by an experimenter who was blind to animal and treatment groups, within the IoN
territory, near the center of the vibrissal pad [25,110–113]. Von Frey hairs were applied in an ascending
order of intensity either ipsi- or contralaterally. The scoring system described by Vos [25] was used
to evaluate the rats’ response to the stimulation (Table 1). For each rat, and at every designated time,
a mean score for the five von Frey filaments was determined.
Table 1. Response categories with the corresponding score values.
SCORE TYPE OF RESPONSE
0 no response
1 detection: the rat turns the head toward the stimulating object and the stimulus object is then explored
2
withdrawal reaction: the rat turns the head slowly away or pulls it briskly backward when the
stimulation is applied; sometimes a single face wipe ipsilateral to the stimulated area occurs
3
escape/attack: the rat avoids further contact with the stimulus object, either passively by moving its
body away from the stimulating object to assume a crouching position against the cage wall,
or actively by attacking the stimulus object, making biting and grabbing movements
4
asymmetric face grooming: the rat displays an uninterrupted series of at least three face-wash strokes
directed toward the stimulated facial area
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4.4. Drug and Experimental Plan
The TRPA1 antagonist ADM_12, synthesized in the Laboratory of Prof. Cristina Nativi (University
of Florence, Italy) and characterized by a high binding constant versus TRPA1 [23], was dissolved in
saline and administered intraperitoneally (i.p.) at the dose of 30 mg/kg in a volume of 1 ml/kg [22–24].
The animals were randomly allocated in four groups of 12 animals each and assigned to different
experimental sets, as shown in Table 2.
Table 2. Experimental groups and number (N) of animals per group that underwent the mechanical
stimulation test (MST). The samples of the subsets were processed for the real time polymerase chain
reaction (RT-PCR) or immunohistochemistry (IHC).
EXPERIMENTAL GROUPS Surgery Treatment on Day +27 MST RT-PCR IHC
Sham1 Sham saline N = 12 N = 6 N = 6
Sham2 Sham ADM_12 N = 12 N = 6 N = 6
IoN-CCI1 IoN-CCI saline N = 12 N = 6 N = 6
IoN-CCI2 IoN-CCI ADM_12 N = 12 N = 6 N = 6
On day +27, sham and operated rats were treated with ADM_12 or saline 1 h prior to the MST
(Figure 8). The timing was chosen on the basis of previous studies reporting a significant effect of acute
ADM_12 treatment on behavioral responses [22–24]. At the end of the behavioral test, each rat was
sacrificed with an i.p. overdose of pentobarbital (150 mg/kg). A subset of 6 rats per experimental group
served for the detection of gene expression levels by means of real time polymerase chain reaction
(RT-PCR); another subset of 6 animals per experimental group underwent the immunohistochemical
evaluation of protein expression (Table 2).
Figure 8. Schematic representation of the experimental design.
4.5. Real Time-PCR
The trigeminal ganglia (TG), cervical spinal cord (CSC, C1-C2 level), and medulla (bregma,
−13.30 to −14.60 mm; Paxinos and Watson 4th edition), containing the Sp5C, of each animal were
quickly removed after completing the MST on day +27 and frozen at –80 ◦C. Samples were then
processed to evaluate the expression levels of the genes encoding for TRPA1 (Trpa1), TRPV1 (Trpv1),
CGRP (Calca), SP (PPT-A), IL-1beta (IL-1beta), IL-6 (IL-6), and TNF-alpha (TNF-alpha). mRNA levels
were analyzed by RT-PCR, as previously described [24,114,115]. After tissue homogenization by means
of ceramic beads (PRECELLYS, Berthin Pharma, Montigny-le-Bretonneux, France), total RNA was
extracted with TRIzol®reagent (Invitrogen, Carlsbad, California, USA) and quantified by measuring
the absorbance at 260/280 nm using a nanodrop spectrophotometer (Euroclone, Pero (MI), Italy).
Following cDNA generation with the iScript cDNA Synthesis kit (BIO-RAD, Hercules, California,
USA), gene expression was analyzed using the Fast Eva Green supermix (BIO-RAD). Primer sequences
were obtained from the AutoPrime software (http://www.autoprime.de/AutoPrimeWeb) (Table 3).
The amplification was performed through two-step cycling (95–60◦C) for 45 cycles with a Light Cycler
480 Instrument RT-PCR Detection System (Roche, Milan, Italy). The expression of the housekeeping
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gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), remained constant in all the experimental
groups considered. All samples were assayed in triplicate.
Table 3. Primer sequences.










According to Terayama et al. [116] and Panneton et al. [117], the central afferent innervations
of the IoN are mostly distributed in (but not restricted to) the dorsal and lateral part of the Sp5C,
projecting to all the laminae. The pattern of CGRP and SP protein related to the painful component of
the IoN was investigated in the superficial laminae of the Sp5C.
Immediately after the MST test, animals were anaesthetized and perfused transcardially with
phosphate buffered saline (PBS) and 4% paraformaldehyde. The medullary segment containing
the Sp5C, between +1 and −5 mm from the obex, was removed and post-fixed for 24 h in
the same fixative; subsequently, samples were transferred in solutions of sucrose at increasing
concentrations (up to 30%) during the following 72 h. All samples were cut transversely at 30
μm on a freezing sliding microtome. CGRP and SP protein expression was evaluated using the
free-floating immunohistochemical technique, as previously reported [24]. For CGRP we used an
anti-rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:3200, and
an anti-rabbit antibody (Chemicon, Temecula, CA, USA) at a dilution of 1:5000 for SP; both primary
antibodies were incubated for 24 h at room temperature. After incubation at room temperature with
the secondary biotinylated antibody (Vector Laboratories, Burlingame, CA, USA) and the avidin-biotin
complex (Vectastain, Vector Laboratories), sections were stained with the peroxidase substrate kit DAB
(3′3′-diaminobenzidine tetrahydrochloride) (Vector Laboratories, Burlingame, CA, USA).
The area covered by CGRP and SP immunoreactive fibers in the Sp5C ipsilateral and contralateral
to the surgery (12 sections per animal), was expressed as optical density (OD) values [24,114,118],
acquired using an AxioSkop 2 microscope (Zeiss) and a computerized image analysis system
(AxioCam, Zeiss, Göttingen, Germany) equipped with dedicated software (AxioVision Rel 4.2, Zeiss,
Göttingen, Germany). All sections were averaged and reported as the mean + SEM of OD values.
4.7. Statistical Evaluation
Data from recent studies [18,27] was used to calculate the required number of animals per
experimental group to obtain a statistical power of 0.80 at an alpha level of 0.05, and a difference of at
least 20% in behavioral responses after IoN-CCI surgery. The calculations were done using software
(Lenth RV. Java Applets for Power and Sample Size) retrieved on 8 April 2013, from http://www.stat.
uiowa.edu/~rlenth/Power, which estimated a sample size of 12 rats per experimental group.
Statistical analysis was performed with the GraphPad Prism program (GraphPad Software,
San Diego, California, USA). In the MST, for each rat and at every designated time, a mean score
for the five Von Frey hairs was determined. The IoN-CCI rats were compared to the sham-operated
rats. For mRNA levels, results were analyzed using the ΔΔCt method to compare expression of genes
of interest with that of GAPDH, used as control gene. All data was tested for normality using the
Kolmogorov–Smirnov normality test and considered normal. Differences between groups, or between
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ipsilateral and contralateral sides, were analyzed by one-way analysis of variance (ANOVA) followed
by Tukey’s Multiple Comparison Test, or by means of two-way ANOVA followed by Bonferroni
post-hoc test, respectively. Differences between two groups were analyzed by the Paired student’s t
test. A probability level of less than 5% was regarded as significant.
5. Conclusions
Antagonism of the TRPA1 channel by means of ADM_12 attenuates experimentally-induced
mechanical allodynia [17,119] in a reliable animal model of trigeminal neuropathic pain. Allodynia is
one of the major clinical features of trigeminal neuropathic pain [120,121], thus the modulation of the
TRPA1 channel may represent a suitable therapeutic target [122,123], and ADM_12 a possible tool, in
trigeminal neuropathic pain management. As a corollary, our data also suggests a possible role for
TRPV1 channels in the behavioral and biomolecular responses related to trigeminal neuropathic pain.
Further exploration of the mechanisms underlying the antinociceptive effects of TRPA1, and studies
directed to better understand the relationship between TRPA1 and TRPV1, would improve our
understanding of the complex nociceptive processing in trigeminal neuropathic pain.
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Abbreviations
CaMKII Ca(2+)/calmodulin-dependent protein kinase II
Calca calcitonin-related polypeptide alpha
CGRP calcitonin gene-related peptide
CREB cAMP response element-binding protein
CSC cervical spinal cord
DRG dorsal root ganglia
GAPDH glyceraldehyde 3-phosphate dehydrogenase
IL interleukin
IoN infraorbital nerve
IoN-CCI chronic constriction injury of the infraorbital nerve
MST mechanical stimulation testing
OD optical density
PPT-A preprotachykinin-A
RT-PCR real time polymerase chain reaction
SP substance P
Sp5C spinal nucleus of trigeminal nerve pars caudalis
TG trigeminal ganglia
TN trigeminal neuralgia
TNF-alpha tumor necrosis factor alpha
TRP transient receptor potential
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Abstract: Recently discovered mechanosensitive Piezo channels emerged as the main molecular
detectors of mechanical forces. The functions of Piezo channels range from detection of touch and
pain, to control of the plastic changes in different organs. Recent studies suggested the role of Piezo
channels in migraine pain, which is supposed to originate from the trigeminovascular nociceptive
system in meninges. Interestingly, migraine pain is associated with such phenomenon as mechanical
hypersensitivity, suggesting enhanced mechanotransduction. In the current review, we present
the data that propose the implication of Piezo channels in migraine pain, which has a distinctive
pulsatile character. These data include: (i) distribution of Piezo channels in the key elements of
the trigeminovascular nociceptive system; (ii) the prolonged functional activity of Piezo channels
in meningeal afferents providing a mechanistical basis for mechanotransduction in nociceptive
nerve terminals; (iii) potential activation of Piezo channels by shear stress and pulsating blood flow;
and (iv) modulation of these channels by emerging chemical agonists and modulators, including
pro-nociceptive compounds. Achievements in this quickly expanding field should open a new road
for efficient control of Piezo-related diseases including migraine and chronic pain.
Keywords: Piezo channels; mechanotransduction; pain; migraine; CGRP
1. Introduction
Touch, proprioception, and nociception are the fundamental senses mediated by activation of
mechanosensitive ion channels, which are expressed in various types of sensory neurons. The detection
of mechanical forces is mediated by different ion channels such as mechanosensitive ion channels
(MSCs), potassium K2P channels, TMEM63/OSCA, and TMC1/2 [1]. In the current review, we will focus
on the potential role of the recently discovered mechanosensitive Piezo1/2 channels in the nociceptive
signaling in migraine. Migraine pain remains poorly understood mainly because of lack of mechanistic
explanations for the initial steps in generation of pain signals in the nociceptive system.
Migraine, a very common neurological disorder, is characterized by severe and long-lasting
headache associated also with mechanical hypersensitivity and allodynia (pain induced by normally
non-painful touch, which, during long-lasting migraine attack, is not limited to the head) [2].
Mechanosensitive ion channels most likely mediate mechanical hypersensitivity in the peripheral or
central parts of the nociceptive system. However, nature of these ion channels remains unknown.
Therefore, mechanosensitive Piezo channels, recently detected in human trigeminal ganglia [3,4],
are the most probable candidates to mediate typical symptoms of migraine, such as mechanical
hypersensitivity and pulsating type of migraine pain [5].
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2. Complex Structure of Gigantic Piezo Channels
Piezo channels are the family of mechanotransducers composed by two nonselective cationic
channels known as Piezo1 and Piezo2 with a relatively homologous structure (Figure 1) [6–9]. Piezo
channels are 2500 amino acids long proteins with up to 38 transmembrane segments per monomer.
These monomers, combined together, build up the functional homo-trimers in the cell membrane [10].
Notably, these channels do not share sequence or structural homology with other above-mentioned
mechanosensitive channels. This makes Piezo channels to be a completely new molecular target for
therapeutic interventions, with their own profile of preferential physical triggers, chemical agonists,
and specific modulators [11].
The molecule of Piezo1 channel is organized as a gigantic ‘three peripheral blade-like structure’
(Figure 1A), three 90-Å-long intracellular beam–resembling components bridging the blades
together [10]. The central pore, formed by the C-terminals, has a main role in determining the
channel conductance and ion selectivity [10]. The intracellular beam, part of the central cap, seems to
be the perfect intermediate structure for mechanical transduction from the periphery to the central
ion-conducting pore [7].
The uncommon structure of Piezo channels suggests their unique role in mechanical
transduction [11], including various important functions in sensory neurons [12].
Figure 1. Schematic presentation of the Piezo channel. (A) Bird view of the Piezo channel with
peripheral blade-like structures located in three subunits forming the trimeric functional unit with the
central pore, blades and anchor regions. (B) Side view of the Piezo channel located in the lipid cell
membrane. The following elements of the single subunit are presented: the intracellular beams, the
C-terminals with the anchor regions and the ATM region containing the Yoda1 binding site and the
extracellular blades.
3. Functional Properties and the Role of Piezo1 vs. Piezo2 in Nociception
After discovery, isolation and cloning of Piezo1 and Piezo2 channels [8], the next challenging step
would be to describe the functional properties of these channels in different cell types [9]. The natural
activation of Piezo1 and Piezo2 channels can be achieved by different types of mechanical stimulation:
stretching, pulling, pushing, exposure to hypo- or hyper-osmotic solutions, and flow-induced shear
stress [8,13,14]. The kinetic properties of Piezo channels, studied by recording of the whole cell-inward
currents in HEK cells, showed the fast activation and inactivation of these channels with recovery in
the range of hundred milliseconds [6].
The comparison of two subtypes of Piezo channels showed that Piezo2 has a faster kinetics, and
typically mediates a rapid membrane response, whereas Piezo1 channels are characterized by slower
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kinetics [8]. Thus, Piezo2 are more specified for detection of transient mechanical forces, whereas Piezo1
can react to more persistent activation [15]. Notably, these properties are sensitive to the channel’s
environment in the membrane. Thus, the reduction of cholesterol in the cell membrane largely slowed
down the inactivation kinetics of Piezo1 channels [16], which can support the persistence of signaling
via this receptor type.
Consistent with fast kinetics, Piezo2 channels mediate the short-lasting mechanosensitive processes
such as touch [6]. Piezo2 channels, implicated in this sensory modality, have been found in dorsal
root ganglion (DRG) neurons [6]. Mechanical pain represents a different sensory modality, which is
also expected to be mechanistically linked either to Piezo1 or Piezo2 channels if they are expressed
in neurons mediating somatic and visceral pain. However, there are some controversies regarding
expression of Piezo channel subtypes in nociceptive neurons. Indeed, one study showed the presence
of Piezo2 but not Piezo1 channel in DRG neurons [17]. Another group [18] presented the evidence for
the expression not only of Piezo2 but also of Piezo1 in DRG neurons. They found Piezo2 transcripts
in sensory neurons of different sizes, including the largest diameter neurons mediating touch and
proprioception. In contrast, Piezo1 was preferentially expressed in small size nociceptive neuron
suggesting their role in pain [18]. Co-expression of Piezo1 and Piezo2 in the same neurons raises an
interesting issue of functional interactions between these channels. The functional interplay between
Piezo1 and Piezo2 channels was analyzed in the study where they found that the deletion of Piezo2 from
the low-threshold mechanoreceptors in mice impaired touch but surprisingly sensitized mechanical
pain, suggesting a negative interaction between Piezo1 and Piezo2 [19].
Our studies indicated that both Piezo1 and Piezo2 channels are expressed in trigeminal sensory
neurons [5], which innervate head and face tissues and implicated in generation of migraine pain. Most
of electrophysiological studies of Piezo channels in sensory neurons were performed by recording
signaling from somas of these cells, representing a surrogate model of nerve terminals. However,
more physiologically relevant approach to study the role of Piezo channels in migraine pain would
be the recording of electrical spiking activity directly from the trigeminal nerve terminals in brain
meninges [20]. Cranial meninges, comprising abundant blood vessels that are densely innervated by
somatic and autonomous nerves, represent the so-called ‘trigeminovascular system’, which is considered
as the origin site of primary headaches including migraine [21]. Application of the pro-inflammatory
compounds to meninges induces mechanical sensitization of meningeal nociceptors [22], suggesting
involvement of the professional mechanotransducers such as Piezo1 channels in this phenomenon. The
repetitive nociceptive traffic in trigeminal neurons is a likely reason for mechanical hypersensitivity
and allodynia, typical for migraine pathology [23]. Mechanical hypersensitivity can be directly linked
to activation of Piezo channels in peripheral neurons whereas allodynia, mostly a central phenomenon,
nevertheless, can also start from excessive and repetitive activation of peripheral Piezo channels in
primary afferents. Taken together, these studies can serve as a background for the hypothesis on the
role of Piezo channels in migraine.
4. Unusual Chemical Activation of Piezo Channels
Since the discovery of Piezo mechanotransducers, the main tools to activate Piezo channels were
the different types of mechanical stimulation. Unexpectedly, a very efficient alternative approach to
activate Piezo channels has been recently found: that is the compound called Yoda1 [24]. The small
lipid soluble molecule Yoda1 is able to activate specifically Piezo1 but not Piezo2 channels [24]. Yoda1
interacts with the C-terminal of the Piezo1 protein in the region of 1961–2063 amino acids, also known
as the Agonist Transduction Motif (ATM) [25] (Figure 1B). The recent molecular dynamic simulations
identified the Yoda1 binding pocket located in the domain approximately 40 Å away from the central
pore [26]. Although the Piezo1 channel has three interacting monomers, interestingly, the binding of
Yoda1 to only one subunit is already enough to open the ion channel [25], which provides a rationale
for the high sensitivity of Piezo1 to this chemical agonist.
117
Int. J. Mol. Sci. 2020, 21, 696
The other Piezo1 agonist, Jedi1/2, acts on the blade-beam structure inducing activation of the
channel from the peripheral extracellular side [10]. However, it remains to be discovered if there are
any endogenous molecules, which, similarly to the synthetic Yoda1 or Jedi1/2 compounds, can activate
and/or sensitize Piezo1 channels in the healthy or disease states.
The discovery of chemical agonists of Piezo channels opened a new toolbox to investigate the
function of mechanotransduction in different tissues, especially, when the traditional mechanical
stimulation is not applicable or when the aim is to provide a widespread activation of Piezo channels
in multiple targets. Thus, we found that the application of Yoda1 to the extended receptive field
of meningeal afferents induced a massive and prolonged activation of trigeminal nerve fibers [5].
The nociceptive effect of Yoda1 in this study was reproduced by the similar prolonged activation of
trigeminal mechanosensitive receptors by the hypo-osmotic solution [5]. Moreover, Yoda1 stimulation
triggered the release of CGRP (calcitonin gene-related peptide) from these trigeminal nerve fibers.
CGRP, the main migraine mediator, is known as a powerful promoter of meningeal inflammation and
sensitization of trigeminal neurons [27–29].
These findings largely supported the proposed role of Piezo channels in peripheral mechanisms of
migraine pain. Consistent with the pro-nociceptive role of Piezo channels activated by Yoda1 found in
our study, Wang et al. [18] showed that Yoda1 induced a mechanical hyperalgesia with the prolonged
time-course which is also typical for migraine pain.
5. Puzzling Phenomenon of Pulsatile Pain: Role of Piezo?
The headache phase of a migraine attack is characterized by pulsating (throbbing) type of headache
as a specific symptom of migraine pain [30]. This puzzling migraine phenomenon has been attracting
attention of many migraine researchers and already served as a basis for the famous Wollf’s vascular
theory of migraine headache [31]. This popular theory was supported by the clear correlation between
the level of pulsations of the temporal artery and the intensity of headache during migraine attack in
the patient treated with ergots [31]. Vascular mechanisms of migraine pain were also supported by the
ability of the migraine mediator neuropeptide CGRP to produce the dilation of cranial vessels [32,33].
However, the role of vessels as the contributors to headache during migraine attack is still debated. As
noted by Waeber and Moskowitz [34], the idea of abnormal dilatation of intracranial blood vessels
leading to mechanical excitation of sensory fibers that innervate these vessels has never been validated.
It is worth noting that there are also observations that the simple vasodilation of cranial vessels induced
by the neuropeptide VIP is not enough to trigger migraine attack per se [35]. These findings added
more intriguing aspects to the puzzling mechanisms of pulsating migraine pain. Notably, the ‘vascular
theory’ suggested only the general explanation of pulsating migraine pain due to regular dilations of
cranial vessels but it did not propose a molecular mechanism supporting this view. The discovery
of Piezo mechanotransducers in trigeminal neurons suggested an attractive possibility to test these
specific transducers as the sensors of the mechanical forces generated by pulsating vessels. Indeed, our
recent investigation of Piezo channels in meningeal sensory nerve fibers allowed us to suggest a new
model of mechanosensation in meninges during migraine attack [5].
6. New Model of Mechanosensation in Meninges during Migraine Attack
Based on the concept of the meningeal trigeminovascular system (TGVS) as the initial site for
the generation of migraine headache [21], we propose the following model potentially explaining the
mechanism of pulsating migraine pain. Figure 2 shows that in interictal state (or in healthy subjects),
meningeal nerves express a plethora of pain transducing channels such as mechanosensitive Piezo1 and
Piezo2 receptors [5], along with capsaicin-sensitive TRPV1 [36] and ATP-activated P2X3 receptors [37],
which all are in low-active non-sensitized state. The main key components of the TGVS, such as
meningeal vessels and neighboring nerves, in this state, have a low chance to interact to each other
either physically or chemically and a low probability to generate pain signals.
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The key event in migraine attack, is the release of the main migraine mediator CGRP [33],
which has multiple actions in the TGVS (Figure 2, right). Thus, CGRP induces dilation of meningeal
vessels, it promotes local neurogenic inflammation and degranulates dural mast cells, which, in turn,
release several pro-inflammatory and pro-nociceptive compounds such as serotonin, histamine, ATP,
prostaglandins, and nitric oxide [38–40]. Notably, most of these compounds are able to increase the
sensitivity of meningeal afferents to mechanical stimuli [22,41]. Among other compounds released
from mast cells, serotonin appeared to be the most strong and fast trigger of nociceptive spiking in
nerve terminals [42,43]. Apart from the immediate firing of nociceptors, serotonin also promotes
neuronal sensitization and local inflammation directly or through the additional release of CGRP [42].
The inflammation induced by CGRP, substance P and mediators of mast cells can sensitize not only
peripheral but also central neurons, expanding the enhanced mechanical sensitivity to extracranial
body regions, presented as the phenomenon of allodynia [22,44].
Notably, Piezo1 channels are expressed not only in neurons but also in vessels. Vasodilatation,
shear stress and enhanced pulse waves in dilated vessels can activate mechanoreceptors in endothelial
cells, triggering, via pannexins, ATP release (Figure 2) [45]. ATP is a strong promoter of nociceptive
firing in meninges by itself [37,43] but it is also a trigger of mast cell degranulation promoting further
release of the pro-inflammatory and pro-nociceptive compounds to meninges.
Figure 2. Schematic presentation of the key elements of the trigeminovascular system comprising
meningeal blood vessels, local mast cells and trigeminal nerve fibers before and during migraine attack.
Left: In the interictal state, before attack, there are only slight pulsations of meningeal vessels with the
minimal activation of vascular Piezo1 channels or Piezo1 and Piezo2 channels in nerve fibers. Right:
During migraine attack, which is often associated with brain oedema and CGRP-induced dilation of
vessels, the extracellular space is reduced, promoting more close contact between pulsating vessels,
nerves and nearby mast cells. The shear stress in dilated vessels and enhanced vascular pulsations
promote mechanosensitive ATP release from the endothelial cells. Mechanical stimulation of calcium
permeable Piezo channels in nerve fibers by pulsating vessels promotes neuronal CGRP release. CGRP
and ATP can degranulate mast cells directly. In addition, the fraction of mast cells contacting vessels,
is directly mechanically activated by blood pulsations. Activation of mast cells induces release of a
plethora of pro-nociceptive compounds such as serotonin, histamine, leukotrienes, prostaglandins,
ATP, and nitric oxide, further exciting the nociceptive fibers and promoting more CGRP release. All
these pro-inflammatory compounds, in long run, together with CGRP, promote neuroinflammation,
neuronal sensitization leading to long-lasting pulsating pain.
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Approximately one third of migraine cases is represented by migraine with aura. The
pathophysiological mechanism underlying migraine aura is a phenomenon called ‘cortical spreading
depression’ (CSD) [46,47]. CSD is a wave of strong depolarization of cortical neurons and glial cells,
leading to meningeal neurogenic inflammation, involving the neuropeptide CGRP and substance P,
ATP, and the mast cells activation [41,48]. Brain oedema, associated with CSD [46,49] compresses the
extracellular space, which assists in the formation of more close contact between blood vessels and
meningeal nerve fibers. Furthermore, CSD can increase the brain volume and raise the intracranial
pressure [46]. Taken together, these factors, along with strongly pulsating vessels, should facilitate
activation of mechanosensitive channels, such as Piezo ones, in nerve fibers [5].
Since meningeal tissues are protected by the skull from the external mechanical forces, the only
source for activation of mechanosensitive Piezo channels in meningeal nerves are internal triggers,
such as pulsating dural vessels. These pulsating dilated vessels can provide the regular Piezo-mediated
excitation of nerve fibers processed towards the high-pain centers and perceived as a pulsating migraine
pain. Notably, in migraine condition, there is an increased expansibility of arteries [50], which is also
consistent with our hypothesis as the factor supporting the increased amplitude of pulsating waves.
The exaggerated mechanical sensitivity of the trigeminal nerves during migraine attack can explain
also the painful sensitivity to slight movements of the head or to cough [41].
7. How to Alleviate Migraine Pain Through Piezo Channels?
Accumulating evidence suggest that Piezo channels represent an attractive new molecular target to
block pathological pain conditions via inhibition of these membrane’s mechanotransducers. Likewise,
the idea of targeting Piezo channel for the novel type of analgesia might be extended to migraine
pain. Given the pro-nociceptive role of Piezo channels in activation of meningeal afferents [5], the
attractive approach would be to alleviate migraine pain through the direct or indirect inhibition of
Piezo channels in trigeminal neurons. The antagonists of Piezo channels are of special interest as they
potentially can block excessive activation of nociceptors in migraine conditions. However, currently
available ligands of Piezo channels (Table 1) cannot directly serve as potential medicines for this
neurological disorder. This is because the list of blockers of Piezo channels is limited and most of them
are not specific (Table 1). Thus, there are Piezo channel inhibitors, such as the antagonist Dooku1,
the blockers neurotoxin GsMTx4 and gadolinium [51]. Unfortunately, Dooku1 has a partial blocking
activity in some cell types, whereas GsMTx4 or gadolinium are not specific for Piezo channels [51].
The main issue is that even if the specific blocker of Piezo1 is found, Piezo1 channels are not limited to
trigeminal neurons but expressed in other cell types such as vessels (as mentioned above). Therefore,
for the translational purposes, in migraine pain the alternative promising approach would be to
find out the functional partners of these mechanosensitive channels or accessory proteins, which
control the function of Piezo proteins. Although a purified Piezo1 protein retains the channel activity
when reconstructed in artificial lipid bilayers [52]; in the natural environment, Piezo channels are
likely under control of membrane lipids and certain intracellular messengers. The beforementioned
functional interactions between Piezo1 and Piezo2, in trigeminal neurons, are of special interest but the
underlying mechanism of such interactions requires further investigations. Likewise, little is known so
far about the intracellular modulatory pathways for Piezo channels. However, it has been shown that,
in response to phospholipase C (PLC) activation, both Piezo1 and Piezo2 channels could be inhibited
by depletion of plasma membrane phosphoinositides [53]. The activation of PLC was supported by
calcium influx via TRPV1 receptors, which are highly expressed in meningeal trigeminal afferents [36].
This finding suggests a negative functional crosstalk between Piezo and TRPV1 channels, which both
are enriched in meningeal nociceptive fibers generating migraine pain [5,36]. Thus, our data showed
that a fraction of trigeminal nerve fibers in meninges responded by nociceptive firing both to the
TRPV1 agonist capsaicin and to the Piezo1 agonist Yoda1 [5]. The latter fact suggests that in trigeminal
afferents in meninges there is a specific profile of nociceptive receptors, which can functionally interact.
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In contrast, in DRG sensory neurons, which mediate somatic pain, Piezo1 has a limited co-expression
with TRPV1 channels [18].
An interesting family of potential Piezo modulators has been identified in the study showing that
margaric acid, a saturated fatty acid that makes membrane stiffer, inhibits Piezo1 channels, whereas
the poly-unsaturated fatty acid docosahexaenoic acid delays the inactivation of these channels [16]
(Table 1). A dietary strategy to diminish the increased activity of Piezo channels in hemolytic anemia
suggested by these authors could be extended to the excessive nociception via Piezo channels in
migraine pain states associated with mechanical hyperalgesia. In particular, food enriched by margaric
acid or other similarly actin fatty acids looks like a promising approach for these aims.
Another open question, which has a translational perspective in migraine, is whether Piezo
channels are modulated by the migraine mediators such as CGRP, serotonin, or NO. One study
proposed the role of Epac1–Piezo2 axis in sensory neurons for the development of mechanical
allodynia during neuropathic pain [54]. Epac, known as the sensor of cAMP, contains the conserved
cAMP-binding domain and the level of cAMP can be raised in trigeminal neurons by the main
migraine mediator CGRP [27,33]. However, all these pathways, activated by migraine mediators,
which potentially can control Piezo channels, were not studied yet in migraine pathology.
Taken together, the pro-nociceptive Piezo channels in the trigeminovascular system represent
a new promising target for the therapeutic interventions in migraine. Thus, the analgesic effect in
migraine pain, can be approached either by the targeted delivery to the TGVS of the novel potent Piezo
blockers, or by the inactivation of these mechanotransducers by modulators acting via changes in the
lipid membrane environment.
Table 1. Main agonists, antagonists and modulators of Piezo1 channels.
Agonists Antagonists Modulators
Yoda1 Jedi1/2 Dooku1 Gadolinium GsMTx4 Margaric acid(saturated)
Docosahexaenoic
acid (unsaturated)








Ion channel pore [51]






8. Summary and Outlook
Migraine is a common neurological disorder with many intractable cases. Despite the many
decades of active investigations of this disorder, the molecular mechanisms implicated in the initial
steps of migraine pain remain unclear. The recent studies suggesting Piezo channels as the vascular and
neuronal sensors of intracranial mechanical forces present a new view on molecular processes implicated
in meningeal nociception leading to migraine headache. These mechanosensitive mechanisms
can underlie the worst migraine’s symptoms such as mechanical hyperalgesia and pulsating pain.
Identification of novel molecular targets in meningeal trigeminovascular nociceptive system such as
Piezo channels suggests the new approach to control this devastating neurological condition.
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Abbreviations
MSCs Mechanosensitive ion channels
K2P Two-pore-domain potassium channels
TMEM63 Transmembrane protein 63
OSCA Hyperosmolality-gated calcium-permeable channels
TMC1/2 Transmembrane channel-like protein 1/2
DRG Dorsal Root Ganglion
CSD Cortical spreading depression
CGRP Calcitonin gene-related peptide
NO Nitric Oxides
Epac Exchange protein activated by cAMP
cAMP Cyclic Adenosine Monophosphate
TGVS Trigeminovascular system
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Abstract: Migraine is a disorder affecting an increasing number of subjects. Currently, this disorder
is not entirely understood, and limited therapeutic solutions are available. Migraine manifests as
a debilitating headache associated with an altered sensory perception that may compromise the
quality of life. Animal models have been developed using chemical, physical or genetic modifications,
to evoke migraine-like hallmarks for the identification of novel molecules for the treatment of
migraine. In this context, experimental models based on the use of chemicals as nitroglycerin or
inflammatory soup were extensively used to mimic the acute state and the chronicity of the disorder.
This manuscript is aimed to provide an overview of murine models used to investigate migraine
pathophysiology. Pharmacological targets as 5-HT and calcitonin gene-related peptide (CGRP)
receptors were evaluated for their relevance in the development of migraine therapeutics. Drug
delivery systems using nanoparticles may be helpful for the enhancement of the brain targeting
and bioavailability of anti-migraine drugs as triptans. In conclusion, the progresses in migraine
management have been reached with the development of emerging agonists of 5-HT receptors and
novel antagonists of CGRP receptors. The nanoformulations may represent a future perspective in
which already known anti-migraine drugs showed to better exert their therapeutic effects.
Keywords: migraine; animal models; experimental approaches
1. Introduction
Migraine is a complex neurological disease considered the primary headache disorder leading
to disabling conditions [1]. The last International Classification of Headache Disorders (3rd edition)
describes migraine as a recurrent headache disorder manifesting as a unilateral and throbbing headache
with pain intensity from moderate to severe [2]. Common symptoms observed are photophobia and
phonophobia, nausea and/or vomiting [2]. Migraine can be distinguished in episodic migraine (EM)
and chronic migraine (CM). EM is defined whether the headache days per month are less than 15,
and CM, whether headache days are equal or more than 15 for a period of more than three months.
Moreover, migraine appears to occur more in women than in men [3]. In addition, it is estimated that
about 30% of patients experience an aura that consists in a short period of visual, sensory, or motor
disturbances [4]. Mechanisms involved in migraine are not yet entirely clarified. To date, it is thought
that the genesis of pain occurs by activation of the trigeminovascular system (TGVS). This system is
composed of the cranial vasculature, the trigeminal nerve and the trigeminal nucleus caudalis (TNC).
TGVS plays an important role as a major control center in regulating the cerebral blood flow and it is
believed as a key conduit for pain transmission [5]. The activation of trigeminal sensory nerve endings
induces the release of vasoactive agents, such as calcitonin gene-related peptide (CGRP), substance P
and neurokinin A, resulting in vasodilation and dural plasma extravasation, leading to neurogenic
inflammation [5]. Current migraine treatments regard the use of drugs aimed to decrease the frequency,
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severity, and last of migraine attacks [6]. In case of mild attacks, medications such as acetaminophen
and aspirin are used, whereas triptans or dihydroergotamine (DHE) are used for the treatment of
a moderate to severe migraine [7,8]. The current pharmacological treatment used in migraine is
summarized in Table 1. Our current knowledge about the pathophysiology of this complex disorder is
based mostly on animal models developed to study the nociceptive pathways of the TGVS and their
ascending projections to the brainstem and the diencephalic nuclei. These models are mostly based on
modifications operated in order to try mimicking headache symptoms, requiring manipulations to
activate the trigeminal nerve or dural nociceptors [5,9,10]. Although animal models show shortcomings
per se, due to difficulties in reflecting all hallmarks of migraine, they have been used as a screening
tool for the development of novel anti-migraine drugs, in which serotonin (5-HT) and CGRP receptors
have importantly contributed as targets, showing to be involved in pathways that result in headache
attacks [11]. Furthermore, drug delivery systems based on the use of formulations composed of
nanoparticles could be considered a new attempt to improve the effects of drugs used in migraine
treatments. The present manuscript has been generated using PubMed as source of information,
with the aim to offer an overview of murine models developed to study migraine pathophysiology.
For the promising results obtained in migraine treatment, in this manuscript the pharmacological
targets 5-HT and CGRP receptors were evaluated. In addition, the database ClinicalTrials.gov [12] has
been used as source of information for the new emerging treatments using agonists of 5-HT receptors
and new antagonists of CGRP receptors. Validated animal models of migraine are summarized to
provide an overview. At last, new therapeutic strategies and nanoparticles tested in experimental
models performed on rats or mice in the last years were considered.
Table 1. Current pharmacological treatment in migraine.
Medication Mechanism of Action Potential Common Side Effects Ref.
NSAIDs (nonsteroidal
anti-inflammatory drugs)








Agonist to: 5-HT -1B, -1D and
-1F receptors; D -1, -2, dopamine
receptors. Partial agonists to
alpha -1A, -1B, 1D adrenergic
receptors.
Nausea and vomiting. [13,14]
beta-blockers (metoprolol,
propranolol, timolol)




fatigue, insomnia, and dizziness.
[13,14]
Triptans Agonists to 5-HT-1B,1D receptors
Dizziness, fatigue, dry mouth,
flushing, feeling hot or cold,
chest pain.
[13,14]
















(at D1, D2, D3 and D4 receptors)
Fatigue, constipation, ringing in
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2. Pharmacological Targets in Migraine Treatment: 5-HT and CGRP Receptors
Research advances are increasingly focusing on the development of anti-migraine drugs. In this
context, 5-HT and CGRP receptors have been mainly investigated. 5-HT receptor agonists and
CGRP receptor antagonists are providing an important contribution in emerging treatments aimed to
counteract migraine attacks [15]. The new emerging treatments, approved or still looking for approval
by FDA, are summarized in Table 2.
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter, widely distributed
both centrally and peripherally, in the human body. It is primarily found in the enteric nervous system
located in the gastrointestinal tract. It is also produced in the central nervous system (CNS), specifically
in the raphe nuclei where neurons containing 5-HT have been observed [16]. 5-HT biological functions
are multiple and complex and its eventual response mainly depends on the nature of the 5-HT receptors
implicated [17]. Seven types of 5-HT receptors have been identified, respectively named: 5-HT1, 5-HT2,
5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7. 5-HT1 and 5-HT2 receptors are respectively divided into the
following subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F and 5-HT2A, 5-HT2B, and 5-HT2C [18,19].
Receptors functional characteristics depend on their molecular structure, being G-protein-coupled
receptors such as: 5-HT1, 5-HT2, 5-HT4, 5-HT5A, 5-HT6 and 5-HT7, or integral to an ion channel such
as 5-HT3 [20]. All 5-HT1 receptor subtypes are coupled to Gi/o, a protein that predominantly inhibits
adenylyl cyclase activity, with consequent inhibition of the release of neurotransmitters and reduction
in neuronal firing [17,20]. Triptans are agonists of 5-HT1B/1D receptors and showed to be efficacious
in the acute treatment of migraine, thus providing an indirect proof suggesting the involvement of
serotonin in the pathogenesis of migraine [21,22]. An increased production of 5-HT seems to occur
in migraineurs brain compared to control subjects, that might lead to cortical hyperexcitability [23].
A reduction in blood concentrations of 5-HT was observed in subjects with migraine in the absence
of aura during the headache phase [24]. Another study indicates that low 5-HT4 receptor binding,
that suggests a high 5-HT concentration in the brain, can be considered a trait marker of migraineurs
rather than a risk factor that can lead to a conversion from EM to CM. Higher concentrations of 5-HT
could lead to an enhancement of the susceptibility to migraine attacks. Therefore, a reduction of
5-HT concentrations could reveal effective to treat migraine, indicating that further studies involving
other 5-HT receptor subtypes and modulation of cerebral 5-HT concentrations in migraine subjects
are required [25]. The increased understanding of migraine pathophysiology recently resulted in
developing novel molecules that are under investigation as emerging options to be used in therapeutics.
The novel ditans are serotonin 5-HT1F receptor agonists, a class of drugs that differentiate from the
known triptans in showing high selectivity at receptors. The ditan Lasmiditan is currently under
investigation in migraine acute treatment [15].
CGRP is a multifunctional neuropeptide that appears to play an important part in migraine
mechanism and its origin was predicted observing the alternative splicing of the calcitonin gene [26].
This neuropeptide is known as one of the most potent vasodilators [27]. Two isoforms have been
characterized, α-CGRP andβ-CGRP. The isoformα is principally expressed in primary sensory neurons,
whereas the isoform β is mainly found in intrinsic enteric neurons [27]. The mature form of this
neuropeptide is composed of 37 amino acids, and its expression has been particularly noticed in sensory
neurons of the dorsal root ganglia (DRG) and trigeminal ganglion (TG) [26,27]. The mature form is stored
in vesicles localized in the terminal region of central and peripheral nerve endings. There, their content
may be secreted in the dorsal spinal cord or in various peripheral tissues, especially surrounding blood
vessels which may modulate vascular tone [28]. In addition, the presence of nociceptors network
positive to CGRP in rodent and human meningeal vessels has been observed [29,30], and about 40–50%
of TG neurons are positive to CGRP [31,32]. Moreover, in areas of the CNS, such as hypothalamus,
thalamus, periaqueductal gray, superior and inferior colliculi, amygdala, trigeminocervical complex
(TCC) and the cerebellum, the expression of CGRP has been observed [33,34]. These mentioned
brain areas may be associated with migraine pathophysiology, considering the capability of CGRP
to change synaptic and neuronal activity at the TCC, and transmission of nociceptive signals to the
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thalamus and cortical areas [35,36]. The structure of CGRP receptor is a complex of proteins composed
as follows: a G-protein-coupled receptor named the calcitonin receptor-like receptor (CLR) [37];
a single transmembrane accessory protein named receptor activity-modifying protein 1 (RAMP1) [38]
(needed to establish the binding of CGRP to CLR), and the receptor component protein (RCP) [39]
that characterizes the G-protein associated with the receptor. The expression of the subunits that
compose the CGRP receptor complex has been observed in peripheral and central sites [32], e.g., in cell
bodies in TG, in the periaqueductal grey, and in the TNC [40,41]. Nevertheless, it is not yet completely
established whether the assembly of all these subunits composing the fully functional receptor form
is performed in these anatomical structures. Despite this, the expression of the functional form of
CGRP-receptor complex has been observed in vascular smooth muscle cells in arteries and arterioles
(also in those of the cranial circulation), as suggested, both in vitro and in vivo [27], by the powerful
vasodilatory effect of CGRP in these blood vessels. To date, CGRP is considered a new important
pharmacological target for migraine treatment [15]. CGRP antagonists act by inhibiting vasodilation
and neurogenic inflammation through release blockage of CGRP in the migraine pathway [42].
Emerging CGRP receptor antagonists, such as ubrogepant and rimegepant, are currently under
assessment in therapeutics [15]. In addition, the development of new CGRP receptor or ligand
antagonists is ongoing, in which monoclonal antibodies (mAbs) such as fremanezumab, galcanezumab
and erenumab (all approved by FDA in 2018 for EM or CM), are opening a new approach in therapeutic
strategy, representing a valuable support to the solutions already available [15].
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3. Animal Models of Migraine
Animal models have been developed with the aim to comprehend migraine disorder, even
though all of them show shortcomings. To be considered reliable, animal models should display a
similar etiology and phenotype to human migraine. Although this disorder is considered complex
with a variable phenotype, there is currently no animal model able to replicate all its features [52].
In this paragraph, we consider murine models developed to study the migraine disorder. In Table 3,
we summarized the current animal models of migraine in which rats or mice were used.
Currently, animal models focus on activation of nerves in TCC. Nociceptors are located in the
terminal structures of meningeal and trigeminovascular afferents deriving from the ophthalmic division
of the trigeminal nerve that innervate intracranial structures sensitive to pain, such as the dura mater
and meningeal vasculature, large cerebral arteries and the paranasal sinuses. Headaches similar
to migraine can be caused by stimulation of nerves that innervate these structures [53,54]. Animal
models based on chemical provocations that use different vasodilating agents are probably the most
investigated in preclinical research. The administration of a mix of inflammatory mediators, named
“inflammatory soup”, e.g., using a mixture composed by prostaglandin (PGE2), histamine, 5-HT and
bradykinin, has been used to stimulate meningeal and trigeminovascular nociceptors [55]. In this
model, the inflammatory soup can be administered by injection using a micro-catheter placed into
the cisterna magna through the atlanto occipital membrane of animals that received anesthetics.
This injection of chemicals induces the activation of the primary sensory fibers supplying the meninges.
In addition, topical application on the dura mater of rats is also used causing a reversible cephalic
mechanical sensitivity [56–58]. Potential limitations of this technique are linked to the use of chemicals
that can compromise the functionality of the blood-brain-barrier (BBB), resulting in activation of central
sites directly rather than synaptically by the activation of meningeal afferent fibers [52].
Another model widely used, based on nitroglycerin (NTG), nitric oxide donor glycerol trinitrate,
intravenously or intraperitoneally administered, has been studied as method to provoke migraine-like
pain [52]. In rodents, hyperalgesia provoked by NTG has been used to develop a model to study sensory
hypersensitivity associated with migraine [59,60]. The infusion of NTG in mice caused thermal and
mechanical allodynia, symptom reversed by sumatriptan [59]. Moreover, in a transgenic mouse model
of familial migraine that was studied, animals that expressed a human migraine gene, casein kinase 1δ,
in which a major sensitivity to hyperalgesia induced by NTG, compared to controls, was observed [61].
In addition, NTG-administered in mice was able to induce aversion to light and increased meningeal
blood flow [60,62]. This mouse model was used to develop a test able to model the progression of the
disorder from an acute to a chronic condition by means intermittent injection of NTG. This modality of
treatment evoked acute hyperalgesia and developed a progressive basal hypersensitivity to mechanical
stimulation [63]. Both acute hyperalgesia and hypersensitivity were blocked by topiramate and
propranolol, whereas hyperalgesia was inhibited by sumatriptan, suggesting that this model may be
considered in the screening of novel therapies in migraine treatment [64]. The use of NTG in rodents
may effectively model migraine-like symptoms [65], even though doses, type of administrations and
the determination of the time of observation need to be carefully monitored when animal models based
on NTG are adopted for the study of the TGVS [52].
Medication overuse headache (MOH) is a condition that in predisposed subjects affected by
migraine or tension-type headache typically occurs. In these conditions, an overusing of drugs such
as triptans and opioids, e.g., for more than 10 days per month over 3 months, may transform the
headache from an episodic to a chronic state. In rodents, MOH may be used as a model in which
repeated administration of these drugs induced a long-lasting state of latent sensitization [66]. It has
been reported that TEV-48125, a humanized CGRP antibody, inhibited cutaneous allodynia both
induced by bright light stress and NO donor in a MOH model, in which rodents were prior treated
with sumatriptan or morphine, thus highlighting the importance of this model in discovering migraine
medications [67].
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In recent decades, several gene mutations have been correlated with some forms of severe and
rare migraine by the use of an approach based on classic linkage analysis. This analysis contributed to
sustain the hypothesis that an inherited trait is implicated in this disorder. A translational step offered
by transgenic mouse technologies, in supporting the understanding about the pathophysiology of
migraine and the evaluation of new therapeutic targets, is represented by behavioral characterization of
genetic models of migraine [68]. The familial hemiplegic migraine (FHM) is a rare monogenic migraine,
in which affected subjects show a severe hemiplegic aura accompanied by weakness perceived on
one side of the body. Specifically, three gene mutations were identified to date, CACNA1A (FHM1),
ATP1A2 (FHM2), and SCNA1A (FHM3), encoding for subunits of ion channels and transporters that
show to have a role in neurotransmission [69]. These mutations, respectively encode for subunits of
voltage-gated calcium channels, sodium-potassium ATPases, and voltage-gated sodium channels [70].
In this frame, genetic models of migraine have been created by inserting human mutated genes in the
mouse genome obtaining knock-in (KI) mouse models, respectively, two of FHM1 [71,72], and one of
FHM2 [73]. The humanized FHM1 KI mouse models contain gain of function missense mutations
(R192Q or S218L) in the CACNA1A gene, one of the most investigated genes whose product is the
pore-forming α1A subunit of Cav2.1 channels (P/Q type) (55). S218L mice showed a phenotype similar
to a severe clinical phenotype of patients showing the same mutation (FHM1 S218L) [72]. In R192Q
mice, decreased CGRP-immunoreactivity was observed when compared to controls, in cells of TG
and in the superficial laminae of the TCC, suggesting that alteration in the expression of CGRP is
induced by FHM-1 CACNA1A mutation [74]. These models showed decreased neuronal response to
nociceptive activation of the TGVS in comparison with controls [75], suggesting that they show different
reactions to common nociceptive signals observed in migraine. In addition, enhanced susceptibility
in showing spontaneous pain behaviors correlated to nociceptive headache and photophobia was
highlighted [76,77]. Only one KI mouse model for FHM2 expressed the loss of function W887R
missense mutation in ATP1A2 [73], whereas no FHM3 KI mouse model has been developed yet.
In a study based on a rodent model, during the process of evaluating baseline periorbital von
Frey thresholds, a male rat affected by spontaneous episodic trigeminal allodynia was discovered [78].
This characteristic was noticed by episodic alteration of periorbital pain threshold. The mating
demonstrated that this trait is inheritable in both sexes and with a diversity of phenotypes. Some
animals showed a similarity to chronic migraineurs, with thresholds lower than normal for more than
two weeks per month. Other animals showed a similarity to episodic migraine, manifesting periods of
normal thresholds and periods of lower thresholds. Chemicals such as sumatriptan, ketorolac and DHE
were tested in order to validate this model, temporarily reversing the pain thresholds. Furthermore,
the treatment with valproic acid for a period of one month blocked spontaneous changes in trigeminal
allodynia. After the discontinuation of the treatments, the animals returned to the initial baseline.
This study might be considered a unique model of spontaneous allodynia with phenotypes similar
to migraine, providing a possible predictive model for drug development and for the investigation
of the pathophysiology of spontaneous episodic trigeminal pain disorders [78]. Research based on
these genetic models offers an advantage due to the fact that animals are manipulated in order to have
predefined phenotypes similar as possible to migraine features. Nonetheless, the disadvantages might
regard the common polygenic forms of this disorder in the general population, in which these specific
mutations might not be relevant.
Migraine aura and cortical spreading depression (CSD) are transient neurological deficits
highlighted in around 30% of migraineurs [79]. CSD is a phenomenon described as a slow wave of
depolarization of neuronal and glial cells in the cortex that can be induced experimentally. In rodent
models, injections of KCl showed to initiate this phenomenon in the cortex. CSD visualization is
operated measuring the electrical activity of cortical neurons by means implanted microelectrodes
or changes in cerebral blood flow through laser doppler flowmetry [52]. Furthermore, CSD can be
also induced by electrical or mechanical stimulation of the cortex [80]. Progresses in the study of CSD
mechanisms have focused to elucidate whether it plays a part in provoking the trigeminovascular
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activation, resulting in migraine triggering. In rodents, studies based on imaging showed that
CSD induces vasodilation of meningeal blood vessels [81], and enhanced neuronal activation at the
level of trigemino nuclear complex and in higher cerebral areas of the trigeminal pain pathway [82].
Considering that migraine frequently occurs without aura, the mechanisms of CSD require further
studies to be better clarified and for drug discovering in migraine aura treatment.




Description Response to Treatment Ref.




unilateral hind paw; facial
grooming; anxiety- and
depression-like behaviors;
altered CGRP-related genes in
the TG and TNC.
Zolmitriptan reduced nociceptive
behaviors. Ketorolac reduced the
nociceptive behavior, ipsilateral












facial expressions of pain.
Propranolol, topiramate, and
amiloride inhibited mechanical
hyperalgesia. Valproic acid were
ineffective. Sumatriptan inhibited
hypoactivity and grimace scale









Topiramate blocked the enhanced
Fos expression in the TNC and
inhibited cutaneous allodynia.
[66,88,89]
Genetic model - Spontaneous episodictrigeminal allodynia.





















neuronal activation at the level
of trigemino nuclear complex
and in higher cerebral areas of
the trigeminal pain pathway.
Valproate, topiramate,
propranolol, amitriptyline and
methysergide were shown to
suppress SD susceptibility.
Lamotrigine was also shown to
block KCl-induced CSD.
[90,91]
4. New Therapeutic Strategies in Experimental Models
The first therapeutic approach to migraine is generally symptomatic and aimed to alleviate acute
pain, and medications are more effective whether quickly administered. Notwithstanding, there are
advances in the development of anti-migraine drugs, and there is a growing need in researching
novel therapeutic approaches aimed to treat more effectively migraine compared to actual treatments.
In this context, we therefore consider studies on animal models developed with this perspective in this
study. The most relevant findings of new compounds and nanoparticles in experimental models are
summarized in Table 4.
In a recent study, Moye et al. [92] studied the efficacy of SNC80, a δ opioid receptor (DOR) agonist,
in mouse models that replicated different headache disorders. In these models, mice were managed in
order to induce CM, post-traumatic headache (PTH), MOH, and opioid-induced hyperalgesia (OIH) [92].
In CM model, mice received NTG by the intraperitoneally intermittent administration. In PTH, mice
received isoflurane to be mildly anesthetized and then underwent the closed head weight-drop method
in order to induce mild traumatic brain injury, and two weeks after PTH was modelled by low
NTG dose intraperitoneally. To model MOH and OIH, animals received intraperitoneally treatment
using respectively sumatriptan or morphine. In CM model, animals treated with NTG showed basal
peripheral and cephalic hypersensitivity. To evaluate the effect of the activation of DOR, an acute
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treatment of SNC80 was performed 24 h after the last injection of NTG. This treatment showed a
relevant attenuation of peripheral and cephalic allodynia compared to controls, indicating that pain
associated with CM was blocked by DOR activation. In PTH model, basal peripheral and cephalic
hypersensitivity were developed in mice treated with NTG compared to controls. Twenty-four hours
after the last NTG injection, cephalic allodynia was inhibited by performing an acute SNC80 treatment,
indicating that also in this case, the pain associated with PTH was attenuated by DOR activation.
In MOH model, basal hind paw and cephalic hypersensitivity were developed in mice treated with
chronic administration of sumatriptan. Twenty-four hours after the final injection of medication, mice
received an acute treatment with SNC80 that resulted in allodynia attenuation, suggesting that MOH
induced by overuse of sumatriptan can be inhibited by DOR activation. In OIH model, mice received
chronic treatment with morphine, showing basal hind paw and cephalic hypersensitivity, an effect
that was also observed 18–24 h after the last drug injection. After, SNC80 was administered resulting
in allodynia effect attenuation induced by morphine treatment. Furthermore, it has been observed
that chronic daily administration of SNC80 causes a limited form of MOH, less severe in comparison
with mice treated with sumatriptan. These results suggest that DOR agonists might represent a novel
therapeutic approach in the treatment in diverse headache disorders showing a different etiology [92].
Pradhan et al., have investigated the therapeutic potential of δ-opioid receptor agonists in mouse
migraine models induced with acute and chronic doses of NTG [93]. Animals were treated with three
different δ-opioid receptor agonists, SNC80, ARM390 or JNJ20788560, about 1 h 30 min following
NTG injection. These receptor agonists were able to significantly reduce NTG-evoked hyperalgesia.
In addition, a model of migraine aura was induced by continuous application of KCl in order to
evaluate the effects of SNC80 on evoked CSD. SNC80 in the 1 h time interval following administration,
was able to reduce the number of CSD events. These data showed the therapeutic ability of the δ-opioid
receptor as a promising therapeutic target for migraine [93].
Hoelig et al., studied the effectiveness of NOX-L41, a CGRP-neutralizing mirror-image (L-) aptamer
(termed Spiegelmer), in a rat model of electrically evoked meningeal plasma protein extravasation
(PPE) [94]. In this study, the authors have tested a Spiegelmer, a molecule synthesized chemically
consisting of mirror-image oligonucleotide, which is able to bind to a pharmacologically relevant target
molecule. Animals received NOX-L41 as a single dose intravenously or subcutaneously, showing a
plasma half-life of 8 h. Furthermore, by means pharmacodynamic studies, after a single administration
an extravasation of NOX-L41 from blood vessels in the dura mater and inhibition of neurogenic
meningeal PPE for at least 18 h was observed. The Spiegelmer action consisted in binding CGRP,
a neuropeptide that promotes meningeal vasodilation, inhibiting CGRP in signaling at its receptor.
NOX-L41 showed increased affinity and selectivity for both isoforms, α and β, of human CGRP
than a previous studied NOX-C89. The capacity of NOX-L41 to extravasate in surrounding tissues
of dural circulation, in order to interact with perivascular vasodilating agents, results in the need
to develop compounds able to antagonize CGRP, preventing neurogenic inflammation. This study
suggests further the involvement of CGRP in neurogenic PPE, indicating NOX-L41 as a future potential
compound for the treatment or prevention of migraine [94].
In recent times, the development of drug delivery systems using nanoparticles has received an
increased attention from the scientific community. In this context, Girotra et al. [95–99] conducted
studies on nanoparticulates formulations with the aim to increase the brain targeting of pharmacological
anti-migraine drugs. Here, we consider some of their investigations.
A dual therapeutic approach was performed on rats and mice in the development of brain-targeted
rizatriptan benzoate-loaded solid lipid nanoparticles (RB-SLNs), with the purpose to improve the drug
potentiality in counteracting migraine [95]. The formulations have been elaborated by fabricating
optimized solutions to obtain particle sizes showing sufficiently high entrapment efficiency and
drug release in about 8 h. To evaluate the typical symptoms related to migraine, acetic acid-induced
writhing test and light/dark box model were respectively used to induce hyperalgesia and light aversive
behavior. Animals that received optimized RB-SLNs by oral administration showed a decrease in
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migraine-related hallmarks. After 2 h of oral drug treatment, pharmacodynamic evaluations showed
that in rats, the brain uptake potential of optimized RB-SLNs was about 18.43-folds greater compared
to the free form of the pure drug, whereas in mice showed to cross the BBB resulting in an improvement
of its anti-migraine effectiveness. These findings indicate that RB-SLNs showed an improvement in
brain target ability, thus providing a potential approach for migraine management [95].
In another study, an innovative approach has been conceived by developing chitosan solid lipid
nanoparticles (SLN) that contained sumatriptan succinate (SS) [96]. The SLN formulations optimized
in brain targeting. The optimization of the formulations was accomplished by multi-level design
factorial in order to obtain a minimize size particles with a high entrapment efficiency and drug
concentrations. Rats received the formulations, previously dispersed in deionized water, by oral
administration. Behavioral studies indicating a reduction in hyperalgesia in the acetic acid induced
writhing test and reduced aversion to light in light/dark box model. The treatment with formulations
showed a major availability of SS in the brain in comparison with controls. These results suggest that
formulations orally administered consisting in hydrophilic drug SS, loaded in chitosan SLN, were able
to cross the BBB, allowing the drug in exerting its pharmacological activity in the brain. Considering
their data, nanoparticulate drug delivery systems might represent a future approach to cross the BBB
and to improve brain targeting of medications in migraine therapeutics [96].
A further study has been conducted on another formulation for brain targeting of SS, with the aim
to evaluate the optimal therapeutic effect of the drug in migraine. For this purpose, nanoparticulate
drug delivery system using poly (butyl cyanoacrylate) (PBCA) and bovine serum albumin linked
with apolipoprotein E3 (BSA-ApoE) was used [97]. SS was incorporated in the BSA-ApoE NPs and
compared with the same drug loaded polysorbate 80 coated optimized PBCA NPs to determine the
brain uptake potential of these formulations. The central composite design was used for the formulation
of PBCA NPs optimized with minimum particle size, maximum entrapment efficiency along with
the sustained drug release. Also, in this study, animals were treated and assessed as described in the
previous investigations, and behavioral studies showed similar improvements. The treatments with
the nanoformulations prepared in this study showed a high brain/plasma drug ratio 2 h after the oral
drug administration. The data obtained by the authors suggest that BSA-ApoE NPs showed a better
activity than polysorbate 80 coated PBCA NPs for brain targeting of SS. This technique might offer a
perspective, as improved therapeutic approach for the treatment of migraine [97].
In another study concerning the use of nanoparticles, Poly (D,L Lactide-co-Glycolide) (PLGA)/
poloxamer nanoparticles (NPs) of the hydrophilic medication zolmitriptan were developed [98].
Randomized factorial design to obtain the critical quality characteristics of minimized particle size
and maximized encapsulation efficiency was applied. To determine the brain uptake potential, rats
received optimized zolmitriptan encapsulated PLGA NPs as oral administration, and at the different
time points, plasma and brain samples were collected. Acetic acid induced writhing test and light/dark
box model were respectively used to induce hyperalgesia and aversion to light in mice. After the
treatment, the in vivo studies for determining the brain uptake potential showed a 14.13-fold increase
in the drug delivered to the brain from the NPs as compared to the free drug. Behavioral tests showed a
decrease in the number of writhings, and a significant reduction of light aversion compared to controls.
These data suggest that PLGA NPs containing zolmitriptan may represent a future tool in providing
systems to cross the BBB for drug delivery that can exert an enhanced anti-migraine effect [98].
Another investigation has been performed using pharmacophore modeling [99]. This technique
led to the identification of nystatin as compound active against the receptors iGluR5 kainate receptor
(1VSO), CGRP (3N7R), β2 adrenoceptor (3NYA) and Dopamine D3 (3PBL). Following this result,
brain targeted chitosan nanoparticles containing nystatin were prepared, later intraperitoneally
administered in rats in order to evaluate brain targeting efficacy. Confocal laser scanning microscopy
showed a higher nanoparticles accumulation in the brain than liver and spleen. After treatment with
nystatin nanoformulations, behavioral tests performed in mice showed a reduction in hyperalgesia,
photophobia and phonophobia compared to controls. This study represents the first approach of the
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therapeutic potential of nystatin nanoformulations, suggesting their future application in the treatment
of migraine [99].
Wang et al., developed a novel ester derivative of gastrodin (Gas), termed Gas-D, and studied
its effectiveness in a model of NTG induced migraine in rats [100]. Gas is a compound obtained
by Gastrodiae Rhizoma (known in China, also as Tianma), and it has already been used for the
treatment of migraine. Rats received Gas-D intragastrically, and subsequently treated by NTG
subcutaneously 1 h after the final treatment. The pretreatment with Gas-D showed a reduction in
head-scratching behavior, previously induced by NTG treatment. Results obtained from this study
require further pharmacokinetic and pharmacodynamic investigations, suggesting that Gas-D, thanks
to its anti-migraine effect, might be considered as a future candidate for migraine treatment [100].
Zhao et al., performed a comparative study evaluating two traditional Chinese drugs, gastrodin and
ligustrazine, in a rat model of nociceptive durovascular trigeminal activation [101]. In this study, Chinese
medications were compared to two Western approaches with propranolol and levetiracetam. Animals
underwent surgical procedures for drug administration by femoral vein cannulation. An electrode was
applied onto the dura mater above the middle meningeal artery and used to record the electrical stimuli
in the TCC. When a reliable baseline to dural electrical stimulation was established, either gastrodin,
levetiracetam, ligustrazine, or propranolol was administered. The treatment showed that gastrodin
was able to inhibit nociceptive dural-evoked neuronal firing in the TCC, whereas ligustrazine showed
no relevant effect on spontaneous activity in the TCC. To perform a comparison with the Chinese drugs,
the established migraine preventive propranolol and the ineffective compound levetiracetam were used.
As a result, propranolol showed a significant inhibition of dural-evoked responses, whereas the use of
levetiracetam showed no effect. Their data suggest that gastrodin showed potential as an anti-migraine
treatment, and on the contrary, ligustrazine appeared less promising. Therefore, these findings suggest
further investigations about the use of gastrodin in migraine treatment. In addition, the results indicate
the usefulness in exploring the traditional Chinese medicine approaches as signposts in developing
new drugs for migraine [101].
In the last years, further experimental models have been developed using different approaches.
Electrical stimulations have been used in experimental models with the purpose to better understand
the mechanisms of migraine. Recently, Zhang et al. developed a repetitive electrical stimulation
rat model [102]. In this study, the authors showed a dynamic model that upon stimuli of the dura
mater, the TG begins to increase the production of the vasoactive neuropeptide pituitary adenylate
cyclase-activating peptide (PACAP). PACAP is released from periphery terminals of the TG to
innervating areas such as the dura mater, leading to vasodilation. PACAP is transported through
central terminals to the TNC, where PACAP binds to PACAP-preferring type 1 (PAC1) receptor and
triggers the excitation of nociceptive neurons with a consequent further increase in PACAP. The new
repetitive electrical stimulation model established by stimulating the dura mater in conscious rats can
simulate the chronification of frequent onset of acute migraine, from the perspective of cutaneous
allodynia and nociceptive behaviors. PACAP appears to have a part in the pathogenesis of migraine
potentially via PAC1 receptor. PACAP is co-expressed with CGRP, and therefore shows the potential
to be considered a new therapeutic target for migraine [102]. The use of electrical stimulations led
to the development of some clinical trials in which their use for the treatment of migraine has been
assessed [103,104].
Furthermore, the effect of electroacupuncture (EA) pretreatment has been investigated. Pei et al.
conducted a study regarding the use of EA in rats [105]. In this study, the authors used a conscious rat
model of migraine induced by repeated electrical stimulation of the dura mater. Animals treated with
EA showed an increase in exploratory, locomotor and eating/drinking behavior and a reduction in
freezing-like resting and grooming behavior. In animals that received dural stimulation, an increase of
c-Fos neurons in the periaqueductal grey, raphe magnus nucleus, and TNC was observed. This study
showed that EA pretreatment may reduce behavioral responses to electrical stimulation of the dura
mater in a rat model of recurrent migraine. These findings suggest that EA pretreatment may improve
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migraine-like symptoms by altering the descending pain modulatory system. Notwithstanding, further
molecular and electrophysiological research is needed to better comprehend the central mechanisms of
EA treatment of migraine [105].
Further emerging therapeutic targets are the acid-sensing ion channels (ASICs), which are
considered neuronal proton sensors. Amiloride (a non-specific ASIC blocker) is a compound that
showed to have benefic effects in animal models of migraine. Verkest et al., investigated the involvement
of the ASIC1-subtype in cutaneous allodynia [106]. The authors conducted an investigation on effects
of systemic administrations of amiloride and mambalgin-1 (a specific inhibitor of ASIC1a- and
ASIC1b-containing channels) on cephalic and extra-cephalic mechanical sensitivity. The treatment was
performed on a rat model of acute and CM induced by intraperitoneally administration of isosorbide
dinitrate. The systemic administration of these compounds reversed cephalic and extra-cephalic
acute cutaneous mechanical allodynia, whereas a single administration caused a delay in the
subsequent establishment of chronic allodynia. Established chronic allodynia was also reversed
by both mambalgin-1 and amiloride. A single daily administration of mambalgin-1 also showed to
have a preventive effect on allodynia chronification. Pharmacological results obtained in this study
suggest the involvement of peripheral ASIC1-containing channels in cutaneous allodynia and in its
chronification. Furthermore, the results indicate the therapeutic potential of ASIC1 inhibitors in acute
and prophylactic migraine treatment [106].
The involvement of TWIK-related spinal cord K+ (TRESK) channels has also been investigated.
These channels are expressed in TG and DRG neurons and are the major background K+ channels in
primary afferent neurons. Mutations in TRESK channels have been associated with familial and sporadic
migraine. Nevertheless, whether enhanced TRESK channel activity would reduce the excitability of
primary afferent neurons has not been evaluated. Guo et al. [107] observed that the over-expression of
TRESK subunits lead to an increase in background K+ currents, a reduction of input resistance, and a
reduction in the excitability of small-diameter TG neurons. The overexpression of TRESK subunits
inhibits capsaicin-evoked spikes in TG neurons, suggesting that a TRESK-specific channel opener may
exhibit analgesic effect via reducing the excitability of primary afferent neurons [107].
Lengyel et al., investigated in in vitro the effects of chemically modified analogs of cloxyquin,
tested on TRESK and other K2P channels. Cloxyquin is known as a specific activator of TRESK
(K2P18.1, TWIK-related spinal cord K+ channel) background potassium channel. In this recent study,
among the modified analogues of cloxyquin used, the authors identified A2764, a selective inhibitor of
TRESK that can inhibit TRESK in native cells, leading to cell depolarization and increased excitability.
This compound may be of use to probe the role of TRESK channel in migraine and nociception [108].
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5. Conclusions
Migraine is a disorder with a multifactorial etiopathogenesis in which the complicated
pharmacological management requires further efforts to develop more efficacious therapies. Research
advances strongly contributed in expanding our understanding of the pathways involved in its complex
pathophysiology. Animal models have been developed on the base of clinical observations and some
of them represent valuable predictive tools for the identification of anti-migraine drugs. Among
the animal models developed to date, chemical provocations models based on the use of NTG or
inflammatory soup have been the most widely used models to induce hyperalgesia and inflammation.
The opioid receptor agonists such as SNC80, ARM390 or JNJ20788560, are revealing to be effective in
counteracting hyperalgesia and CSD, respectively induced by chemical provocation using NTG and
KCl. Nanoparticulate drug delivery systems might represent novel avenues to improve drug efficacy
in brain targeting. In these novel formulations, triptans are encapsulated in nanoparticulates in order
to better exert their pharmacological activity in brain by crossing the BBB. Furthermore, new emerging
classes of medications, including 5-HT receptor agonists (ditans), CGRP receptor antagonists (gepants)
and receptor or ligand antagonists (mAbs) are opening further options in therapeutics for EM and CM.
Despite the medications already used in migraine therapeutics, further efforts are required to improve
research in the translational pharmacological approach, from animal models to humans, in order to
develop new therapeutic strategies.
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TNC Trigeminal nucleus caudalis
CGRP Calcitonin gene-related peptide
DHE Dihydroergotamine
5-HT Serotonin
CNS Central nervous system
DRG Dorsal root ganglia
TG Trigeminal ganglion
TCC Trigeminocervical complex
CLR Calcitonin receptor-like receptor
RAMP1 Receptor activity-modifying protein 1
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NTG Nitroglycerin
MOH Medication overuse headache
FHM Familial hemiplegic migraine
KI Knock-in
CSD Cortical spreading depression
DOR Delta opioid receptor
PTH Post-traumatic headache
OIH Opioid-induced hyperalgesia
PPE Plasma protein extravasation
RB-SLNs Rizatriptan benzoate-loaded solid lipid nanoparticles
ZNPs Zolmitriptan nanoparticles
SS Sumatriptan succinate
SLN Solid lipid nanoparticles
NPs Nanoparticles
PBCA Poly (butyl cyanoacrylate)
BSA-ApoE Bovine serum albumin linked with apolipoprotein E3
Gas Gastrodin
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Abstract: Substance P (SP), an 11-amino-acid neuropeptide, has long been considered an effector of
pain. However, accumulating studies have proposed a paradoxical role of SP in anti-nociception.
Here, we review studies of SP-mediated nociception and anti-nociception in terms of peptide features,
SP-modulated ion channels, and differential effector systems underlying neurokinin 1 receptors
(NK1Rs) in differential cell types to elucidate the effect of SP and further our understanding of SP in
anti-nociception. Most importantly, understanding the anti-nociceptive SP-NK1R pathway would
provide new insights for analgesic drug development.
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1. Background
Substance P (SP) was first described by von Euler and Gaddum, in 1931 [1]. The authors observed
an unknown substance that stimulated contraction of the intestine ex vivo. This substance was
identified and Euler and Gaddum named it substance P, from the bottle containing it, labeled P1, P2
etc., meaning “powder”. In the 1970s, SP was homogeneously purified by Chang and Leeman [2]
and was later determined to be an 11 amino-acid peptide, H-Arg Pro Lys Pro Gln Gln Phe Phe
Gly Leu Met-NH2 (RPKPQQFFGLM), with an amidation at the C-terminus [3]. SP belongs to
the tachykinin family and serves as a neurotransmitter and a neuromodulator. It is encoded by
preprotachykinin-1 (or tachykinin 1 (TAC1)) that produces SP and neurokinin A via alternative slicing
and post-translational modifications [4].
SP is widely distributed in the human body, especially in nervous systems and inflammatory
cells. A general assumption of the SP action describes SP as a neuropeptide released from pain-sensing
fibers (nociceptors) to increase pain sensitivity through its actions in the dorsal horn of the spinal
cord [5]. SP also triggers proinflammatory cytokine release resulting in inflammation, vasodilation and
plasma extravasation [6]. Although considerable evidence indicates that SP transmits pain signaling
and serves as a mediator of pain [7–9], accumulating studies reveal that SP also has an anti-nociceptive
effect [10,11]. Interestingly, evidence showing the antinociceptive role of SP has been built over several
years and can be dated back to 1976 [10]. The discrepant function of SP is believed to depend on the
cell type regarding the expression of neurokinin receptors with unique underlying effector systems
modulating differential ion channels.
2. SP-Mediated Signaling
There are three tachykinin receptors: Neurokinin 1 (NK1), 2 (NK2), and 3 (NK3). SP preferentially
binds to NK1 receptor (NK1R). NKRs are G-protein-coupled receptors located in both the central
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nervous system (CNS) and peripheral nervous system (PNS). G proteins have Gα, Gβ, and Gγ
subunits. The Gα subunit is classified into 5 families (Gs, Gi, Go, Gq/11, and G12/13). In most cases,
NK1R is coupled to the pertussis toxin-insensitive Gq/11 cascade [12,13]; nevertheless, crosstalk
with other G proteins such as G12/13 [14], Go, and Gs [15] has been reported. In Gq/11-mediated
signaling, phospholipase C is activated by Gβγ binding, which in turn results in hydrolysis of
membrane phospholipid PtdIns(4,5)P2 to form diacylglycerol (DAG) and inositol triphosphate (IP3).
IP3 further triggers calcium release in cytoplasm from sarcoplasmic reticulum, whereas DAG activates
protein kinase C (PKC) and results in calcium influx from the L-type calcium channel in the plasma
membrane [16]. The increase in calcium ion in the cytoplasm further leads to an array of cell responses.
There are two natural forms of NK1R: A full-length receptor with 407 amino acids and a truncated
receptor with 311 amino acids, lacking 96 amino acids in the carboxyl terminal [17,18]. The human
NK1R gene contains five exons. The truncated version is generated when the intron between exons 4
and 5 is not removed that encounters a premature stop codon before the start of exon 5. These two types
of NK1Rs have differential features. The binding affinity of SP is 10 times less to the truncated NK1R
than the full-length form. Furthermore, the underlying signaling of the two different NK1Rs differs. The
carboxyl terminus of full-length NK1R is a crucial element for G-protein coupling. The truncated form
of NK1R impairs the ability of G-protein binding and results in G-protein-independent mechanisms.
Indeed, the truncated form of NK1R fails to interact with β-arrestin, an important protein mediating
the desensitization and internalization of activated G-protein-coupled receptors [19]. Furthermore,
activation of the truncated NK1R has different effects on calcium mobilization, phosphorylation of
PKCδ, extracellular signal-regulated kinase 1/2, and regulation of interleukin 8 mRNA expression as
compared with the full-length NK1R [20].
The two NK1Rs are differentially distributed in peripheral tissues and in the nervous system.
In the brain, full-length form is abundantly expressed in striatum, caudate nucleus, putamen, globus
pallidus, nucleus accumbent, and hypothalamus; whereas the truncated NK1R expression is relatively
low in the brain, and most represented in the PNS and peripheral tissues including heart, lung, prostate,
and bone [21]. To sum up, the different NK1R subtypes could trigger differential effector systems and
further result in distinct cellular responses in different tissues and organs.
3. SP and Pain
Pain is an unpleasant sensation and can be divided into two major categories: Acute and chronic
pain. Acute pain lasts only short time and can be ameliorated over time. Acute pain helps us avoid
the physical damage to our body and serves as a warning signal. In contrast, chronic pain has no
biological function and is a disease itself rather than symptom of a disease. Chronic pain usually lasts
for more than six months. People with chronic pain represent about 10.1% to 55.2% of the population
in various countries according to epidemiological study [22]. People with chronic pain often show
other symptoms, such as fatigue, sleep disorder, memory problems, anxiety, and depression, which
greatly affect their quality of life.
Chronic pain can be further divided into two subtypes: Inflammatory and neuropathic pain.
Inflammatory pain is related to tissue injuries, which lead to inflammatory reactions. In contrast,
neuropathic pain results from nerve injury and neuronal sensitization in the CNS and PNS. However,
inflammatory pain and neuropathic pain are also closely correlated. Nerve injuries result in tissue
inflammatory responses, which lead to inflammatory pain. Likewise, tissue inflammation triggers an
inflammatory cascade releasing a variety of inflammatory mediators such as SP, calcitonin gene-related
peptide, and neurokinin A to damage nerves [23,24]. Clinical studies have demonstrated that many
forms of chronic pain have mixed components of inflammation and neuropathy [25].
Substantial evidence suggests that SP is the key element in neurogenic inflammation and has
an important role in eliciting pain sensation in both the CNS and PNS. In the CNS, SP results in
central sensitization by activating excitatory post-synaptic potential [26]. In the PNS, releasing SP from
peripheral nociceptive nerve fibers can cause neurogenic inflammation in the skin [27,28]. In addition,
people with fibromyalgia, a chronic pain disorder, showed elevated SP level in cerebrospinal
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fluid [29,30]. Chemical ablation of neurons expressing SP receptors in lamina I [31] and genetic
disruption of the encoding gene of SP [32] or its receptor [33] reduced pain responses. Furthermore, a
recent study showed that selectively ablating TAC1-expressing neurons in the spinal cord abolished
the sustained pain but not the reflexive defensive response [34]. Together, these studies support that
SP is an important signal molecule in pain transmission.
Thus, many studies have focused on developing selective NK1R antagonists as a potential analgesic
drug. Although several preclinical studies showed an anti-nociceptive effect of NK1R antagonists, most
clinical trials failed to show analgesia effects. The reasons for failure of most NK1R antagonists in
clinical trials are still elusive. Several reasons for discrepancy between preclinical and clinical results
have been proposed such as species differences in NKRs distribution [35], species differences in affinities
to antagonists for NK1R [36–38], and the ability of animal models in predicting clinical pain [39]. The
discovery of an antinociceptive effect of SP may also explain in part the failure of those clinical trials [10].
One hypothesis is that neurons innervating distinct locations may respond differently to SP—some
neurons excited by SP and some inhibited by SP. Thus, elucidation of SP-mediated responses in different
tissues and organs becomes a crucial step in developing specific NK1 antagonists as analgesic drugs.
4. SP-Mediated Anti-Nociception
The antinociceptive effect of SP was first reported in 1976 [10]. Although SP had been identified for
more than four decades, in the early time, the impure natural SP contaminated by bradykinin or some
other kinin-like compounds impeded SP research. In the 1970s, SP was homogenously synthesized.
With purely synthetic SP, the effect of SP could be clearly deciphered. Stewart et al. first reported that SP
treatment by intracerebral and intraperitoneal injection could produce naloxone-reversible analgesia,
and the site of action was in the CNS [9]. Subsequently, several studies confirmed the SP-mediated
anti-nociception via opioid receptors in the CNS, and SP seemed to be a regulatory peptide to normalize
the responses to pain stimuli. In 1978, Frederickson et al. claimed that a small amount of SP (1.25 to 5 ng
per mouse) by intracerebroventricular injection produced a naloxone-reversed anti-nociception effect in
mice [32]. However, higher doses (>50 ng per mouse) caused hyperalgesia. The authors also reported
that although the C-terminus of SP (SP6–11) is very similar to that of endogenous opioid peptides,
neither SP nor the SP6–11 acted on opioid receptors. At low doses, SP triggered the release of endorphins
but at higher doses, directly excited neurons in the brain [40]. In 1980, Oehme et al. suggested that
SP produced naloxone-reversed analgesia in mice with high sensitivity to thermal stimulation but
induced hyperalgesia in mice with low sensitivity to thermal stimulation [41]. In addition, SP has been
found to effectively reduce neuropathic pain [42] and inflammatory pain [43]. To sum up, these studies
demonstrated that SP can regulates opioid-dependent analgesic effects in distinct cell types, probably
via different receptors.
Because it has also been reported that the C-terminus of SP is sufficient for biological activities
in nociception [44], a certain active fragment of SP may be essential for anti-nociception. Indeed,
evidence has shown that the N-terminal and C-terminal domains of SP have opposite functions.
Hall and Stewart demonstrated that the N-terminus of SP (SP1–7) was related to naloxone-reversible
anti-nociceptive and anti-aggressive actions, whereas the C-terminus (SP7-11) was thought to mediate
pain transmission [45,46]. Furthermore, Skilling et al. showed that N-terminus of SP (SP1–7) but
not the C-terminus (SP5–11) inhibited the release of excitatory neurotransmitters into spinal-cord
extracellular fluid, which was reversed by naloxone [47]. These studies agree with the findings of
the naloxone-reversible analgesic effect by SP in the CNS and PNS. The 11 amino-acid SP may be
cleaved by enzymatic degradation into differential fragments. Those fragments could interact with
differential receptors to induce an anti-nociceptive effect possibly via release of met-enkephalin or
other endogenous opioid peptides [48–50].
Other evidence has shown that SP could act on NK1R to modulate opioid receptors [51,52].
Bowman and colleagues showed that SP increased the recycling of mu-opioid receptors in sensory
neurons and led to elevated sensitivity of opioids [53]. Together, these studies suggest that the
anti-nociceptive role of SP could act via opioid signaling.
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5. SP-Mediated Anti-Nociception in Muscle
Accumulating evidence has shown a role for SP in anti-nociception in the PNS, especially
in muscle. Despite much evidence indicating that SP can cause cutaneous pain, applying SP to
muscle induced neither neurogenic inflammation nor painful perception in humans and rats [54–56].
In contrast, Lin et al. showed that SP had an anti-nociceptive role in muscle rather than causing
pain [57]. With whole-cell patch clamp recordings on dissociated muscle-afferent dorsal root ganglion
(DRG) neurons, the authors revealed that SP attenuated the acid sensing ion channel 3 (ASIC3)-induced
inward current by enhancing M-channel-like potassium current. ASIC3 is a voltage-independent
sodium channel activated by the extracellular protons. It has been found as a molecular determinant
involved in pain-associated tissue acidosis [58,59]. As well, a recent study showed that ASIC3 can
detect extracellular acidification and also respond to mechanical stimuli [60,61].
The in vivo antinociceptive role of SP was demonstrated in a rodent model of chronic widespread
muscle pain induced by dual intramuscular acid injections, one of the fibromyalgia pain models
developed by Sluka et al., in 2001 [62]. Two injections, separated by one to five days, of pH-4 acidic
saline in the unilateral gastrocnemius muscle in rodents produced chronic and bilateral mechanical
hyperalgesia of hind paws and muscle that required activation of ASIC3 [63]. Blocking ASIC3 activation,
at the first or the second or both acid injections, abolished the induction and development of chronic
muscle hyperalgesia. Furthermore, in the dual acid-injection model, the first acid injection could
depolarize ASIC3-expressing muscle nociceptors and also simultaneously trigger SP release, which
further enhanced the M-channel-like potassium current to attenuate ASIC3-induced depolarization
in gastrocnemius muscle-afferent DRG neurons. In mice lacking TAC1 (no SP and neurokinin A
production), chronic pain could be induced by a single acid injection, which suggests that the
anti-nociceptive effect was produced by the first acid injection but was diminished with the second
injection [57]. The reason for ineffective SP in a second acid injection is still unclear and requires
further investigation.
Regarding the acid-induced anti-nociception via SP release, the other important question is
what types of acid sensors contribute to the release of SP as an anti-nociceptive acid sensor. The
anti-nociceptive acid sensors are still unknown. Although previous study indicated that an acid sensor
other than ASIC3 and transient receptor potential cation channel subfamily V member 1 (TRPV1)
could trigger SP release [64], the possibility of the co-contribution of ASIC3, TRPV1, and other acid
sensors such as other ASIC subtypes and/or proton-sensing G protein-coupled receptors is still not
excluded. A recent study demonstrated that low-level laser therapy (LLLT) was effective in reducing
mechanical hyperalgesia in the dual acid-injection model. The analgesic mechanism is associated
with activation of TRPV1 to release SP in muscle [65]. This study provides new insights regarding the
involvement of TRPV1 in acid-mediated anti-nociception. Furthermore, it reveals the involvement
of SP in LLLT analgesia, which is widely used in pain control for musculoskeletal pain in the field of
physical medicine and rehabilitation. In light of the antinociceptive role of SP in muscle, NK1R agonists
might be promising candidates for pain relief in intractable musculoskeletal pain, such as fibromyalgia.
6. Ion Channels Involved in SP Signaling
SP can modulate a variety of ion channels (Table 1) resulting in an increase or decrease of neuronal
excitability [66]. In most studies, SP excites neurons by increasing the function of excitatory ion
channels and decreasing that of inhibitory ion channels. For example, SP has been shown to excite
neurons by elevating the conductance of sodium channels and decreasing that of potassium channels
in locus coeruleus neurons [67]. SP also inhibits inwardly rectifying K+ channels in nucleus basalis
neurons via Gq/11 [68,69], and inhibits Ca2+-activated potassium channels [IK(Ca)] in stellate ganglion
neurons via pertussis toxin-insensitive G proteins [70]. Other studies showed that SP can inhibit the
N-type calcium channel in sympathetic neurons via pertussis toxin-insensitive G proteins [71,72].
The above studies suggest that SP mainly modulates ion channel activity via the G-protein-dependent
pathway. However, non-G-protein effector systems are also reported in SP-mediated signaling. Lu
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and colleagues revealed that SP-induced increase of sodium conductance was mediated by activating
the sodium ion-permeable cation channel complex of NALCN (sodium leak channel, non-selective)
and UNC-80 in mouse hippocampal and ventral tegmental area neurons independent of G-protein
but mediated by Src family tyrosine kinase [73]. Accordingly, SP can modulate diverse channels and
activate the neurons by G-protein-dependent or -independent signaling.
A few studies showed that SP hyperpolarizes neurons in the PNS. SP hyperpolarized vagal
sensory neurons of ferrets by inducing a Ca2+-dependent outward potassium current [74]. SP decreased
non-selective cation channel conductance in outer hair cells of guinea pig cochlea [75]. SP enhanced
the M-type potassium current independent of G-protein but dependent on tyrosine kinase in half of
muscle-afferent DRG neurons [57]. Similarly, an SP-mediated Gi/o-dependent pathway could augment
the M-type potassium current in DRG neurons and trigeminal ganglion (TG) neurons [76]. Finally,
SP could inhibit T-type calcium channels in DRG and TG neurons [77]. Together, SP can modulate a
variety of ion channels via different signaling pathways, which are cell type-specific.
Table 1. Ion channels modulated by substance P.









nucleus basalis neurons Rat ↓ [67–69]
KCa
PTX-insensitive








rat, frog ↓ [70–72]
NALCN Src familykinases
Hippocampal and ventral
tegmental area neurons Mice ↑ [73]
TRP3C Via NK2R HEK293 ↑ [82]
Nav1.8 PKCε DRG Rat ↑ Pro-nociception [83]
TRPV1 PKCε DRG Rat ↑ Pro-nociception [84–86]
L, N type calcium channel PKC DRG Rat ↑ [87]
Low threshold
potassium channel (Kv4) DRG Rat ↓ Pro-nociception [88]
P2X3 TG Rat ↑ Pro-nociception [89]
GABAAR Gi/o Spinal dorsal horn neurons Rat ↑ Anti-nociception [90]
Glycine receptor Gi/o Spinal dorsal horn neurons Rat ↑ Anti-nociception [90]
M-type potassium channel Tyrosine kinase DRG Mice ↑ Anti-nociception [57]
M-type potassium channel Gi/o DRG, TG Rat ↑ Anti-nociception [76]
T-type calcium channel Gi/o DRG Rat ↓ Anti-nociception [77]
KCa Vagal sensory neurons Ferret ↑ [74]
Ih Vagal sensory neurons Ferret ↓ [91]
Non-selective cation channel PTX-insensitiveG protein Outer hair cells of cochlea Guinea pig ↓ [75]
Abbreviations: NMDAR, N-methyl-D-aspartate receptor; Kir, inward rectifier potassium channel; KCa, calcium-
activated potassium channel; Ih, hyperpolarization-activated channel; PLC, phospholipase C; PTX, pertussis toxin;
PKC, Ca2+/phospholipid-dependent protein kinase; DRG, dorsal root ganglion; TG, trigeminal ganglion; Symbols:
↑, increase; ↓, decrease.
7. Ion Channels Involved in SP-Mediated Nociception
SP has a well-known role in the transmission of nociceptive information in the spinal cord.
In the supraspinal level, microinjection of SP in the rostral ventromedial medulla (RVM) has also
been found to induce hyperalgesia via descending facilitation mechanisms in a glutamate- and
GABAA-dependent manner [92,93]. Furthermore, SP release is increased in the spinal dorsal horn
after peripheral nociceptive stimulation [94]. Overall, the amount of nociceptive neurotransmitter
released by primary afferent nerve terminals determines the level of pain. The release of SP in the
spinal dorsal horn would interact with glutamate to enhance peripheral inputs. Previously, SP and
glutamate were found to co-exist in small-diameter DRG neurons and their nerve terminals in the
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spinal dorsal horn [95]. Glutamate acts as the molecule transmitting the fast excitatory signal, whereas
SP modulates relatively slow excitatory synapse responses [96]. Besides, SP signaling can enhance the
N-methyl-D-aspartate (NMDA) channel function leading to greater pain sensitivity [78–81]. Thus, the
two transmitters, glutamate and SP, are considered to interact and convey the nociceptive information
in the spinal cord.
In the peripheral system, SP is an important element in neurogenic inflammation causing
extravasation and sensory neuron sensitization. During inflammatory processes, inflammatory cells
and peripheral nerve terminals release SP, which, in turn, modulates a variety of ion channels rendering
sensitization of sensory neurons in an autocrine or paracrine manner. In the PNS, SP mainly exists in the
small sensory nociceptors. Release of SP can act on NK1R via differential intracellular mechanisms to
potentiate the channel activities of TRPV1 [84–86], Nav1.8 [83], and L- and N-type calcium channels [87]
in a subset of small-diameter DRG neurons, thereby resulting in hyperalgesia. SP could also decease
the activity of low-threshold potassium channel (kv4) in capsaicin-sensitive DRG neurons and thus
sensitize the nociceptors [88]. In the orofacial region, SP can potentiate the P2X3 receptor in TG neurons,
leading to elevated pain sensitivity [89]. In summary, SP predominantly acts on peripheral sensory
small neurons (presumably nociceptors) to excite the neurons, thereby increasing nociceptive responses.
8. Ion Channels Involved in SP-Mediated Anti-Nociception
The role of SP in anti-nociception has been confirmed in both the CNS and the PNS. In the CNS,
the analgesic effect of SP is mainly associated with opioid-dependent pathways, although other studies
also demonstrated the involvement of GABAAR and glycine receptors in the lamina V of the spinal
cord [90,97].
Figure 1. Schematic diagram of substance P-mediated signaling and ion channels in the peripheral
sensory neurons. Release of substance P (SP) in the nerve terminal acts on neurokinin 1 receptor (NK1R)
via two different effector systems modulating M-type K+ and T-type Ca2+ channels. First, activated
NK1R coupled to tyrosine kinase augments the M-type potassium channels, resulting in neuronal
hyperpolarization. Second, activated NK1R coupled to Gi/o triggers reactive oxygen species (ROS)
release from mitochondria simultaneously to augment M-type potassium channels and inhibit T-type
calcium channels, which inhibits neural firing in peripheral sensory neurons.
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In the PNS, SP can act on NK1R via either tyrosine kinase or Gi/o effector system to potentiate
the inhibitory M-type potassium channels and inhibit excitatory T-type calcium channels in a specific
subset of sensory neurons [76,77]. In muscle afferent DRG neurons, the SP-NK1R signaling is coupled
with tyrosine kinase to enhance M-type potassium channel activity [57]. Enhancing the M-type
potassium current and inhibiting the T-type calcium current results in dampening neuronal excitability,
in turn further leading to an anti-nociceptive effect (Figure 1).
9. M-type Potassium Channels
M-type potassium channels are voltage-gated potassium channels (M for muscarine) encoded
by KCNQ genes. KCNQ genes encode five Kv7 subunits (Kv7.1–7.5) [98]. Kv7.2, 7.3, 7.4, and 7.5 are
expressed in the nervous system. The M-type potassium channel mainly features Kv7.2 and Kv7.3,
although other subunits can also contribute to the formation of M channels in some locations.
M channels were first discovered in sympathetic neurons [99]. When muscarinic agonists activate
the muscarinic acetylcholine receptors, sympathetic neurons become more responsive to the synaptic
inputs and can become burst firing, rather than fire a single spike. This situation is due to the
suppression of a unique channel, which led to the name “M” channel.
M-type channels are able to conduct a non-inactivating outward current with a threshold of about
−60 to −80 mV and regulated by many neurotransmitters such as SP and bradykinin. The biophysical
features of this current include slow activation and deactivation potassium current. Because M channels
can be opened near the resting membrane potential, they also play a role in clamping the resting
membrane potential, so they are ideally suited to control neuronal excitability.
M channels are functionally expressed in various central and peripheral neurons including
hippocampal [100] and DRG neurons [101]. KCNQ2, 3, and 5 are variably expressed in sensory neurons,
including small-diameter nociceptors and large-diameter proprioceptors. Because pathological pain
such as inflammatory and neuropathic pain features for neuronal hypersensitivity responds to
nociceptive inputs, M-type potassium channels are considered a potential analgesic target in controlling
nociceptive excitability. Opening of M channels results in hyperpolarization of the neurons, which
decreases cell membrane excitability. Accordingly, the M-channel openers retigabine and flupirtine
can effectively attenuate muscle pain [102] and inflammatory pain [101].
In 2012, Lin and colleagues showed that SP-enhanced M channel activity in muscle-afferent DRG
neurons via an unconventional signal pathway by activating NK1R coupled with phosphotyrosine
kinase to attenuate the mechanical hyperalgesia [57]. Then, Gamper’s group demonstrated that SP
could augment the M channel in a subset DRG neurons mainly by acting on NK1R via Gi/o and a
redox-dependent pathway [76]. The similar result but discrepant cellular mechanisms could be due to
the different subset of DRG neurons examined. The SP-enhanced M current via the phosphotyrosine
kinase pathway is prominent on medium to large DRG neurons expressing ASIC3 innervating muscle,
whereas the SP-enhanced M current via the Gi/o pathway acts mainly on small neurons expressing
TRPV1 innervating skin.
These studies provide insight into SP-mediated anti-nociception in local tissues. Activating the
SP-NK1R pathway specifically in muscle afferents becomes an attractive therapeutic target to treat
chronic pain. Although the pro-nociceptive effect of SP in the spinal cord has been well documented,
local peripheral application of SP can be diluted and has little effect on the spinal cord. Thus, targeting
the SP-NK1R pathway in the PNS creates a strategy for pain relief without producing severe side
effects in the CNS.
10. T-type Calcium Channels
T-type calcium channels (Cav3) are low-voltage activated calcium channels opened with small
membrane depolarization and can generate Ca2+-dependent burst firing, pacemaker activity, and
low-amplitude neuronal oscillation [103]. In contrast to high-threshold L-type calcium channels
(long-lasting calcium channels), T-type calcium channels only mediate a “transient” calcium influx,
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with the voltage threshold about −60 with slower activation. T channels also form a window current
in the resting membrane potential controlling the sub-threshold neuronal excitability.
The α1 subunit consists of the major channel pore of T-type calcium channels, allowing for
calcium influx through it. The channel pore-forming α subunits include Cav3.1, Cav3.2, and Cav3.3
encoded by calcium voltage-gated channel subunit alpha1 G (CACNA1G), H, and I, respectively.
T-type calcium channels were first found in small sensory neurons by Carbone and Lux in 1984 [104].
Subsequently, functional expression of T-type channels was confirmed in nociceptive DRG neurons,
with Cav3.2 as the predominant isoform. Nelson et al. further characterized the expression profile
of T channels and indicated that a subtype of DRG neurons highly expressed T channels, named
T-rich cells, which were also highly sensitive to capsaicin and ATP stimuli [105]. Those T-rich cells
are mainly small-diameter neurons with narrower APs and after depolarizing potentials during the
action potential falling phase. Altering gating parameters or directly increasing the amplitude of the T
current can result in burst firing and neuronal excitability [105]. Inhibiting the T-type channels can
effectively reduce the neuropathic and inflammatory pain [106–108].
Recently, Huang et al. demonstrated that T channels were modulated by SP [77]. The authors found
that SP release in damaging tissue would act on NK1R via Gi/o to release mitochondria reactive oxygen
species, which further inhibited the T channels. This study revealed SP-mediated anti-nociception in a
subtype of small-diameter sensory neurons. Further studies are required to determine whether medium-
to large-diameter sensory neurons also show the same modulation of SP in T-type calcium channels.
11. Conclusions
Accumulating evidence has shown SP-mediated anti-nociception in both the CNS and PNS.
However, SP has a mixed effect of pro-nociception and anti-nociception in the nervous system. Especially,
blocking NK1R signaling in the CNS can result in adverse outcomes. In contrast, the anti-nociceptive
effect of SP in the PNS has been well characterized, especially in muscle. Applying SP to muscle-afferent
DRG neurons enhances the M-channel outward current, which further hyperpolarizes the neurons.
Accordingly, locally targeting the SP-NK1R pathway on muscle afferent neurons could be a promising
analgesic strategy.
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Abstract: Chronic inflammatory pain is one of the most common complaints that seriously affects patients’
quality of life. Previous studies have demonstrated that the analgesic effect of electroacupuncture (EA)
stimulation on inflammatory pain is related to its frequency. In this study, we focused on whether the
analgesic effects of EA are related to the period of stimulation. Purinergic receptor P2X3 (P2X3) is
involved in the pathological process underlying chronic inflammatory pain and neuropathic pain.
We hypothesized that 100 Hz EA stimulation alleviated Freund’s complete adjuvant (CFA) induced
inflammatory pain via regulating P2X3 expression in the dorsal root ganglion (DRG) and/or spinal
cord dorsal horn (SCDH). We also assumed that the analgesic effect of EA might be related to the
period of stimulation. We found that both short-term (three day) and long-term (14 day) 100 Hz EA
stimulation effectively increased the paw withdrawal threshold (PWT) and reversed the elevation
of P2X3 in the DRG and SCDH of CFA rats. However, the analgesic effects of 100 Hz EA were not
dependent on the period of stimulation. Moreover, P2X3 inhibition or activation may contribute to or
attenuate the analgesic effects of 100 Hz EA on CFA-induced inflammatory pain. This result indicated
that EA reduced pain hypersensitivity through P2X3 modulation.
Keywords: electroacupuncture; alleviates; inflammatory pain; DRG; SCDH; P2X3
1. Introduction
Inflammatory pain is a common clinical symptom that widely exists in various acute and chronic
diseases [1]. However, its underlying mechanism is still unclear. At present, anti-inflammatory and
analgesic drugs are commonly used in the clinic, but drug treatment is accompanied by gastrointestinal
discomfort and other side effects [2].
Electroacupuncture (EA), a modified technique based on the theory of traditional manual
acupuncture, has been widely used in clinical and scientific research [3,4]. Acupoints, frequency and
the period of stimulation are three main elements that affect the effect of EA. Different frequencies
of EA stimulation at the same acupoint may lead to different therapeutic effects, while the same
frequency may also exert “pain-type” specific analgesic effects on different pathological conditions [5,6].
Our previous studies compared the analgesic effects of 2, 100 and 2/100 Hz EA on chronic pain models
of inflammatory pain and neuropathic pain, e.g., Freund’s complete adjuvant (CFA) injection and
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spared nerve injury (SNI), respectively. We found that 100 Hz exhibited the best analgesic effect on
inflammatory pain [7]. However, whether the analgesic effects of EA are related to the period of
stimulation is largely unknown.
P2X3 is purinoceptor with ion channel activity in response to extracellular adenosine triphosphate
(ATP) [8,9]. P2X3 is highly expressed in small- and medium-sized nociceptors of dorsal root ganglions
(DRGs) and has been associated with pain response in multiple animal pain models, including the
bone cancer pain model, chronic constriction nerve injury (CCI) model, spared nerve injury (SNI)
model, and the CFA model [10–13]. P2X3 can be found in the peripheral terminals where it senses
the ATP leaked from damaged tissues or released from inflammatory cells [14]. In addition, P2X3 is
distributed in the central terminals of nociceptors, indicating that P2X3 might play presynaptic roles
in the spinal cord dorsal horn [15]. Indeed, blockage of P2X3 at the spinal cord level significantly
reduced postsynaptic neuronal hyperexcitability in a model of bone cancer pain [16]. Previous studies
demonstrated that the expression of P2X3 was upregulated by CFA induced inflammation and CCI in
the DRG and spinal cord dorsal horn (SCDH), respectively [7,17]. Notably, EA stimulation was reported
to attenuate CFA (100 Hz) and CCI (15 Hz) induced pain hypersensitivity [18,19]. We speculated that
EA stimulation modulated P2X3 levels in pain pathways and then exerted analgesic actions on chronic
inflammatory pain.
In this study, the analgesic effects of short-term and long-term 100 Hz EA stimulation on
CFA-induced chronic inflammatory pain were detected and compared. The potential involvement of
P2X3 underlying EA mediated analgesia was also explored.
2. Results
2.1. Both Short-Term and Long-Term EA Stimulation Attenuated CFA Induced Mechanical Allodynia
Rats were injected with CFA into the surface of the right hindpaw to induce persistent inflammatory
pain. The paw withdrawal threshold (PWT) of the rats was significantly decreased after CFA injection,
indicative of mechanical allodynia establishment. The pain hypersensitivity was sustained throughout
the experiment (P < 0.05, Figure 1). With daily EA stimulation for 3 days, 100 Hz EA significantly
increased the PWT on days 1 and 3 when compared with the CFA group and sham EA group at the
same time points (P < 0.05, Figure 1C). With daily EA stimulation for 14 days, 100 Hz EA significantly
increased the PWT on days 1, 3, 7, and 14 when compared with the CFA group and sham EA group at
the same time point (P < 0.05, Figure 1D). Compared with the no acupuncture group (i.e., the CFA only
group), sham EA had no significant effect on the PWT.
Figure 1. Cont.
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Figure 1. The analgesic effect of 3 days and 14 days 100 Hz electroacupuncture (EA) stimulation on
the paw withdrawal threshold (PWT). (A) The procedure of short-term (3 days) high frequency EA
stimulation experiment. (B) The procedure of long-term (14 days) high frequency EA stimulation
experiment. (C) The analgesic effect of 3 days 100 Hz EA stimulation on the PWT. (D) The analgesic
effect of 14 days 100 Hz EA stimulation on the PWT. Data are presented as the mean ± SEM, n = 9.
* P < 0.05, compared with the control group; # P < 0.05, compared with the Freund’s complete adjuvant
(CFA) group;  P < 0.05, compared with the CFA + sham EA group.
2.2. Both Short-Term and Long-Term 100 Hz EA Stimulation Reversed P2X3 Elevation in L4-6 DRG and
SCDH after CFA Injection
To investigate the effects of the short-term and long-term 100 Hz EA stimulation on the expression
of P2X3 in the DRG and SCDH following CFA injection, we used immunofluorescence and western
blotting to measure the P2X3 protein levels in the DRG and SCDH in the control group, CFA group,
100 Hz EA group and sham EA group, 3 or 14 days after 100 Hz EA stimulation. As expected, CFA
injection significantly increased the mean intensity of P2X3-ir in L4-6 DRG (Figure 2A,B, P < 0.05;
Figure 4A,B, P < 0.05) and SCDH (Figure 3A,B, P < 0.05; Figure 5A,B, P < 0.05). Short-term and
long-term 100 Hz EA stimulation significantly reduced the mean intensity of P2X3-ir in L4-6 DRG
(Figure 2A,B, P < 0.05; Figure 4A,B, P < 0.05) and SCDH (Figure 3A,B, P < 0.05; Figure 5A,B, P < 0.05)
when compared with the control group. In contrast, sham EA had no observable effects. As shown in
Figures 2C and 4C, P2X3 was mainly expressed in the small- and medium- diameter DRG neurons
(diameter less than 35 μm). Neither short-term nor long-term 100 Hz EA changed the distribution
of P2X3.
We also used western blotting to measure the P2X3 protein expression. CFA injection increased
P2X3 protein expression in L4-6 DRG (Figure 2D,E, P < 0.05; Figure 4D,E, P < 0.05) and SCDH
(Figure 3C,D, P < 0.05; Figure 5C,D, P < 0.05). Consistent with the immunofluorescence staining
results, short-term and long-term 100 Hz EA stimulation significantly reversed paw inflammation
induced P2X3 up-regulation in L4-6 DRG (Figure 2D,E, P < 0.05; Figure 4D,E, P < 0.05) and SCDH
(Figure 3C,D, P < 0.05; Figure 5C,D, P < 0.05). Sham EA had no effect on P2X3 expression either in L4-6
DRG or SCDH.
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Figure 2. The 100 Hz EA stimulation for 3 days repressed the up-regulation of P2X3 in the L4-6 dorsal
root ganglions (DRG) of inflamed rats. (A) Representative images of L4-6 DRG immunofluorescence
staining from the control, CFA, CFA+100 Hz EA and CFA + sham EA groups. Scale bars = 100 μm.
(B) Mean intensity analysis of P2X3-ir in L4-6 DRG in each group. Data are presented as the mean ±
SEM, n = 3. (C) Size distribution of P2X3 in L4-6 DRG in different groups. (D) Representative western
blotting images of L4-6 DRG in each group. E. Relative protein level of P2X3 in rat L4-6 DRG from
different groups. Data are presented as the mean ± SEM, n = 6. * P < 0.05, compared with the control
group; # P < 0.05, compared with the CFA group;  P < 0.05, compared with the CFA + sham EA group.
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Figure 3. The 100Hz EA stimulation for 3 days inhibited the up-regulation of P2X3 in (spinal cord
dorsal horn) SCDH of inflamed rats. (A). Representative images of SCDH immunofluorescence staining
from the control, CFA, CFA + 100 Hz EA and CFA + sham EA groups. Scale bars = 100 μm. (B) Mean
intensity analysis of P2X3-ir in SCDH in each group. Data are presented as the mean ± SEM, n = 3.
(C) Representative western blotting images of SCDH in each group. (D) Relative protein level of P2X3
in SCDH from different groups. Data are presented as the mean ± SEM, n = 6. * P <0.05, compared
with the control group; # P <0.05, compared with the CFA group;  P <0.05, compared with the CFA +
sham EA group.
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Figure 4. The 100Hz EA stimulation for 14 days repressed the up-regulation of P2X3 in the L4-6 DRG of
inflamed rats. (A) Representative images of L4-6 DRG immunofluorescence staining from the control,
CFA, CFA + 100 Hz EA and CFA + sham EA groups. Scale bars = 100 μm. (B) Mean intensity analysis of
P2X3-ir in L4-6 DRG in each group. Data are presented as the mean ± SEM, n = 3. (C) Size distribution
of P2X3 in L4-6 DRG in different groups. (D) Representative western blotting images of L4-6 DRG
in each group. (E) Relative protein level of P2X3 in rat L4-6 DRG from different groups. Data are
presented as the mean ± SEM, n = 6. * P < 0.05, compared with the control group; # P <0.05, compared
with the CFA group;  P <0.05, compared with the CFA + sham EA group.
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Figure 5. The 100 Hz EA stimulation for 14 days inhibited the up-regulation of P2X3 in the SCDH of
inflamed rats. (A) Representative images of SCDH immunofluorescence staining from the control, CFA,
CFA + 100 Hz EA and CFA + sham EA groups. Scale bars = 100 μm. (B) Mean intensity analysis of
P2X3-ir in the SCDH in each group. Data are presented as the mean ± SEM, n = 3. (C) Representative
western blotting images of SCDH in each group. (D) Relative protein level of P2X3 in the SCDH from
different groups. Data are presented as the mean ± SEM, n = 6. * P <0.05, compared with the control
group; # P < 0.05, compared with the CFA group;  P < 0.05, compared with the CFA + sham EA group.
2.3. Short-Term and Long-Term EA Stimulation Exerted Comparable Effects on Pain Hypersensitivity and
P2X3 Expression
To investigate the effects of short-term and long-term EA stimulation, we compared the ratio
of change in PWT and P2X3 expression in L4-6 DRG and SCDH. As shown in Figure 6A, there was
no significant difference in the ratio of changes in PWT between EA stimulation for 3 and 14 days
(P > 0.05). Additionally, there was no significant difference in the ratio of changes in P2X3 expression
either in L4-6 DRG or SCDH between EA stimulation for 3 and 14 days (Figure 6B, P > 0.05).
Figure 6. Short-term and long-term EA stimulation treatments exerted comparable effects on pain
hypersensitivity and P2X3 expression. (A) The ratio of changes in PWT after 100 Hz EA stimulation for
3 and 14 days. (B) The ratio of changes in P2X3 after 100 Hz EA stimulation for 3 and 14 days. Data are
presented as the mean ± SEM.
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2.4. P2X3 Levels in L4-6 DRG and SCDH Are Involved in Chronic Inflammatory Pain
Previous studies demonstrated that the P2X3 agonist αβ-me ATP might induce pain
hypersensitivity in rats. In this study, intraplantar injection (i.pl.) or intrathecal injection (i.t.)
of αβ-me ATP can induce mechanical hyperalgesia in normal rats. Compared with the control +
vehicle, the PWTs of control + i.pl. α β-me ATP, and control + i.t. α β-me ATP both decreased
rapidly after αβ-me ATP administration (Figure 7B,D, P < 0.05). In contrast, treatment with A317491
(P2X3 antagonist) via i.pl. or i.t., significantly alleviated CFA induced mechanical hypersensitivity
(Figure 7B,D). These outcomes suggested that P2X3 activation is sufficient to cause pain hypersensitivity,
and that P2X3 might play essential roles in the modulation of pain signal transmission from the DRG
to the spinal cord.
Figure 7. The effect of intraplantar injection or intrathecal injection of α β-me ATP (P2X3 agonist) and
A317491 (P2X3 antagonist) on the PWT. (A) Schematic flow diagram of the intraplantar injection of α
β-me ATP (P2X3 agonist) and A317491 (P2X3 antagonist). (B) The effect of intraplantar injection of α
β-me ATP (P2X3 agonist) and A317491 (P2X3 antagonist) on the PWT. Data are presented as the mean
± SEM, n = 5.  P < 0.05, compared with the control + intraplantar injection (i.pl.) vehicle; P < 0.05,
compared with the control + i.pl. α β-me ATP;  P < 0.05, compared with the CFA + i.pl. vehicle group.
(C) Schematic flow diagram of the intrathecal injection of α β-me ATP (P2X3 agonist) and A317491
(P2X3 antagonist). (D)The effect of intrathecal injection of α β-me ATP (P2X3 agonist) and A317491
(P2X3 antagonist) on the PWT. Data are presented as the mean ± SEM, n = 5.  P < 0.05, compared
with the control + intrathecal injection (i.t.) vehicle; ¤ P <0.05, compared with the control + i.t. α β-me
ATP group;  P < 0.05, compared with the CFA + i.t. vehicle.
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2.5. P2X3 Inhibition Contributed to the Analgesic Effects of 100 Hz EA on CFA-Induced Inflammatory Pain
To investigate whether P2X3 is involved in the analgesic effect of 100 Hz EA on chronic inflammatory
pain, A317491 was co-administered via i.pl. and i.t. to observe the changes in PWT in rats of each
group. Consistent with the findings in Figure 7, i.pl. and i.t. of A317491 exerted significant analgesic
effects on CFA induced inflammatory pain (Figure 8B,D). Similarly, EA stimulation also efficiently
alleviated CFA induced mechanical allodynia, as indicated by the results of CFA + i.pl. vehicle versus
CFA + 100 Hz + i.pl. vehicle (Figure 8B) and CFA + i.t. vehicle versus CFA + 100 Hz + i.t. vehicle
(Figure 8D). Notably, co-treatment with EA and i.t. A317491 did not further increase the analgesia
compared with EA alone (Figure 8D).
Figure 8. P2X3 inhibition contributed to the analgesic effects of 100 Hz EA on CFA-induced inflammatory
pain. (A) Schematic flow diagram of the intraplantar injection of P2X3 antagonist A317491. (B) The
effect of intraplantar injection of A317491 on the PWT. Data are presented as the mean ± SEM, n = 6.
 P < 0.05, compared with the CFA + i.pl. vehicle group;  P < 0.05, compared with the CFA + 100
Hz + i.pl. vehicle group. (C) Schematic flow diagram of the intrathecal injection of A317491. (D) The
effect of intrathecal injection of A317491on the PWT. Data are presented as the mean ± SEM, n = 6.
P < 0.05, compared with the CFA + i.t vehicle group; $ P < 0.05, compared with the CFA + 100 Hz+
i.t vehicle group.
To further confirm that 100 Hz EA has an analgesic effect on chronic inflammatory pain by
regulating P2X3, α β-me ATP was administered via i.pl. and i.t. to observe the changes in PWT in rats
of each group. As shown in Figure 9, i.pl. and i.t. of α β-me ATP can reverse the analgesic effect of
electroacupuncture, as indicated by the results of the CFA + 100 Hz + i.pl. vehicle group versus the
CFA + 100 Hz + i.pl. α β-me ATP group (Figure 9B) and the CFA + 100 Hz + i.t. vehicle group versus
167
Int. J. Mol. Sci. 2019, 20, 3248
the CFA + 100 Hz + i.t. α β-me ATP group (Figure 9D). This result provided evidence that EA reduced
pain hypersensitivity through P2X3 modulation.
Figure 9. α β-me ATP (P2X3 agonist) attenuated the analgesic effect of 100 Hz EA on PWT in CFA rats.
(A) Schematic flow diagram of the intraplantar injection of α β-me ATP. (B) The analgesic effect of
100Hz EA can be attenuated by intraplantar injection of α β-me ATP. Data are presented as the mean ±
SEM, n = 6.  P < 0.05, compared with the CFA + i.pl. vehicle group;  P < 0.05, compared with the
CFA + 100Hz + i.pl. vehicle group. (C) Schematic flow diagram of the intrathecal injection of α β-me
ATP. (D) Intrathecal injection of α β-me ATP may reduce the analgesic effect of 100 Hz EA. Data are
presented as the mean ± SEM, n = 6. P < 0.05, compared with the CFA + i.t vehicle group; $P < 0.05,
compared with the CFA + 100Hz + i.t vehicle group.
3. Discussion
The frequency of EA stimulation appears to be a determinant of the analgesic effect of EA [20].
The optimal frequency of EA treatment is not constant in different types of pathological pain [21].
While both 2 and 100 Hz EA treatment relieved type 2 diabetic neuropathic pain, 2 Hz exerted stronger
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analgesic effects 100 Hz [22]. However, we have demonstrated that the analgesic effect of EA was
greater at 100 Hz than at 2 Hz in the scenario of inflammatory pain [7]. Similarly, 100 Hz, but not 2
Hz EA stimulation, could relieve post-incision pain [23]. In addition to the frequency, the number of
stimulations may also significantly affect the analgesic effects of EA, indicative of the presence of a
cumulative effect [24,25]. However, in the current study, we observed that daily EA stimulations for 3
days and 14 days provided comparable analgesia for persistent inflammatory pain. We concluded that
a “ceiling” effect can occur during the application of EA stimulation. This finding may help determine
the regimen of EA application for the treatment of chronic inflammatory pain.
Clinical studies and scientific studies have proved that EA has eminent analgesic effects, but
the mechanism of EA analgesia is still an open question [26–28]. Cheng RS et al. reported that 4 Hz
EA attenuated pain through the modulation of endorphins, whereas the analgesic effect of 200 Hz
EA may be mediated through serotonin [29]. Wang Y et al. demonstrated that 100 Hz EA relieved
inflammatory pain by increasing CXCL10, which chemoattracted opioid-containing macrophages and
mediated the anti-nociceptive effect in the model of inflammatory pain [30]. Kim H W et al. proposed
that 1 Hz electroacupuncture suppressed carrageenan-induced paw inflammation via sympathetic
post-ganglionic neurons, while inflammation was restrained by 120 Hz EA in connection with the
sympathoadrenal medullary axis [31]. Recently, increasing evidence has shown that the analgesic
effect of EA is closely related to its regulation of ion channels in sensory neurons [32,33]. Particularly,
increased attention has been paid to P2X3, which has been regarded as a potential target of inflammatory
pain and neuropathic pain [34,35].
Inhibition of the P2X3 receptor through a selective antagonist, e.g., A317491 has been assessed as
a potential approach for inflammatory pain management [36,37]. Using the model of CFA induced
chronic inflammation, Qian Jiang et al. reported that the expression of P2X3 was markedly increased
in DRG tissues [13]. Similar results were obtained in the current study. On the 3rd and 14th days
after CFA injection, the expression of P2X3 was significantly increased in L4-6 DRG as indicated by
immunofluorescence staining and western blotting. We confirmed that P2X3 was distributed in small-
and medium-sized neurons, especially in the diameter range of 5–10 μm. Several studies shown that
EA can be applied to treat different types of pain (such as neuropathic pain, inflammatory pain, and
bone cancer pain) by down-regulating DRG P2X3 [34,38,39]. Consistently, we demonstrated that both
short-term and long-term EA stimulation can effectively down-regulate the up-regulation of P2X3
in DRG induced by CFA. Few studies have focused on the expression of the P2X3 in the SCDH of
CFA model. In this study, we found that the mean intensity of immunoreactivity and protein level
of the P2X3 in the SCDH were significantly increased at three days and 14 days after CFA injection.
In relation to DRG, elevation of P2X3 was also reversed by short-term and long-term EA in SCDH.
Notably, that P2X3 is distributed in the presynaptic part of the spinal cord, i.e., the central terminal of
nociceptors. Therefore, EA mediated inhibition of spinal P2X3 is relies on its effects on the DRG. The
current findings suggested that EA might directly modulate pain signal transmission from first-order
neurons (DRG) to second-order neurons (SCDH). Indeed, post-treatment with P2X3 inhibitor via
intrathecal injection failed to further enhance the anti-nociceptive effects by EA, indicating that spinal
P2X3 played essential roles underlying EA mediated analgesia. While overexpression of DRG and
SCDH P2X3 in CFA rats nearly returned to normal levels after EA stimulation, but the hyperalgesia of
CFA rats still existed despite relief. The reason for this phenomenon may be due to proinflammatory
cytokines, NLRP, CB2, and other substances that are involved in CFA-induced chronic inflammatory
pain. P2X3 is not the only determinant, even though it plays an important role in the occurrence and
maintenance of chronic inflammatory pain [40–42].
α β-me ATP and A317491 were co-administered via i.pl. and i.t. to further prove that P2X3 is
involved in the pathological process of chronic inflammatory pain. We found that α β-me ATP injection
in normal rats can induce hyperalgesia, while A317491 injection in CFA rats can effectively reverse
CFA-induced hyperalgesia, indicating that P2X3 is closely related to inflammatory pain induced by
CFA. Then A317491 was administered, and the analgesic effect was consistent with 100 Hz EA, and
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effectively relieved CFA-induced mechanical hyperalgesia. However, α β-me ATP administered via
i.pl. and i.t. effectively reduced the analgesic effect of 100 Hz EA. This finding reveals that P2X3
regulation may be a potential mechanism for the analgesic effect of EA.
We compared the ratio of change in the PWT and the P2X3 expression in DRG and SCDH between
short-term and long-term EA stimulation in CFA rats. We discovered that the ratio of change in DRG
P2X3 in long-term EA stimulation was slightly higher than that in short-term EA stimulation, but
there was no significant difference. However, the ratio of change in SCDH P2X3 in short-term EA
stimulation was slightly higher than that in long-term EA stimulation, and the difference was not
significant. Therefore, we speculated that the analgesic effect of EA on chronic inflammatory pain may
not be related to the term of stimulation.
4. Materials and Methods
4.1. Animals
Male Sprague-Dawley (SD) rats (180–220 g) were purchased from the Experimental Animal Center
of Zhejiang Chinese Medical University. All rats in this experiment were housed in a controlled
environment (five rats per cage, temperature: 25 ± 2 ◦C, humidity: 55% ± 5%, and light: 12 h light/dark
cycle) and were fed a standard rodent food and allowed distilled water ad libitum. All experimental
procedures were approved by the Animal Care and Welfare Committee of Zhejiang Chinese Medical
University, Zhejiang, China (ZSLL, 2015-022).
4.2. Experimental Design
This study was divided into three parts.
In part one, the effects of short-term or long-term 100 Hz EA stimulation on CFA induced pain
were monitored. For short-term EA stimulation experiments, rats were randomly assigned into four
groups (n = 9/group): (1) control group, (2) CFA group, (3) CFA + EA group, and (4) CFA + sham EA
group. Rats were treated by acupuncture with (EA) or without (sham EA) 100 Hz electric current
stimulation for 3 days after CFA injection. Pain behavioral tests were conducted according to the
schedule (Figure 1A), i.e., on days -3, -2, -1, and zero before EA stimulation, and on days 1 and 3
after EA stimulation, respectively. After 3 days post EA stimulation, rats were sacrificed for tissue
collection. The L4–6 DRG and lumbar spinal cord were removed for immunofluorescence staining
or western blotting. For long-term EA stimulation experiments, rats were assigned to four groups
as above, and administered with EA or sham EA for 14 days after CFA injection. Pain behavioral
tests were conducted according to the schedule (Figure 1B), i.e., on days -3, -2, -1 and zero before EA
stimulation, and on days 1, 3, 7 and 14 after EA stimulation. After fourteen days post EA stimulation,
tissues were collected and applied as above.
In part two, the involvement of P2X3 in EA-mediated pain modulation was explored through the
administration of a P2X3 antagonist (A317491) or agonist (α β-me ATP) via intraplantar injection (i.pl.)
or intrathecal injection (i.t.). Rats were randomly assigned to eight groups (n = 5/group), i.e., (1) control
+ i.pl. vehicle group, (2) control + i.pl. α β-me ATP group, (3) CFA + i.pl. A317491 group, (4) CFA +
i.pl. vehicle group, (5) control + i.t. vehicle group, (6) control + i.t. α β-me ATP group, (7) CFA + i.t.
A317491 group, and (8) CFA + i.t. vehicle group. For i.pl., antagonists or agonists were administered
ipsilaterally on day three after CFA injection, and paw withdrawal thresholds (PWT) were recorded
according to the schedule (Figure 7A). For i.t., antagonists or agonists were delivered via implanted PE
tubes. PWT was recorded according to the schedule (Figure 7C).
In part three, to explore the role of P2X3 in DRG and SCDH on the analgesic effect of 100 Hz
EA stimulation on CFA rats, we investigated whether peripheral subcutaneous injection or central
intrathecal injection of P2X3 inhibitors could simulate the analgesic effect of 100 Hz EA (Figure 8).
A group of 42 adult male rats (n = 6/group) were divided into a (1) CFA + i.pl. vehicle group, (2) CFA
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+ i.pl. A317491 group, (3) CFA + 100 Hz + i.pl. vehicle group, (4) CFA + i.t. vehicle group, (5) CFA
+ i.t. A317491 group, (6) CFA + 100 Hz + i.t. vehicle group, and a (7) CFA + 100 Hz + i.t. A317491
group. Then, we observed whether peripheral subcutaneous injection or central intrathecal injection of
a P2X3 agonist (α β-me ATP) could reverse the analgesic effect of 100 Hz EA (Figure 9). We randomly
assigned 36 adult male rats to six groups, including a (1) CFA + i.pl. vehicle group, (2) CFA + 100 Hz +
i.pl. α β-me ATP group, (3) CFA + 100 Hz + i.pl. vehicle group, (4) CFA + i.t. vehicle group, (5) CFA +
100 Hz + i.t. α β-me ATP group, and a (6) CFA + 100 Hz + i.t. vehicle group.
4.3. Persistent Inflammatory Pain Model
Persistent inflammatory pain like responses were induced via i.pl. of 0.1mL CFA (Sigma-Aldrich,
St. Louis, MO, USA) into the plantar surface of the right hind paws of SD rats. For the sham control,
saline was applied via i.pl.
4.4. Paw Withdraw Threshold (PWT)
PWT was determined by the von Frey behavioral test, which was performed according to the
up-down method described by Chaplan et al. [43]. Rats were placed in the individual testing cages
for 30 min per day for three continuous days to adapt to the test environment. Before each test, rats
were placed into the cage for at least 15 min to acclimate to the environment. The von Frey hairs
(Stoelting Co, Thermo, Gilroy, CA, USA) were applied in a consecutive ascending order (0.4, 0.6, 1,
2, 4, 6, 8, 15, and 26 g) to the central surface of the hind paw and sustained for 5 s. The first hair
applied corresponded to a force of 4 g. Brisk withdrawal or paw flinching was considered a positive
response and marked as “X”. A weaker stimulus was then applied. In the case of no responses, “O”
was recorded, followed by a stronger stimulus. The interval between each stimulus was not less than
2 min. After the combination of “OX” or “XO” appeared, a series of four stimuli were applied and
recorded as above. The 50% PWTs of the rats were calculated by the formula 50% PWTs (g) = 10 ˆ (xf +
k *δ- 4). “xf” is the logarithmic value of the last von Frey hair in the sequence, “k” is the corresponding
value of the resulting sequence in the k-value table, and “δ” is the mean difference of each filament
strength after logging (0.231 in the current cases). If a positive stimulus appeared five consecutive
times, PWT was marked as 26 g. If five “X”s were recorded, PWT was marked as 0.4 g. If the value of
50% PWTs was greater than 26 g, 26 g was used as the maximum. And if the value of 50% PWTs was
less than 0.4 g, 0.4 g was used as the minimum. The measuring time was fixed at 9:00–16:00, and the
ambient temperature was 23 ± 2 ◦C.
4.5. EA Treatment
All rats in CFA + 100 Hz EA group were treated with the EA stimulus. Zusanli (ST36) and Kunlun
(BL60) acupoints were taken from the bilateral legs of the rats. Acupuncture needles, 0.25 mm * 13 mm
were used in this study. The needles were inserted into the acupoints at a depth of 5 mm and then
stimulated by HANS Acupuncture Point Nerve Stimulator (HANS-200A Huawei Co., Ltd., Beijing,
China). The parameters of the stimulator were as follows: 100 Hz, 0.5–1.5 mA (initial strength 0.5 mA,
increased by 0.5 mA every 10 min) for a total of 30 min. The stimulus was conducted once daily in a
period of 3 or 14 days. The rats in the CFA group were only given the same fixed time as the EA group.
No treatment was performed in the control group. The CFA + sham EA group animals received needle
insertion subcutaneously into ST36 and BL60 (1 mm in depth). The needles were connected to the
electrodes without electrical stimulation. After finishing the EA or sham EA stimulation, the PWT was
measured immediately.
4.6. Drug Treatment
α β-me ATP (P2X3 agonist) and A317491 (P2X3 antagonist) were purchased from Sigma-Aldrich
(Sigma-Aldrich, Saint Louis, MO, USA), and dissolved in sterile 0.9 % saline solution to prepare stock
solution (stored at –20 ◦C). They were diluted to the requested concentrations before each experiment.
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For i.pl, α β-me ATP (600 nmol,10 μL) and A317491 (300 nmol,10 μL) were injected subcutaneously
into the dorsal surface of the right hindpaw of rats. For i.t., α β-me ATP (300 nmol, 25 μL) and A317491
(100 nmol, 25 μL) were administered once on days 3 after CFA injection.
4.7. Immunofluorescence
Animals were sacrificed after the behavioral testing on days 3 and 14. Rats were deeply anesthetized
using pentobarbital (80 mg/kg, i.p.) and transcardially perfused with 150 mL normal saline (4◦C) and
400 mL 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for prefixation. The L4–6
segments of the dorsal root ganglion (DRG) and lumbar spinal cord were removed and postfixed in 4%
paraformaldehyde for 3 hours at 4 ◦C before transfer to 15% and 30% sucrose for dehydration. Tissues
were embedded in Tissue-Tek O.C.T compound (SAKURA, Torrance, CA, USA). DRGs were cut at
thickness of 14 μm, and frozen sections of the lumbar spinal cord were cut at thickness of 20 μm using
a CryoStar (NX50 HOP, Thermo, Walldorf, Germany).
Sections were rinsed with TBST (0.1 % Tween-20) and blocked with 5% normal donkey serum for
one hour at 37 ◦C. Sections were then incubated with rabbit anti-P2X3 (1:800 in 5 % normal donkey
serum, Alomone, Jerusalem, Israel) overnight at 4 ◦C. The slides were then incubated in Alexa Fluor
647-conjugated AffiniPure donkey anti-rabbit IgG (H + L) (Jackson, West Grove, PA, USA) for one
hour at 37 ◦C. Images were taken using the A1R confocal microscope (Nikon, Tokyo, Japan). We used
NIS-Elements AR to calculate the mean intensity of P2X3-immunoreactivity (-ir) in the region-of-interest
(ROI) in DRG and SCDH. The relative level of P2X3 in each group was normalized to the expression in
the control group.
4.8. Western Blotting Analysis
Animals were sacrificed after the behavioral testing on days 3 and 14. Rats were deeply anesthetized
using pentobarbital (80 mg/kg, i.p.) and transcardially perfused with 150 mL normal saline (4 ◦C).The
L4–6 segments of the DRG and lumbar spinal cord were removed and stored at −80 ◦C. Tissues were
homogenized in strong RIPA buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, sodium orthovanadate, 0.1% Sodium dodecyl sulfate, Ethylene Diamine Tetraacetic
Acid, sodium fluoride, leupeptin, and 1 nM PMSF). The homogenate was allowed to rest on ice for
30 min and centrifuged at 15,000 rpm for 15 min at 4 ◦C. The supernatant was then collected for further
operations. The protein concentration of tissue lysates was determined with a BCA protein assay kit.
Lysates were denatured and loaded (15 μg total protein per lane). Protein samples were separated
on 5–10% Sodium dodecyl sulfate-polyacrylamide gelelectrophoresis gels and electrophoretically
transferred to polyvinylidene difluoride (PVDF) membranes (Merck KGaA, Darmstadt, Germany). The
membranes were blocked with 5% low-fat milk in TBST for one hour at room temperature. We used
rabbit anti-P2X3 (1:1000 in 5% low-fat milk, Alomone, Jerusalem, Israel) as the primary antibody and
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG as the secondary antibody (1:10,000,
CST, Danvers, MA, USA). Rabbit anti-GAPDH (HRP Conjugate) (1:1000, CST, Danvers, MA, USA) was
used as the internal control. The membranes were developed with an ECL kit (Pierce, Rockford, lL ,
USA), and the signals were captured with an Image Quant LAS 4000 (GE, Pittsburgh, PA, USA). The
density of each band was measured using Image Quant TL 7.0 analysis software (GE, Pittsburgh, PA,
USA). The relative level of P2X3 in each group was normalized to the expression of the control group.
4.9. Statistical analysis
All data are expressed as the mean ± standard error of the mean (SEM). The PWTs among groups
were compared by multi-factor analysis of variance (ANOVA), followed by Bonferroni’s post hoc test
to compare the significant difference between groups or between time points. All other data were
analyzed by one-way ANOVA, followed by Bonferroni’s post hoc tests. P < 0.05 was considered
statistically significant.
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5. Conclusions
In summary, we concluded that both short-term and long-term 100 Hz EA stimulation provided
significant pain relief for chronic inflammatory pain, and this analgesic effect was related to the
suppression of P2X3 in the DRG and SCDH.
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Splaiul Independenţei 91-95, 050095 Bucharest, Romania
* Correspondence: mradu@nipne.ro
† These authors contributed equally to this work.
Received: 17 March 2019; Accepted: 19 April 2019; Published: 22 April 2019
	

Abstract: The neuron-specific Elav-like Hu RNA-binding proteins were described to play an important
role in neuronal differentiation and plasticity by ensuring the post-transcriptional control of RNAs
encoding for various proteins. Although Elav-like Hu proteins alterations were reported in diabetes or
neuropathy, little is known about the regulation of neuron-specific Elav-like Hu RNA-binding proteins
in sensory neurons of dorsal root ganglia (DRG) due to the diabetic condition. The goal of our study
was to analyze the gene and protein expression of HuB, HuC, and HuD in DRG sensory neurons in
diabetes. The diabetic condition was induced in CD-1 adult male mice with single-intraperitoneal
injection of streptozotocin (STZ, 150 mg/kg), and 8-weeks (advanced diabetes) after induction was
quantified the Elav-like proteins expression. Based on the glycemia values, we identified two types of
responses to STZ, and mice were classified in STZ-resistant (diabetic resistant, glycemia < 260 mg/dL)
and STZ-sensitive (diabetic, glycemia > 260 mg/dL). Body weight measurements indicated that
8-weeks after STZ-induction of diabetes, control mice have a higher increase in body weight compared
to the diabetic and diabetic resistant mice. Moreover, after 8-weeks, diabetic mice (19.52 ± 3.52 s) have
longer paw withdrawal latencies in the hot-plate test than diabetic resistant (11.36 ± 1.92 s) and control
(11.03 ± 1.97 s) mice, that correlates with the installation of warm hypoalgesia due to the diabetic
condition. Further on, we evidenced the decrease of Elav-like gene expression in DRG neurons of
diabetic mice (Elavl2, 0.68 ± 0.05 fold; Elavl3, 0.65 ± 0.01 fold; Elavl4, 0.53 ± 0.07 fold) and diabetic
resistant mice (Ealvl2, 0.56 ± 0.07 fold; Elavl3, 0.32 ± 0.09 fold) compared to control mice. Interestingly,
Elav-like genes have a more accentuated downregulation in diabetic resistant than in diabetic mice,
although hypoalgesia was evidenced only in diabetic mice. The Elav-like gene expression changes
do not always correlate with the Hu protein expression changes. To detail, HuB is upregulated and
HuD is downregulated in diabetic mice, while HuB, HuC, and HuD are downregulated in diabetic
resistant mice compared to control mice. To resume, we demonstrated HuD downregulation and HuB
upregulation in DRG sensory neurons induced by diabetes, which might be correlated with altered
post-transcriptional control of RNAs involved in the regulation of thermal hypoalgesia condition
caused by the advanced diabetic neuropathy.
Int. J. Mol. Sci. 2019, 20, 1965; doi:10.3390/ijms20081965 www.mdpi.com/journal/ijms177
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1. Introduction
Hu proteins are members of the RNA-binding proteins (RBP) superfamily and are encoded by
Embryonic Lethal, Abnormal Vision, and Drosophila (ELAV) genes. The Hu proteins family has four
members HuB (encoded by ELAV-like 2 gene), HuC (encoded by ELAV-like 3 gene), HuD (encoded
by ELAV-like 4 gene), and HuR or HuA (encoded by ELAV-like 1 gene). Three of these proteins have
identified as neuronal specific (i.e., HuB, HuC, and HuD), while the fourth is ubiquitary (HuR).
RBP are well known for the post-transcriptional control of RNAs encoding multiple proteins [1].
In particular, RBPs play essential roles in the nervous system, such as alternative splicing of neuronal
proteins (i.e., neurotransmitters, membrane receptors, cell adhesion molecules, and components of
signal transduction proteins), protection of the mRNAs for long-distance transport and guidance of
the protein localization [2–5].
Neuronal-enriched ELAV-like (nELAVL) Hu proteins were described to play essential roles in
neuronal development and plasticity [6,7] in the central and peripheral nervous system. nELAVL
Hu proteins are binding to the adenylate-uridylate-rich (ARE) RNA elements in the 3′ untranslated
regions (3′-UTR) of target proteins, including growth associated protein 43 (GAP-43) [8,9], c-myc
and vascular endothelial growth factor (VEGF) [10], and neprilysin (a potent amyloid β degrading
enzyme) [11] stabilizing them. Moreover, nELAVL Hu proteins autoregulate themselves [12] or
interact/stabilize other neuronal RBPs, e.g., Musashi-1 [13] and NOVA1 [14]. In the central nervous
system, nELAVL Hu-proteins have been involved in regulating neuronal excitability by controlling the
glutamate synthesis pathway and their gene deletion induces spontaneous epileptic seizure activity [15],
by binding to the mRNA encoding Kv1.1 voltage-gated potassium channels [16]. In the peripheral
nervous system, nELAVL Hu proteins are localized in the dorsal root ganglia (DRG) neurons [17–20].
This anatomical localisation of nELAVL Hu-proteins is correlated with their functional role of binding
mRNA encoding proteins (i.e., brain-derived neurotrophic factor, GAP-43) involved in peripheral
nerve regeneration upon lesion [8,21,22], being upregulated in the early stages of nerve recovery.
The role of RBPs in diabetes and its complications was extensively documented [23]. To detail,
it was described the regulation of beta-pancreatic cell function by various RBPs [24], including
neuronal-enriched RBPs [25]. The altered regulatory function exerted by the ubiquitary HuR protein
in diabetes was often described [25–28]. On the other hand, although the role of nELAVL Hu proteins
was described in diabetes [29–31], yet no attention was paid so far to their expression changes in DRG
sensory neurons associated with the diabetic condition.
We aimed to elucidate the role played by Hu proteins expressed by the DRG sensory neurons in
diabetes. To this purpose, we have employed the streptozotocin (STZ)-induced model of diabetes in
CD-1 adult male mice. We have explored the gene and protein expression for nELAVL Hu proteins in
DRG neurons between diabetic and control mice and we correlated them with the changes in animal
glycemia, body weight, or their response to hot thermal stimulation. We also analyzed the distinct
changes between animals sensitive or resistant to the STZ-induction of diabetes.
2. Results
2.1. Diabetic Mice Have Changes in Glycemia and Body Weight Compared to Diabetic Resistant or Control Mice
We started our experimental protocol with two CD-1 mice groups: citrate buffer-injected group
(N= 20) and STZ-injected group (N= 20). In the STZ-injected group, seven out of 20 animals died quickly.
We measured the glycemia weekly for 7 weeks. Hyperglycemia was considered above 260 mg/dL,
as previously described [32,33]. Considering the hyperglycemia threshold, at the end of 7 weeks we
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separated the surviving animals of the STZ-injected group (N = 13) into two subgroups: STZ-sensitive
group (N = 7, glycemia > 260 mg/dL) and STZ-resistant group (N = 6, glycemia < 260 mg/dL), that will
be further called diabetic group and diabetic resistant group, respectively. Then, we plotted the
glycemia variation for the diabetic, diabetic resistant, and control mice groups (Figure 1).
Figure 1. Blood glucose values (in mg/dL) were represented as mean ± SD for control, diabetic resistant,
and diabetic mice. Statistical significance was indicated *** p < 0.001, ** p < 0.01, * p < 0.05.
Only the diabetic group had an increase in glycemia (from 144.16 ± 17.29 mg/dL to
615.50 ± 45.05 mg/dL, N = 7), while the diabetic resistant group (from 106.85 ± 18.73 mg/dL to
152.14 ± 33.55 mg/dL, N = 6) and the control group (from 127.89 ± 26.63 mg/dL to 107.89 ± 36.63 mg/dL,
N = 20) had no significant changes. The two-way ANOVA analysis indicated statistical significance of
the glycemia, for the diabetic condition, and for their interaction (Table S1). The one-way ANOVA
weekly comparison between the animal groups indicated that diabetic mice had higher glycemia
compared to diabetic resistant and control mice, starting from the first week after STZ-induction
of diabetes and with this difference accentuating to fifth–seventh week (Table S2) and is indicated
in Figure 1. The weekly comparison in the diabetic group showed the increase of glycemia up to
the fifh week, followed by a plateau-like evolution up to the eighth week (Table S3). Meanwhile,
the weekly comparison of the glycemia values for the control and diabetic groups did not indicate
significant changes.
We have also measured the body weight for the diabetic, diabetic resistant and control CD-1
mice groups weekly, for 8 weeks, after the STZ-diabetes induction (Figure 2). All animal groups
had an overall increase of the body weight, but the increase rate was higher for the control group
(from 21.75 ± 2.75 g to 34.19 ± 2.66 g, N = 20) compared to the diabetic group (from 22.74 ± 2.68 g
to 30.08 ± 2.66 g, N = 7) and diabetic-resistant group (from 22.74 ± 2.18 g to 28.65 ± 2.78 g, N = 6).
The two-way ANOVA analysis indicated statistical significance of the body weight, of the diabetic
condition, and of their interaction (Table S4). The one-way ANOVA comparison between the animal
groups indicated that control mice were heavier than diabetic mice and diabetic resistant mice,
starting from the fourth wk after STZ-induction of diabetes (Table S5). The one-way ANOVA weekly
comparison in each animal group showed a continuous body weight increase, for the whole duration
of the protocol (for 8 weeks), with statistical significance in all three animal groups (Table S6).
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Figure 2. Body weight (in g) monitored for 8 weeks after streptozotocin (STZ)-induction of diabetes.
Body weight values were represented as mean ± SD for control, diabetic resistant, and diabetic mice.
Statistical significance is indicated * p < 0.05, ** p < 0.01, *** p < 0.001.
2.2. Diabetic Mice Have Longer Paw Withdrawal Latencies to Nociceptive Thermal Stimulation than Diabetic
Resistant or Control Mice
We employed the hot-plate test at the fixed temperature of 55 ◦C and we measured the paw
withdrawal latency in order to evaluate the thermal response in diabetic, diabetic resistant, and control
mice groups (Figure 3). The two-way ANOVA analysis indicated statistical significance of the latency,
of the diabetic condition, and of their interaction (Table S7). We compared the initial paw withdrawal
latency (L0) measured at the beginning of the protocol (before any treatment), with the final paw
withdrawal latency (Lf) measured after 8 weeks of the STZ-induction of diabetes. In the diabetic
group, the final latency (Lf = 19.52 ± 3.52 s, N = 7) is significantly longer than the initial latency
(L0 = 11.35 ± 1.69 s, unpaired t-test, p < 0.001). On the other hand an intergroup comparison of the final
latency showed a statistical significant increase in the diabetic group (19.52 ± 3.52 s, N = 7) compared
to the diabetic resistant group (11.36 ± 1.92 s, N = 6) or to the control group (11.03 ± 1.97 s, N = 20)
(Table S8).
2.3. Elav-Like Gene Expression in Mouse DRG Neurons Is Decreased in Diabetic and Diabetic Resistant Mice
Compared to Control Mice
The qRT-PCR analysis revealed the decrease of the Elav-like gene expression in mouse DRG
neurons for all three Elavl (i.e., Elavl2, Elavl3, and Elavl4) in diabetic mice and diabetic resistant mice
compared to control mice (Figure 4). In the DRG neurons of control mice, we obtained similar levels
for Elavl2, Elavl3, and Elavl4 genes (unshown data).
We demonstrated that Elavl genes expression is altered in diabetes, the two-way ANOVA analysis
being statistical significant for the Elavl expression, for the diabetic condition and for their interaction
(Table S9). Elavl genes were downregulated in the diabetic condition and strongly downregulated in
the diabetic resistant condition in comparison with control. To detail, Elavl2 expression decreased
to 0.68 ± 0.05 fold in diabetic group and to 0.56 ± 0.07 fold in the diabetic resistant group compared
to the control group. Elavl3 expression decreased to 0.65 ± 0.01 fold in the diabetic group and to
0.32 ± 0.09 fold in the diabetic resistant group compared to control group. Elavl4 expression decreased
to 0.53 ± 0.07 fold in the diabetic resistant group compared to the control group, while in the diabetic
group there was a tendency of expression increase without significance (Table S10).
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Figure 3. Paw withdrawal latencies (in s) in response to radiant heat (55 ◦C). Initial (L0) and final (Lf)
withdrawal latencies were represented as mean ± SD for control, diabetic resistant, and diabetic mice.
Statistical significance is indicated *** p < 0.001.
Figure 4. Fold change of Elav-like gene expression with respect to Gapdh expression in dorsal root
ganglia (DRG) neurons of control, diabetic resistant, and diabetic mice. Statistical significance is
indicated * p < 0.05, ** p < 0.01.
2.4. Hu Proteins Expression in Mouse DRG Neurons Is Decreased in Diabetic and Diabetic Resistant Mice
Compared to Control Mice
The Hu protein expression in mouse DRG neurons was evaluated by immunofluorescence in
control (Figure 5A–C), diabetic resistant (Figure 5D–F), and diabetic (Figure 5G–I) mice. We evidenced
the expression of HuB, HuC, and HuD proteins in DRG neurons for all three CD-1 mice groups.
We localized all three Hu proteins both in the soma and the neurites of the DRG neurons. Each Hu
protein has a distinct distribution pattern in the soma and particularly HuC tends to organize in
clusters. We observe a pronounced localisation of HuB and HuC in the neurites in diabetic conditions
compared to diabetic resistant or control conditions.
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Figure 5. Hu proteins (HuB, HuC, and HuD ) expression in DRG neurons of control (A–C), diabetic
resistant (D–F), and diabetic mice (G–I). The red labeling is obtained with rabbit polyclonal anti-ELAVL2,
anti-ELAVL3, and anti-ELAVL4 antibodies, respectively, followed by the staining with donkey
polyclonal anti-rabbit conjugated with Rhodamine Red X. Images are captured with an LSM 710
Zeiss laser scanning microscope using a 63× oil objective. Scale bar 10 μm.
Further on, we performed the quantitative analysis of the neuronal Hu proteins expression based
on the mean fluorescence intensity (Figure 6) and we correlated these results with the Elav-like gene
expression. In control mice, we obtained the following ranking for the protein expression HuD > HuC
>HuB, and the one-way ANOVA analysis followed by post-hoc Bonferroni test indicated statistical
significance between HuD and HuB expression (p < 0.001) and between HuD and HuC expression
(p < 0.001). However, the distinct levels of HuB, HuC, and HuD expression in control mice are not
in agreement with the Elav-like gene levels that are comparable. In diabetic and diabetic resistant
conditions neuronal HuB, HuC, and HuD proteins were distinctly regulated compared to control
conditions. The two-way ANOVA analysis indicated statistical significance of Hu proteins expression,
for the diabetic condition and for their interaction (Table S11). In comparison with control mice,
HuB protein was significanly downregulated in diabetic resistant mice and upregulated in diabetic
mice, HuC protein was significantly downregulated in diabetic resistant mice, and HuD protein was
significantly downregulated both in diabetic and diabetic resistant mice (Table S12).
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Figure 6. Hu protein expression based on mean fluorescence intensity analysis in DRG neurons of
control, diabetic resistant, and diabetic mice. Data are expressed as mean ± SD in the captured images.
Statistical significance is indicated * p < 0.05, ** p < 0.01, *** p < 0.001.
3. Discussion
In this study, we brought evidence that Hu proteins undergo expression changes that might be
associated with the diabetic condition. First of all, it is necessary to discuss the model of diabetes that
we employed in our study. Indeed, several mouse models for type 1 diabetes have been developed,
the most employed being the STZ-induced diabetes, despite its variability, depending on the mice
strain [34] or the development of diabetic neuropathy [35]. To detail, variable concentrations of STZ
(single i.p. injection) were used in different mice strains to induce diabetes, i.e., ICR, ddY and BALB/c:
100–200 mg/kg and C57BL/6: 75–150 mg/kg [34]. Considering the different mice strain sensitivity to
STZ-induction of diabetogenic state [35–37], in our study, we decided to induce diabetes in CD-1 adult
mice with single i.p. STZ injection (150 mg/kg).
Despite its variability the STZ-induced model of diabetes is robust and used in multiple studies.
However, researchers focus either on the mortality rate or on the resistance of the animal strain when
injected with STZ, but in the STZ-“sensitive” animal strains little attention is paid to the rate of surviving
animals that are resistant to the STZ-induction of diabetes. Some studies reported a subpopulation of
mice [37] or rats [38] remains normoglycemic upon STZ-induction of diabetes, but do not explicitly
consider these animals as “diabetic resistant”. In our study, we are classifying STZ-resistant CD1-mice
as “diabetic resistant” mice.
The resistance to STZ-induction of diabetes was previously described in different mice strains,
including mice lacking phosphatase and a tensin homolog deleted from chromosome 10 [39] or
nonobese diabetes-resistant mice [40,41]. On the other hand, the resistance to STZ-induction of diabetes
in a certain percentage of animals belonging to the so-called ‘sensitive’ strains (e.g., CD-1 mice) is
generally not discussed. For example, in CD-1 mice, the distinction between the induction of type 1
diabetes by single injection of high STZ dose (130 mg/kg or 150 mg/kg) and the induction of type 2
diabetes by multiple injections of low STZ dose (40 mg/kg) was reported [42], but the percentage
of 100% reported in the text for the induction of diabetes animals by single injection of high STZ
dose is not in agreement with the percentage of animals with hyperglycemia ≥600 mg/dL, one out of
five animals (130 mg/kg STZ, 16% mortality) and three out of three (150 mg/kg STZ, 50% mortality)
presented in the same study. In our study, we demonstrate the resistance to the induction of diabetes
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with a single injection of high STZ dose (150 mg/kg) in approximately 46% (CD-1 adult male mice,
six out of 13 mice) of the surviving animals (37% mortality). We also evidence that diabetic-resistant
mice have lower body weight values compared to control mice, but remain normoglycemic. Our data,
indicating that diabetic mice have a lower body weight and a higher glycemia compared to control
mice, are in agreement with previous protocols of STZ-induction of diabetes [37]. To resume, our study
demonstrates that, in addition to the expected population of STZ-induced hyperglycemic CD-1 mice,
a mice subpopulation develops resistance to STZ and we consider that a distinct analysis of the
STZ-resistant normoglycemic mice should be done in each study, as the findings might be relevant in
understanding the mechanisms of insulin resistance development in human patients.
In diabetic patients, diabetic peripheral neuropathy is gradually characterized by hyperalgesia and
allodynia, followed by the development of hypoalgesia and finally the complete loss of sensation [43].
STZ-induced diabetes in mice or rat is associated with thermal hyperalgesia in early phases [43] and
with thermal hypoalgesia in late stages of diabetes [44–46] in the absence of insulin therapy. Commonly
thermal hypoalgesia precedes epidermal denervation in STZ-diabetic mice [47]. We confirm an increase
in the paw withdrawal latency (thermal hypoalgesia) in diabetic mice 8-weeks after STZ-induction of
diabetes, while diabetic resistant mice have similar paw withdrawal latencies compared to control
mice. The absence of changes in the algesic profile of diabetic resistant mice is supported by previous
reports showing that ~50% male Sprague-Dawley rats remain normoglycemic after STZ-injection,
without significant changes in the algesic profile (no changes in the threshold or latency to heat noxious
stimuli, or in the pressure pain threshold and frequency of withdrawal to brush and 20-g von Frey
filament) compared to control rats [38].
Considering previous studies that reported the role played by Hu proteins from DRG neurons in
hyperalgesia [19,48–52], we analyzed the expression changes of Hu proteins in diabetic and diabetic
resistant mice compared to control mice and correlated these data with algesic profile to radiant heat
exposure. To detail, HuR contributes to hyperalgesia either associated with experimental autoimmune
encephalomyelitis [48] or with inflammation (exposure to bradykinin and interleukin-1) where
stabilized cyclooxygenase-2 mRNA [49]. HuD is upregulated and contributes to pain hypersensitivity
to mechanical and cold stimulation in antiretroviral-evoked painful neuropathy by regulating
spinal ryanodine receptor-2 [50] or GAP43 [19,51] or contributes to thermal hot hyperalgesia in
oxaliplatin-induced neuropathy by regulating GAP43 [52]. On the other hand, to the best of our
knowledge, this is the first study documenting the role of Hu proteins in hypoalgesia associated with
the diabetic condition, addressing the expression of Hu proteins in DRG neurons. Considering the
previous reports regarding the role of nELAVL Hu-proteins in neuronal excitability by binding to the
mRNAs encoding proteins from the glutamate synthesis pathway [15], or encoding Kv1.1 voltage-gated
potassium channels [16], we might suppose that nELAVL Hu-proteins might also stabilize / regulate
mRNA encoding other proteins (i.e., ion channels) involved in DRG neuronal excitability and being
important players in the algesic profile and diabetes.
Our study brings evidence that Elavl genes and Hu proteins expression is distinctly regulated
in DRG sensory neurons in diabetic, diabetic resistant, and control conditions, and we have tried to
correlate these expression data with the final paw withdrawal latency in the hot plate test. Interestingly,
the final paw withdrawal latency in diabetic-resistant mice has not significantly changed in comparison
to control mice, which indicates that diabetic-resistance mice do not undergo changes in the algesic
profile in radiant heat exposure after 8 weeks. In diabetic mice, Elavl2 and Elavl3 are downregulated,
while HuB is upregulated and HuD is downregulated, compared to control mice. In diabetic resistant
mice, both Elavl genes and Hu proteins are strongly downregulated, compared to control mice.
It is very interesting to remark that, despite the lack of changes in the algesic profile of diabetic
resistant mice, we reported significant Elavl gene and Hu protein expression changes in diabetic
resistant mice compared to diabetic or control mice. Previous studies indicated HuD upregulation in
thermal hyperalgesia [19,50–52] and our study brings evidence that HuD is downregulated in thermal
hypoalgesia induced by the advanced diabetes status. Considering the role played by HuD upregulation
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in nerve regeneration upon lesion [21], a possible scenario in diabetes would be: (i) hyperalgesia
(early phases of diabetes) is associated with HuD upregulation involved in nerve regeneration,
(ii) hypoalgesia (late phases of diabetes) is associated with HuD downregulation, when its ability to
regulate mRNA proteins involved in nerve recovery is overcome. However, HuD downregulation in
late diabetes should be considered with caution as STZ-induced the same kind of expression changes
in normoglycemic diabetic resistant mice. Extensive analysis of the algesic profile in diabetic and
diabetic resistant mice in correlation with Hu proteins expression is necessary.
Our study also analyzed the immunolocalization of Hu proteins in correlation with the diabetic
status. Previous immunostaining studies documented the expression of HuD [8,53], HuC/HuD
(anti-16A11 antibody) [17], or all Hu proteins (anti-16A11 antibody) [18] in adult DRG neurons. The HuD
immunopositivity in DRGs neurons was analyzed: (i) in the cell compartments, with distribution both
in the soma and the axons [19] or (ii) in the subcellular structures (strong staining in the cytoplasm [8,18]
and low staining in the nucleus, Golgi apparatus and mitochondria [18]). Our study indicates HuB, HuC,
and HuD expression in the soma and neurites of the DRG neurons. However, our semi-quantitative
analysis of Hu protein expression was limited to the soma of DRG neurons.
Although specific immunostaining was obtained for all three neuronal Hu proteins in different
structures of the central nervous system or in the spinal cord [54], only HuD specific immunopositivity
was analyzed in DRGs [8,53], but no specific targeting of HuB and HuC expression in DRGs was done.
In our study, we bring evidence of the specific localisation of HuB and HuC in DRG neurons, and we
also demonstrate that all three Hu proteins undergo expression changes in late diabetes.
Different neuronal types from hippocampus, cerebellum, olfactory cortex, neocortex, etc. were
demonstrated to express from one to several Hu genes [54]. We might suppose that different
subtypes of DRG neurons express various combinations of Hu genes, distinctly contributing to
the regulation/stabilization of mRNA encoding proteins involved in the development of diabetic
neuropathy and/or thermal hypoalgesia. To this purpose, subsequent colocalization studies of Hu
proteins in DRG neurons might bring new insights.
To resume, our study analyzed the distinction between diabetic and diabetic resistant mice in
the STZ-induction model and compares them with the control mice. We correlate the diabetic state
with hyperglycemia, lower body weight, presence of late thermal hypoalgesia, Elavl2 and Elavl3
downregulation, HuB upregulation, and HuD downregulation in comparison to control conditions.
Meanwhile, we correlate the diabetic resistant state with normoglycemia, slightly lower body weight,
normal algesia, strong Elavl2, Elavl3, and Elavl4 downregulation, HuB, HuC, and HuD downregulation
compared to control conditions. In conclusion, we demonstrate the distinct expression regulation of
nELAVL Hu proteins in diabetes and we consider that it is very important to understand if these Hu
protein expression changes are also present in patients with peripheral diabetic neuropathy and if
there is any correlation with the status of the disease.
4. Materials and Methods
4.1. Animals
Adult CD-1 male mice aged 6 weeks with a mean body weight of 20 g were acquired from the
“Cantacuzino” Medico-Military National Institute of Research and Development. Animals (N = 40)
were housed 3/cage in the animal husbandry of ‘Horia Hulubei’ National Institute of Physics and
Nuclear Engineering, with food and water ad libitum. All procedures were in accordance with the
European Guidelines on Laboratory Animal Care, and with the approval of the institutional Ethics
Committee of the ’Horia Hulubei’ National Institute of Physics and Nuclear Engineering (approval
number 31/11.06.2015).
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4.2. Streptozotocin-Induced Diabetes
Animals were divided into equal groups: 20 mice treated with citrate buffer solution and
20 mice treated with streptozotocin (STZ, #S0130, Sigma-Aldrich, St. Louis, MO, USA). Diabetes was
induced with a single intraperitoneal injection of STZ, at a fixed volume of 300 μL/animal, at the final
concentration of 150 mg/kg/body weight in 0.05 mol/L sodium citrate buffer, pH 4.5, as previously
described [37,55,56]. Citrate buffer solution was also injected intraperitoneal at a fixed volume of
300 μL/animal. Upon data analysis, the surviving animals from the STZ-injected group were divided
into two subgroups: STZ-sensitive group and STZ-resistant group (see Results Section 2.1). The timeline
of the experimental protocol is presented in Figure 7.
 
Figure 7. Timeline of the experimental protocol. Abbreviations W-weight, G-glycemia.
4.3. Body Weight Measurements
The body weight measurement was performed before the intraperitoneal injection (STZ or citrate
buffer solution), and then repeated once per week (in the same day, at the beginning of the week, and at
the same hour) for 8 weeks, as shown in Figure 2.
4.4. Glycemia Measurements
Blood glucose was measured from the tail vein blood by a glucometer (OneTouch, LifeScan,
Milpitas, CA, USA). The blood glucose measurement was performed before the intraperitoneal injection
(STZ or citrate buffer solution), and then repeated once per week (in the same day and at the same
hour) for 7 weeks, as shown in Figure 1. Animals were fastened 12 h before the glycemia measurement.
The body weight measurement was done alternately done before/after the glycemia measurement.
In order to prevent any experimental bias, in the 8th week, the glycemia measurement was not
performed, as animals were subjected to the hot-plate test.
4.5. Hot-Plate Test
In order to determine the occurrence of thermal hypersensitivity, the mice subgroups (control,
STZ-sensitive and STZ-resistant) were subjected to the hot plate test. To detail, CD-1 mice were placed
individually on a Hot Plate Analgesia Meter (Ugo Basile, Comerio, Varese, Italy), maintained at 55 ◦C
and the latency to hind paw licking or flicking (whichever occurs first) was measured. The animals that
did not respond within 30 s were removed from the hot plate to prevent paw damage. The hot plate
test was performed before the intraperitoneal injection with STZ or citrate buffer solution (initial paw
withdrawal latency, L0), and repeated after 8 weeks (final paw withdrawal latency, Lf), as shown in
Figure 3.
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4.6. Primary Cultures of Neurons from Dorsal Root Ganglia
Animals were sacrificed after 8 weeks from the intraperitoneal injection (at 16 weeks of age) and
DRG neurons were obtained from all spinal levels of adult male CD1 mice as previously described [32,33].
The animals were exposed to CO2 inhalation (1 min) followed by decapitation according to the European
Guidelines on Laboratory Animal Care, with the approval of the institutional Ethics Committee of the
‘Horia Hulubei’ National Institute of Physics and Nuclear Engineering (approval number, 31/11.06.2015).
DRGs were removed under sterile conditions and were immediately transferred into IncMix solution
(in mM, NaCl 155, K2HPO4 1.5, HEPES 5.6, Na-HEPES 4.8, glucose 5). After cleaning the ganglia from
the surrounding tissue and counting them, DRGs were incubated in a mixture of 1 mg/mL Collagenase
from Clostridium histolyticum, type 1A (#C9891, Sigma-Aldrich, St. Louis, MO, USA) and 1 mg/mL
Dispase from Bacillus polymyxa (#17105041, GIBCO, Invitrogen, Carlsbad, CA, USA) in IncMix solution
for 1 h at 37 ◦C. Following enzyme treatment, the ganglia were washed once in Dulbecco’s modified
Eagle’s medium Ham’s F-12 (DMEM F-12, #D8900, Sigma-Aldrich, St. Louis, MO, USA) with 10%
horse serum (#H1270, Sigma-Aldrich, St. Louis, MO, USA), before mechanical trituration in 0.5 mL
DMEM F-12. The dissociated neurons were then washed by centrifugation (at 1000× g for 10 min, 25 ◦C)
followed by resuspension in fresh medium. Following the final wash, the cell pellet was resuspended in
DMEM F-12, containing 10% horse serum and 50 μg/mL gentamicin (#G1272, Sigma-Aldrich, St. Louis,
MO, USA). Following a second trituration, neurons were seeded on 13-mm coverslips, previously
coated with 1 mg/mL poly-D-lysine (#P0899, Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 37 ◦C and
after 24 h were further processed for the immunostaining protocol. In the case of qRT-PCR protocol,
the extracted DRGs were directly subjected to the RNA extraction protocol.
4.7. RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)
In order to quantify the expression levels of ELAV2, ELAV3, and ELAV4 in the DRG neurons
from STZ-sensitive, STZ-resistant and control CD-1 mice subgroups, the total RNA was extracted from
dissociated ganglia using the GenElute Mammalian Total RNA MiniPrep Kit (#RTN70, Sigma-Aldrich,
St. Louis, MO, USA) according to the manufacturer’s instructions. RNA concentrations were determined
by spectrophotometric measurements at 260 and 280 nm (Beckman Coulter DU 730). In agreement
with the manufacturer guidelines (Sigma-Aldrich, St. Louis, MO, USA) for the GenElute™Mammalian
Total RNA Miniprep Kit, in our experiments the A260:A280 ratio was 2.038 ± 0.07. Reverse transcription
was performed using the High-Capacity cDNA Archieve Kit (Applied Biosystems, Foster City,
California, USA). The relative abundance of ELAV transcripts was assessed by qRT-PCR using TaqMan
methodology and the ABI Prism 7300 Sequence Detection System (Applied Biosystems). Reactions
were carried out for 35 cycles in triplicate. Elavl2 (#Mm00516015_m1), Elavl3 (#Mm01151962_m1),
Elavl4 (#Mm01263580_mH) and the mouse control assay for glyceraldehydes-3-dehydrogenase
(Gapdh, #Mm999999_g1) were obtained from Life Technologies (Carlsbad, CA, USA), and used
in accordance with manufacturer’s guidelines. From each animal group, 3 animals were sacrificed for
the qRT-pCR analysis, and each gene was analyzed in triplicate. Quantitative RT-PCR data for each
Elavl were normalized with Gapdh mRNA levels and relative amounts of mRNA were determined
using the comparative cycle thresholds [57].
4.8. Immunofluorescence
DRG neurons in primary culture seeded on 13-mm coverslips were washed with PBS, fixed in
4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and immunostained. Non-specific
binding was blocked with donkey serum (#017-000-001, Jackson ImmunoResearch Laboratories,
UK). DRG neurons were incubated with the primary antibodies overnight at 4 ◦C. We have used
the following primary antibodies: rabbit polyclonal IgG anti-ELAVL2 antibody (1:100; #ab96471,
Abcam, Cambridge, UK), rabbit polyclonal IgG anti-ELAVL3 antibody (1:100; #ab78467, Abcam),
and rabbit polyclonal IgG anti-ELAVL4 antibody (1:100; #ab96474, Abcam), considering the target
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specificity of these antibodies described by previous studies [20,25,58,59]. Then, DRG neurons were
incubated with the secondary antibody donkey polyclonal anti-rabbit IgG (H+L) conjugated with
Rhodamine Red X (1:100; #111-295-003, Jackson ImmunoResearch Laboratories, UK) for 1h at room
temperature. The primary antibody was omitted in negative-control samples. Images were captured
using a confocal fluorescence microscope (LSM 710, Carl Zeiss, Oberkochen, Germany) equipped
with a 63× oil objective. The following acquisition parameters were used: pinhole corresponding
to 1 Airy Unit, 62 μm for the 488 nm laser, digital gain of 1.00, and 5% intensity of the laser, as we
previously employed [60]. The acquisition parameter settings were kept fixed across all the image
acquisition sessions. Image acquisition was carried out using Zeiss LSM Image Browser software
(Carl Zeiss, Germany).
4.9. Digital Image Analysis
The fluorescence images were preprocessed using ImageJ. The outline of each neuronal soma
was manually drawn and the quantitative analysis of the fluorescence signal was done (mean pixel
intensity), as presviously described [61,62]. This quantification was carried out on both negative
control (the primary antibody was omitted in the immunofluorescence protocol) and positive samples
(full immunostaining protocol, including primary antibody). The average per group (control, diabetic
and diabetic resistant) negative control mean intensity was subtracted from the mean intensity values
of positive samples resulting the corrected mean pixel intensity. For each Hu protein, ~30 cells were
scored from each mice group. Finally, we plotted the corrected mean pixel intensity calculated for each
Hu protein (i.e., HuB, HuC, and HuD ) for the samples obtained from the control, diabetic and diabetic
resistant mice group.
4.10. Statistical Analysis
Statistical analysis was performed using OriginPro 8 (OriginLab Corporation, Northampton,
MA, USA).
Glycemia values were compared by: (i) by two-way ANOVA followed by post-hoc Bonferroni
test (for testing the significance of glycemia change, diabetic condition contribution, and of their
interaction), (ii) by one-way ANOVA followed by post-hoc Bonferroni test (for testing the inter-group
significance of glycemia change for each week after the STZ-induction of diabetes), and (iii) by one-way
ANOVA followed by post-hoc Bonferroni test (for testing the intra-group significance of glycemia
change between different weeks after the STZ-induction of diabetes).
Body weight values were compared as follows: (i) by two-way ANOVA followed by post-hoc
Bonferroni test (for testing the significance of body weight change, diabetic condition contribution
and of their interaction), (ii) by one-way ANOVA followed by post-hoc Bonferroni test (for testing the
inter-group significance of body weight change for each week after the STZ-induction of diabetes),
and (iii) by one-way ANOVA followed by post-hoc Bonferroni test (for testing the intra-group
significance of body weight change between different weeks after the STZ-induction of diabetes).
Paw withdrawal latency values obtained in the hot plate test were analyzed as follows:
(i) by two-way ANOVA followed by post-hoc Bonferroni test (for testing the significance of final latency
change, diabetic condition contribution and of their interaction), (ii) by one-way ANOVA followed by
post-hoc Bonferroni test (for testing the inter-group significance of the final latency change), and (iii)
by unpaired Student t-test (for testing the intra-group differences between the initial and final latency).
Quantitative RT-PCR data were analyzed as follows: (i) by two-way ANOVA followed by post-hoc
Bonferroni test (for testing the significance of Elavl expression change, diabetic condition contribution
and of their interaction) and (ii) by one-way ANOVA followed by post-hoc Bonferroni test (for testing
the inter-group significance of Elavl-2 expression, Elavl-3 expression or Elavl-4 expression change).
Mean grey levels obtained by immunofluorescence data analysis were compared as follows:
(i) by two-way ANOVA followed by post-hoc Bonferroni test (for testing the significance of Hu protein
expression change, diabetic condition contribution and of their interaction), (ii) by one-way ANOVA
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followed by post-hoc Bonferroni test (for testing the inter-group significance of HuB expression, HuC
expression or HuD expression change and (iii) by one-way ANOVA followed by post-hoc Bonferroni
test (for testing the intra-group significance of ELAV expression change in control mice).
Data were represented in OriginPro 8 (OriginLab Corporation, Northampton, MA, USA) as the
mean ± SD. Differences were considered significant at p < 0.05. Statistical significance is indicated in
figures as follows: * p < 0.05, ** p < 0.01, ** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/8/1965/s1.
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Abstract: The prime task of nociceptors is the transformation of noxious stimuli into action potentials
that are propagated along the neurites of nociceptive neurons from the periphery to the spinal cord.
This function of nociceptors relies on the coordinated operation of a variety of ion channels. In this
review, we summarize how members of nine different families of ion channels expressed in sensory
neurons contribute to nociception. Furthermore, data on 35 different types of G protein coupled
receptors are presented, activation of which controls the gating of the aforementioned ion channels.
These receptors are not only targeted by more than 20 separate endogenous modulators, but can
also be affected by pharmacotherapeutic agents. Thereby, this review provides information on how
ion channel modulation via G protein coupled receptors in nociceptors can be exploited to provide
improved analgesic therapy.
Keywords: nociceptor; inflammatory pain; G protein-coupled receptor; voltage-gated ion channel;
TRP channel; K2P channel; Ca2+-activated Cl− channel
1. Introduction
Nociception refers to “neural processes of encoding and processing noxious stimuli” as defined by
the International Association for the Study of Pain. Noxious stimuli are “actually or potentially tissue
damaging events” that need to act on nociceptors in order to cause pain. Accordingly, nociceptors
are viewed as “sensory receptors that are capable of transducing and encoding noxious stimuli”. As such,
nociceptors are peripheral nerve endings of first order nociceptive neurons; these are part of the
peripheral nervous system with neuronal cell bodies located mostly in dorsal root ganglia and with
central neurites projecting to second order nociceptive neurons located in the dorsal horn of the spinal
cord [1].
Noxious stimuli that impinge on nociceptors comprise mechanical forces, temperature changes
(heat and cold), and chemical agents (e.g., protons and plant-derived irritants such as capsaicin,
menthol, or isothiocyanates). Apart from acting directly on nociceptors, such injurious impact may
lead to inflammation, as do infections. This pathologic response is characterized by the release of
a plethora of mediators from various types of cells including, amongst others, macrophages, mast
cells, immune cells, platelets and the nociceptive neurons themselves [2]. Together, these mediators
are called inflammatory soup and lead to an increased responsiveness of nociceptive neurons. This
latter mechanism is known as sensitization and forms the pathophysiological basis of allodynia
and hyperalgesia: pain in response to a non-nociceptive stimulus and increased pain sensitivity,
respectively [1].
Constituents of the inflammatory soup comprise protons, nucleotides and nucleosides, enzymes
(proteases), fatty acid derivatives (prostanglandins), biogenic amines (histamine, noradrenaline, and
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serotonin), cytokines, chemokines, neurotrophins and other peptides (bradykinin, endothelin, and
tachykinins) [3]. These multifarious endogenous agents influence nociceptor signaling through a
variety of different receptors:
• Protons act directly on ion channels that are members of either the TRP or the ASIC family [4,5].
• ATP as a prototypic nucleotide may activate a subset of ligand-gated ion channels known as P2X
receptors [6].
• Cytokines such as various interleukins or tumor necrosis factors (TNFs) target different subtypes
of cytokine receptors [7].
• Neurotrophins, in particular nerve growth factor, bind to high affinity tyrosine receptor kinases
(trks) and to the low affinity receptor p75 [8].
• All others of the aforementioned inflammatory mediators and ATP elicit their actions on
nociceptors via some type of G protein-coupled receptor (GPCR).
Hence, most of the influence of the inflammatory soup on nociceptors is mediated by GPCRs [3].
The common outcome of the separate actions of the single components contained in the inflammatory
soup is sensitization of nociceptors, as mentioned above. The prime task of nociceptors is the
transformation of noxious stimuli into action potentials that are propagated along the neurites of
nociceptive neurons from the periphery to the spinal cord. Accordingly, sensitization means that this
transformation of noxious stimuli into action potentials is facilitated, and this may occur through one
of two possible mechanisms: reduction in the action potential threshold or increased responses to
suprathreshold stimuli. In principle, these two pathophysiological alternatives underlie the clinical
phenomena of allodynia and hyperalgesia, respectively [1]. Consequently, this review summarizes
how activation of certain GPCRs can impinge on either of these two mechanisms underlying the
sensitization of nociceptors.
Obviously, the transformation of noxious stimuli into action potentials relies on the coordinated
operation of a variety of ion channels. Therefore, inflammatory mediators must ultimately act on the
function of these ion channels to be able to sensitize nociceptors. In this regard, the present review
summarizes signaling mechanisms that link an activation of GPCRs to changes in ion channel function
in nociceptors.
When dealing with GPCRs expressed in peripheral nociceptive neurons, one must take into
account that not all of them subserve stimulatory actions that in the end lead to sensitization. Several
of these GPCRs mediate inhibitory effects which rather diminish than enhance neuronal excitability.
For the sake of comprehensiveness, such inhibitory receptors are considered as well.
2. Ion Channels as Targets of GPCR Signaling in Peripheral Nociceptive Neurons
In this section, ion channel families are described in light of their roles in nociceptive neurons.
In this respect, one can discern between ion channels that are directly involved in the sensation of
noxious stimuli and those that are rather responsible for the ensuing generation and propagation
of action potentials. The former group comprises TRP channels, ASICs, and mechanosensitive K+
and Piezo channels, whereas voltage-activated Na+ and Ca2+ channels as well as various types of
K+ channels belong to the latter. This basic characterization of each of these ion channel families
is followed by a description of the mechanisms that link activation of various GPCRs to changes in
functions of these ion channels.
2.1. TRP Channels Involved in Pain Sensation
Transient receptor potential (TRP) channels are expressed in a variety of tissues throughout
the body, such as skin, kidney, bladder, vascular smooth muscle cells and the nervous system [9].
The TRP channel family consists of six sub-families: TRPA (Ankyrin), TRPC (canonical), TRPM
(melastatin), TRPML (mucolipin), TRPP (polycystin), and TRPV (vanniloid), encoded by a total of
28 genes [10]. The latter five can be further divided into subtypes: TRPC1-7, TRPM1-8, TRPML1-3,
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TRPP1-3, and TRPV1-6 [11]. The broad variety of TRP channels allows sensing both noxious and
innocuous signals [12]. Thus far, TRPV1-4 [12] and TRPM3 [13] channels have been implicated in the
sensation of noxious heat. TRPA1, TRPC5 and TRPM8 channels have been suggested to detect noxious
cold temperatures [14]. In addition, both TRPA1 and TRPV4 subtypes are thought to be involved in
the detection of noxious mechanical stimuli [12], while TRPA1, TRPV1, TRPV3, TRPV4, TRPM8, and
TRPC3 may contribute to the sensation of itch [15,16].
The aforementioned TRP channel subtypes are expressed in different types of peripheral sensory
neurons such as dorsal root ganglion (DRG) and trigeminal ganglion (TG) neurons. TRPV1 channels
and TRPM8 channels are mainly expressed on separate sets of neurons. TRPV1 channels can be found
in C-fibers, whereas TRPM8 channels can be found on both fiber types transferring noxious signals
(Aδ- and C-fibers) [17]. Nevertheless, coexpression of TRPM8 and TRPV1 in one DRG neuron has
been reported as well [18,19]. TRPA1 and TRPV1, in contrast, are mostly coexpressed in sensory
neurons [17,19]. TRPV2 channels have been detected in Aδ-fibers [12]. TRPV3 channels can be found
on keratinocytes rather than sensory neurons [20], and TRPV4 channels are expressed in variety of
tissues including the CNS and peripheral neurons [21]. TRPM3 channels are expressed in a large
subset of DRG and trigeminal ganglion neurons. TRPM3 mRNA can be detected in approximately
80% of these sensory neurons at a level that is comparable to that of TRPA1 and TRPV1. However,
only small-diameter neurons produce currents mediated by TRPM3 [22].
The role of TRPV1 channels as sensors of noxious heat is well established [23]. In general, TRP
channels resemble the structure of voltage-gated K+ (KV) channels. Each channel is made up of four
subunits, each having six membrane spanning domains. Similar to KV channels, transmembrane
domains 5 and 6 comprise the channel pore, whereas transmembrane domains 1–4 resemble a voltage
sensor. Both N- and C-termini are found on the intracellular side [14] and harbor a number of regulatory
domains. Channel trafficking and assembly is regulated by six so-called ankyrin repeats located at
the N-terminus [24,25]. TRPV1 channels are not just activated by noxious heat, but also by voltage,
binding of vanilloids, such as capsaicin, or high concentrations of H+ ions [10]. As compared to KV
channels, TRPV1 channels display a rather weak voltage sensitivity [26], which can be explained by the
fact that the voltage-sensing transmembrane domains 1–4 remain fairly static during activation [26–28].
In addition, transmembrane domain 4 of TRPV1 channels contains a lower number of positively
charged amino acids as compared to KV channels. Hence, an additional voltage-sensing segment
might be required for TRP channels [14]. The gating in response to heat is regulated by the so-called
TRP domain. However, this process remains incompletely understood [29]. The TRP domain spans 25
amino acid residues and is located immediately adjacent to transmembrane domain 6. It contains the
TRP box, a stretch of conserved amino acid residues (WKFQR), which is a hallmark of TRP channels.
The TRP domain is thought to be involved in a number of processes, like PIP2 binding or channel
assembly, but the exact mechanism still needs to be fully elucidated [24]. As mentioned before, PIP2 is
thought to regulate TRPV1 channel function, however it is still under debate if PIP2 is a positive or a
negative regulator [30]. Cryo-EM studies in nanodiscs revealed the position of PIP2 in proximity to
the vanilloid binding site. Binding of a vanilloid displaces a part of the PIP2 molecule, which reaches
into the vanilloid binding pocket. The removal of the phosphoinositide is thought to lead to channel
gating [26]. Such an effect would rather point towards a negative regulatory effect of PIP2.
The threshold value for classifying a thermal response as noxious was determined to be 43 ◦C [2].
TRPV1 channels activate at temperatures that exceed 43 ◦C, TRPV2 activate at even higher temperatures
(>52 ◦C), whereas TRPV3 and TRPV4 channels gate in a temperature range between 26 ◦C and
34 ◦C [20]. Similar to TRPV1 channels, heterologously expressed TRPM3 channels activate at a
temperature exceeding 40 ◦C [22]. Interestingly, mice lacking TRPV1 channels display a delayed
nocifensive response only at temperatures exceeding 50 ◦C [31,32]. However, as compared to TRPV1
channels, the role of the other TRPV channels linked to the detection of noxious signals remains
incompletely understood [12]. The role of TRPV2 to TRPV4 channels in detecting noxious signals
remains debated [13], since both TRPV2 knock-out [33] and TRPV3/TRPV4 double knock-out [34]
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animals retain normal thermal and mechanical sensation. The nocifensive response times of TRPM3
knock-out mice is prolonged at temperatures exceeding 52 ◦C [22]. Mice lacking both TRPV1 and
TRPM3 show a significantly increased nocifensive response time already at 45 ◦C. However, some
sensory neurons still produce currents in response to heat. Only a triple knock-out of TRPV1, TRPM3
and, interestingly, TRPA1 leads to a complete heat-insensitivity of sensory neurons. Furthermore, these
mice were completely heat insensitive in behavioral tests [35].
The detection of both noxious and innocuous cold signals is suggested to involve TRPM8 and
TRPA1 channels [23]. TRPM8 channels gate at temperatures below 25 ◦C [20]. Knock-out animals of
TRPM8 channels lose the ability to detect cool temperatures, but retain the ability to detect noxious cold
signals below 15 ◦C [13]. Hence, the role of TRPM8 channels as cold sensors is well established, but an
additional set of ion channels needs to be involved in detecting noxious cold temperatures. TRPA1
channels are thought to be involved, but their role remains controversial [20]. Rodent TRPA1 channels
were found to be gated by noxious cold temperatures, however, that function is lost in primate TRPA1
channels [36]. By contrast, human TRPA1 channels, reconstituted in lipid bilayers, were found to be
activated by noxious cold temperatures [37]. In addition to these conflicting results, TRPA1 channels are
usually expressed on the same set of neurons as TRPV1 channels, which appears counterintuitive [17].
Furthermore, animal studies involving TRPA1 knock-out mice point towards an insignificant role in
the detection of noxious cold temperatures [20]. While their role in the detection of mechanical stimuli
remains controversial as well, their contribution to the detection of noxious chemical signals is well
established [12]. A large number of structurally unrelated electrophilic compounds can gate TRPA1
channels [13]. These compounds covalently modify one or more of the 31 cysteine residues, which
causes channel opening [38].
GPCR Regulation of TRP Channels
TRPV1 channels have been studied extensively for their modulation by GPCRs. Currents through
TRPV1 channels are increased in response to inflammation, which mediates an enhanced depolarization
and increased excitability [2]. The sensitization of TRPV1 channels can be mediated by both Gαq- and
Gαs-coupled receptors. Stimulation of a Gαq-coupled receptor leads to activation of phospholipase C
(PLC), which hydrolyzes membrane bound phosphatitylinositol 1,4, bisphosphate (PIP2) into soluble
inositol 1,4,5 trisphosphate (IP3) and membrane bound diacylglycerol (DAG, Figure 1). Subsequently,
IP3 binds to IP3 receptors located at the membrane of the endoplasmic reticulum, which triggers the
release of Ca2+. DAG in turn activates protein kinase C, which phosphorylates target proteins. Every
step of this cascade can interfere with the function of TRPV1 channels [39]. Presence of PIP2 in the
membrane is thought to decrease TRPV1 channel function by interfering with agonist binding [26].
If PIP2 is depleted from the membrane in response to PLC activation, TRPV1 activity may increase [30].
The exact role of PIP2 remains debated, as it was also shown to activate TRPV1 channels [30]. Activated
PKC was shown to phosphorylate two serine residues at the C-terminus, which is thought to mediate
sensitization [40]. A rise in cytosolic Ca2+ is not considered to contribute to sensitization as it usually
leads to rapid channel desensitization in response to prolonged activation [39]. A large number
of inflammatory modulators was shown to increase TRPV1 channels via one of these mechanisms
(Table 1).
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Figure 1. TRPV1 channels can be gated by different mechanisms (as indicated). Three major G-protein-
dependent pathways modulate the function of TRPV1 channels. Activation of Gαq/11-coupled
receptors (left) leads to activation of phospholipase C (PLC), which hydrolyzes phosphatitylinositol 1,4,
bisphosphate (PIP2) into inositiol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). DAG activates
protein kinase C (PKC), which phosphorylates TRPV1 channels, thereby increasing their function.
Activation of a Gαs-coupled receptor (center) stimulates adenylyl cyclase (AC), which produces
cyclic adenosine monophosphate (cAMP). Subsequent activation of protein kinase A (PKA) leads
to phosphorylation of TRPV1 channels and an increase in current. Stimulation of a Gαi/o-coupled
receptor (right) decreases AC activity. Therefore, less cAMP is formed, PKA is less active and hence
TRPV1 channels are not phosphorylated which decreases their activity.
Table 1. GPCRs modulating TRPV1 function.
GPCR Ligand Involved GPCR Pathway Effect on TRPV1 Reference
Bradykinin B2 Gαq-DAG-PKC increased current [2,41]
Serotonin 5-HT2 Gαq-DAG-PKC increased current [42–44]
5-HT4 Gαs-AC-PKA increased current [43]
5-HT7 Gαs-AC-PKA increased current [42]
UTP P2Y2 Gαq-DAG-PKC increased current [45–47]
BAM 8-22 MRGPRX1 Gαq-DAG-PKC-PIP2 increased current [48]
Proteases PAR2 Gαq-PKC increased current [49,50]
PAR1 Gαq-PKC increased current [51]
PAR4 Gαq-PKC increased current [51]
PGE2 EP1 Gαq-PKC increased current [52]
EP2 Gαs-PKA increased current [52–54]
PGI2 IP Gαq-PKC increased current [52]
IP Gαs-PKA increased current [52]
Endothelin-1 ETA Gαq -PKC increased current [55,56]
Substance P NK1 Gαq -PKCε increased current [57]
NK2 Gαq-PKC increased current [58]
H+ TDAG8 (GPR65) Gαs-PKA increased current [59]
Morphine MOP Gαi-reduced AC decreased current [60,61]
Endocannabinoids CB1 Gαi-reduced AC decreased current [62]
CB2 Gαi-reduced AC decreased current [63]
AC, adenylyl cylcase; DAG, diacylglycerol; PKA, proteinkinase A; PKC, protein kinase C; BAM 8–22, bovine adrenal
medulla peptide 8–22.
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Activation of a Gαs-coupled receptor stimulates the activity of adenylyl cyclase, which produces
cyclic adenosine monophosphate (cAMP). This nucleotide is needed to activate protein kinase A (PKA),
which then phosphorylates its target proteins. PKA-mediated phosphorylation of TRPV1 channels
increases their sensitivity towards their agonists and reduces Ca2+-mediated desensitization [54].
Several inflammatory mediators were found to sensitize TRPV1 channels utilizing this pathway
(Table 1).
By contrast, activation of a Gαi-coupled receptor decreases the activity of adenylyl cyclase which
reduces the abundance of cAMP and subsequent activation of PKA (Table 1). Indeed, activation of
Gαi-coupled cannabinoid [62,63] and μ-opioid (MOP) [60,61] receptors was shown to reduce currents
of TRPV1 receptors, which is thought to contribute to the peripheral analgesic action of opioids [60,61]
and cannabinoids [62,63].
In addition to the three major GPCR pathways, TRPV1 channels were shown to be sensitized
by nerve growth factor (NGF), which requires the early activation of PI3 kinase and the presence of
PKC and CamKII (Ca2+/calmodulin dependent protein kinase II) [64]. The inflammatory mediator
histamine sensitizes TRPV1 channels via Gαq-coupled H1 receptors. Instead of utilizing the signaling
cascade described above, histamine-mediated sensitization requires activation of phospholipase A2
and lipoxigenases [65–67].
In sensory neurons, a variety of Gαi/o-coupled receptors were found to inhibit currents through
TRPM3 channels: including GABAB receptors [68–70], μ-opioid receptors [68,69], somatostatin
receptors [68,70], CB1- [69], as well as, CB2 receptors [68], and neuropeptide Y receptors [69]. Likewise,
low concentrations of noradrenaline reduce TRPM3 activity, hinting towards α2 as mediating receptor.
However, the adrenergic receptor involved was not further characterized [68]. Whether δ-opioid
receptors also mediate a TRPM3 inhibition remains controversial: while deltorphin, a δ-selective
peptide was able to reduce TRPM3 function [68], the small-molecule δ-selective agonist SB205607
was not [69]. Likewise, activation of Gαi/o-coupled metabotropic glutamate receptors (mGluR4/6/7/8)
did not reduce TRPM3 function [69]. In a heterologous system, Gαq/11-coupled M1 receptors were
found to inhibit currents through TRPM3 channels [70]. However, in sensory neurons, activation
of Gαq/11-coupled mGluR5 only weakly inhibited TRPM3 [68]. The inhibition of TRPM3 in sensory
neurons involves activation pertussis toxin (PTX)-sensitive Gαi/o-coupled receptors [68–70]. The effect
did not require signaling downstream of Gαi/o activation, but relied on a direct interaction with the βγ
dimer [68–70].
TRPA1 channels are sensitized by Gαs- and Gαq-coupled receptors in sensory neurons.
A Gαi-mediated interaction has not been reported for sensory neurons. Activation of Gαq-coupled
PAR2 receptors increased currents mediated by TRPA1 receptors in dorsal root ganglion neurons.
This interaction required the activation of PLC but none of the downstream products. Consequently,
depletion of PIP2 from the membrane was shown to be sufficient for this interaction [12].
The inflammatory mediator bradykinin was shown to increase currents through TRPA1 channels
in dorsal root ganglion neurons. This effect was mediated by Gαq-coupled B2 receptors and required
the activation of PLC. Interestingly, activation of PKA was further required for the interaction of
B2 receptors and TRPA1 channels [71]. An interaction of Gαq-coupled bradykinin B1 receptors with
TRPA1 channels was reported in behavioral experiments. This interaction relied on activation of PLC
and PKC [72]. Histamine was shown to cause nocifensive behavior in a TRPA1 dependent manner.
It is thought to involve Gαq-coupled H1 receptors and activation of PLC [73]. Adenosine, another
component of the inflammatory soup, was found to sensitize esophageal C-fibers and increase TRPA1
currents via Gαs-coupled A2A receptors. Activation of PKA is necessary for this interaction [74].
Electrophilic metabolites of prostaglandins, however, were demonstrated to activate TRPA1 channels
directly [75,76].
The inflammatory mediators prostaglandin E2 (PGE2), bradykinin and histamine were tested for
their influence on TRPM8 channel function. As opposed to the previously described members of the
TRP channel family, the activity of the cool sensor TRPM8 is reduced in the presence of bradykinin
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and PGE2. However, application of histamine did not interfere with TRPM8 channel function [77].
The action of bradykinin required the mobilization of PKC [77,78], whereas PGE2 involved activation
of PKA [77]. Bradykinin is assumed to act via Gαq-coupled B2 receptors [79] and several modes
of action have been suggested: it was found that depletion of PIP2 from the plasma membrane
reduced heterologously expressed TRPM8 channel function [80]. However, these experiments were
performed in absence of GPCRs and it remains to be established if PIP2 depletion is also sufficient
to reduce TRPM8 channel function in a native cell system. PIP2 is hydrolyzed to form IP3 and DAG,
which is required to activate PKC. PKC is thought to activate protein phosphatase I (PPI), which
is suggested to dephosphorylate TRPM8 channels. The dephosphorylation of TRPM8 channels is
proposed to finally inhibit TRPM8 channel function [79]. More recently, both bradykinin and histamine
were found to inhibit TRPM8 channels via a direct interaction of Gαq subunits with the channels.
The inhibitory effect of both mediators did not require activation of PLC or any of the subsequent steps
in the signaling cascade [81]. The receptor via which PGE2 exerts its effect has not been determined,
however it was found that activation of a Gαs-coupled receptor and subsequent PKA stimulation was
required. Furthermore, the exact mechanism how PKA modulates TRPM8 channel function remains
unknown [79].
2.2. Acid-Sensing Ion Channels
Acid-sensing ion channels (ASIC) represent one of many ion channel families that detect noxious
chemical stimuli. Additional chemical sensors are TRP channels, namely TRPA1 and TRPV1, as well as
ATP-gated P2X receptors [82]. As the name suggests, acid sensing ion channels are activated in low pH
conditions [83]. Such acidic conditions occur during an inflammatory response, ischemia, or fatiguing
exercise [82]. ASICs can be divided into three subtypes ASIC1 to ASIC3. ASIC1 and ASIC2 can even
be further subclassified into two splice variants each (ASIC1a, ASIC1b; ASIC2a, ASIC2b) [84]. A fourth
analog, sometimes referred to as ASIC4 [85], rather affects expression levels of ASIC1a and ASIC3,
instead of producing proton-gated currents [84]. The EC50 for proton-mediated currents via ASIC1
and ASIC3 channels ranges between a pH of 6.2 to 6.8, whereas ASIC2 channels have an EC50 between
pH 4.1 and 5 [84]. All forms of ASICs can be detected in somata and peripheral ends of sensory
neurons [85]. ASIC1a and ASIC3 channels are preferentially expressed in small diameter DRG neurons
which also express TRPV1 and most likely subserve nociceptive function [86]. A functional channel is
composed of three subunits and all but one subunit can participate in both homo- and heteromeric
channels. Only ASIC2b does not form functional homomeric channels [87]. One subunit consists of
two transmembrane domains, having both the N- and C-termini at the intracellular side [88,89]. Most
of the protein is located at the extracellular side forming the large extracellular domain (termed ECD).
The structure of the extracellular domain was compared to a hand holding a ball, which explains
the peculiar terminology for parts of the ECD, such as palm, knuckle, thumb, finger and β-ball [90].
The ECD contains a number of regulatory domains: for example, an acidic pocket is formed by acidic
amino acid residues at the subunit–subunit interface, which is involved in binding of H+ ions and
subsequent gating [89]. ASIC channels follow a three-state kinetic model, from a closed to an activated
to an inactivated state. The recovery from inactivation can only be achieved in high pH conditions [88]
and this desensitized state is thought to be regulated by the thumb domain within the ECD [90].
Genetic studies have suggested that ASICs play a role in sensing mechanical signals, but the exact
gating mechanism is unknown, and their role remains heavily debated [91].
GPCR Regulation of ASICs
A few components of the inflammatory soup have been tested for their modulatory effect on
acid-sensing ion channels: histamine was shown to selectively potentiate heterologously expressed
ASIC1a channels. This process involved a direct action of histamine and did not require the presence
of a GPCR [92]. The nucleotides UTP and ATP were shown to increase acid-induced currents (Figure 2)
in rat dorsal root ganglion neurons as well as acid-induced membrane excitability. In this respect,
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UTP was found to act via Gαq-coupled P2Y2 receptors and required the activation of PLC, subsequent
stimulation of PKC and the presence of the anchoring protein PICK-1 (protein interacting with
C-kinase 1) [93]. A similar effect can be observed when serotonin is applied: both ASIC-mediated
currents and neuronal excitability are increased [94]. Serotonin was found to act via Gαq-coupled 5-HT2
receptors [94] and required activation of PKC [94,95]. Two phosphorylation sites, one at the N-terminus
and one at the C-terminus of ASIC3, need to be phosphorylated for the full effect. Again, PICK-1
is necessary for PKC-mediated phosphorylation of ASIC channels. This scaffold protein is thought
to bind to ASIC2b subunits in heterotrimeric channels and to link PKC to the channel and to enable
phosphorylation [95]. Another Gαq-coupled receptor, PAR2, was found to increase ASIC-mediated
currents in rat pulmonary sensory neurons. Interestingly, neither PLC nor PKC were required for the
PAR2 mediated current increase but the pathway involved was not studied further [96]. Depending
on the activation mechanism of PAR2, one may observe an increase of cytosolic Ca2+ following the
Gαq-dependent activation of PLC and formation of IP3. On the other hand, PAR2 activation was
shown to signal also via Gα12/13 proteins, which activate Rho kinase and lead to ERK phosphorylation.
Additionally, PAR2 activation may lead to β-arrestin recruitment. Whether PAR2 activation may also
decrease or increase cAMP levels remains controversial [97].
α αβγ βγ
α
Figure 2. Acid sensing ion channels (ASIC) are gated by increasing concentrations of H+. Two
G-protein pathways modulate the function of ASICs. Activation of Gαq/11-coupled receptors (left) leads
to activation of phospholipase C (PLC) which hydrolyzes phosphatitylinositol 1,4, bisphosphate (PIP2)
into inositiol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). DAG activates protein kinase C (PKC)
which phosphorylates ASICs increasing their function. The interaction of PKC with ASICs requires
the presence of PICK-1 (protein interacting with C-kinase 1). By contrast, activation of Gαq/11-coupled
V1A receptors (center) were shown to decrease ASIC-mediated currents via an unknown mechanism.
Stimulation of Gαi/o-coupled receptors (right) was shown to decrease currents through ASICs involving
an undetermined mechanism.
By contrast, activation of Gαi/o-coupled receptors was shown to decrease currents through ASIC
channels. First, stimulation of cannabinoid CB1 receptors was found to reduce nocifensive behavior
triggered by local acidosis which relies on an interaction between CB1 receptors and ASIC channels [98].
Second, activation of μ-opioid receptors was shown to decrease ASIC-mediated currents, neuronal
excitability in dorsal root ganglion neurons and nocifensive behavior induced by local acidification [99].
In addition, nocifensive behavior provoked by mechanical stimuli [100] or local acidification [101] is
reduced by local application of oxytocin. Oxytocin reduces ASIC-mediated currents in dorsal root
ganglion neurons via activation of vasopressin V1A receptors. This effect was found to be dependent
on Gαq activation, but further steps of the cascade were not tested [101]. It remains to be determined
if the observed differences in Gαq-mediated effects on ASIC channels, for example, depend on the
recruitment of PICK-1.
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2.3. Mechanosensitive Channels in Pain Sensation
The variety of mechanical stimuli detected by so-called mechanosensors in the sensory
nervous system ranges from light to noxious mechanical stimuli. These specialized neurons
express mechanotransducer channels [102]. To sense noxious mechanical stimuli, high-threshold
mechanosensors are required, which should express ion channels that open in response to strong
mechanical stimuli and lead to a depolarization of these neurons [103]. Acid sensing ion channels
(as described above) were suggested to act as mechanotransducer channels in C. elegans. However,
heterologously expressed mammalian ASICs do not gate in response to mechanical stimuli. Hence,
such depolarizing mechanotransducer channels in nociceptive neurons remain to be identified [103].
One family of ion channels that contributes to the sensation of noxious mechanical stimuli is
the family of two-pore K+ channels (K2P) [103]. The family of K2P channels consist of 15 members,
which usually provide so-called background or leak currents, which are the major contributors to
the resting membrane potential [11]. Three members of the K2P family were found to be involved in
sensing noxious mechanical stimuli: K2P2.1 (TREK1), K2P4.1 (TRAAK), and K2P10.1 (TREK2) [104].
A functional K2P channel is formed by two subunits consisting of four transmembrane segments
each (TMS1–4). Both the N- and C-termini are located in the intracellular space and the linker
regions between TMS1 and -2, as well as TMS3 and -4 are located inside the plasma membrane to
form one selectivity filter each [105]. Accordingly, a total of eight transmembrane domains and four
selectivity filter regions line the ion conduction pore. This structure of the pore is highly homologous
to that of voltage-gated K+ channels [104]. In closed conformation, the ion conduction pathway is
blocked by lipid acyl side chains and membrane stretch directly gates K2P channels [104]. K2P2.1 and
K2P4.1 channels are strongly expressed in small-diameter DRG neurons and only weakly expressed
in medium- and large-diameter DRG neurons, whereas K2P10.1 channels are exclusively expressed
in small-diameter neurons [106]. Interestingly, knock-out of these channels leads to an increased
nocifensive response to mechanical stimuli [107]. Since all these channels are selective K+ channels,
opening of K2P channels leads to an efflux of K+ ions and subsequent hyperpolarization. It is thought
that stretch-activation of K2P channels counteracts the activation of depolarizing mechanotransducer
channels and thereby finetunes the mechanically induced nociceptive signal which is transferred to the
brain [102]. Hence, it is clear that these three members of the K2P family contribute to the perception of
noxious mechanical stimuli, but they cannot represent the primary depolarizing mechanotransducer
channel [103]. Such a functional entity is rather provided by Piezo channels, in particular Piezo2,
which contributes to mechanically activated currents in DRG neurons [108]. However, deletion of
Piezo2 impairs touch, but sensitizes mechanical pain in mice [109]. Therefore, additional sensors of
mechanical pain remain to be identified.
2.3.1. GPCR Regulation of Mechanosensitive Potassium Channels
The function of mechanosensitive K2P channels can be adjusted by a number of modulators like
arachidonic acid, polyunsaturated fatty acids, glutamate, noradrenaline, acetylcholine, TRH [105] or
serotonin [107] (Figure 3). Arachidonic acid and polyunsaturated fatty acids activate these channels
directly [105]. The other modulators influence K2P channel function via activation of GPCR pathways.
All three major GPCR pathways affect K2P2.1 and K2P10.1 channel activity: phosphorylation of two
different C-terminally located serine residues either by cAMP activated PKA or PKC leads to an
inhibition of both subtypes. Phosphorylation of yet another serine residue by protein kinase G (PKG)
on the other hand activates K2P2.1 and K2P10.1 channels. PKG is activated by an increase of cyclic
guanosine monophosphate (cGMP) which in turn is formed by soluble guanylyl cyclase. Soluble
guanylyl cyclase is directly activated by nitric oxide and does not involve activation of a GPCR [105].
In dorsal root ganglion neurons, prostaglandin F2a (PGF2a) was shown to decrease K2P mediated
currents [106]. The exact coupling mechanism was not elucidated, however, PGF2a is the endogenous
ligand for Gαq-coupled FP prostanoid receptors [110] and it is likely that PKC activation is involved
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in this process. In addition, prostaglandin E2 (PGE2)-induced nocifensive behavior was reduced in







Figure 3. K2P channels are opened in response to mechanical stimuli. Stimulation of a Gαq/11-coupled
receptor (left) activates phospholipase C (PLC). Hydrolyzation of phosphatitylinositol 1,4, bisphosphate
(PIP2) forms inositiol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). DAG activates protein kinase
C (PKC) which phosphorylates K2P channels decreasing their function. Activation of Gαs-coupled
receptors (center) leads to activation of adenylyl cyclase (AC) which produces cyclic adenosine
monophosphate (cAMP). Thereafter, protein kinase A (PKA) is activated which phosphorylates K2P
channels and decreases their currents. Stimulation of Gαi/o-coupled receptors (right) decreases AC
activity. Therefore, less cAMP is formed, PKA is less active and subsequently K2P channels are not
phosphorylated, which increases their activity.
Activation of a K+ permeable ion channel leads to an efflux of K+ ions and a subsequent
hyperpolarization. K2P channels are active at resting conditions and contribute to the formation of the
resting membrane potential. Inhibition of these channels leads to a depolarization and a subsequent
increase in excitability [107]. Other components of the inflammatory soup were examined for their
effects on K2P channels: for example, serotonin was also found to inhibit K2P2.1 and K2P10.1 channels
via activation of 5-HT4 receptors in a heterologous cell system [112]. These GPCRs are Gαs-coupled
and activate PKA, which is thought to mediate this effect [107]. Application of UTP, which may act
through Gαq-coupled P2Y2, P2Y4 or P2Y6 receptors, leads to an inhibition of K2P channels in mammary
epithelial cells [113]. It remains to be determined if these inflammatory mediators also interact with
mechanosensitive K2P channels in dorsal root ganglion neurons.
On the other hand, activation μ-opioid receptors were found to increase K2P2.1 currents in
hippocampal astrocytes [114], in a heterologous cell system [115], and in substantia gelatinosa
neurons of the spinal cord. The latter mechanism is thought to be involved in the antinociceptive
actions of opioids [116]. All opioid receptors are coupled to Gαi/o G-proteins, which reduce the
activity of adenylyl cyclase [110]. Subsequently, less cAMP is formed, which in turn leads to
reduced PKA activity and less PKA-mediated phosphorylation of K2P channels [105]. Since opioid
receptors are also expressed in peripheral sensory neurons [117], such an interaction between
μ-opioid receptors and K2P channels might also exist in peripheral sensory neurons and contribute to
opioid-mediated antinociception.
2.3.2. GPCR Regulation of Piezo Channels
Mechanically activated and rapidly adapting currents in DRG neurons are carried by Piezo2
channels [108] and get sensitized by the activation of B2 bradykinin receptors, an effect that appears
to involve PKA as well as PKC [118]. Akin currents are enhanced in the presence of ATP and
UTP which act most likely through an activation of P2Y2 receptors [119]. Likewise, mechanically
activated and rapidly adapting currents in DRG neurons as well as currents in cells expressing
recombinant Piezo2 channels are enhanced by intracellular GTP or GTPγS which both lead to the
activation of G proteins [120]. This confirms that the function of mechanosensitive Piezo2 channels
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can be enhanced by inflammatory mediators acting on GPCRs. Interestingly, Piezo2 channels can be
inhibited by a depletion of membrane PIP2, and this mechanism is believed to underlie the reduction
of mechanically activated rapidly adapting currents in DRG neurons in response to an activation
of TRPV1 by capsaicin [121]. Why such an effect cannot be observed in DRG neurons during the
activation of Gαq-linked GPCRs, such as B2 bradykinin and P2Y2 receptors [118,119], remains open for
future investigation.
2.4. Calcium-Activated Chloride Channels in Pain Sensation
Calcium-activated chloride (CaCC) channels occur in a variety of tissues. They are widely
expressed in the nervous system but also other tissues like vascular smooth muscle cells. In addition,
CaCCs are used as a marker for stroma tumors in the gastrointestinal tract and were initially
termed DOG1 [122]. Functionally described CaCCs were linked to transmembrane proteins of
unknown function 16A and B (TMEM16) [123–125]. Thereafter, the term anoctamin was introduced
to account for its predicted eight (lat. octo) membrane spanning domains and its function as
an anion channel [122,126]. The family of TMEM16 proteins consists of ten members termed
TMEM16A to TMEM16K (I is left out), which correspond to anoctamin 1 to anoctamin 10 (ANO1 to
ANO10) [127]. Only ANO1 and ANO2 were unequivocally identified as mediating calcium-activated
anion currents, the other members were either identified as calcium-activated lipid scramblases or
as dual-function scramblases/ ion channels [128,129]. The subtypes ANO1, ANO2 and ANO3 were
found to be expressed in sensory neurons [130,131]. ANO1 was only detected in TRPV1 positive
neurons [132], whereas about 50% of ANO3 positive neurons were also TRPV1 positive [131]. Both
ANO1 [133] and ANO3 [131] are involved in nociceptive behavior in mouse models of inflammatory
pain. Cyro-EM- [134–136] and X-ray studies [137] revealed that TMEM16 analogs actually consist
of ten transmembrane domains. TMEM16A forms homodimers [138,139], where transmembrane
domains 3–7 of both subunits form one separate ion conduction pathway creating a two-pore anion
channel [134–136]. Calcium, needed for gating, binds to two regions of negatively charged amino
acid residues in transmembrane domains 6–8. Subsequently, transmembrane domain 6 is displaced,
which ultimately opens the channel [134,135]. In the absence of Ca2+, CaCC function is not altered by
changes in membrane voltage within physiological limits. Only voltages exceeding 100 mV may gate
CaCCs directly if Ca2+ is absent [140], presence of cytosolic Ca2+ merely shifts the voltage-dependence
to more physiological levels [141]. In sensory neurons, Ca2+ can either rise in response to activation of
a Gαq-coupled receptor and subsequent release from intracellular stores [142], or due to an influx of
extracellular Ca2+ via Ca2+-permeable ion channels like TRPV1 channels [143], or to a lesser extend
voltage-gated Ca2+ channels [142].
Mice lacking TRPV1 receptors, the canonical heat sensor, retain some sensitivity to noxious heat
and CaCCs were suggested to fulfill that task [122]. Indeed, heterologously expressed TMEM16A
channels produced currents at temperatures that exceeded 44 ◦C [144] and tissue specific knock-out
reduced mechanically and thermally induced nocifensive behavior [132,133].
GPCR Regulation of Calcium-Activated Chloride Channels
As described above, there are three possible sources for Ca2+ to activate CaCCs. One of these
possibilities is to activate a Gαq-coupled receptor and the subsequent signaling cascade (Figure 4).
In dorsal root ganglion neurons, the inflammatory mediator bradykinin was demonstrated to increase
neuronal excitability via gating of CaCCs which leads to a depolarizing Cl− efflux due to comparably
high intracellular Cl− concentrations. The induction of Cl− currents through CaCCs by bradykinin
required activation of PLC, formation of IP3 and an increase of cytosolic Ca2+ levels [145]. In addition,
it was also shown that activation of proteinase-activated receptor 2 (PAR2) induced currents through
CaCCs in dorsal root ganglion neurons. This action is dependent on increasing levels of cytosolic Ca2+
and a close proximity of IP3 receptors, which are located on the membrane of the endoplasmic
reticulum, to ANO1 channels, which are located at the plasma membrane [142]. Furthermore,
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expression of both TMEM16A (ANO1) and PAR2 is induced in a model of neuropathic pain and
both proteins are co-expressed in the same set of dorsal root ganglion neurons [146]. The inflammatory
mediator serotonin was shown to induce currents mediated via CaCCs in dorsal root ganglion
neurons. Even though all three types of 5-HT2 receptors are expressed on small-diameter dorsal root
ganglion neurons, only activation of 5-HT2C receptors was able to induce such currents. Furthermore,
the according increase in excitability also required activation of TRPV1 channels, which provides an
additional Ca2+ source [44]. Other possible mediators for sensitization include nucleotides: Both,
UTP and ATP were found to interact with CaCCs via activation of Gαq-coupled P2Y1 and P2Y2
receptors. However, this interaction was only investigated in kidney [147] and pancreatic cells [148].
It remains to be established if such an interaction also contributes to nucleotide-mediated sensitization
of sensory neurons.
α αβγ βγ
Figure 4. Calcium-activated Cl− channels (CaCC) are gated by increasing concentrations of cytosolic
Ca2+ and influenced by membrane voltage. The source of Ca2+ may be Ca2+-permeable ion channels
located in proximity to CaCCs (not shown) or Ca2+ released from intracellular stores. Stimulation
of Gαq/11-coupled receptors (left) activates phospholipase C (PLC). The subsequent hydrolysis of
phosphatitylinositol 1,4, bisphosphate (PIP2) forms inositiol 1,4,5 trisphosphate (IP3) and diacylglycerol
(DAG). DAG activates protein kinase C (PKC) which influences CaCC function. IP3 binds to IP3
receptors located in the membrane of the endoplasmic reticulum (ER) which causes Ca2+ release from
the ER. Activation of Gαi/o-coupled receptors (right) was shown to decrease CaCC currents via an
unknown mechanism.
In animal experiments, it was determined that activation of Gαi coupled cannabinoid CB1
receptors may contribute to peripheral antinociception via an interaction with CaCCs [149]. In addition,
central antinociception via activation of Gαi-coupled δ-opioid (DOP) receptors may involve an
interaction with CaCCs [150]. However, it remains unclear how Gαi-coupled receptors interfere
with CaCC function.
2.5. Voltage-Gated Na+ Channels
Voltage-gated Na+ channels (NaV) are crucial not just for excitable cells like central or peripheral
neurons, skeletal or cardiac muscle cells, but also occur in immune cells, which are considered
non-excitable [151]. In excitable cells, the principal role of NaV channels is generating action potentials.
Action potentials are generated, if a sufficient number of NaV channels are activated in response to a
local depolarization. As opposed to local depolarizations which can only spread over a few millimeters,
action potentials can travel along several meters and thus transfer the information to the central nervous
system. The stronger a local depolarization is, for example in response to a noxious stimulus, the more
action potentials are triggered [2]. If NaV channels are rendered non-functional, action potentials cannot
be evoked and information transfer to the central nervous system is stopped [152–155]. This mechanism
is highlighted by patients carrying loss-of-function mutations in their NaV1.7 or NaV1.9 genes, who
experience insensitivity towards painful stimuli [156].
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To date, nine pore-forming α-subunits of NaV channels are described, designated NaV1.1 to
NaV1.9 [11]. Only NaV1.6 to NaV1.9 channels can be found in nociceptive neurons. A functional
voltage-gated Na+ channel is formed by a pore-forming α-subunit and one additional auxiliary
β-subunit, of which four (β1 to β4) have been described. An α-subunit is composed of 24
transmembrane segments, which can be grouped into four domains (DI–DIV) of six transmembrane
segments each (S1–S6) [151]. The transmembrane segments S1–S4 of each domain form the
voltage-sensor, whereas all four S5 and S6 segments contribute to the channel pore. The S4 segments are
of particular interest as they harbor a number of positively charged amino acid residues. These residues
move the entire S4 segment upwards upon depolarization and lead to the gating of these ion channels.
This basic principle of activation is conserved among all members of voltage-gated ion channels [157].
Voltage-gated Na+ channels activate within a fraction of a millisecond and subsequently enter a
fast-inactivated state. This inactivation is mediated by the intracellularly located DIII-DIV linker [151].
The subunits NaV1.5, NaV1.8 and NaV1.9 have a low affinity for tetrodotoxin (TTX) as it ranges from
10 to 100 μM. The affinity for all other subtypes ranges between 1 to 10 nM [11]. The former subtypes
are therefore described as TTX-insensitive and this represents a simple experimental tool to distinguish
between NaVs relevant for nociception and those that are not relevant for nociception [151]. In addition
to the previously described channelopathies leading to pain-insensitive patients, the importance of
voltage-gated Na+ channels for nociception is highlighted by the fact that the most widely used
local anesthetic drug, lidocaine, leads to a use-dependent block of these channels, which prevents the
propagation of painful stimuli [151].
2.6. GPCR Regulation of Voltage-Gated Na+ Channels
The activity of TTX-resistant voltage-gated Na+ channels is affected by activation of Gαs coupled
receptors (Figure 5). Direct activation of adenylyl cyclase by forskolin increases TTX-resistant Na+
currents in dorsal root ganglion neurons. Activation of adenylyl cyclase increases the formation of
cAMP, which wash shown to be involved in this process [158]. In sensory neurons, the inflammatory
mediators serotonin [158], PGE2 [159,160] and CGRP [161] were found increase TTX-resistant Na+
currents via a mechanism involving Gαs-coupled 5-HT4 [162,163], EP4 [164], and CGRP [161] receptors,
respectively. Application of substance P leads to an increase in neuronal excitability in small diameter
dorsal root ganglion neurons [165]. Substance P activates neurokinin 1 (NK1) receptors, amongst
others [110]. These Gαs- and Gαq-coupled receptors were found to increase TTX-resistant Na+ currents
in dorsal root ganglion neurons in a PKCε dependent manner [166]. In addition, ATP, another
component of the inflammatory soup, was also found to increase TTX-resistant Na+ currents in
sensory neurons. By contrast, TTX-sensitive currents were not affected by application of ATP [167].
The underlying signaling cascade was not elucidated and hence it remains to be determined if,
for example, Gαs-coupled P2Y11 receptors could be involved.
On the other hand, activation of protease activated receptor 2 (PAR2) does not affect TTX-resistant
Na+ currents in nociceptive neurons [168]. These GPCRs are coupled to heterotrimeric Gαq-proteins
and lead to release of Ca2+ from intracellular stores as well as activation of PKC [142].
With respect to Gαi/o-coupled receptors, only activation of μ-opioid receptors by the agonist
DAMGO was investigated. In sensory neurons, application of DAMGO was able to prevent the
PGE2-mediated increase of TTX-resistant Na+ channels [169]. The involved pathway was not
investigated, but is seems reasonable to assume an interference of the Gαi/o-pathway with the
Gαs-mediated potentiation of these NaV channels.
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Figure 5. NaV1.x channels are activated by depolarizing voltages (as indicated). Activation of
Gαs-coupled receptors stimulates adenylyl cyclase (AC) activity (center). Subsequently, cyclic
adenosine monophosphate (cAMP) is formed, which activates protein kinase A (PKA). PKA-mediated
phosphorylation of voltage-gated Na+ channels increases their currents. By contrast, activation of
Gαi/o-coupled receptors (right) decreases AC activity and counteracts Gαs-mediated current increases.
Activation of a Gαq/11-receptor (left)was shown to increase NaV-mediated currents involving protein
kinase C ε (PKCε).
2.7. Voltage-Gated Ca2+ Channels
Neuronal calcium channels are protein complexes formed by a pore-forming α1 subunit, one β
and one α2δ subunit, the latter regulating membrane trafficking and voltage dependence [170]. There
are ten different α1 subunits that can be divided into three families (CaV1.x–3.x). Each of these families
consists of several subtypes that differ in biophysical parameters, expression pattern and physiological
function. In addition, there is a clear distinction in the voltage dependence of CaV1.x and CaV2.x when
compared to CaV3.x. While the latter activates at quite hyperpolarized potentials (<−50 mV), thus
being termed low voltage activated channel (LVA), the former need much higher depolarizations to be
opened and are called high voltage activated channels (HVA). In DRG neurons, all three families of
CaVs are found [171] and all can be modulated by GPCRs to different extents. Depending on the type
of GPCR, the channels are modulated via different pathways.
GPCR Regulation of Voltage-Gated Ca2+ Channels
The most prominent and by far best studied mechanism is the so-called voltage-dependent
inhibition (Figure 6). This is found in CaV2.x channels, where the G-protein Gβγ subunits can
directly bind to the calcium channel α1 subunit. This binding event leads to a shift in the gating
mode from “wiilling” to a “reluctant” one that manifests itself mainly in a marked slowing of
activation [172–174]. The term “voltage dependent” refers to the fact that depolarization can relief
the channels from inhibition and restore normal gating. As this type of inhibition is mostly exerted
by Gαi/o-coupled receptors it can be abolished by treating the cells with pertussis toxin (PTX) that
ribosilates Gαi/o-proteins and renders them inactive.
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Figure 6. CaV channels are activated by depolarizing voltages (as indicated). Activation of
a Gαi/o-coupled receptor (right) leads to a phenomenon called “voltage-dependent inhibition”.
This involves direct binding of the Gβγ dimer to CaV2.x channels. Activation of Gαs-coupled
receptors (center) leads to activation of adenylyl cyclase (AC), which forms cAMP (cyclic adenosine
monophosphate) to activate protein kinase A (PKA). PKA-mediated phosphorylation of CaV1.x
channels was shown to increase their currents. Activation of a Gαq/11-coupled receptor (left) stimulates
phospholipase C (PLC), which hydrolyzes phosphatitylinositol 4,5 bisphosphate (PIP2). Depletion of
PIP2 is sufficient to decrease currents through CaV channels.
One of the best studied examples for voltage dependent calcium channel inhibition is the
action of opioid receptors. All three types of opioid receptors, μ (MOP), κ (KOP) and δ (DOP),
are found in DRG neurons, with the exact expression pattern depending on the cell type [175,176].
Initially, it was found that exposure of nociceptive neurons to opioids leads to a shortening of action
potential durations [177–181]. It was demonstrated that application of [D-Ala2]-enkephalin (DADLE),
an unspecific opioid receptor agonist, not only reduced action potential duration, but also diminished
substance P release in these neurons [177]. As became clear later on, both effects were caused
mainly by the inhibition of Ca2+ channels [172,182]. The major target for opioid modulation are
CaV2.x channels [183–188]. These channels are found at the presynapse and govern neurotransmitter
release [170], thus inhibition of CaV2.x channels leads to reduced Ca2+ influx and concomitantly
reduced transmitter release from peripheral nociceptive neurons onto second-order neurons of the
pain pathway located in the spinal dorsal horn. In line with the fact that opioid receptors couple
predominantly to Gαi/o G proteins [110], opioid induced calcium channel inhibition was found to be
PTX sensitive [188], and voltage dependent [172]. These findings were corroborated by intracellular
administration of Gαo antiserum, that strongly reduced opioid receptor mediated ICa inhibition [189],
unequivocally demonstrating the mechanism of action.
Besides opioid receptors, many other GPCRs expressed in DRG neurons were found to lead
to a similar kind of calcium channel modulation. For example GABAB [190], adenosine A1 [191],
5-HT [163,192–195], P2Y [196], cannabinoid [197], neuropeptide Y Y2 receptors [198–200], somatostatin
SST4 [201] or α2 adrenoceptors [202].
Besides the well-studied Gβγ mediated voltage dependent inhibition, other mechanisms have
also been described [174]. Most prominently, phospholipase C (PLC) mediated PIP2 depletion can
lead to inhibition of calcium channels [203–205]. Similar to KV7 and Kir3 channels (see below), PIP2
stabilizes the open state of calcium channels. Thus, a reduction in membrane PIP2 leads to a voltage
independent decrease in channel open probability.
While several reports about this kind of inhibition exist from sympathetic neurons [174], there are
few data from nociceptive neurons. However, given the similarity of receptor and channel expression
between sympathetic and sensory neurons, it is reasonable to assume that these findings will also hold
true in DRG neurons. Only recently, the Mas-related G protein coupled receptor type C (MrgC) was
found to inhibit high voltage-gated calcium channels in a PLC dependent manner [206].
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Recently, a potentially novel form of calcium channel inhibition has been described.
Huang et al. [207] found that GABAB receptors not only inhibit HVA channels but also LVA channels.
Inhibition of both channel types was PTX sensitive, however the LVA inhibition was strongly reduced
by application of DTT, pointing to a novel mechanism that involves redox processes.
GPCRs cannot only inhibit Ca2+ channels but they are also known to be able to facilitate their
function. A classic example would be PKA which phosphorylates CaV1.x channels and increases their
currents [208]. In line with this, a broadening of the action potential upon application of noradrenaline
to DRG neurons was reported. This increase in action potential duration could finally be attributed to
an increase in CaV1.x currents [202].
2.8. Voltage-Gated K+ Channels
2.8.1. KV7 Channels
Amongst potassium channels, KV channels constitute the most diverse group with 12 known
families [209]. Literature abounds on how various KV channels modulate nociception at different
levels of the pain pathway [210]. The prototypical structural assembly of KV channels involves six
transmembrane segments of which the first four (S1-S4) constitute the voltage-sensing domain (VSD)
while the S5 and S6 segments constitute the pore through which K+ ions pass [211,212]. Amongst
others, the KV7 channel family has received immense attention in lieu of its amenability by GPCR
modulation [213,214], with five known members (KV7.1– KV7.5) encoded by KCNQ1-5 genes [209].
Four monomers come together in a homo- or heterotetrameric configuration in a subunit-specific
way to yield a functional KV7 channel [215]. The electrophysiological correlate of KV7 channel
activity is a slowly deactivating, non-inactivating current that has an activation threshold below
−60 mV. This conductance is also known as M current as it was originally described as a current
that is suppressed by an activation of muscarinic acetylcholine receptors [216]. In nociceptors, these
channels contribute majorly to the resting membrane potential [217]. KV7 channels are expressed
in all functional parts of a first-order neuron which include free nerve endings, nodes of Ranvier,
and the somata of dorsal root ganglion (DRG) neurons [218]. They regulate action potential (AP) firing,
which is the basis for encoding of noxious stimuli in the pain pathway [219]. Enhancing KV7 currents
exerts analgesic effects since hyperpolarizing the resting membrane potential of nociceptors decreases
neuronal excitability [220,221]. Similarly, inhibiting KV7 currents is proalgesic since concomitant
depolarization of the resting membrane potential enhances neuronal firing [222,223].
2.8.2. GPCR Regulation of KV7 Channels
A plethora of neurotransmitters and neuropeptides modulate KV7 channel function via GPCR
signaling (Figure 7), specifically of the Gαq/11 class [224]. One of the early reports was of the
nociception-relevant neuropeptide Substance P (SP) that inhibited KV7 currents in bullfrog DRG
neurons [225]. Subsequently it was revealed that neurokinin A (NKA inhibited currents through
KV7 channels in bullfrog DRG neuronsvia NK1 receptors which were coupled to PTX-insensitive G
proteins [226], even though this receptor may impinge on the functions of KV7 channels through
G protein-independent mechanisms as well [227]. The activation of Gαq/11-coupled receptors
leads phospholipase Cβ (PLCβ) to hydrolyze the membrane phospholipid phosphatidylinositol
4,5-bisphosphate (PIP2) into inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [228].
The function of KV7 channels is governed by the presence of sufficient membrane PIP2 pools and
depletion of membrane PIP2 levels leads KV7 channels to close [229]. The proalgesic mediator
bradykinin mediates inhibition of KV7 currents via its actions on the B2 receptor, a Gαq/11-coupled
receptor [230]. The active nociception mediated by bradykinin, consequent to enhanced neuronal
excitability can be attenuated by prior application of the KV7 channel opener retigabine [145].
In addition to membrane PIP2 depletion, the inhibition of KV7 channels via IP3-mediated increase in
intracellular Ca2+ levels and subsequent binding to calmodulin is well known [231,232]. In sympathetic
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neurons, the governing factor for substrate (PIP2)- versus product (Ca2+)-mediated inhibition
consequent to application of bradykinin is contingent upon Ca2+ availability and rate of PIP2
synthesis [233]. B2 receptors are closely opposed to the endoplasmic reticulum (ER) where IP3 can
diffuse and consequently mobilize Ca2+ reserves [216]. In DRG neurons, bradykinin primarily employs
the Ca2+ axis to inhibit KV7 currents as evidenced by the fact that inhibition of Ca2+ release from
IP3-sensitive stores with pharmacological tools as well as chelation of intracellular Ca2+ prevents
bradykinin-mediated inhibition of KV7 channels, akin to direct activation of PLC [145]. One of the
targets of the inflammatory soup is the protease-activated receptor 2 (PAR2), a Gαq/11-coupled receptor
expressed in nociceptors [49,234]. Activation of these receptors has an inhibitory impact on KV7
currents leading to nociception which requires concurrent increase in cytosolic Ca2+ levels in addition
to depletion of PIP2 levels [235]. Another example is the modulation of excitability in nociceptors
by nucleotides. The P2Y1 and P2Y2 receptors are Gαq/11-coupled receptors [236]. Activation of
these receptors by the nucleotides adenosine diphosphate (ADP), and 2-thio-uridine triphosphate
(2-thio-UTP), respectively, leads to the inhibition of currents through KV7 channels [47]. Moreover,
the observed effects were prevented by the application of U73122, a PLC inhibitor, inhibition of
Ca2+ATPases by thapsigargin, and chelation of intracellular Ca2+ levels by BAPTA-AM [47].
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Figure 7. KV7 channels are activated by depolarizing voltages (as indicated). Gαq/11-coupled receptors
(left) activate phospholipase C (PLC), which cleaves phosphatitylinositol 4,5, bisphosphate (PIP2)
into inositol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). Depletion of PIP2 from the plasma
membrane is sufficient to decrease currents through KV7 channels. In addition, Ca2+ is released
from the endoplasmic reticulum subsequent to formation of IP3. Ca2+ decreases KV7 currents via an
interaction with calmodulin. Activation of a Gαi/o-coupled receptor (right) was shown to decrease
KV7 currents in a PLC-dependent manner.
The GPCRs encoded by Mas-related genes (Mrgs) are a more recently identified subset of GPCRs
that are widely expressed in sensory neurons and implicated in the modulation of nociceptive
information [237,238]. Specifically, the MrgD isoform is expressed in DRG neurons especially in
non-peptidergic, small-diameter IB4-postive C-fiber somata [239,240]. Activation of endogenous
MrgD with the agonist alanine results in the inhibition of KV7 currents in DRG neurons, mainly
employing a pertussis toxin-sensitive pathway implicating the involvement of Gαi/o. Such an inhibition
translates into enhanced neuronal firing in phasic DRG neurons, which classically shoot single single
APs [241]. Recombinant cell-lines coexpressing MrgD receptors and KV7.2/7.3 heteromers exhibit an
inhibition of KV7 currents upon stimulation with alanine, an effect that could be reversed partially by
pharmacologically blocking Gαi/o and reversed completely by PLC inhibition [241].
2.8.3. KV1.4, KV3.4 and KV4 Channels
The KV channels KV1.4, KV3.4 and KV4 members contribute to the so-called transient A-current
(IA) [242,243], which plays a key role in regulating AP firing in DRG neurons [210,244]. The somata,
axons and central terminals of DRG neurons that abut the spinal dorsal horn are enriched with
KV3.4 channels. The expression of KV4.3 channels, on the other hand is restricted to the somata of
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non-peptidergic DRG neurons [245]. The rapidly inactivating KV3.4 channel is a key player in AP
repolarization in DRG neurons [246,247]. Activating PKC through physiological or pharmacological
means leads to a decline in fast N-type inactivation in endogenously expressed KV3.4 channels. This
directly impacts the biophysical properties of the nociceptor: the AP gets narrowed while the AP
repolarization is accelerated [248]. Specific siRNAs that selectively target KV3.4 channel expression
abolish the changes in AP waveform mediated by PKC activation [248]. In a rat model of cervical
spinal cord injury (SCI), the surface expression of KV3.4 channels was shown to be impaired; such
dysregulation was associated with the failure of PKC to shorten the AP duration in DRG neurons [249].
Similarly, the phosphatase calcineurin (CaN) antagonizes PKC activity as revealed by a reduction in
the inactivation of KV3.4 channels upon pharmacological inhibition of the former [250].
2.8.4. GPCR Regulation of KV1.4, KV3.4 and KV4 Channels
Neuromedin U (NMU) is a neuropeptide that decreases neuronal excitability in DRG neurons
via the enhancement of IA currents through its actions on the NMU type 1 receptor (NMUR1,
Figure 8) [251]. NMUR1 couples to Gαo proteins, PKA and the ERK pathway in a sequential
manner [251]. On the other hand, the cyclic undecapeptide urotensin-II activates the urotensin-II
receptor (UTR), which couples to Gαq/11 [252,253]. This leads to a reduction in IA in a dose-dependent
fashion in trigeminal ganglion neurons, mediated via the activation of PKC [254]. The concomitant
recruitment of ERK signaling cascade culminates in an enhanced excitability of TG neurons [254]. In rat
TG neurons, the KV1.4, KV3.4, KV4.2 and KV4.3 channels are co-expressed with P2Y2 receptors [255],
which in turn couple to different G proteins [256]. The application of UTP, an agonist at the P2Y2
receptor inhibits IA currents via the ERK pathway and enhances excitability in these neurons, an effect
that can be reversed by the P2Y2 receptor antagonist suramin [255].
Figure 8. The so-called A-current is mediated by voltage-activated KV1.4, KV3.4, and KV4 channels.
Activation of a Gαo-coupled receptor (right) increases A-type currents via a mechanism involving the
Gβγ dimer, protein kinase A (PKA) and extracellular signal-regulated kinase (ERK). Stimulation of
Gαq/11-coupled receptors (left) activates phospholipase C (PLC) leading to hydrolysis of phosphatityl
4,5 bisphosphate (PIP2) to diacylglycerol (DAG) and IP3. DAG activates protein kinase C (PKC), which
phosphorylates A-type channels and thus inhibits these channels. ERK is activated in parallel which
also phosphorylates A-type channels and thereby decreases their function.
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2.9. G-Protein Activated, Inwardly Rectifying Potassium Channels
G protein activated, inwardly rectifying potassium channels (GIRK) are homo- or heterotetrameric
channels formed from four different subunits (Kir3.1–3.4) encoded by the genes KCNJ3, KCNJ6, KCNJ9
and KCNJ5, respectively [257,258]. They are activated by pertussis toxin sensitive G proteins via
binding of βγ dimers to the channel [257]. In addition, it has also been demonstrated that the Gα
subunit can directly bind to the channels modulating their basal activity in the absence of GPCR
activation [259]. Besides their G protein-mediated modulation, it has been demonstrated several times
that Kir3 channels bind PIP2 and that this is necessary for their function [260,261].
GPCR Modulation of Girk Channels
Compared to their role in the CNS, data on their physiological role in DRG neurons is scarce [258].
In rat DRG neurons, co-localization of GIRK channels and μ-opioid receptors has been found [262].
The picture is complicated by the fact that, while all four subunits are expressed in rat and human
DRG neurons [117,263], only low mRNA levels and a lack of immunostaining have been reported in
mice [117]. This is corroborated by the fact that local application of DAMGO (Figure 9), a μ-opioid
receptor agonist, is ineffective in inflammatory pain mouse models [117]. This lack of effect, however,
could be overcome by expressing Kir3.2 in NaV1.8 expressing nociceptive neurons [117], demonstrating
the importance of Kir3 channels for peripheral analgesia. These findings are contrasted by the fact
that GIRK currents could be induced in a small number of about 15–20% of mouse DRG neurons by
application of DAMGO [264], rendering the interpretation of mouse data difficult.
αβγ
Figure 9. G-protein activated, inwardly rectifying K+ channels (GIRK) are activated subsequent to
stimulation of Gαi/o-coupled receptors. The dissociated Gβγ dimer binds directly to GIRK channels.
3. Conclusions
In this review, members of ten different ion channel families that are expressed in sensory neurons
are described with respect to their contribution to nociception. Appropriate gating of these channels
is subject to modulation by at least 35 different types of GPCRs, which are targeted by more than
20 separate endogenous modulators (Table 2). Thereby, GPCRs provide the largest superfamily
of receptors, activation of which can mediate pro- as well as antinociceptive effects . Accordingly,
these GPCRs are relevant as potential targets for analgesic drugs. However, only a few of them
are currently exploited in analgesic therapy, such as opioid, cannabinoid, and CGRP receptors or
prostanoid receptors as indirect targets of cyclooxygenase inhibitors. Therefore, this review should be
viewed as incitement to further investigate how the modulation of ion channels via GPCRs might be
tackled to provide novel pharmacotherapeutic agents for improved analgesic therapy.
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Table 2. Endogenous ligands for GPCRs modulating ion channel function.
Endogenous














BAM 8-22 MRGPRX1 TRPV1
Bradykinin B1 TRPA1




Endo- CB1 ASIC CaCC TRPV1
cannabinoids CB2 TRPV1
CB? CaV





Neuromedin U NMUR1 KV1.4
KV3.4
KV4
Neuropeptide Y Y2 CaV
Noradrenaline α2 CaV
β CaV
Nucleotides P2Y1 CaCC CaV KV7












PAR2 ASIC CaCC TRPV1
PAR4 TRPV1
Serotonin 5-HT2 ASIC CaCC TRPV1




Substance P/ NK1 KV7 NaV TRPV1





ASIC, acid sensing ion channel; CaCC, Ca2+-activated Cl− channel; CaV , voltage-gated Ca2+ channel; GIRK,
G-protein activated; inwardly rectifying K+ channel; K2P, two-pore K+ channel; KV , voltage-gated K+ channel;
NaV , voltage-gated Na+ channel; TRP, transient receptor potential channel; TRPA, ankyrin family; TRPM, melastatin
family; TRPV, vanilloid family; BAM 8-22, bovine adrenal medulla peptide 8-22; CGRP, calcidonin-gene related
peptide; CGRP-R, CGRP receptor; GABA, γ-amino butyric acid; ?, unknown.212
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Abbreviations
The following abbreviations are used in this manuscript:
α2 AR α2 adrenoceptor
β AR β adrenoceptor
μ-OR μ opioid receptor
5-HT2/4 5-hydroxytryptamine receptor 2 or 4
A1 adenosine A1 receptor
AC adenylyl cyclase
ADP adenosine diphosphate
ANO1-10 anoctamin 1 to 10
AP action potential
ASIC acid sensing ion channel
ATP adenosine triphosphate
B2 bradykinin B2 receptor
BAPTA-AM 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester)
CaV voltage-gated Ca2+ channel
CaCC Ca2+-activated Cl− channel
CamKII Ca2+/calmodulin dependent protein kinase II
cAMP cyclic adenosine monophosphate
CaN calcineurin
CB1/2 cannabinoid CB1 or CB2 receptor
cGMP cyclic guanosine monophosphate
CGRP calcitonin gene-related peptide
CGRP-R calcitonin gene-related peptide receptor
CNS central nervous system
Cryo-EM cryogenic electron microscopy
DADLE [D-Ala2]-enkephalin
DAG diacylglycerol
DAMGO [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
DI-IV domain I to IV of CaV and NaV channels
DOG1 discovered on GIST 1
DOP δ opioid receptor
DRG dorsal root ganglion
ECD extracellular domain
EP2/4 prostanoid EP2 or EP4 receptor
ER endoplasmic reticulum
ERK extracellular signal-regulated kinase
ETA endothelin ETA receptor





GABAB γ-aminobutyric acid receptor B
GIRK G-protein activated, inwardly rectifying potassium channels
GIST gastrointestinal stroma tumor
GPCR G-protein coupled receptor
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HVA high voltage activated Ca2+ channel
I+A A-type K+ current
IP prostanoid IP receptor
IP3 inositol 1,4,5 trisphosphate
K2P two-pore K+ channel
Kir inwardly rectifying potassium channel
KV voltage-gated K+channel
KCNJ gene name potassium voltage-gated channel subfamily J
KCNQ gene name potassium voltage-gated channel subfamily Q
KOP κ opioid receptor
LVA low voltage activated Ca2+ channel
MOP μ opioid receptor
MrgC mas-related G protein coupled receptor type C
MrgD mas-related G protein coupled receptor type D
mRNA messenger ribonucleic acid
NaV voltage-gated Na+ channel
NGF nerve growth factor




P2X purinergic P2X receptor
P2Y purinergic P2Y receptor
PAR2/ 4 protease-activated receptor type 2 or type 4
PGE2 prostaglandin E2
PGF2a prostaglandin F2a
PICK-1 protein interacting with C-kinase 1
PIP2 phosphatitylinositol 4,5 bisphosphate
PKA protein kinase A
PKC protein kinase C
PKG protein kinase G
PLA−2 phospholipase A2
PLC phospholipase C
PPI protein phosphatase I
PTX pertussis toxin
S1–4 transmembrane segment 1–4 of voltage-gated channels
SCI spinal cord injury
siRNA small interfering RNA
SP substance P
SST4 somatostatin SST4 receptor
TG trigeminal ganglion
TMEM16 transmembrane protein of unknown function family 16
TMS transmembrane segment
TNF tumor necrosis factor
TRAAK TWIK-related arachidonic acid activated K+ channel = K2P4.1
TREK1/2 TWIK-related K+ channel 1 (K2P2.1) or TWIK-related K+ channel 2 (K2P10.1)
TRH thyrotropin-releasing hormon
trk tyrosine receptor kinase
TRPA1 transient receptor potential channel ankyrin family
TRPM8 transient receptor potential channel melastatin family
TRPV transient receptor potential channel vanilloid family
TTX tetrodotoxin
TWIK tandem of pore domains in a weak inward rectifying K+ channel
UTP uridine triphosphate
UTR urotensin-II receptor
V1A vasopressin V1A receptor
Y2 neuropeptide Y Y2 receptor
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Abstract: The tooth has an unusual sensory system that converts external stimuli predominantly
into pain, yet its sensory afferents in teeth demonstrate cytochemical properties of non-nociceptive
neurons. This review summarizes the recent knowledge underlying this paradoxical nociception,
with a focus on the ion channels involved in tooth pain. The expression of temperature-sensitive
ion channels has been extensively investigated because thermal stimulation often evokes tooth pain.
However, temperature-sensitive ion channels cannot explain the sudden intense tooth pain evoked
by innocuous temperatures or light air puffs, leading to the hydrodynamic theory emphasizing the
microfluidic movement within the dentinal tubules for detection by mechanosensitive ion channels.
Several mechanosensitive ion channels expressed in dental sensory systems have been suggested
as key players in the hydrodynamic theory, and TRPM7, which is abundant in the odontoblasts,
and recently discovered PIEZO receptors are promising candidates. Several ligand-gated ion channels
and voltage-gated ion channels expressed in dental primary afferent neurons have been discussed
in relation to their potential contribution to tooth pain. In addition, in recent years, there has been
growing interest in the potential sensory role of odontoblasts; thus, the expression of ion channels in
odontoblasts and their potential relation to tooth pain is also reviewed.
Keywords: tooth pain; TRP channels; odontoblasts; piezo; purinergic; trigeminal ganglion
1. Introduction
The tooth is a unique sensory system that senses external stimuli predominantly as nociception.
Most of the nerves innervating tooth pulp have been presumed to be nociceptors since most axons
in tooth pulp are unmyelinated or small fibers that are myelinated [1]. However, this belief was
challenged by multiple observations that pulpal nerves possess physical and chemical properties of
large myelinated Aβ fibers. Due to these paradoxical findings, a new concept of “algoneurons” was
introduced [2,3].
The structure of the tooth is comprised of densely vascularized and innervated tooth pulp covered
by two layers of hard tissue—the dentin and enamel [3,4]. The dentin and enamel are distinguished
by their microstructure and mineral content. The outermost enamel layer is the hardest tissue in the
body, with minerals forming 97% of its weight. The dentin layer lies between the tooth pulp and the
enamel layer and has an intermediate hardness with a mineral content slightly higher than that of bone,
providing resilience to the enamel. The most notable property of dentin is its microstructure. Dentin is
made of thousands of microtubules—dentinal tubules—filled with dentin tubular fluid. Odontoblasts
are the cells that deposit the calcium matrix to form dentin and constitute a cellular single layer at the
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inter-surface of the dentin and the tooth pulp. Each odontoblast possesses a process that protrudes
into the dentinal tubules (Figure 1).
Figure 1. Anatomical features of the dental pain sensory system. Odontoblasts comprise the outermost
cell layer of dental pulp tissue, which is advantageous to odontoblasts playing the role of a sensory
transducer. Some nerve endings of dental primary afferents (DPAs) spread into the dentinal tubule.
This structural nature establishes a distinctive sensory mechanism for the tooth.
The structure of teeth results in a unique pattern of nociception. One example is a special condition
known as dentin hypersensitivity—the exaggerated nociception in teeth caused by non-noxious
mechanical, chemical, or thermal stimuli without the pulpal inflammation predisposed or the
nerve damage in the adjacent tissue [5–8]. While the molecular mechanisms underlying dentin
hypersensitivity have not been fully elucidated, one promising hypothesis—the hydrodynamic
theory—states that external stimuli cause the movement of the dentin tubular fluid to, ultimately,
excite nerve fibers in the pulp to initiate pain. This provides the most plausible explanation for
dental cold hypersensitivity of all the hypotheses that have been proposed, although not without
controversy [9–20]. Another example is the pulsating nature of tooth pain often described by chronic
pulpitis patients. This phenomenon is presumed to be caused by hydrostatic pressure applied to
the edematous tooth pulp in the restricted space within the dentin and enamel. Both the pulsating
pain associated with pulpal inflammation and the hydrodynamic theory of dental hypersensitivity
require a mechanosensitive receptor as a key molecule. However, understanding such a receptor and
its associated mechanism of action only began not long ago. This review summarizes the most recent
advances in the understanding of the molecular and cellular mechanisms of mechanotransduction in
the context of tooth pain.
The tooth is exposed to drastic temperature changes of the oral cavity. Although the harsh thermal
conditions from food consumption hardly induce tooth pain under normal circumstances because of
the excellent thermal insulating of the enamel tissue [21–24], mild temperature changes can induce
intense pain with exposed dentin or pulpal inflammation. For example, noxious cold induces sharp
and transient pain while noxious heat induces dull and lasting pain [25,26]. To elucidate the molecular
mechanisms associated with temperature-driven tooth pain, the expression and physiology of molecular
thermosensor candidates, such as the transient receptor potential (TRP) channel superfamily, have been
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investigated. A large variety of temperature receptors that may play critical roles in the transduction
of tooth pain are expressed in dental primary afferent nerves [22,27] and odontoblasts [5,6,8–10,18].
In addition, voltage-gated and ligand-gated ion channels take important roles in tooth pain.
Not only are various types of voltage-gated ion channels expressed in the trigeminal sensory nerve
on common nerve cells, but they are also expressed in odontoblast cells [22,28–32]. Previous studies
have indicated that small molecules, such as adenosine 5′-triphosphate (ATP), and their ionotropic
receptors, the P2X family, play an important role in the sensory system for tooth pain [19,33–35]. In this
review, we summarize the research on temperature-sensitive, mechanosensitive, ligand-gated, and
voltage-gated ion channels and their role in the sensory system for tooth pain.
2. Thermo-Sensitive Ion Channels
Since the temperature-gated TRPV1 ion channel was first cloned from a subset of trigeminal
and dorsal root ganglia (DRG) neurons [36,37], several members of the TRP superfamily have been
discovered and proposed as potential molecular temperature sensors [38]. These TRP channels have
been hypothesized to be key contributors for the keen sense of temperature in teeth, and the functional
expression of TRP channels in dental primary afferent neurons and in odontoblasts has been massively
investigated (Figure 2) [24,26].
Figure 2. Thermosensitive ion channels in the dental sensory system. External heat or cold stimuli
cause activation of thermosensitive ion channels in dental primary afferent (DPA) nerve ending or
odontoblast cells, therefore dental pain transduces from thermal stimuli.
2.1. Thermo-Sensing Ion Channels in the Trigeminal Nerve
TRPV1 is a polymodal receptor activated by high temperatures over 43 ◦C or irritant chemicals
including capsaicin and proton. TRPV1 is believed to play a central role in nociception because it
is primarily expressed in small- to medium-peptidergic nociceptive neurons, and its activation is
modulated by various inflammatory and nerve-damage-inducing mediators. Immunohistochemical
investigation demonstrated TRPV1 expression in 20% of rat trigeminal ganglion (TG) cells, mostly in
small- to medium-sized, as expected [39]. Interestingly, a retrograde labeling study revealed that only
8% of tooth pulpal neurons were TRPV1-positive, whereas 26% of TG neurons innervating facial skin
were TRPV1-positive, which was contrary to the previous speculation that most nerves innervating the
tooth pulp are nociceptive [40–42]. Conversely, the functional analysis of retrograde-labeled dental
primary afferent neurons showed the opposite results; the neuron response to capsaicin application
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was more abundant for dental primary afferents than for TG neurons in calcium imaging studies [43]
and in whole-cell patch clamp experiments [44]. Single-cell RT-PCR analysis revealed that most dental
primary afferents are TRPV1-positive, whereas two other immunohistochemical analyses reported that
only 17–34% of pulp-innervating neurons were TRPV1-positive [45,46]. The reason for this discrepancy
is not clear. Of note, lipopolysaccharides (LPS) from Gram (−) bacteria upregulated TRPV1 expression
in TG [47], and Complete Freund’s Adjuvant (CFA) upregulated TRPV1 in TG neurons innervating
adjacent teeth [48], suggesting the potential contribution of TRPV1 to tooth pain under the pulpitis
condition. Interestingly, estrogen is also upregulated TRPV1 and anoctamin-1 (ANO1)—a potential
heat-sensing ion channel—in female rat TG neurons and induced an increased pain response to TRPV1
agonists [49]. The physiological meaning of estrogen-induced upregulation for heat sensing ion
channels is not clear and needs to be considered when designing pain studies.
TRPV2 is an ion channel homolog to TRPV1 with a higher threshold (>52 ◦C). TRPV2 is different
from TRPV1 in that it does not respond to capsaicin nor acid and is preferentially expressed in medium-
to large-sized myelinated neurons [50]. The immunohistochemical analysis of retrograde-labeled
TG neurons revealed a TRPV2 expression pattern quite the opposite to that of TRPV1 [51]. While
14% of the TG cells showed immunoreactivity to TRPV2 mostly in medium- to large-sized, 37% of
neurons innervating tooth pulp was TRPV2-positive, whereas only 9% of neurons to the facial skin
were positive. Another immunohistochemical analysis using a double-labeling technique confirmed
the mutually exclusive expression of TRPV1 and TRPV2 in pulpal neurons, with 32–51% TRPV2
positive cells [45,46]. These findings are consistent with previous reports that pulpal neurons are
mostly medium- to large-sized myelinated neurons that lose their myelination upon entering tooth
pulp [2,4,52–56], suggesting that teeth might have a distinct nociceptive system.
In addition, the expression of TRPV4 and TRPM3 was observed in retrogradely labeled dental
afferent neurons [57–59]. Because TRPV4 activates at innocuously warm temperature between 27 and
35 ◦C, it is believed to play a role in the maintenance of body temperature, rather than in nociception [60].
On the other hand, TRPM3, or long TRPC3 as previously known, was recently discovered to have an
activation threshold of 40 ◦C and became a prominent candidate of noxious heat detector [61].
Since cold stimuli induce tooth pain more frequently than hot, cold-sensitive TRP channels might
play a role in the transduction of tooth pain. TRPA1 and TRPM8 are cold-sensitive TRP channel subtypes
activated at temperatures below 17 and 25 ◦C, respectively [62,63]. Calcium imaging experiments with
cold stimuli under 18 ◦C revealed that cold-sensitive neurons are more abundant in the TG than in the
DRG (15% and 7%, respectively) [43]. TRPA1 upregulation in a tooth injury rat model proposes the
importance of TRPA1 in tooth pain [64]. A subsequent study combining electrophysiological recording
with single-cell RT-PCR and immunocytochemistry revealed the functional expression of TRPA1 and
TRPM8 in rodent dental primary afferent neurons [43]. Interestingly, the expression of TRPA1 and
TRPM8 channels was lower than that of TRPV1 in dental primary afferent (DPA) neurons. TRPA1
and TRPM8 were, moreover, co-expressed in some of the TRPV1-positive DPA neurons, suggesting
an ambiguity between cold and hot stimuli-induced tooth pain. A recent study suggested that acute
heat sensation requires any of functional TRPV1, TRPA1, and TRPM3 ion channels, and only triple
knock-out mice showed a lack of acute withdrawal response to noxious heat compared to the intact
normal response to cold stimuli, which suggests a redundant mechanism for heat detection [65].
Whether dental sensory systems utilize a similar mechanism is unclear.
2.2. Thermo-Sensing Ion Channels in Odontoblast Cells
Odontoblasts deposit calcium matrix at the outer surface of tooth pulp to form the dentin layer.
Due to this anatomical location, the potential secondary role of odontoblasts as a member of the sensory
system has been continuously proposed [3,21,22,66–74]. The expression of temperature-sensing TRP
channels in odontoblasts has been investigated by several researchers, but the results have been
diverse. While calcium imaging, immunohistochemical detection, and single cell RT-PCR all revealed
the negative expression of heat-sensing TRPV1 and TRPV2 channels in acutely isolated odontoblasts
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from adult rat incisors [71], calcium imaging and electrophysiological recording of the odontoblasts
cultured from neonatal rat pulpal slices showed positive responses to TRPV1, TRPV2, TRPV3, TRPV4,
and TRPM3 [69,72]. It was not clear whether TRPV1 or TRPV2 channel-expressing odontoblasts were
damaged or lost during acute isolation, whether the odontoblasts cultured from pulpal slices did
not faithfully reflect the naïve odontoblasts, or whether it was from the age difference. Results from
cold-sensing TRPA1 and TRPM8 investigation are more perplexing. While TRPA1 and TRPM8 were
not detected in both acutely isolated odontoblasts and in pulpal slice-derived odontoblasts [71,72],
another study showed both TRPA1 and TRPM8 in rat odontoblasts cultured from pulpal slices [70].
The results from human odontoblasts are less diverse. TRPV1-4 and TRPM8 have been detected by
functional, immunohistochemical, western-blotting and electron microscopic tests [66,67,75]. TRPA1,
however, showed controversial results. While in one study [67] immunohistochemical analysis of
decalcified healthy human molar sections detected TRPA1 expression, another study did not [68].
Further clarification is required to determine the expression of TRPA1 in human odontoblasts.
Nonetheless, it is very probable that odontoblasts functionally express temperature-sensing TRP
channels and that these channels might confer odontoblasts with the ability to detect hot and cold
temperatures. Many questions remained to be answered, including whether odontoblasts, if activated,
can transfer these signals to pulpal neurons.
2.3. Other Aspects of the Thermo-Sensing Ion Channels in the Dental Sensory System
TRAAK and TREK-1 channels are also considered as potent thermosensitive ion channels [32,38].
Noël and his colleagues demonstrated that TRAAK and TREK-1 participate in the heat and cold
sensing functions of TRP channels [76]. Their expression in odontoblast cells was demonstrated in
a rodent model and in human pulp tissue [8,77]. Many other ion channels, including voltage-gated
Na+ (NaV) channels (VGSCs), have been thoroughly studied as molecular thermosensors [78,79].
Recently, other types of dental cells, such as human tooth pulp fibroblasts and periodontal ligament
(PDL) cells, were also shown to express temperature sensitive TRP channels [80,81]. These findings
suggest that apart from odontoblasts, other cell types, such as pulp fibroblast cells or PDL cells, might
contribute to the response to noxious thermal stimuli. Further studies are needed to elucidate the
thermosensing mechanisms of various cell types surrounding tooth tissue. Alternatively, some efforts
to characterize the dental sensory system by Next Generation Sequencing (NGS) studies have also been
performed [82,83]. Combining these results with new emerging experimental methodologies, such as
NGS or multi-omics studies of dental sensory systems, understanding of the temperature-induced
tooth pain perception mechanisms may prove to be a significant scientific breakthrough.
3. Mechanosensitive Channels in Tooth Pain
It is difficult to explain tooth pain strictly by transduction of noxious temperatures by thermo-TRP
channels. Temperature transduction cannot explain the sudden and intense tooth pain elicited by
innocuous stimuli, such as an air puff, water spray, or sweet substances, or the pulsating pain often
described by chronic pulpitis patients. Evidence from clinical studies suggests that the movement of
dentin tubular fluid by temperature change might cause the sudden intense tooth pain from an air puff
or spray of water. The sudden intense pain can also be generated in the micro-movement of cracked
tooth parts during mastication. In addition, tooth structure can be mechanically deformed in response
to thermal changes [3,13–16]. Pulsating pain in chronic pulpitis results from hydrostatic blood pressure
applied to inflamed and swollen pulp tissue contained within the hard dentin structures [84,85]. All of
these are suggested molecular transducers of mechanical force or stretch expressed in the dental
sensory system, that are activated upon mechanical stimulation from movement of dentinal fluid,
or deformation of microstructure (Figure 3) [13,18].
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Figure 3. Mechanosensitive ion channels in the dental sensory system. According to the hydrodynamic
theory of dental nociception, movement of the dentine tubular fluid generated by external stimuli,
such as thermal or mechanical stress, activates mechanosensitive ion channels in odontoblasts or dental
primary afferent (DPA) nerve ending extend into the dentinal tubule. Thus, mechanosensitive ion
channels are regarded as major players in dental nociception. These ion channels can also be activated
with directly applied mechanical stress.
3.1. TRP Channels
Several TRP channel superfamily members that exhibit mechanosensitivity include TRPC1,
TRPC6, TRPV1, TRPV2, TRPV4, TRPM3, TRPM4, TRPM7, TRPA1, and TRPP2 [86]. Of these
channels, the expression of TRPV1, TRPV2, TRPV4, TRPM3, TRPM7, and TRPA1 was reported in TG
neurons [59,87,88], while TRPV1, TRPV2, TRPV4, TRPM3, and TRPA1 were shown in dental afferent
neurons with retrograde labelling [43,57–59,72,89,90].
TRPV1, although this is still in debate, has been proposed to have mechanosensitivity. Bladder
and urothelial epithelial cells from TRPV1-deleted mice showed markedly diminished responses
to stretch [91]. The expression of TRPV1 in TG neurons innervating tooth pulp or in odontoblasts
is also controversial, as elaborated in the previous section. The mechanosensitivity of TRPA1 is
similar. While TRPA1-deleted mice showed a higher threshold and reduced response to mechanical
stimuli [92], another TRPA1-null mouse line reported no difference in mechanical threshold compared
to wild-type mice [89]. Ex vivo skin-nerve recordings from TRPA1-null mice showed deficits in
mechanical sensitivity [93]. Although the role of TRPA1 as a cellular mechanical transducer is unclear,
it suggests that TRPA1 may be implicated in mechanical hyperalgesia under pathological conditions.
A recent report on the upregulation of TRPA1 in an experimental tooth injury model suggests that
TRPA1 is still a promising candidate transducer in teeth [94].
TRPV4 is expressed in many cell types and tissues where mechanosensitivity is critical, such as
hair cells of the inner ear, vibrissae Merkel cells, sensory ganglia, chondrocytes, osteoclasts, osteoblasts,
and keratinocytes, as well as cutaneous A- and C-fiber terminals [95]. Studies conducted in
TRPV4-null mice revealed that TRPV4 is related to the development of acute inflammatory mechanical
hyperalgesia [95–97]. TRPV4-deleted mice showed reduced C-fiber sensitization for mechanical
and hypotonic stimuli [98], suggesting TRPV4 involvement in osmotic mechanical hyperalgesia and
nociceptor sensitization [98,99]. Recently, one study showed TRPV4 expression in the nerves of human
tooth pulps and that TRPV4 expression was upregulated in human tooth pulp nerves of symptomatic
teeth associated with pulpitis [100].
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The investigation of non-neuronal cells revealed the expression of TRPC1, TRPC6, TRPV4,
TRPM3, TRPM7, TRPP1, and TRPP2 in rodent odontoblasts [72,90,101,102] and TRPV1, TRPV2,
TRPV4, and TRPM3 in pulp cells from neonate rats after in vitro differentiation into odontoblasts [72];
this suggests that these channels might function as molecular mechanotransducers that possibly
confer mechanosensitivity to odontoblasts. TRPM7 is a unique ion channel with mechanosensitivity
attached to a kinase, as shown by a touch-unresponsive zebrafish mutant [103]. Interestingly, TRPM7
expression was detected in most odontoblasts, predominantly in the odontoblastic process region [101],
and TRPM7-specific inhibitor blocked mechanically-evoked calcium responses in odontoblasts [101],
suggesting that TRPM7 might mediate mechanical sensitivity in odontoblasts. TRPP1 and TRPP2,
which act together as a mechanical receptor, are present on the surface of odontoblasts and appear to
be located at the base of the primary cilium [104].
Recent publications strongly suggest that IB4-positive non-peptidergic afferents play an important
role transducing mechanical stimuli in the skin [105,106]. Chung and his colleagues showed a
non-peptidergic mechanosensitive subpopulation in TG neurons that might be responsible for the
detection of dentin tubular fluid [107]. However, the mechanical transducer molecule responsible for
tooth pain in non-peptidergic polymodal nociceptors remains to be elucidated by future research.
3.2. PIEZO Channels
Since PIEZO family ion channels were cloned in mammals, the PIEZO gene family have been
considered as putative mechanosensitive ion channel proteins [108–114]. PIEZO1 and PIEZO2
were identified by efforts to elucidate mammalian mechanosensing mechanisms which could not
be clearly understood by TRP channels. While PIEZO channels are broadly expressed in a wide
range of mammalian mechanosensitive cell types, PIEZO2 channels are identified as low-threshold
mechanoreceptors in sensory DRG neurons and Merkel cells [115–117]. Moreover, the depletion
of PIEZO2 in sensory DRG neurons and Merkel cells resulted in the dramatic reduction of rapidly
adapting mechanically induced currents, suggesting a critical role of PIEZO2 as low threshold
mechanoreceptor [118]. These findings have great implications for tooth pain research because low
threshold mechanoreceptors are regarded as major players in tooth pain sensory systems, considering
that mild mechanical stimuli could cause severe tooth pain. Moreover, several studies revealed that
major populations of dental primary afferent neurons consist of A-fibers regarded as low-threshold
mechanoreceptors [2,53]. Recently, many groups have examined the functional expression of PIEZO2
in the dental sensory system. Won et al. demonstrated PIEZO2 expression in murine dental primary
afferent neurons by single-cell RT-PCR and in situ hybridization and function by recording rapidly
adapting inward current induced by direct pocking [119]. Interestingly, PIEZO2 positive dental primary
afferent neurons were medium-to-large sized and co-expressed with TRPV1, Nav1.8, and CGRP, which
are regarded as nociceptive neuronal marker genes. These results indicate that PIEZO2 positive
low-threshold mechanoreceptor neurons innervating teeth are ‘algoneurons’ that also, paradoxically,
act as nociceptors.
To verify the role of these low-threshold mechanoreceptors in the odontoblast cells, other studies
have been performed to verify PIEZO expression in odontoblast cells. An electrophysiological study
with odontoblast cells co-cultured with IB4-negative medium-sized TG neurons elucidated the role
of odontoblasts as mechanosensitive transducer cells [120]. Inward currents were detected from TG
neurons when mechanical stimulation was applied to neighboring odontoblast cells. Interestingly,
this odontoblast-induced inward current from TG neurons was antagonized with a PIEZO1 selective
blocker. Three-dimensional imaging with focused ion beam-scanning electron microscopy revealed
that PIEZO2 is expressed in nearly all rodent matured odontoblast cells and is absent in immature
cells [121]. PIEZO2 proteins were detected selectively in odontoblastic processes that protrude into
dentinal tubules. In another study, however, odontoblastic response to mechanical stimulation was
inhibited by a specific antagonist of PIEZO1 [120]. These controversial results indicate the essential
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role of PIEZO ion channels in dental sensory systems as putative mechanosensors but also suggest that
more research is needed to comprehensively understand complex dental mechanosensing systems.
3.3. ASIC Channels
Acid-sensing ion channels (ASICs) were initially implicated in mechanotransduction because their
phylogenetic homologs in Caenorhabditis elegans—the mechanosensory (MEC) channel subunits—are
essential for the perception of touch. Three members of the ASIC family (ASIC1-3) are expressed
in peripheral mechanoreceptors and nociceptors in mammals. Six ASIC proteins encoded by four
genes have been identified, ASIC1a, ASIC1b, ASIC2a, ASIC2b, ASIC3, and ASIC4, which differ in their
kinetics, external pH sensitivity, tissue distribution, and pharmacological properties [122]. ASIC-2
mRNA is expressed in both small-diameter and large-diameter neurons and colocalized within single
sensory neurons in the TG [123]. One-third of TG neurons that project towards the tooth pulp are
immunoreactive (IR) to ASIC3 [124]. A single-cell RT-PCR study revealed that the ASIC3 mRNA is
expressed in 67% of pulpal afferent neurons [58,59]. Human odontoblasts display immunoreactivity
for ASIC2 as well as the ENaC-β and ENaC-γ, but not the ENaC-α, subunits [125]. These findings
suggest a role for ASIC3 in the mechanotransduction of tooth sensitivity.
3.4. TREK-1 Potassium Channels
The primary function of the two-pore potassium (K2P) channels is to mediate K+-selective leak
currents that regulate cell excitability through a hyperpolarized resting membrane potential [126].
Several members of the K2P channel family including TRESK, TRAAK/KCNK4, TASK, TREK, and
THIK are intrinsically mechanosensitive, and all are expressed in the DRG [127,128]. K2P channels
are well established regulators of primary afferent fibers excitability. Two kinds of high conductance
Ca2+-activated K+ (KCa) channels and TREK-1 channels (TWIK-related K+ channels) have been
identified as putative mechanotransduction channels [19,46,102,113,114,129–131]. Investigation of K2P
ion channels in the mammalian tooth pulp and in the odontoblast membrane revealed TREK1 mRNA
expression in human odontoblasts [58,77]. Consequently, TREK-1 channels when stretch-activated
may participate in the signal transduction to afferent nerve endings.
4. Ligand-Gated Channels
ATP: Purinergic Receptors
ATP acts as an extracellular signaling molecule that affects numerous downstream factors and
signaling cascades. Signaling involving a purine nucleotide or nucleoside, such as ATP, is called
purinergic signaling and is associated with multiple levels of nociception and immune responses
in the oral system [132]. For example, P2X receptors (P2XRs) are expressed in the nociceptive TG
cells [133,134] as well as in tooth pulp cells [35,135,136]. P2X positive nerve fibers have been detected
in the subodontoblastic plexus close to odontoblasts [33,135,137]. P2XR2 and P2XR3 receptors have
been found in both pulp nerves and a subpopulation of rat TG neurons [134,138–141]. In addition,
a study showed that the presence of the P2X3 receptor and possibly the heteromeric P2X2/3 receptor in
the trigeminal subnucleus caudalis (Vc) initiates and maintains the central sensitization in rat tooth
pulp nociceptive neurons [142].
Recent studies suggest that P2X3 receptor activation by ATP induces tooth nociception in rat
tooth pulp [33,139]. Importantly, an ATP derivative is sufficient to elicit behavioral pain sensation
in tooth pulp [143] and odontoblasts contribute to the sensory function of teeth by releasing ATP
in response to physical stimuli [19,66,129,144,145]. Furthermore, odontoblasts themselves express
different P2XR subtypes (Figure 4) [34,146]. Since blocking extracellular ATP release results in the
inhibition of interodontoblastic communication, ATP might regulate the physiology of odontoblasts
via autocrine or paracrine mechanisms [19]. G-protein coupled P2Y ATP receptors are also present in
pulp cells [136], TG neurons [147,148], trigeminal satellite glial cells [149], and odontoblasts [129,136].
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Figure 4. Other types of ion channels such as ligand gated ion channels and voltage gated ion channels
expressed in the dental sensory system. ATP molecules released by adjacent odontoblast or fibroblast
cells in pulp by external stimuli and they induce activation of purinergic receptors in odontoblasts or
DPA neurons. Various types of voltage gated ion channels are also expressed in dental pain sensory
cells but their functions are not clearly revealed.
5. Voltage-Gated Ion Channels
5.1. Voltage-Gated Sodium Channels
VGSCs are responsible for action potential generation and excitability of the cell membrane.
Nine different VGSC isoforms have been discovered in the mammalian nervous system, with NaV1.6
and NaV1.7 being the most abundant in the peripheral nervous system [150] and nociceptive sensory
neurons [151], respectively. Immunohistochemical analysis of pulp tissue taken from pulpitis patients
revealed expression of NaV1.7 and NaV1.8 with greater immunoreactivity in the pulp from patients
with painful pulpitis [152–154]. Closer investigation of tooth pulp from pulpitis patients showed an
increased expression of NaV1.7 in the nerve bundles at intact and demyelinating nodes of Ranvier
compared with healthy tooth pulp [155], while no significant difference for NaV1.6 expression was
observed [156]; together, this suggests that NaV1.7 might play a role in inflammatory tooth pain.
Since expression of VGSCs is an important property of excitable cells, the demonstration of NaV1.6
expression in non-neuronal pulpal cells, such as pulpal immune cells, dendritic pulpal cells, and
odontoblasts [29], has gathered a robust interest. In addition, electrophysiology, immunohistochemistry,
RT-PCR, and in situ hybridization of odontoblasts differentiated from human dental pulp explants has
revealed the expression and functionality of NaV1.1, NaV1.2, and NaV1.3 [28]. Interestingly, patch-clamp
recording of the cultured human tooth pulp cells revealed rapidly inactivating TTX-sensitive Na+
currents and membrane properties similar to neuronal satellite cells but not to odontoblasts [157].
The molecular and cellular identity of such pulpal cells is still unknown, and whether odontoblasts or
other pulpal cells are indeed excitable and, if so, what their function would be, is unclear.
NaV1.9 is the VGSC most recently identified [158]. NaV1.9 is preferentially expressed in small-diameter
DRG neurons, TG neurons, and myenteric neurons [159–162] NaV1.9 is activated at voltages near
the resting membrane potential and generates a relatively persistent current [159]. NaV1.9 channels
may also have a role in inflammatory pain, but not in neuropathic pain [158,163]. In addition,
an investigation of NaV1.9 in rats revealed the innervation of NaV1.9-IR fibers in lip skin and in the
tooth pulp of non-painful teeth, suggesting a role of this VGSC isoform in orofacial pain [164]. Recently,
a study found that NaV1.9 was increased in the axons of symptomatic pulpitis of permanent painful
human teeth compared to the tooth pulp of permanent non-painful teeth (Figure 4) [165].
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5.2. Voltage-Gated Calcium Channels
Several lines of evidence have shown that DRG and spinal cord neurons express CaV1.2 [166],
while L-type CaV channels are broadly expressed in skeletal and cardiac muscle, neurons, auditory
hair cells, pancreatic cells, and the retina [167]. Electrophysiological examination of the DRG showed
that L-type CaV channels are present largely in small and large neurons, although these channels are
regulated during chronic pain [168]. One study using RT-PCR showed that L-type CaV channels are
downregulated in DRG upon chronic constriction injury (CCI) and sciatic nerve axotomy in rats [169].
suggesting that decreases in CaV1.2 and CaV1.3 in DRG could contribute to the hyperexcitability of
neuropathic pain by modulating Ca2+-dependent inactivation or facilitation as negative feedback [170].
Inversely, CaV1.2 is upregulated in the spinal cord in a spinal nerve ligation (SNL) model. One study
reported that Cav1.2 functions as a key factor for the differentiation of tooth pulp stem cells [171]. In
addition, several lines of evidence indicate that CaV1.2 may have a central role in odontoblast behavior
at both the physiological and pathological levels [31,172–174].
5.3. Voltage-Gated Potassium Channels
Patch-clamp recording revealed the presence of the voltage-gated potassium channel (KV channel)
in cultured human dental pulp cells [175] and in human odontoblasts [73]. Calcium-activated potassium
(KCa) channels that display mechanosensitivity are also present in odontoblast cells [30,31,176], and their
concentration at the apical pole of odontoblasts could have relevance in the sensory transduction
process of teeth [73].
6. Conclusions
Tooth pain greatly undermines patient quality of life. Tooth pain arises from distinct mechanisms
from other pain types because of the unique neurochemical properties and anatomical structure of
dense innervation and vascularization under hard tissue. The physiology of tooth pain involves
the complex orchestration of ion channels introduced in this review (Table 1). Still, the present
understanding is vague. Many questions remain, such as how mechanosensitive ion channels involved
in tooth pain are molecular identified, whether odontoblasts function as primary sensory cells, and, if
so, how they provide signals to underlying nerves. Elucidating these questions will provide the basis
for understanding tooth pain and can lead to the development of therapeutics specifically targeting
tooth pain.
Table 1. Tabular summary of ion channels expressed in dental pain sensory system and their functions.
Ion Channel Type Cell Type Expressed Ion Channels Remarks
Thermo-sensitive
Odontoblast
Heat sensing ion channels
TRPV1? TRPV2? TRPV3
TRPV4 TRPM3
Heat-induced dental pain in healthy
or pathological state (Odontoblast
transducer theory)
Cold sensing ion channels
TRPA1 TRPM8
Cold-induced dental pain in healthy
or pathological state (odontoblast
transducer theory)
TRAAK, TREK-1 K2p channels may play a role asthermos-sensors (Neural theory)
DPA neurons
Heat sensing ion channels
TRPV1 TRPV2 TRPV4 TRPM3 ANO1
Heat induced dental pain in healthy
or pathol gical state (Neural theory)
Cold sensing ion channels
TRPA1 TRPM8
Cold induced dental pain in healthy
or pathological state (Neural theory)
Others PDL
cells/Fibroblast Thermosesing TRP channels
Function in dental pain sensing
mechanism is not clear
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Table 1. Cont.




TRPV1 TRPV2 TRPV4 TRPC1 TRPC6
TRPP1 TRPP2 TRPM7 TRPM3
Sensing movement of dentine
tubular fluid (Hydrodynamic













Odontoblast Purinergic receptorsP2X4, P2X7
Paracrine or autocrine
signaling molecule




Odontoblast Voltage gated ion channelsNaV1.6 CaV1.2 KV1.1 KV1.2
Role of voltage gated ion channels
in odontoblasts is not clear
DPA neurons Voltage gated ion channelsNaV1.6-9 CaV1.2 KV1.1 KV1.2
Function in transmission of
nociceptive information
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Abstract: Acid-sensing ion channel 3 (ASIC3) is an important member of the acid-sensing ion channels
family, which is widely expressed in the peripheral nervous system and contributes to pain sensation.
ASICs are targeted by various drugs and toxins. However, mechanisms and structural determinants
of ligands’ action on ASIC3 are not completely understood. In the present work we studied ASIC3
modulation by a series of “hydrophobic monoamines” and their guanidine analogs, which were
previously characterized to affect other ASIC channels via multiple mechanisms. Electrophysiological
analysis of action via whole-cell patch clamp method was performed using rat ASIC3 expressed
in Chinese hamster ovary (CHO) cells. We found that the compounds studied inhibited ASIC3
activation by inducing acidic shift of proton sensitivity and slowed channel desensitization, which
was accompanied by a decrease of the equilibrium desensitization level. The total effect of the drugs
on the sustained ASIC3-mediated currents was the sum of these opposite effects. It is demonstrated
that drugs’ action on activation and desensitization differed in their structural requirements, kinetics
of action, and concentration and state dependencies. Taken together, these findings suggest that
effects on activation and desensitization are independent and are likely mediated by drugs binding
to distinct sites in ASIC3.
Keywords: acid-sensing ion channel (ASIC); drug action; ligand-gated ion channel; pharmacology;
small molecule; nociception; ASIC3
1. Introduction
Acid-sensing ion channels (ASICs) are cation channels from the degenerin/epithelial sodium
channel (DEG/ENaC) superfamily. They are activated by fast acidification of the media, while
prolonged exposure leads to their desensitization. There are five paralogous genes in this group,
with the expression products of ASIC1, 2, and 3 forming functional trimeric channels. ASIC1 and
ASIC2 are predominantly expressed in the central nervous system, whereas ASIC3 is more common in
the peripheral nervous system [1]. The functions they fulfill also vary. ASIC1 and ASIC2 have been
shown to contribute to the excitatory postsynaptic currents [2] and synaptic plasticity [3], and are also
involved in the pathologic processes in stroke and ischemia [4,5]. On the other hand, ASIC3 is typically
associated with peripheral nociception [6]. Another important difference is that ASIC3 channels, unlike
other ASICs, do not fully desensitize during prolonged activation, supporting a significant sustained
current [7].
The involvement of ASICs, in particular ASIC3, in the perception of pain has been firmly
established in a number of studies (for review see [8]). The use of ASIC inhibitors in rats and humans
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was shown to alleviate cutaneous pain and hyperalgesia [9–11]. Surprisingly, knockout of the ASIC3
gene in mice did not lead to a loss or significant decrease of their pain responses compared to wild
type [12]. In fact, in the study of Kang et al. [13], triple knockout (for ASIC1a, 2 and 3 genes) mice
showed enhanced pain sensitivity. This phenomenon can potentially be explained by the different
roles of the ASIC channels in different species or particular levels and by specific details of their
expression [14]. Large acidification-evoked currents were also shown in cardiac afferents, where they
propagated cardiac pain and angina [15]. Characteristics of those currents are closely matched by
heteromeric ASIC3/ASIC2b channels [16]. Other pain-associated conditions are also mediated by
ASIC3, such as migraines [17], osteoarthritis [18], and muscle inflammation [19].
Given the importance of their role and the potential of new functions’ discovery, it is not surprising
that ASIC pharmacology receives quite a lot of attention [20]. The pioneering paper by Waldmann et
al. [21] described the action of amiloride, a common modulator of ENaC channels, which was found
to be a low-affinity inhibitor of ASICs. Focusing on ASIC3 for the purposes of this work, there are
several groups of drugs to be noted. The abovementioned amiloride inhibits peak currents of ASIC3
but does not affect the window current. Even more interestingly, in high concentrations it is capable of
inducing said window current by itself, without acidification [22]. 2-Guanidine-4-methylquinazoline
(GMQ) was also originally described as an ASIC3 modulator, although, unlike its predecessor, it has a
potentiating effect. Like amiloride, GMQ can also evoke ASIC3 currents in neutral pH [23]. Later it
was found that GMQ and its derivatives can also modulate ASIC1a [24].
Several endogenous compounds were shown to potentiate ASIC3 currents, including
FMRFamides and related peptides [25], agmatine [26], and serotonin [27], with the last one
only affecting the sustained component of the response. Agmatine was also able to activate the
channels directly.
On the other hand, toxins mostly display inhibitory action on ASIC3. A number of sea anemone
toxins, such as APETx2 [28] and Ugr 9-1 [29], inhibit both peak and window currents in ASIC3.
MitTx [30], which locks the channel in the open state, also works on ASIC3 but in significantly higher
concentrations than on the other subunits.
In our research [31] we focused our attention on a group of small-molecule ligands we collectively
called hydrophobic monoamines. Despite their structural simplicity, further investigations revealed quite
complex effects that they can induce on ASIC channels [32]. We found that they can block the channel
pore, affect the activation curve in either direction, and shift the desensitization curve to more acidic
values, often with several effects observed for a single compound. Additionally, through this line of
investigation a potential physiological modulator of ASICs (i.e., histamine) was discovered [33]. Its
effects were specific to ASIC1a homomers. However, outside of initial assessment [31], the action of
monoamines on ASIC3 was never studied. Thus, in the present work we attempted to elucidate the
mechanisms of action of hydrophobic monoamines and their guanidine analogs on ASIC3 channels.
Other compounds that were found to affect ASIC1a and/or ASIC2a, such as some antidepressants [34]
and histamine receptor agonists [35], were also included in the study.
2. Results
2.1. Drug Selection
Several groups of compounds were selected for the present study. The IEM line ofcompounds
was originally designed as glutamate receptor agonists [36,37]. Their activity on ASIC channels
was subsequently shown by our group [31,32]. Memantine [38] and 9-aminoacridine [39] also affect
glutamate receptors as well as ASICs [31]. Other drugs included long-established antidepressants
amitriptyline and tianeptine [40,41] and histamine receptor modulators imetit, dimaprit, and
thioperamide [42,43]; their effects on ASICs were recently established in [34] and [35], respectively. It
is important to note that in previous studies only the effects on ASIC1a and ASIC2a were examined,
with ASIC3 covered very briefly in [31].
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2.2. Estimation of Drug Activities
For the sixteen compounds presented in Figure 1 we estimated the effects on peak and sustained
currents evoked by acidification from pH 7.4 to 6.85, which caused 10% ± 7% (n = 11) of maximal peak
response, and to pH 6.0, which caused 74% ± 16% (n = 11) maximal peak response. The compounds
were applied simultaneously with acidification at a concentration of 0.5 mM. These applications were
repeated 3–7 times to reach the effect’s equilibrium point and then 3–10 washout acidifications were

























Figure 1. Chemical structure of the tested compounds. The first row represents common hydrophobic
moieties (Ph-Ch, Ad, and dimet-Ad) of IEM compounds and memantine, with their terminal radicals
(R) shown directly below.
The results are presented in Figure 2. At pH 6.85 (Figure 2A, with sample traces shown in
Figure 2B,C) the peak component of the response was strongly inhibited by a number of compounds,
the most potent being IEM-2195 at 85% ± 7% (n = 6) inhibition, and only IEM-2117 slightly potentiated
the peak response by 42% ± 21% (n = 5). On the other hand, sustained current was typically potentiated,
with the strongest effect by IEM-2117 at 382% ± 84% (n = 5). IEM-2163 and IEM-2151 were the
only compounds that reduced the sustained current by 42% ± 21% (n = 9) and 29% ± 4% (n = 5),
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respectively. At pH 6.0 (Figure 2D, with sample traces shown in Figure 2E,F) the drugs’ effect on peak
current disappeared, while for sustained current the overall picture stayed the same and the effects
even somewhat increased in magnitude, with maximal potentiation by IEM-2117 reaching 498% ±
196% (n = 5) and inhibition by IEM-2163 at 54% ± 23% (n = 8). We can conclude from the data that
(1) structural determinants of the effects on peak and sustained components of the response did not
coincide and (2) only the effect on peak component demonstrated pronounced pH-dependence.
Figure 2. Estimation of the drug activities. Number of * denotes statistical significance at * p < 0.05,
** p < 0.01, or *** p < 0.001, respectively, n ≥ 5. (A) Effects of 500 μM of the compounds studied on the
ASIC3 activated by pH drop from 7.4 to 6.85. Compounds were applied simultaneously with activation.
(B,C) Representative examples of ASIC3 responses in control and in the presence of IEM-2044 (B) and
IEM-2174 (C) when activated by pH drop from 7.4 to 6.85. (D) effects of 500 μM of the compounds
studied on the ASIC3 activated by pH drop from 7.4 to 6.0. Compounds were applied simultaneously
with activation. (E,F) Representative examples of ASIC3 responses in control and in the presence of
IEM-2044 (E) and IEM-2174 (F) when activated by pH drop from 7.4 to 6.0.
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Typically, potentiation of the sustained current was accompanied by deceleration of the response
decay, reflecting an effect on desensitization. In control experiments the decay time constant was
462 ± 143 ms (n = 8). The most drastic increase was seen for IEM-2195, which changed the decay time
constant of the response to 4891 ± 1996 ms (n = 6). Inhibition of sustained current by IEM-2163 or
IEM-2151 did not elicit significant changes of the response kinetics.
2.3. pH and Concentration Dependencies
For detailed analysis we selected IEM-2163 and IEM-2195, as they demonstrate opposite
effects (inhibition and potentiation, respectively) on the sustained currents. First, we estimated the
pH-dependence of action on peak currents (Figure 3A). Figure 3B demonstrates that both compounds
caused a parallel shift of activation to more acidic values without affecting maximal response. IEM-2163
at 0.5 mM shifted the pH50 value from 6.26 ± 0.02 in control to 6.17 ± 0.06. The shift caused by IEM-2195
was about equal, with the pH50 of activation being 6.17 ± 0.04 in the presence of this drug.
Figure 3. pH and concentration dependencies of IEM-2163 and IEM-2195 action. (A) Peak current
inhibition was pH-dependent, the effects of both drugs disappeared under strong acidification.
(B) IEM-2163 and IEM-2195 caused acidic shift of the ASIC3 activation curve. (C–F) Concentration
dependencies of IEM-2163 (D,F) and IEM-2195 (C,E) action on peak (C,D) and sustained (E,F) currents.
Fitting is shown in solid lines. Note that the concentration dependence of IEM-2163’s action on
sustained current was biphasic at pH 6.0 where the current inhibition was small. Low concentrations
caused inhibition, but at high concentrations the effect was inverted.
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We then studied the concentration dependencies of the actions of IEM-2163 and IEM-2195 on
peak and sustained components of the response at pH 6.85 and 6.0 (Figure 3C–F). At pH 6.85, peak
inhibition by IEM-2195 (Figure 3C)—which reflects its effect on activation—was well-fitted by the Hill
equation, with optimal parameters nH = 0.82 ± 0.54, IC50 = 21 ± 15 μM. At pH 6.0, no significant
effect was detected for concentrations up to 1 mM (Figure 3C). Our attempts to further increase the
concentration led to poor clamp stability, resulting in highly diverging data at higher concentrations.
In contrast, potentiation of the sustained current was well established at pH 6.0 (Figure 3E), where
inhibition of activation was absent. The fitting resulted in EC50 = 784.2 ± 122.8 μM, nH = 1.31 ± 0.06,
and maximal effect 588% ± 55% potentiation.
IEM-2163 also strongly inhibited peak current. The IC50 at pH 6.85 (Figure 3D) was 245.64 ± 16.62
μM, nH = 1.17 ± 0.08. Similar to IEM-2195, peak inhibition at pH 6.0 was not significant. Sustained
currents were significantly inhibited by IEM-2163 at pH 6.85 as well (Figure 3F), IC50 = 117.3 ± 5.6 μM,
nH = 1.12 ± 0.07. A peculiar concentration dependence was observed for IEM-2163’s action at pH 6.0.
Low concentrations caused progressive inhibition, but at around 1 mM the effect reached saturation
at the level of 52% ± 16% of inhibition (n = 5), and at 3 mM, despite large data diversity, we saw an
apparent potentiation by 84% ± 111% (n = 5). To ensure this was not an artifact of data variation, we
performed additional experiments at 2 mM, which complied with the observed reversion of the effect
resulting in 101% ± 56% (n = 6) potentiation.
An explanation of such concentration dependencies could be that they reflect a mixture of two
distinct effects: pH-dependent inhibition of activation, which is responsible for the inhibition of
peak component and window component in low concentrations; and reduction of desensitization,
which determines the potentiation of the sustained current at high concentrations. Thus, analysis
of concentration dependencies provided arguments in favor of the independence of drug effects on
activation and desensitization.
2.4. Dependence of Action on the Application Protocols
Next, we compared drug effects in different application protocols. In addition to the protocol of
simultaneous application (see above) we applied the drugs continuously or during 30 s immediately
before activation by pH drop. The results are shown in Figure 4. The peak response evoked by
pH 6.0 was not strongly affected, regardless of the application protocol for both compounds. More
interestingly, peak response evoked by pH 6.85 was inhibited only if the drug was present during
acidification and not only before it (Figure 4A,E). This finding can be explained by two different
mechanisms: (1) the compounds interact only with the open channels and/or (2) the kinetics of their
action is very fast. The effects on the sustained currents also depended on the application protocol.
Application of IEM-2163 before activation by pH 6.0 resulted in 143% ± 41% (n = 5) potentiation,
while under other conditions the drug caused inhibition (Figure 4B). For IEM-2195, in all protocols
potentiation at pH 6.0 was higher than at pH 6.85 (two-way ANOVA for “protocol” and “pH” as
factors, F(1,36) = 25.838, p < 0.001). This complex behavior is readily explained by the existence of two
separate effects: pH-dependent inhibition of activation, which was also seen as peak inhibition; and
pH-independent reduction of desensitization, with the total effect on the sustained currents being a
sum of them.
As we diminished inhibition by the use of pH 6.0 for activation or by drug application only
at neutral pH before activation, the anti-desensitizing effect on the sustained current increased (for
IEM-2195) or became apparent (in the case of IEM-2163).
2.5. Kinetics of Action
Observation of the drug effects throughout the series of activations in the drug presence revealed
an interesting tendency (Figure 5). Unlike the typical monotonic effect development, in experiments
with IEM-2163, the sustained current was strongly inhibited during the first activation in the presence
of the drug, but in subsequent activations the inhibition became less pronounced. The washout
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process was also non-monotonic—in the first activation it demonstrated a significant “overshoot”—the
response decay was much slower than in control, resulting in the current at the end of activation being
higher than the control one (Figure 5A). The control parameters were eventually reached after 5–7
activations. For IEM-2195, its potentiation developed monotonically but, similarly to IEM-2163, there
was also a washout “overshoot”—in the first washout activation the current at the end of the response
was even higher than in the last activation with the drug (Figure 5B).
Figure 4. Effects of drug application protocol on peak and sustained currents of ASIC3 in different
activating pH. Number of * denotes statistical significance at * p < 0.05, ** p < 0.01, or *** p <
0.001, respectively, n ≥ 5. (A) Effects of IEM-2163 on peak current and (B) sustained current.
(C,D) Representative examples of ASIC3 responses in different activating pH (6.85 in (C) and 6.0
in (D)) and application protocols (left panels: application before activation, right panels: continuous
application). (E–H) Same for IEM-2195. IEM-2163 (A–D) had mostly similar effects regardless of the
protocol used, inhibiting peak current at pH 6.85 and sustained current for both pH values, with two
notable exceptions. When applied before activation with activating pH 6.85 it had no effect at all, and
in the same protocol but with activating pH 6.0 it strongly potentiated sustained current. IEM-2195
(E–H) mostly had a similar profile, but it typically potentiated the sustained current, although this
effect was significantly weaker at pH 6.85, essentially disappearing when applied before activation.
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Figure 5. Non-monotonic effect development and washout of IEM-2163 and IEM-2195.
(A,B) Representative recordings of the time course of experiments with IEM-2163 (A) and IEM-2195
(B). To the right are overlaid responses from the main panel. (C) The effect was the most pronounced
in the protocol of continuous application. Number of * denotes statistical significance at * p < 0.05,
** p < 0.01, or *** p < 0.001, respectively, n ≥ 5. The average values were calculated as the ratio of
amplitudes for the first drug application, last drug application, and first washout to the last control
response, respectively.
This phenomenon was the most pronounced with continuous drug application (Figure 5C).
However, if the drugs were applied only before the channel activation, the overshoot effect
disappeared. In this case both IEM-2163 and IEM-2195 caused potentiation, and recovery from
it developed monotonically.
Our explanation of these effects is that inhibition of activation is fast while the effect on
desensitization is much slower. Inhibition develops during the first activation in the presence of
the drugs and is just as rapidly washed out during the first activation without them, while the
reduction of desensitization requires several minutes to develop and wash out. This explanation agrees
with the protocol dependence—fast peak inhibition required the drug’s presence during activation,
whereas a slow effect on desensitization could be obtained during long pre-application and remained
even if the drug was absent from the solution during the activation. Thus, the effects on activation and
desensitization differed not only in structural determinants (Figure 2) as well as concentration and pH
dependence (Figure 3), but also in their kinetics.
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2.6. Biphasic Drug Effects, when Applied Exclusively to the Sustained Current
The fact that ASIC3s do not desensitize completely and can mediate significant sustained current
allows for one more type of experiment (Figure 6), which is helpful for the analysis of the mechanism
of action. We activated the channels in the absence of a drug and only applied it when the current
reached the sustained level. Washout was also performed during this prolonged activation, without
returning to the neutral pH. Typical currents are presented in Figure 6A,B. Application of IEM-2195
(Figure 6A) caused fast transient “on current”, which then slowly returned to the equilibrium level
similar to the value of sustained current potentiation observed in the previous experiments. Removal
of the drug resulted in a large transient “tail current” before returning to the control value. Application
and removal of IEM-2163 caused similar “on“ and “tail” transient currents, although they had smaller
amplitude (Figure 6B). The main difference between the drugs was the direction of the change in
the sustained current’s amplitude at the equilibrium level, which was potentiated by IEM-2195 and
inhibited by IEM-2163, respectively. We were especially careful to ensure that this unusual behavior was
not an artifact of the solution exchange. Additionally, “tail” currents for both compounds demonstrated
clear concentration dependence (Figure 6C), with fitting resulting in EC50 = 269.06 ± 15.35 μM, nH =
1.76 ± 0.11 for IEM-2195 and EC50 = 319.69 ± 44.08 μM, nH = 2.00 ± 0.33 for IEM-2163.
Figure 6. IEM-2163 and IEM-2195 cause transient currents when applied to sustained response.
(A,B) Representative recordings. Fast drug application caused transient current decrease (“on” current),
while washout induced transient increase (“tail” current). These transients reflect the presence of two
opposite effects with different kinetics. (C) Concentration dependencies of “tail” currents.
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We suggest that the observed “on” and “tail” currents reflect kinetics and complex mechanisms
of drug action, which include the inhibition of activation and reduction of desensitization. We suggest
that the “on” current appears because inhibitory action develops quickly, while slow modulation of
desensitization is responsible for the subsequent equilibrium level of the sustained current. The change
of this equilibrium effect (potentiation by IEM-2195 and inhibition by IEM-2163) may depend on the
balance between these two opposite actions. Fast inhibition of activation would also be responsible for
the “tail” currents, resulting from an acidic shift of activation (see Figure 3B). Purportedly, in this case
the drug-bound channels would remain in the resting state even under conditions of acidic pH. Thus,
fast removal of a drug would allow protons to bind and activate the channels.
To further check this suggestion, we performed analogous experiments with some other drugs
(Figure 7). 9-Aminoacridine and IEM-2044, which inhibit peak and potentiate the sustained component
of the response, also demonstrated pronounced “on” and “tail” currents. In contrast, for IEM-2059 and
IEM-1755 these transient currents were absent. In analogous experiments with agmatine performed by
Li et al. [26], no “on” or “tail” currents were shown, probably because agmatine leads to an alkaline
shift of activation and has an overall potentiating effect on ASIC3 currents.
Figure 7. “On” and “tail” currents for different drugs. Transient currents were pronounced for the drugs
which caused peak inhibition at pH 6.85 due to the activation shift (9AA, IEM-2044, see Figure 2A).
3. Discussion
In the present work we demonstrated that many hydrophobic monoamines and their guanidine
analogs affected ASIC3 in submillimolar concentrations. Two of them, IEM-2163 and IEM-2195, were
studied in detail, whereby we found that their effects are best explained by the existence of two distinct
mechanisms. The first mechanism is the acidic shift of activation that results in fast pH-dependent peak
inhibition. The second one is deceleration of the ASIC3 desensitization, which raises the equilibrium
level of the sustained current, thus effectively increasing its amplitude. The total drug effect on the
sustained current depended on the ratio of these two independent types of actions.
We found that in a large series of drugs there was no correlation between these two types of
action. Effect on activation was found to be pH-dependent, whereas modulation of desensitization
was similar at pH 6.85 and pH 6.0. Elucidation of these types of action in turn required different
application protocols. Concentration dependencies were also apparently separated, with effect on
activation developing at lower concentrations than the effect on desensitization. There was also a
drastic difference in kinetics, as the effect on activation was much faster than on desensitization.
Taken together, these data suggest that two distinct types of action are mediated by drugs binding to
different sites.
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Drug effects on ASIC3 have been the subject matter of numerous studies. For instance, a detailed
examination of GMQ and a representative series of its derivatives [44] allows for comparison with
our data. In particular, compounds containing two aromatic rings and a guanidine group used at a
concentration of 1 mM induced an acidic shift in the activation curve of ASIC3, similarly to IEM-2163,
IEM-2195, and some other compounds in our work (Figure 2). On the other hand, GMQ and a few other
derivatives induced an alkaline shift of activation, while we found no such effect for our compounds.
Amiloride, a known ASIC blocker, also causes an alkaline shift of activation in high concentrations
(0.5–1 mM). [24]. A similar but much weaker effect was induced by agmatine [26].
Notably, to detect a shift of activation it is necessarily to study the ligands’ effects with both weak
and strong acidifications, and such data are not available for a number of other compounds.
Analysis of drugs’ action on sustained current is more complex, as it can be mediated by the
effects on both channel activation and desensitization. Additionally, in some experimental setups
ASIC3 does not mediate such currents in control, complicating quantitative estimations of effects.
Various drugs, including GMQ [23], agmatine [26], and amiloride [22], induce or potentiate sustained
ASIC3-mediated currents evoked by modest acidifications. Serotonin [27] and FMRFamide [25]
potentiate the sustained current, while simultaneously slowing down desensitization kinetics under
conditions of strong acidification. Note that these two compounds did not affect the peak component.
In the present work we showed that drugs reduced the speed of response decay and increased final
equilibrium level of sustained current amplitude under conditions of modest acidifications. We also
experimentally separated this effect from their influence on activation, allowing us to detect such an
effect for IEM-2163 despite its total inhibitory action. We are not aware of the proven examples of the
compounds inhibiting the sustained current via modulation of desensitization.
In this regard it is interesting to compare drugs’ effect on ASIC1a and ASIC3. In our previous
paper [32] we demonstrated that many monoamines and their guanidine analogs affect the steady-state
desensitization of ASIC1a by shifting its pH dependence to more acidic values, although this effect does
not lead to the appearance of sustained current. The opposite effect, alkaline shift of the steady-state
desensitization, was not revealed for small molecules but only for psalmotoxin [45]. Thus, if we
assume that a similar process underlies desensitization in both ASIC1a and ASIC3, there is an apparent
commonality in the direction of drug action, although it manifests differently, according to the channel
type. In contrast, the drug action on activation properties is notably diverse. For instance, IEM-2044
and amitriptyline have opposite effects on different channels, inducing an alkaline shift of activation
on ASIC1a [32,34] and an acidic one on ASIC3, while 9AA shifts the activation to more acidic values in
both cases [32]. Histamine only enhanced the activation of ASIC1a and was inactive against ASIC3 [33].
Thus, we do not see a correlation for action on activation of ASIC1a and ASIC3. Similarly, in [44], GMQ
and its derivatives also demonstrated varying effects on ASIC1a and ASIC3, with some compounds
acting differently on different channels and others having the same effect regardless of the target.
The problem of the binding site(s) of ASIC ligands in the extracellular domain is intensely debated.
According to recent structural data, channel “activation involves ‘closure’ of the thumb domain into
the acidic pocket, expansion of the lower palm domain and an iris-like opening of the channel gate.
The linkers between the upper and lower palm domains serve as a molecular ‘clutch’, and undergo
a simple rearrangement to permit rapid desensitization” [46]. Another study [47] suggests that the
protonable residues in the acidic pocket affect ASIC pH dependence, but in the palm domain they
are responsible for the regulation of desensitization kinetics as well as prevention of the sustained
currents. Thus, different regions participate in complex allosteric interactions which contribute to
activation and desensitization, which in turn significantly complicates estimation of ligands’ binding
site(s). In addition, particular mutations can unequally affect different modes of ligands’ action. One
such example is Glu-79 in the palm domain of ASIC3 [48]. While it has been shown to be a crucial
element for direct opening of the channel by GMQ, its mutation did not elicit any changes in GMQ’s
effects on activation, but instead altered GMQ’s influence on the channel inactivation. The effect of
mutations on ligands’ binding and action can also be either direct or allosteric. These data, together
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with the complex structure–activity relationships revealed in the present and other studies, raise the
possibility that low-weight drugs can bind to more than one site in the extracellular domain of ASICs.
For instance, binding to the acidic pocket could control effects on activation, whereas binding to the
palm domain could be responsible for desensitization effects.
In our work we have focused our attention primarily on the low-to-moderate (pH 6.85–6.0)
acidification range. While the more powerful acidification (pH < 5.0) that is frequently used in other
studies can indeed occur [49] in vivo, it typically accompanies severe conditions such as tumors and
open fractures. However, physiological processes and less-drastic pathologies usually stay in the
less-acidic pH range [50–53]. Additionally, the research of Salinas et al. [54] indicates that ASIC3
activations by different levels of acidification are facilitated by distinct mechanisms. If one were to
assume that those mechanisms in turn mediate specific physiological responses, then our work shows
potential for the development of state-dependent drugs, which would affect only the specific response,
without influencing other channel functions.
4. Materials and Methods
4.1. Chemicals and Synthesis
The synthesis of IEM compounds was performed at the Institute of Experimental Medicine,
Saint-Petersburg, Russia as described in References [55–58]. The rest of the drugs were obtained from
Tocris Bioscience and Sigma Aldrich.
4.2. Cell Culture and Transfection
Chinese hamster ovary (CHO) cells, purchased from Evrogen company (Evrogen, Moscow,
Russia), were cultured in a humidified atmosphere of 5% CO2 at 37 ◦C. Standard culture conditions
were used for cell maintenance (Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum,
5% gentamicin). Transfection of plasmid encoding rat ASIC3 subunit was done using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer′s protocol. We received expression
vectors encoding rat ASIC3 as a gift from A. Staruschenko [59]. Those vectors were described in
Reference [60]. Cells were transfected with 0.5 mg rASIC3 cDNA + 0.5 mg eGFP per 35-mm dish to
achieve the expression of homomeric channels.
4.3. Drugs and Solutions
Pipette solution was prepared as 100 mM CsF, 40 mM CsCl, 5 mM NaCl, 0.5 mM CaCl2, 10 mM
HEPES, and 5 mM EGTA, and its pH was adjusted to 7.35 with CsOH. For cells’ perfusion, an
extracellular solution with 143 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 2 mM MgCl2, 18 mM D-glucose,
10 mM HEPES, and 10 mM MES was used, with its pH adjusted to 7.4. Drug-containing solutions
were prepared from extracellular solution and their pH was adjusted again if necessary.
4.4. Electrophysiology
Electrophysiological experiments were performed 48–72 h after transfection. Green fluorescence
detected with a Leica DMIL microscope was used to identify transfected cells. Current recordings were
acquired with an EPC-8 (HEKA Elektronik, Lambrecht, Germany) patch clamp amplifier in whole-cell
voltage-clamp mode at a membrane potential of −80 mV. The data were stored on a personal computer
via Patchmaster software (HEKA Elektronik, Lambrecht, Germany). The recordings where access
resistance and capacitance changed by more than 10% over the course of the experiment were excluded
from the analysis.
4.5. Experimental Protocol
A standard experiment included a 30 s application of conditioning solution, followed by 20 s
of activating solution. Then, the process was repeated until at least three responses in a row were
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differing from each other by less than 10% of their amplitude. In experiments where the drug was
applied during conditioning period, we had to reduce its potential effect on the open channels. To
achieve this, channel activation was preceded by a 3 s flush of drug-free conditioning solution.
When the drug was applied only to the sustained current, both activating solution and the drug
were applied until sustained current stabilized, with no other time constraints.
To account for response variability during the experiment, the control responses were averaged
before drug application and after washout.
4.6. Data Analysis and Statistics
The values in the text are given as mean ± standard deviation (SD) with n ≥ 5. To test for effects’
significance, paired t-tests (drug versus control) or ANOVA were used, as appropriate, via the IBM
SPSS Statistics software package (IBM, Armonk, NY, USA). OriginPro 8.1 (OriginLab Corporation,
Northampton, MA, USA) was used for fitting of the data.
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